UCB  28 Mar 2019  
Statistical Analysis Plan SP0982  
STATISTICAL ANALYSIS PLAN 
Study: SP0982  
Product: Lacosamide  
A double-blind, randomized, placebo-controlled, parallel-group, multicenter study to evaluate 
the efficacy and safety of lacosamide as adjunctive therapy for uncontrolled primary generalized 
tonic-clonic seizures in subjects with idiopathic generalized epilepsy 
SAP/Amendment Number  Date  
Final SAP  09 Aug 2016  
Amendment #1  24 Feb 2017  
Amendment #2  14 Mar 2017  
Amendment #3  4 Jan 2019 
Amendment #4  28 Mar 2019  
Confidentiality Statement 
Confidential 
This document is the property of UCB and may not – in full or in part – be passed on, 
reproduced, published, or otherwise used without the express permission of UCB.  REDACTED COPY 09 Aug 2016
REDACTED COPY 09 Aug 2016
24 Feb 2017
REDACTED COPY 24 Feb 2017
14 Mar 2017REDACTED COPY 14 Mar 2017
201REDACTED COPY 201
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.group, multicenter study to evaluate 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.group, multicenter study to evaluate 
the efficacy and safety of lacosamide as adjunctive therapy for uncontrolled primary generalized 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.the efficacy and safety of lacosamide as adjunctive therapy for uncontrolled primary generalized 
clonic seizures in subjects with idiopathic generalized epilepsy
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.clonic seizures in subjects with idiopathic generalized epilepsy
14 Mar 2017
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.14 Mar 2017
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.201
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.2019
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.9
Mar 2019
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Mar 2019
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
UCB   28 Mar 2019  
Statistical Analysis Plan  SP0982  
TABLE OF CONTENTS  
LIST OF ABBREVIATIONS .................................................................................................... 8  
1 INTRODUCTION ........................................................................................................... 10  
2 PROTOCOL SUMMARY ............................................................................................... 10  
2.1 Study objectives ........................................................................................................... 10  
2.1.1  Primary objective ................................................................................................. 10  
2.1.2  Seco ndary objective ............................................................................................. 10  
2.2 Study variables ............................................................................................................. 10  
2.2.1  Efficacy variables ................................................................................................ 10  
2.2.1.1  Primary efficacy variable .......................................................................... 10  
2.2.1.2  Secondary efficacy variables ..................................................................... 10  
2.2.1.3  Other efficacy variables ............................................................................. 10  
2.2.2  Safety variables .................................................................................................... 12  
2.2.2.1  Other safety variables ................................................................................ 12  
2.2.3  Pharmacokinetic variables ................................................................................... 12  
2.3 Study design and conduct ............................................................................................ 12  
2.3.1  Study description ................................................................................................. 12  
2.3.2  Rationale for study design ................................................................................... 14  
2.4 Determination of sample size ....................................................................................... 15  
3 DATA ANALYSIS CONSIDERATIONS ...................................................................... 15  
3.1 General presentation of summaries and analyses ........................................................ 15  
3.2 General study level definitions .................................................................................... 16  
3.2.1  Analysis time points ............................................................................................ 16  
3.2.2  Seizure cluster ...................................................................................................... 17  
3.2.3  Event .................................................................................................................... 17  
3.2.4  Censoring ............................................................................................................. 17  
3.2.5  AEDs and benzodiazepines ................................................................................. 18  
3.2.5.1  Prohibited concomitant treatments (medications and therapies) ............... 18  
3.2.6  Relative day ......................................................................................................... 19  
3.2.7  Last Visit .............................................................................................................. 19  
3.2.8  Month ................................................................................................................... 19  
3.3 Definition of Baseline values ....................................................................................... 19  
3.4 Protocol deviations....................................................................................................... 19  
3.5 Analysis sets................................................................................................................. 20  
3.5.1  Screened Set  ......................................................................................................... 20  
3.5.2  Randomiz ed Set ................................................................................................... 20  
3.5.3  Safety Set  ............................................................................................................. 20  
3.5.4  Full Analysis Set .................................................................................................. 20  REDACTED COPY ................................
REDACTED COPY ................................
................................
REDACTED COPY ................................
................................
REDACTED COPY ................................
................................
REDACTED COPY ................................
ERATIONS
REDACTED COPY ERATIONS
General presentation of summaries and analyses
REDACTED COPY General presentation of summaries and analyses
General study level definitions REDACTED COPY General study level definitions
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.10
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.10
.............
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.............. 10
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.10
................................
This document cannot be used to support any marketing authorization application and any extensions or variations thereof................................. 10
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.10
................................
This document cannot be used to support any marketing authorization application and any extensions or variations thereof................................. ..........
This document cannot be used to support any marketing authorization application and any extensions or variations thereof...........
................................
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.................................
................................
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.................................
................................
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.................................
................................
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.................................
................................
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.................................
................................
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.................................
................................
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.................................
................................
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.................................
................................
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.................................
................................
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.................................
General presentation of summaries and analyses
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.General presentation of summaries and analyses
................................
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.................................
................................
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.................................
................................
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.................................
................................
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.................................
................................
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.................................
AEDs and benzodiazepines
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.AEDs and benzodiazepines
Prohibited concomitant treatments (medications and therapies)
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Prohibited concomitant treatments (medications and therapies)
Relative day
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Relative day
Last Visit
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Last Visit
Month
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Month
Definition of Base
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Definition of Base
3.4
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.3.4 Protocol deviations
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Protocol deviations
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.3.5
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.3.5
UCB   28 Mar 2019  
Statistical Analysis Plan  SP0982  
3.5.5  Per Protocol Set ................................................................................................... 20  
3.6 Treatment assignment and treatment groups ............................................................... 20  
3.7 Center pooling strategy ................................................................................................ 21  
3.8 Coding dictionaries ...................................................................................................... 21  
3.9 Changes to protocol-defined analyses ......................................................................... 21  
4 STATISTICAL/ANALYTIC AL ISSUES  ....................................................................... 21  
4.1 Adjustments for covariates .......................................................................................... 21  
4.2 Handling of dropouts or missing data .......................................................................... 21  
4.2.1  Missing seizure diary days ................................................................................... 21  
4.2.2  Incomplete dates for first epilepsy diagnosis ....................................................... 22  
4.2.3  Incomplete dates for adverse events and concomitant medications .................... 22  
4.2.4  Incomplete date for the last administration of study medication ......................... 23  
4.2.5  Missing adverse event intensity ........................................................................... 24  
4.2.6  Missing adverse event relationship to study medication ..................................... 24  
4.3 Interim analyses and data monitoring .......................................................................... 24  
4.4 Multicenter studies ....................................................................................................... 24  
4.5 Multiple comparisons/multiplicity ............................................................................... 24  
4.6 Use of an efficacy subset of subjects ........................................................................... 24  
4.7 Active-control studies intended to show equivalence .................................................. 25  
4.8 Examination of subgroups ........................................................................................... 25  
4.9 Stratum Pooling ........................................................................................................... 26  
5 STUDY POPULATION CHARACTERISTICS ............................................................. 26  
5.1 Subject disposition ....................................................................................................... 26  
5.2 Protocol deviations....................................................................................................... 27  
6 DEMOGRAPHICS AND OTHER BASELINE CHARACTE RISTICS  ........................ 27  
6.1 Demographics .............................................................................................................. 27  
6.1.1  Derivation of demographics variables ................................................................. 27  
6.1.1.1  BMI  ........................................................................................................... 27  
6.1.2  Analysis of demographics variables .................................................................... 28  
6.2 Other Baseline characteristics ...................................................................................... 28  
6.2.1  Derivation of other Baseline characteristics ........................................................ 28  
6.2.1.1  Time since first diagnosis .......................................................................... 28  
6.2.1.2  Age at diagnosis ........................................................................................ 28  
6.2.2  Analysis of other Baseline characteristics ........................................................... 28  
6.3 Subgroups .................................................................................................................... 28  
6.4 Medical history and concomitant diseases ................................................................... 29  
6.5 Procedure history ......................................................................................................... 29  
6.6 Prior and concomitant medications .............................................................................. 29  REDACTED COPY ................................
REDACTED COPY ................................
................................
REDACTED COPY ................................
control studies intended to show equivalence
REDACTED COPY control studies intended to show equivalence
................................
REDACTED COPY ................................
................................
REDACTED COPY ................................
RACTERISTICSREDACTED COPY RACTERISTICS
This document cannot be used to support any marketing authorization application and any extensions or variations thereof...........
This document cannot be used to support any marketing authorization application and any extensions or variations thereof........... 21
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.21
...................
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.................... 21
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.21
.......................
This document cannot be used to support any marketing authorization application and any extensions or variations thereof........................
....................
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.....................
.........................
This document cannot be used to support any marketing authorization application and any extensions or variations thereof..........................
................................
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.................................
................................
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.................................
................................
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.................................
................................
This document cannot be used to support any marketing authorization application and any extensions or variations thereof................................. ................................
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.................................
................................
This document cannot be used to support any marketing authorization application and any extensions or variations thereof................................. ................................
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.................................
................................
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.................................
control studies intended to show equivalence
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.control studies intended to show equivalence
................................
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.................................
................................
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.................................
RACTERISTICS
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.RACTERISTICS
................................
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.................................
................................
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.................................
DEMOGRAPHICS AND OTH
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.DEMOGRAPHICS AND OTH ER BASELINE CHARACTE
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.ER BASELINE CHARACTE
................................
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.................................
Derivation of demographics variables
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Derivation of demographics variables
BMI
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.BMI ................................
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.................................
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Analysis of demographics variables
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Analysis of demographics variables
Other Baseline characteristics
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Other Baseline characteristics
Derivation of other Baseline characteristics
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Derivation of other Baseline characteristics
6.2.1.1
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.6.2.1.1
6.2.1.2
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.6.2.1.2
6.2.2
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.6.2.2
6.3
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.6.3
UCB   28 Mar 2019  
Statistical Analysis Plan  SP0982  
7 MEASUREMENTS OF TREATMENT COMPLIANCE ............................................... 29  
8 EFFICACY ANALYSES ................................................................................................ 30  
8.1 Statistical analysis of the primary efficacy variable .................................................... 30  
8.1.1  Derivations of primary efficacy variable ............................................................. 30  
8.1.2  Primary analysis of the primary efficacy variable ............................................... 30  
8.1.3  Secondary analyses of the primary efficacy variable .......................................... 31  
8.1.4  Supportive and sensitivity analyses of the primary efficacy variable ................. 31  
8.2 Statistical analysis of the secondary efficacy variables ............................................... 31  
8.2.1  Derivations of secondary efficacy variables ........................................................ 32  
8.2.1.1  Variable: Seizure freedom for PGTCS for the 166-day Treatment Period 32  
8.2.1.2  Variable: Time to first PGTCS during the 166-day Treatment Period ..... 32  
8.2.2  Analysis of secondary efficacy variables............................................................. 32  
8.2.2.1  Analysis: Seizure freedom for PGTCS for the 166-day Treatment Period32  
8.2.2.2  Analysis: Time to first PGTCS during the 166-day Treatment Period ..... 33  
8.3 Analysis of seizure related other efficacy variables .................................................... 34  
8.3.1  Derivations of seizure related other efficacy variables ........................................ 34  
8.3.1.1  Variable: PGTCS frequency per 28 days .................................................. 34  
8.3.1.2  Variable: Days with seizures per 28 days ................................................. 35  
8.3.1.3  Variable: Seizure-free status ..................................................................... 35  
8.3.1.4  Variable: Responder status – reduction in PGTCS frequency .................. 35  
8.3.1.5  Variable: PGTCS frequency - worsening .................................................. 36  
8.3.1.6  Variable: Responder status – reduction in days with absence seizures ..... 36  
8.3.1.7  Variable: Responder status – reduction in days with myoclonic seizures 36  
8.3.1.8  Variable: Days with absence and myoclonic seizures – worsening .......... 36  
8.3.1.9  Variable: Absence and myoclonic seizure frequencies per 28 days ......... 36  
8.3.1.10  Variable: Responder status – reduction in absence and myoclonic seizure 
frequencies ................................................................................................. 37  
8.3.1.11  Variable: Absence and myoclonic seizure frequency - worsening ........... 37  
8.3.2  Analysis of seizure related other efficacy variables ............................................ 37  
8.3.2.1  Analysis: Percent change in PGTCS frequency per 28 days from 
Combined Baseline .................................................................................... 37  
8.3.2.2  Analysis: Reduction in days with seizures per 28 days ............................. 37  
8.3.2.3  Analysis: Seizure-free status ..................................................................... 38  
8.3.2.4  Analysis: Responder status – reduction in PGTCS frequency .................. 38  
8.3.2.5  Analysis: Responder status – reduction in days with absence seizures..... 39  
8.3.2.6  Analysis: Responder status – reduction in days with myoclonic seizures 39  
8.3.2.7  Analysis: Percent change in absence and myoclonic seizure frequency per 
28 days from Prospective Baseline............................................................ 40  REDACTED COPY Variable: PGTCS frequency per 28 days
REDACTED COPY Variable: PGTCS frequency per 28 days
Variable: Days with seizures per 28 days
REDACTED COPY Variable: Days with seizures per 28 days
free status
REDACTED COPY free status ................................
REDACTED COPY ................................
Variable: Responder status 
REDACTED COPY Variable: Responder status –
REDACTED COPY –
Variable: PGTCS frequency 
REDACTED COPY Variable: PGTCS frequency 
Variable: Responder status REDACTED COPY Variable: Responder status 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof................
This document cannot be used to support any marketing authorization application and any extensions or variations thereof................ 31
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.31
........................
This document cannot be used to support any marketing authorization application and any extensions or variations thereof......................... 32
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.32
day Treatment Period
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.day Treatment Period
day Treatment Period
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.day Treatment Period
.............................
This document cannot be used to support any marketing authorization application and any extensions or variations thereof..............................
day Treatment Period
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.day Treatment Period
day Treatment Period
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.day Treatment Period
................................
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.................................
Derivations of seizure related other efficacy variables
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Derivations of seizure related other efficacy variables ................................
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.................................
Variable: PGTCS frequency per 28 days
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Variable: PGTCS frequency per 28 days ................................
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.................................
Variable: Days with seizures per 28 days
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Variable: Days with seizures per 28 days
................................
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.................................
reduction
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.reduction
Variable: PGTCS frequency 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Variable: PGTCS frequency -
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.-worsening
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.worsening
Variable: Responder status 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Variable: Responder status 
Variable: Responder status 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Variable: Responder status 
Variable: Days with absence and myoclonic seizures 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Variable: Days with absence and myoclonic seizures 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Variable: Absence and myoclonic seizure frequencies per 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Variable: Absence and myoclonic seizure frequencies per 
Variable: Responder status 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Variable: Responder status 
frequencies
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.frequencies
Variable: Absence and myoclonic seizure frequency 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Variable: Absence and myoclonic seizure frequency 
Analysis of seizure related other efficacy variables
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Analysis of seizure related other efficacy variables
Analysis: Percent change in PGTCS frequency per 28 days from 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Analysis: Percent change in PGTCS frequency per 28 days from 
8.3.2.2
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.8.3.2.2
8.3.2.3
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.8.3.2.3
8.3.2.4
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.8.3.2.4
UCB   28 Mar 2019  
Statistical Analysis Plan  SP0982  
8.3.2.8  Analysis: Responder status – reduction in absence and myoclonic seizure 
frequency ................................................................................................... 40  
8.4 Analysis of health outcome other efficacy variables ................................................... 41  
8.4.1  Derivations of health outcome other efficacy variables ...................................... 41  
8.4.1.1  QOLIE-31-P variables ............................................................................... 41  
8.4.1.2  PedsQL variables ....................................................................................... 42  
8.4.1.3  EQ-5D-3L quality of life variables ........................................................... 42  
8.4.1.4  Hospital stays ............................................................................................ 42  
8.4.2  Analysis of health outcome other efficacy variables ........................................... 43  
8.4.2.1  QOLIE-31-P variables ............................................................................... 43  
8.4.2.2  PedsQL variables ....................................................................................... 43  
8.4.2.3  EQ-5D-3L quality of life variables ........................................................... 43  
8.4.2.4  Concomitant medical procedures .............................................................. 44  
8.4.2.5  Healthcare provider consultations ............................................................. 44  
8.4.2.6  Hospital stays ............................................................................................ 44  
8.4.2.7  Number of working or school days lost due to epilepsy ........................... 44  
8.4.2.8  Number of days with help from a paid caregiver due to epilepsy ............. 44  
8.4.2.9  Socio-professional data ............................................................................. 44  
9 PHARMACOKINETICS ................................................................................................. 44  
10 SAFETY ANALYSES ..................................................................................................... 45  
10.1  Extent of exposure ....................................................................................................... 45  
10.1.1  Derivation of exposure variables ......................................................................... 45  
10.1.2  Analysis of exposure variables ............................................................................ 45  
10.2  Adverse events ............................................................................................................. 45  
10.3  Clinical laboratory evaluations .................................................................................... 47  
10.4  Vital signs, physical findings, and other observations related to safety ...................... 48  
10.4.1  Vital signs ............................................................................................................ 48  
10.4.2  Electrocardiograms .............................................................................................. 48  
10.4.2.1  Derivation of corrected QT values ............................................................ 48  
10.4.2.2  Analysis of ECG parameters ..................................................................... 49  
10.4.3  Physical examination ........................................................................................... 49  
10.4.4  Safety Seizure Information .................................................................................. 49  
10.4.4.1  New Seizure Type ..................................................................................... 49  
10.4.4.2  Increase in days with absence seizures ...................................................... 50  
10.4.4.3  Increase in days with myoclonic seizures ................................................. 50  
10.4.4.4  Increase in absence seizure frequency ....................................................... 50  
10.4.4.5  Increase in myoclonic seizure frequency .................................................. 50  
10.4.5  Tanner stage assessment ...................................................................................... 50  REDACTED COPY Number of days with help from a paid caregiver due to epilepsy
REDACTED COPY Number of days with help from a paid caregiver due to epilepsy
................................
REDACTED COPY ................................
................................
REDACTED COPY ................................ ................................
REDACTED COPY ................................
................................
REDACTED COPY ................................
................................
REDACTED COPY ................................
ivation of exposure variablesREDACTED COPY ivation of exposure variables
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.42
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.42
...........
This document cannot be used to support any marketing authorization application and any extensions or variations thereof............ 43
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.43
...............
This document cannot be used to support any marketing authorization application and any extensions or variations thereof................
.......................
This document cannot be used to support any marketing authorization application and any extensions or variations thereof........................
...........................
This document cannot be used to support any marketing authorization application and any extensions or variations thereof............................
..............................
This document cannot be used to support any marketing authorization application and any extensions or variations thereof...............................
................................
This document cannot be used to support any marketing authorization application and any extensions or variations thereof................................. .............................
This document cannot be used to support any marketing authorization application and any extensions or variations thereof..............................
................................
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.................................
Number of working or school days lost due to epilepsy
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Number of working or school days lost due to epilepsy
Number of days with help from a paid caregiver due to epilepsy
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Number of days with help from a paid caregiver due to epilepsy
................................
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.................................
................................
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.................................
................................
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.................................
................................
This document cannot be used to support any marketing authorization application and any extensions or variations thereof................................. ................................
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.................................
ivation of exposure variables
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.ivation of exposure variables ................................
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.................................
Analysis of exposure variables
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Analysis of exposure variables
................................
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.................................
laboratory evaluations
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.laboratory evaluations
Vital signs, physical findings, and other observations related to safety
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Vital signs, physical findings, and other observations related to safety
................................
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.................................
Electrocardiograms
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Electrocardiograms
Derivation of corrected QT values
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Derivation of corrected QT values
10.4.2.2
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.10.4.2.2 Analysis of ECG parameters
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Analysis of ECG parameters
Physical examination
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Physical examination
10.4.4
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.10.4.4 Safety Seizure Information
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Safety Seizure Information
10.4.4.1
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.10.4.4.1
UCB   28 Mar 2019  
Statistical Analysis Plan  SP0982  
10.4.6  Neurological examination .................................................................................... 51  
10.4.7  Assessment of suicidality .................................................................................... 51  
10.4.8  Achenbach Child Behavior Checklist .................................................................. 51  
10.4.8.1  Derivation of Achenbach variables ........................................................... 51  
10.4.8.2  Analysis of Achenbach variables .............................................................. 52  
10.4.9  BRIEF -P and BRIEF assessment ......................................................................... 53  
10.4.9.1  BRIEF -P scores ......................................................................................... 53  
10.4.9.2  BRIEF scores ............................................................................................. 54  
10.4.10  Vagus nerve stimulation ...................................................................................... 55  
10.4.11  Ketogenic diet ...................................................................................................... 56  
11 REFERENCES ................................................................................................................ 57  
12 APPENDICES ................................................................................................................. 58  
12.1  Appendix 1: QOLIE -31-P total and subscale score calculations ................................. 58  
12.2  Appendix 2: Adverse Events ....................................................................................... 62  
12.2.1  Other Significant AEs .......................................................................................... 62  
12.2.2  List of AEs for Potentially Drug Induced Liver Injury (PDILI).......................... 64  
12.3  Appendix 3: Markedly abnormal values ...................................................................... 67  
12.3.1  Hematology .......................................................................................................... 67  
12.3.2  Chemistry ............................................................................................................. 68  
12.3.3  Vital signs ............................................................................................................ 70  
12.3.4  ECGs .................................................................................................................... 72  
12.4  Appendix 4: NCI CTC ................................................................................................. 73  
12.5  Appendix 5: Registry Required Tables ........................................................................ 75  
12.6  Additional Subgroups to be programmed in ADSL .................................................... 76  
13 AMENDMENT(S) TO THE STATISTICAL ANALYSIS PLAN (SAP) ...................... 77  
13.1  Amendment 1 ............................................................................................................... 77  
13.1.1  Rationale for the amendment ............................................................................... 77  
13.1.2  Modification and changes .................................................................................... 77  
13.1.2.1  Specific changes ........................................................................................ 77  
13.2  Amendment 2 ............................................................................................................... 80  
13.2.1  Rationale for the amendment ............................................................................... 80  
13.2.2  Modification and changes .................................................................................... 81  
13.2.2.1  Specific changes ........................................................................................ 81  
13.3  Amendment 3 ............................................................................................................... 82  
13.3.1  Rationale for the amendment ............................................................................... 82  
13.3.2  Modification and changes .................................................................................... 82  
13.3.2.1  Specific changes ........................................................................................ 82  
13.4  Amendment 4 ............................................................................................................. 114  REDACTED COPY ................................
REDACTED COPY ................................
................................
REDACTED COPY ................................
................................
REDACTED COPY ................................
................................
REDACTED COPY ................................ ................................
REDACTED COPY ................................
................................
REDACTED COPY ................................
................................ REDACTED COPY ................................
This document cannot be used to support any marketing authorization application and any extensions or variations thereof..............................
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.............................. 54
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.54
......................
This document cannot be used to support any marketing authorization application and any extensions or variations thereof....................... 55
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.55
................................
This document cannot be used to support any marketing authorization application and any extensions or variations thereof................................. ......
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.......
................................
This document cannot be used to support any marketing authorization application and any extensions or variations thereof................................. ................
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.................
................................
This document cannot be used to support any marketing authorization application and any extensions or variations thereof................................. .................
This document cannot be used to support any marketing authorization application and any extensions or variations thereof..................
................................
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.................................
................................
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.................................
................................
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.................................
List of AEs for Potentially Drug Induced Liver Injury (PDILI)
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.List of AEs for Potentially Drug Induced Liver Injury (PDILI)
................................
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.................................
................................
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.................................
................................
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.................................
................................
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.................................
................................
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.................................
................................
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.................................
endix 5: Registry Required Tables
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.endix 5: Registry Required Tables
Additional Subgroups to be programmed in ADSL
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Additional Subgroups to be programmed in ADSL
AMENDMENT(S) TO THE 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.AMENDMENT(S) TO THE STATISTICAL ANALYSIS
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.STATISTICAL ANALYSIS
................................
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.................................
for the amendment
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.for the amendment
Modification and changes
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Modification and changes
Specific changes
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Specific changes
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.ndment 2
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.ndment 2
Rationale for the amendment
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Rationale for the amendment
13.2.2
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.13.2.2
13
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.13.2.2.1
This document cannot be used to support any marketing authorization application and any extensions or variations thereof..2.2.1
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.13.3
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.13.3
UCB   28 Mar 2019  
Statistical Analysis Plan  SP0982  
13.4.1  Rationale for the amendment ............................................................................. 114  
13.4.2  Modification and changes .................................................................................. 114  
13.4.2.1  Specific changes ...................................................................................... 115  
STATISTICAL ANALYSIS  PLAN SIGNATURE PAGE ................................................... 126  
 
LIST OF TABLES  
Table 1:  Number of PGTC Seizures for Study Entry .................................................... 13  
Table 2:  CBCL/1½-5 ...................................................................................................... 51  
Table 3:  CBCL/6 -18 ....................................................................................................... 52  
Table 4:  BRIEF -P questionnaire scoring ....................................................................... 53  
Table 5:  BRIEF questionnaire scoring ........................................................................... 54  
Table 6:  Other Significant AEs ...................................................................................... 62  
Table 7:  AEs for PDILI .................................................................................................. 64  
Table 8:  Hematology - Markedly Abnormal Values ...................................................... 67  
Table 9:  Chemistry: Markedly Abnormal Values .......................................................... 68  
Table 10:  Vital Signs - Abnormality Criteria ................................................................... 70  
Table 11:  ECGs - Abnormality Criteria ........................................................................... 72  
Table 12:  NCI CTC .......................................................................................................... 73  
 
 REDACTED COPY Chemistry: Markedly Abnormal Values
REDACTED COPY Chemistry: Markedly Abnormal Values ................................
REDACTED COPY ................................
Abnormality Criteria
REDACTED COPY Abnormality Criteria ................................
REDACTED COPY ................................
................................
REDACTED COPY ................................
................................
REDACTED COPY ................................
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.13
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.13
......
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.......51
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.51
................................
This document cannot be used to support any marketing authorization application and any extensions or variations thereof................................. .......
This document cannot be used to support any marketing authorization application and any extensions or variations thereof........
................................
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.................................
................................
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.................................
................................
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.................................
................................
This document cannot be used to support any marketing authorization application and any extensions or variations thereof................................. ................................
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.................................
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.................................
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.................................
................................
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.................................
................................
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.................................
................................
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.................................
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.................................
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.................................
UCB   28 Mar 2019  
Statistical Analysis Plan  SP0982  
LIST OF ABBREVIATION S 
AE adverse event 
AED  antiepileptic drug 
ALT Alanine aminotransferase 
AST  Aspartate aminotransferase 
ATC  Anatomic Therapeutic Chemical 
BMI  body mass index 
BP Blood pressure 
BRI Behavioral Regulation index 
BRIEF® Behavior Rating Inventory of Executive Function® 
BRIEF®-P Behavior Rating Inventory of Executive 
Function®-Preschool version 
CB combined baseline 
CBCL  Child Behavior Checklist 
CRF  case report form 
C-SSRS  Columbia-Suicide Severity Rating Scale 
ECG  Electrocardiogram 
ET Early Termination 
EQ-5D-3L 3-Level EuroQol-5 Dimension Quality of Life 
Assessment 
FAS Full Analysis Set 
GEC  Global Executive Composite 
GGT  Gamma glutamyl transferase 
HR hazard ratio 
HRQoL  health-related quality of life 
IDMC  independent data monitoring committee 
IGE idiopathic generalized epilepsy 
II Generalized seizures 
IIA Absence seizures 
IIB Myoclonic seizures 
IIC Clonic seizures 
IID Tonic seizures 
IIE (primary generalized) tonic-clonic seizures 
IIF Atonic seizures REDACTED COPY Suicide Severity Rating Scale
REDACTED COPY Suicide Severity Rating Scale
lectrocardiogram
REDACTED COPY lectrocardiogram
Early Termination
REDACTED COPY Early Termination
-
REDACTED COPY -Level 
REDACTED COPY Level 
AssessmentREDACTED COPY Assessment
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Behavior Rating Inventory of Executive Function
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Behavior Rating Inventory of Executive Function®
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.®
Behavior Rating Inventory of Executive 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Behavior Rating Inventory of Executive 
Suicide Severity Rating Scale
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Suicide Severity Rating Scale
lectrocardiogram
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.lectrocardiogram
Early Termination
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Early Termination
Level 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Level EuroQol
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.EuroQol
Assessment
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Assessment
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Full Analysis Set
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Full Analysis Set
Global Executive Composite
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Global Executive Composite
IIA
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.IIA
IIB
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.IIB
IIC
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.IIC
UCB   28 Mar 2019  
Statistical Analysis Plan  SP0982  
III Unclassified seizures 
ILAE  International League Against Epilepsy 
IRT Interactive response technology 
KM Kaplan- Meier  
LCM  Lacosamide 
LLN  lower limit of normal 
MedDRA Medical Dictionary for Regulatory Activities 
MI Metacognition Index 
NCI CTC  National Cancer Institute Common Terminology Criteria 
for Adverse Events 
PCH  percent change 
PedsQL Pediatric Quality of Life Inventory  
PGTC  primary generalized tonic-clonic 
PGTCS  Primary generalized tonic-clonic seizure 
PH proportional hazard 
PHREG proportional hazards regression 
PPS Per-Protocol Set 
PT preferred term 
QOLIE -31-P Patient-Weighted Quality of Life in Epilepsy 
Inventory-Form 31 
QTcB  Bazett corrected QT 
QTcF  Fridericia corrected QT 
RS Randomized Set 
SAP Statistical Analysis Plan 
SAS® Statistical analysis software 
ScS Screened Set 
SF seizure frequency 
SOC  system organ class  
SS Safety Set 
TEAE  treatment emergent adverse event 
TEMA treatment emergent markedly abnormal 
ULN  upper limit of normal 
VAS  visual analog scale 
VNS  vagus nerve stimulation 
WHO- DD World Health Organization Drug Dictionary REDACTED COPY proportional hazards regression
REDACTED COPY proportional hazards regression
Protocol Set
REDACTED COPY Protocol Set
preferred term
REDACTED COPY preferred term
Patient
REDACTED COPY Patient -
REDACTED COPY -Weighted Quality of Life in Epilepsy 
REDACTED COPY Weighted Quality of Life in Epilepsy 
Inventory
REDACTED COPY Inventory
Bazett corrected QTREDACTED COPY Bazett corrected QT
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.National Cancer Institute Common Terminology Criteria 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.National Cancer Institute Common Terminology Criteria 
clonic seizure
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.clonic seizure
proportional hazards regression
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.proportional hazards regression
preferred term
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.preferred term
Weighted Quality of Life in Epilepsy 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Weighted Quality of Life in Epilepsy 
Inventory
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Inventory -
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.-Form 31
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Form 31
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Bazett corrected QT
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Bazett corrected QT
Fridericia corrected QT
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Fridericia corrected QT
Randomized Set
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Randomized Set
TEAE
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.TEAE
TEMA
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.TEMA
ULN
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.ULN
UCB   28 Mar 2019  
Statistical Analysis Plan  SP0982  
1 INTRODUCTION  
The purpose of the statistical analysis plan (SAP) is to describe the analyses of study SP0982. 
2 PROTOCOL SUMMARY  
2.1 Study objectives 
2.1.1  Primary objective 
The primary study objective is to demonstrate the efficacy of oral lacosamide (LCM) vs placebo 
as adjunctive therapy for uncontrolled primary generalized tonic-clonic seizures (PGTCS) in subjects with idiopathic generalized epilepsy (IGE) currently taking 1 to 3 concomitant antiepileptic drugs (AEDs) independent of the number of prior failed AEDs. 
2.1.2  Secondary objective 
The secondary study objective is to assess the safety and tolerability of LCM in subjects with 
IGE with uncontrolled PGTCS. 
2.2 Study variables  
2.2.1  Efficacy variables  
2.2.1.1 Primary efficacy variable 
The primary efficacy variable is the time to the second PGTCS during the 24-week Treatment Period. 
2.2.1.2 Secondary efficacy variables 
The key secondary efficacy variable is: 
 Seizure freedom for PGTCS during the 24-week Treatment Period, estimated using Kaplan-
Meier analysis 
The other secondary efficacy variable is: 
  Time to first seizure during the 24-week Treatment Period 
2.2.1.3 Other efficacy variables 
Other efficacy variables are: 
 The percent change in PGTCS frequency per 28 days during the first 6 weeks of the 
Treatment Period (Titration Period) relative to the Combined Baseline Period (combined 12-
week Historical and 4-week Prospective Baseline Periods) 
 The percent change in PGTCS frequency per 28 days during the first 12 weeks of the 
Treatment Period relative to the Combined Baseline Period 
 The percent change in PGTCS frequency per 28 days during the Treatment Period relative to the Combined Baseline Period 
 Change in days with absence seizures per 28 days during the Treatment Period relative to the Prospective Baseline Period REDACTED COPY he time to the second PGTCS during the 24
REDACTED COPY he time to the second PGTCS during the 24
Secondary efficacy variables
REDACTED COPY Secondary efficacy variables
Seizure freedom for PGTCS during the 24 REDACTED COPY Seizure freedom for PGTCS during the 24
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.(LCM) vs placebo 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.(LCM) vs placebo 
clonic seizures (PGTCS) in 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.clonic seizures (PGTCS) in 
The secondary study objective is to assess the safety and tolerability of LCM in subjects with 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.The secondary study objective is to assess the safety and tolerability of LCM in subjects with 
he time to the second PGTCS during the 24
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.he time to the second PGTCS during the 24
Secondary efficacy variables
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Secondary efficacy variables
Seizure freedom for PGTCS during the 24
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Seizure freedom for PGTCS during the 24 week Treatment Period, estimated using Kaplan
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.week Treatment Period, estimated using Kaplan
efficacy variable is:
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.efficacy variable is:
Time to first seizure during the 24
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Time to first seizure during the 24
Other efficacy variables
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Other efficacy variables
Other efficacy variables are:
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Other efficacy variables are:
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.The percent change in PGTCS frequency per 28 days during the first 6 weeks of the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.The percent change in PGTCS frequency per 28 days during the first 6 weeks of the 
Treatment Period (Titration Period) re
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Treatment Period (Titration Period) re
week Historical and 4
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.week Historical and 4
The percent change in PGTCS frequency per 28 days during the first 12 weeks of the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.The percent change in PGTCS frequency per 28 days during the first 12 weeks of the 
Treatment Period relative to the Combined Baseline Period
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Treatment Period relative to the Combined Baseline Period

This document cannot be used to support any marketing authorization application and any extensions or variations thereof.The pe
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.The pe
UCB   28 Mar 2019  
Statistical Analysis Plan  SP0982  
 Percent change in days with absence seizures per 28 days during the first 6 weeks of the 
Treatment Period (Titration Period) relative to the Prospective Baseline Period 
 Percent change in days with absence seizures per 28 days during the Treatment Period relative to the Prospective Baseline Period 
 Percentage of subjects with at least a 50% reduction in absence seizure days compared to Prospective Baseline Period 
 Change in days with myoclonic seizures per 28 days during the Treatment Period relative to the Prospective Baseline Period 
 Percent change in days with myoclonic seizures per 28 days during the first 6 weeks of the 
Treatment Period (Titration Period) relative to the Prospective Baseline Period 
 Percent change in days with myoclonic seizures per 28 days during the Treatment Period 
relative to the Prospective Baseline Period 
 Percentage of subjects with at least a 50% reduction in myoclonic seizure days compared to Prospective Baseline Period 
 Seizure-free status (yes, no) for PGTCS for the first 12 weeks of the Treatment Period  
 Seizure-free status (yes, no) for PGTCS for the 24-week Treatment Period 
 Percentage of subjects with at least a 50% reduction in PGTCS frequency during the Titration Period compared to Combined Baseline Period 
 Percentage of subjects with at least a 50% reduction in PGTCS frequency during the first 12 
weeks of the Treatment Period compared to Combined Baseline Period 
 Percentage of subjects with at least a 50% reduction in PGTCS frequency during the 
Treatment Period compared to Combined Baseline Period 
 Seizu re-free status (yes, no) for all generalized seizure types for the first 12 weeks of the 
Treatment Period  
 Seizure-free status (yes, no) for all generalized seizure types for the 24-week Treatment 
Period  
 Change from Baseline in Patient-Weighted Quality of Life in Epilepsy Inventory-Form 31 
(QOLIE-31-P) subscale (Seizure Worry, Daily Activities/Social Functioning, Energy/Fatigue, Emotional Well-being, Mental Activity/Cognitive Functioning, Overall 
Quality of Life and Medication Effects) and total scores in subjects ≥18 years of age or 
change from Baseline in the Pediatric Quality of Life Inventory (PedsQL) subscale (Physical 
Functioning, Emotional Functioning, Social Functioning, and School Functioning) and total scores in subjects <18 years of age 
 Change from Baseline to end of treatment or early termination (ET) in the 3-Level EuroQol-5 
Dimension Quality of Life Assessment (EQ-5D-3L) visual analogue scale (VAS) score and change in utility as converted from the 5 dimensions (for subjects ≥12 years of age) 
 Healthcare resource use: medical procedures, hospitalizations, and healthcare provider visits 
 Number of working or school days lost by subject due to epilepsy REDACTED COPY week Treatment Period
REDACTED COPY week Treatment Period
Percentage of subjects with at least a 50% reduction in PGTCS frequency during the 
REDACTED COPY Percentage of subjects with at least a 50% reduction in PGTCS frequency during the 
Titration Period compared to Combined Baseline Period
REDACTED COPY Titration Period compared to Combined Baseline Period
Percentage of subjects with at least a 50% re
REDACTED COPY Percentage of subjects with at least a 50% re
weeks of the Treatment Period compared to Combined Baseline Period
REDACTED COPY weeks of the Treatment Period compared to Combined Baseline Period
Percentage of subjects with at least a 50% reduction in PGTCS frequency during the REDACTED COPY Percentage of subjects with at least a 50% reduction in PGTCS frequency during the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Change in days with myoclonic seizures per 28 days during the Treatment Period relative to 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Change in days with myoclonic seizures per 28 days during the Treatment Period relative to 
Percent change in days with myoclonic seizures per 28 days during the first 6 weeks of the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Percent change in days with myoclonic seizures per 28 days during the first 6 weeks of the 
Percent change in days with myoclonic seizures per 28 days during the Treatment P
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Percent change in days with myoclonic seizures per 28 days during the Treatment P
Percentage of subjects with at least a 50% reduction in myoclonic seizure days compared to 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Percentage of subjects with at least a 50% reduction in myoclonic seizure days compared to 
for the first 12 weeks of the Treatment Period 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.for the first 12 weeks of the Treatment Period 
week Treatment Period
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.week Treatment Period
Percentage of subjects with at least a 50% reduction in PGTCS frequency during the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Percentage of subjects with at least a 50% reduction in PGTCS frequency during the 
Titration Period compared to Combined Baseline Period
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Titration Period compared to Combined Baseline Period
Percentage of subjects with at least a 50% re
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Percentage of subjects with at least a 50% re duction in PGTCS frequency during the first 12 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.duction in PGTCS frequency during the first 12 
weeks of the Treatment Period compared to Combined Baseline Period
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.weeks of the Treatment Period compared to Combined Baseline Period
Percentage of subjects with at least a 50% reduction in PGTCS frequency during the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Percentage of subjects with at least a 50% reduction in PGTCS frequency during the 
Treatment Period compared to Combined Baseline Period
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Treatment Period compared to Combined Baseline Period
free status (yes, no) for all 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.free status (yes, no) for all generalized 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.generalized 
free status (yes, no) for all 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.free status (yes, no) for all 
Change from Baseline in Patient
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Change from Baseline in Patient
P) subscale (Seizure Worry, Daily Activities/Social Functioning, 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.P) subscale (Seizure Worry, Daily Activities/Social Functioning, 
Energy/Fatigue, Emotional Well
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Energy/Fatigue, Emotional Well
Quality of Life and Medication Effects) and total scores in 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Quality of Life and Medication Effects) and total scores in 
change from Baseline in the Pediatric Quality of Life Inventory (PedsQL) subscale (Physical 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.change from Baseline in the Pediatric Quality of Life Inventory (PedsQL) subscale (Physical 
Functioning, Emotional Functioning, Social Functioning, and School Functioning) and total 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Functioning, Emotional Functioning, Social Functioning, and School Functioning) and total 
scores in subjects <18 years of age
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.scores in subjects <18 years of age

This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Change fr
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Change fr
UCB   28 Mar 2019  
Statistical Analysis Plan  SP0982  
 Number of days with help from a caregiver due to epilepsy 
2.2.2  Safety variables  
The safety variable is: 
 Adverse events (AEs) as reported spontaneously by the subject and/or caregiver or observed 
by the investigator 
2.2.2.1 Other safety variables 
Other safety variables are: 
 Subject withdrawal due to AEs 
 Incidence of new seizure types during the Treatment Period 
 Subjects with an increase of up to 25%, >25% to 50%, >50% to 75%, and >75% in the days 
with absence seizures per 28 days during the Treatment Period relative to the Prospective 
Baseline 
 Subjects with an increase of up to 25%, >25% to 50%, >50% to 75%, and >75% in the days with myoclonic seizures per 28 days during the Treatment Period relative to the Prospective Baseline 
 Changes in hematology, chemistry, endocrinology, and urinalysis parameters 
 Changes in 12-lead electrocardiograms (ECGs) 
 Changes in vital sign measurements (ie, blood pressure [BP] and pulse rate) (including body weight and height) and physical and neurological examination findings 
 Behavioral assessment (Achenbach Child Behavior Checklist [CBCL]/1½-5 or CBCL/6-18) 
 Cognitive function assessment (Behavior Rating Inventory of Executive Function
®-Preschool 
Version [BRIEF-P] or Behavior Rating Inventory of Executive Function® [BRIEF]) for 
pediatric subjects only 
2.2.3  Pharmacokinetic variables 
The plasma concentrations of LCM will be assessed. 
2.3 Study design and conduct 
2.3.1  Study description 
SP0982 is a double-blind, randomized, placebo-controlled, parallel-group, multicenter study 
designed to assess the efficacy of oral LCM vs placebo as adjunctive therapy for uncontrolled PGTCS in subjects ≥4 years of age with IGE currently taking 1 to 3 concomitant AEDs independent of the number of prior failed AEDs.  
Up to 250 subjects across 150 to 180 sites in the US, Europe, Asia, and Australia, with possible 
extension to other countries and regions, are planned to be randomized in this study to see 125 
events. An event is the occurrence of each subject’s second PGTCS. The maximum duration of 
study medication administration is 28 weeks. The study will last a maximum of 36 weeks per subject.  REDACTED COPY Changes in hematology, chemistry, endocrinology, and urinalysis parameters
REDACTED COPY Changes in hematology, chemistry, endocrinology, and urinalysis parameters
lead electrocardiograms (ECGs)
REDACTED COPY lead electrocardiograms (ECGs)
measurements (ie, blood pressure [BP] and pulse rate) (including body 
REDACTED COPY measurements (ie, blood pressure [BP] and pulse rate) (including body 
weight and height) and physical and neurological examination findings
REDACTED COPY weight and height) and physical and neurological examination findings
Behavioral assessment (Achenbach Child Behavior Checklist [CBCL]/1½REDACTED COPY Behavioral assessment (Achenbach Child Behavior Checklist [CBCL]/1½
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.cts with an increase of up to 25%, >25% to 50%, >50% to 75%, and >75% in the days 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.cts with an increase of up to 25%, >25% to 50%, >50% to 75%, and >75% in the days 
with absence seizures per 28 days during the Treatment Period relative to the Prospective 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.with absence seizures per 28 days during the Treatment Period relative to the Prospective 
Subjects with an increase of up to 25%, >25% to 50%, >50% to 75%, and >75% 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Subjects with an increase of up to 25%, >25% to 50%, >50% to 75%, and >75% 
with myoclonic seizures per 28 days during the Treatment Period relative to the Prospective 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.with myoclonic seizures per 28 days during the Treatment Period relative to the Prospective 
Changes in hematology, chemistry, endocrinology, and urinalysis parameters
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Changes in hematology, chemistry, endocrinology, and urinalysis parameters
measurements (ie, blood pressure [BP] and pulse rate) (including body 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.measurements (ie, blood pressure [BP] and pulse rate) (including body 
weight and height) and physical and neurological examination findings
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.weight and height) and physical and neurological examination findings
Behavioral assessment (Achenbach Child Behavior Checklist [CBCL]/1½
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Behavioral assessment (Achenbach Child Behavior Checklist [CBCL]/1½
ehavior Rating Inventory of Executive Function
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.ehavior Rating Inventory of Executive Function
P] or Behavior Rating Inventory of Executive Function
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.P] or Behavior Rating Inventory of Executive Function
Pharmacokinetic variables
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Pharmacokinetic variables
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.The plasma concentrations of LCM will be assessed.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.The plasma concentrations of LCM will be assessed.
Study design a
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Study design a
Study description
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Study description
SP0982 is a double
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.SP0982 is a double
designed to assess the efficacy of oral LCM vs placebo as adjunctive therapy for uncontrolled 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.designed to assess the efficacy of oral LCM vs placebo as adjunctive therapy for uncontrolled 
PGTCS in subjects ≥4 years of age with IG
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.PGTCS in subjects ≥4 years of age with IG
independent of the number of prior failed AEDs. 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.independent of the number of prior failed AEDs. 
Up to 250 subjects across 150 to 180 sites in the US, Europe, Asia, and Australia, with possible 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Up to 250 subjects across 150 to 180 sites in the US, Europe, Asia, and Australia, with possible 
extension to other countries and regions, are planned to be randomi
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.extension to other countries and regions, are planned to be randomi
UCB   28 Mar 2019  
Statistical Analysis Plan  SP0982  
Eligibility to enter SP0982 will be based on a 12-week Historical Baseline prior to screening at 
Visit 1. In rare cases where there is a gap between consenting and Visit 1 procedures, the 12-
week Historical Baseline will be calculated from the date of Informed Consent/Assent.  
Prior to randomization, the following 3 criteria concerning PGTCS frequency must be met: 
 The subject must have experience at least 3 PGTCS during the 16-week Combined Baseline 
Period, 
 The subject must have experienced at least 2 PGTCS during the 12-week Historical Baseline 
Period, 
 Of the above seizures, at least 1 PGTCS should have occurred during the first 8 weeks and at least 1 PGTC seizure should have occurred during the second 8 weeks of the 16-week 
Combined Baseline Period. 
Examples of different scenarios and the subjects’ eligibility in terms of Baseline Period PGTCS 
are presented in Table 1 . Seizures reported on the Historical Seizure Count CRF with 
incomplete dates will be assumed to have occurred with the 12-week Historical Baseline Period 
when checking eligibility for the study and inclusion in baseline PGTCS frequency per 28 days. 
Table 1: Number of PGTC Seizures for Study Entry 
Number of PGTCS for Study Entry Subject Eligible for 
Study? Historical Baseline 
Weeks -16 to -9 Historical Baseline 
Weeks -8 to -5  Prospective Baseline 
Weeks -4 to 0  
(Visit 1 to Visit 2)  
2 1 0 Yes 
3 0 0 No 
1 1 1 Yes 
0 2 1 No 
1 2 0 Yes 
2 0 1 Yes 
1 0 2 No 
1 1 0 No 
The study consists of a 4-week Prospective Baseline Period and a 6-week (minimum) to 24-week 
(maximum) Treatment Period, which includes a 6-week Titration Period and an 18-week 
(maximum) Maintenance Period. Eligible subjects who choose to enter the open-label extension 
study (EP0012) after the completion of Visit 10 (Week 24) or the ET Visit will complete a 4-week blinded transition. Subjects who choose not to continue in EP0012 must complete an up to 4-week blinded taper followed by a 30-day Safety Follow-up Period. 
At the end of the 4-week Prospective Baseline (Visit 2), eligible subjects will be randomized to 
receive LCM or placebo in a 1:1 fashion (active:placebo) and stratified by Baseline PGTCS frequency (≤2 per 28 days vs >2 per 28 days for the 16 week Combined Baseline Period prior to 
randomization) and by age at informed consent (≥4 to <12 years of age vs ≥12 to <18 years of REDACTED COPY Number of PGTCS for Study Entry
REDACTED COPY Number of PGTCS for Study Entry
REDACTED COPY Prospective Baseline
REDACTED COPY Prospective Baseline
REDACTED COPY REDACTED COPY REDACTED COPY REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.line 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.line 
Of the above seizures, at least 1 PGTCS should have occurred during the first 8 weeks and at 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Of the above seizures, at least 1 PGTCS should have occurred during the first 8 weeks and at 
least 1 PGTC seizure should have occurred during the second 8 weeks of the 16
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.least 1 PGTC seizure should have occurred during the second 8 weeks of the 16 -
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.-week 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.week 
ubjects’ eligibility in terms of Baseline Period PGTCS 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.ubjects’ eligibility in terms of Baseline Period PGTCS 
Seizures reported on the Historical Seizure Count CRF with 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Seizures reported on the Historical Seizure Count CRF with 
week Historical Baseline Period 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.week Historical Baseline Period 
when checking eligibility for the study and inclusion in baseline PGTCS frequency per 28 days.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.when checking eligibility for the study and inclusion in baseline PGTCS frequency per 28 days.
Number of PGTC Seizures for Study Entry
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Number of PGTC Seizures for Study Entry
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Prospective Baseline
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Prospective Baseline
Weeks 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Weeks 
(Visit 1 to Visit 2)
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.(Visit 1 to Visit 2)
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.1
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.1
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.2
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.2
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.The study consists of a 4
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.The study consists of a 4
(maximum) Treatment Period, which includes a 6
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.(maximum) Treatment Period, which includes a 6
(maximum) Maintenance Period. Eligible subjects who choose to
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.(maximum) Maintenance Period. Eligible subjects who choose to
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.study (EP0012) after the completion of Visit 10 (Week 24) or the ET Visit will complete a 4
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.study (EP0012) after the completion of Visit 10 (Week 24) or the ET Visit will complete a 4
week blinded transition. Subjects who choose not to continue in EP0012 must complete an up to 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.week blinded transition. Subjects who choose not to continue in EP0012 must complete an up to 
4
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.4week blinded taper followed by a 30
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.week blinded taper followed by a 30
UCB   28 Mar 2019  
Statistical Analysis Plan  SP0982  
age, and ≥18 years of age). The Treatment Period starts at the time of the Randomization Visit 
(Visit 2). 
The Treatment Period continues until 1 of the following occurs (whichever occurs first): 
 Completion of ≥6 weeks of the Treatment Period and occurrence of ≥2 PGTCS 
 Completion of 24 weeks of the Treatment Period without occurrence of 2 PGTCS 
 Occurrence of the 125th event (an event is each subject’s 2nd second PGTCS). 
Subjects will be required to exit the study and complete the ET Visit if either of the following 
events occur: 
 Subject completes the first 6 weeks of the Treatment Period (after randomization) and 
experiences ≥2 PGTCS during that time 
 Subject experiences a second PGTCS after the first 6 weeks of the Treatment Period 
If the 125th event occurs while the subject is still participating in the study, the subject can: 
 Complete the Visit 10 (Week 24) or ET Visit (if the next scheduled visit is not Visit 10) and 
choose to continue in EP0012 by completing a blinded transition followed by a Final Clinic 
Visit. 
 Discontinue from the study by completing the Visit 10 (Week 24) or ET Visit (if the next scheduled visit is not Visit 10) and an up to 4-week blinded taper followed by an End of Taper visit.  
The study design is discussed in more detail in Section 5 of the protocol. 
2.3.2  Rationale for study design 
Clinical experience has shown that up to 30% of patients with PGTCS who are treated with 
currently available AEDs have insufficient PGTCS control or unacceptable drug tolerability.  
Thus, there is a significant unmet medical need for new treatment options in this patient population.  
The primary efficacy variable, the time to the second PGTCS, has several advantages from a 
clinical and methodological perspective. In traditional adjunctive study designs, the primary endpoint is percent reduction in PGTCS frequency over the entire Treatment Period; which 
requires a higher frequency of PGTCS at entry. Using the time to second PGTCS, the frequency 
of Baseline PGTCS and the duration of the Prospective Baseline can be reduced as the endpoint is time to reach an event (second PGTCS), rather than a percentage decrease in the number of 
events (PGTCS). This expands the patient population under study and allows for enrollment of 
subjects more representative of the broader PGTCS population. Furthermore, subjects are treated for up to 24 weeks in a traditional adjunctive design, depending upon the titration schedule of the 
active treatment. Subjects must remain on treatment as they continue to experience PGTCS. In 
the time to nth seizure design, subjects are required to remain in the study for a minimum of 6 weeks. If a subject experiences ≥2 PGTCS while on treatment, then after 6 weeks the subject 
exits the study, rather than continuing to have PGTCS, while remaining eligible to receive LCM 
in the open-label extension study (EP0012). REDACTED COPY Discontinue from the study by completing the Visit 10 (Week 24) or ET Visit (if the next 
REDACTED COPY Discontinue from the study by completing the Visit 10 (Week 24) or ET Visit (if the next 
week blinded taper followed by an End of 
REDACTED COPY week blinded taper followed by an End of 
The study design is discussed in more detail in Section 5 of the protocol.
REDACTED COPY The study design is discussed in more detail in Section 5 of the protocol.
Rationale for study design
REDACTED COPY Rationale for study design
Clinical experience has shown that up to 30% of patients with PREDACTED COPY Clinical experience has shown that up to 30% of patients with P
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Subjects will be required to exit the study and complete the ET Visit if either of the following 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Subjects will be required to exit the study and complete the ET Visit if either of the following 
Subject completes the first 6 weeks of the Treatment Period (after randomization) and 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Subject completes the first 6 weeks of the Treatment Period (after randomization) and 
Subject experiences a second PGTCS after the first 6 weeks of the Treatment Period
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Subject experiences a second PGTCS after the first 6 weeks of the Treatment Period
event occurs while the subject is still participating in the study, the subject can:
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.event occurs while the subject is still participating in the study, the subject can:
Visit (if the next scheduled visit is not Visit 10) and 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Visit (if the next scheduled visit is not Visit 10) and 
choose to continue in EP0012 by completing a blinded transition followed by a Final Clinic 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.choose to continue in EP0012 by completing a blinded transition followed by a Final Clinic 
Discontinue from the study by completing the Visit 10 (Week 24) or ET Visit (if the next 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Discontinue from the study by completing the Visit 10 (Week 24) or ET Visit (if the next 
week blinded taper followed by an End of 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.week blinded taper followed by an End of 
The study design is discussed in more detail in Section 5 of the protocol.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.The study design is discussed in more detail in Section 5 of the protocol.
Rationale for study design
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Rationale for study design
Clinical experience has shown that up to 30% of patients with P
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Clinical experience has shown that up to 30% of patients with P
currently available AEDs have insufficient PGTCS control or unacceptable drug tolerability.  
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.currently available AEDs have insufficient PGTCS control or unacceptable drug tolerability.  
Thus, there is a significant unmet medical need for new treatment options in this patient 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Thus, there is a significant unmet medical need for new treatment options in this patient 
The primary efficacy variable, the
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.The primary efficacy variable, the
clinical and methodological perspective. In traditional adjunctive study designs, the primary 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.clinical and methodological perspective. In traditional adjunctive study designs, the primary 
endpoint is percent reduction in PGTCS frequency over the entire Treatment Period; which 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.endpoint is percent reduction in PGTCS frequency over the entire Treatment Period; which 
r frequency of PGTCS at entry. Using the time to second PGTCS, the frequency 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.r frequency of PGTCS at entry. Using the time to second PGTCS, the frequency 
of Baseline PGTCS and the duration of the Prospective Baseline can be reduced as the endpoint 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.of Baseline PGTCS and the duration of the Prospective Baseline can be reduced as the endpoint 
is time to reach an event (second PGTCS), rather than a percentage decrease in the nu
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.is time to reach an event (second PGTCS), rather than a percentage decrease in the nu
events (PGTCS). This expands the patient population under study and allows for enrollment of 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.events (PGTCS). This expands the patient population under study and allows for enrollment of 
subjects more representative of the broader PGTCS population. Furthermore, subjects are treated 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.subjects more representative of the broader PGTCS population. Furthermore, subjects are treated 
for up to 24 weeks in a traditional adjunctive design, depe
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.for up to 24 weeks in a traditional adjunctive design, depe
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.active treatment. Subjects must remain on treatment as they continue to experience PGTCS. In 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.active treatment. Subjects must remain on treatment as they continue to experience PGTCS. In 
the time to nth seizure design, subjects are required to remain in the study for a minimum of 6 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.the time to nth seizure design, subjects are required to remain in the study for a minimum of 6 
weeks. If a subject experi
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.weeks. If a subject experi
UCB   28 Mar 2019  
Statistical Analysis Plan  SP0982  
The rationale for time to second PGTCS was established by using data from an adjunctive study 
in subjects with PGTCS, using an 8-week Baseline, 7-week Titration, and 12-week Maintenance 
Period comparing lamotrigine and placebo (French et al, 2007). This post-hoc analysis using a Cox proportional hazards model revealed that time to third PGTCS was statistically significant 
with a hazard ratio of 0.533 (lamotrigine 48.2%, placebo 25.4%). Lamotrigine requires a long 
Titration Period, where a minimally effective dose is not reached until the fifth week of the Titration Period (100mg/day). Lacosamide, by comparison, reaches a minimally effective dose in 
the second week (200mg/day) for a majority of trial subjects. Since a majority of the events in 
the lamotrigine study occurred before Day 21, it is likely that fewer events would occur using LCM as it reaches an effective dose earlier; therefore, time to second PGTCS was chosen as a reasonable endpoint from a clinical and statistical perspective. 
2.4 Determination of sample size 
Observing 125 events (subjects who had a second PGTCS during the 24-week Treatment Period) 
will provide 90% power to observe a hazard ratio of 0.56 at the 2-sided 5% level, assuming a 
dropout rate of 15%. The observed hazard ratio was based on a 25.4% survival rate for placebo and 48.2% for lamotrigine from a previous study comparing lamotrigine and placebo (French et 
al, 2007). The observed hazard ratio in the lamotrigine study was 0.533; however, in order to 
account for the possibility of an increased placebo response, as has been documented in recent clinical studies of AEDs, the hazard ratio was increased by 5% to 0.56 for estimating a sample 
size for this study. The rationale for the increase in the hazard ratio included the following 
considerations: different active compounds (LCM and lamotrigine) and a choice of time to second PGTCS as the primary efficacy endpoint (in the lamotrigine study, percent change in PGTCS frequency was the primary endpoint).  
This is an event-driven study. Enrollment in the study will continue up to 125 events occurring 
or a maximum of 250 subjects randomized, whichever comes first.  
3 DATA ANALYSIS CONSID ERATIONS  
3.1 General presentation of summaries and analyses 
Statistical analysis and generation of tables, figures, subject data listings, and statistical output 
will be performed using SAS® Version 9.4 or higher. All tables and listings will use Courier New font size 9. 
Descriptive statistics will be used to provide an overview of the primary, secondary, and other 
variable results. For categorical parameters, the number and percentage of subjects in each 
category will be presented. The denominator for percentages will be based on the number of 
subjects appropriate for the purpose of the analysis. Unless otherwise noted, all percentages will 
be displayed to 1 decimal place. No percentage will be displayed for zero counts, and no decimal 
will be presented when the percentage is 100%. For continuous parameters, descriptive statistics 
will include number of subjects, mean, standard deviation, median, minimum, and maximum.  
Decimal places for descriptive statistics will always apply the following rules: 
 “n” will be an integer 
 Mean, SD and median will use 1 additional decimal place compared to the original data. 
 Minimum and maximum will have the same number of decimal places as the original value. REDACTED COPY clinical studies of AEDs, the hazard ratio was increased by 5% to 0.56 for estimating a sample 
REDACTED COPY clinical studies of AEDs, the hazard ratio was increased by 5% to 0.56 for estimating a sample 
size for this study. The rationale for the increase in the hazard ratio included the following 
REDACTED COPY size for this study. The rationale for the increase in the hazard ratio included the following 
considerations: different active compounds (LCM and lamotr
REDACTED COPY considerations: different active compounds (LCM and lamotr
second PGTCS as the primary efficacy endpoint (in the lamotrigine study, percent change in 
REDACTED COPY second PGTCS as the primary efficacy endpoint (in the lamotrigine study, percent change in 
PGTCS frequency was the primary endpoint). 
REDACTED COPY PGTCS frequency was the primary endpoint). 
driven study. Enrollment in the study will continue up to 125 events occu
REDACTED COPY driven study. Enrollment in the study will continue up to 125 events occu
or a maximum of 250 subjects randomized, whichever comes first. REDACTED COPY or a maximum of 250 subjects randomized, whichever comes first. 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.itration Period (100mg/day). Lacosamide, by comparison, reaches a minimally effective dose in 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.itration Period (100mg/day). Lacosamide, by comparison, reaches a minimally effective dose in 
wer events would occur using 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.wer events would occur using 
LCM as it reaches an effective dose earlier; therefore, time to second PGTCS was chosen as a 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.LCM as it reaches an effective dose earlier; therefore, time to second PGTCS was chosen as a 
week Treatment Period) 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.week Treatment Period) 
sided 5% level, assuming a 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.sided 5% level, assuming a 
dropout rate of 15%. The observed hazard ratio was based on a 25.4% survival rate for placebo 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.dropout rate of 15%. The observed hazard ratio was based on a 25.4% survival rate for placebo 
trigine from a previous study comparing lamotrigine and placebo (French et 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.trigine from a previous study comparing lamotrigine and placebo (French et 
al, 2007). The observed hazard ratio in the lamotrigine study was 0.533; however, in order to 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.al, 2007). The observed hazard ratio in the lamotrigine study was 0.533; however, in order to 
account for the possibility of an increased placebo response, as has been documented in
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.account for the possibility of an increased placebo response, as has been documented in
clinical studies of AEDs, the hazard ratio was increased by 5% to 0.56 for estimating a sample 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.clinical studies of AEDs, the hazard ratio was increased by 5% to 0.56 for estimating a sample 
size for this study. The rationale for the increase in the hazard ratio included the following 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.size for this study. The rationale for the increase in the hazard ratio included the following 
considerations: different active compounds (LCM and lamotr
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.considerations: different active compounds (LCM and lamotr
second PGTCS as the primary efficacy endpoint (in the lamotrigine study, percent change in 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.second PGTCS as the primary efficacy endpoint (in the lamotrigine study, percent change in 
driven study. Enrollment in the study will continue up to 125 events occu
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.driven study. Enrollment in the study will continue up to 125 events occu
or a maximum of 250 subjects randomized, whichever comes first. 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.or a maximum of 250 subjects randomized, whichever comes first. 
DATA ANALYSIS CONSID
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.DATA ANALYSIS CONSID
General presentation of summaries and analyses
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.General presentation of summaries and analyses
Statistical analysis and generation of tables, figures, subject data listings, and statistical output 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Statistical analysis and generation of tables, figures, subject data listings, and statistical output 
performed using SAS® Version 9.4 or higher. All tables and listings will use Courier 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.performed using SAS® Version 9.4 or higher. All tables and listings will use Courier 
Descriptive statistics will be used to provide an overview of the primary, secondary, and other 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Descriptive statistics will be used to provide an overview of the primary, secondary, and other 
variable results. For categorical parameters, the number 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.variable results. For categorical parameters, the number 
category will be presented. The denominator for percentages will be based on the number of 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.category will be presented. The denominator for percentages will be based on the number of 
subjects appropriate for the purpose of the analysis. Unless otherwise noted, all percentages will 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.subjects appropriate for the purpose of the analysis. Unless otherwise noted, all percentages will 
be displayed to 1 decimal place
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.be displayed to 1 decimal place
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.will be presented when the percentage is 100%. For continuous parameters, descriptive statistics 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.will be presented when the percentage is 100%. For continuous parameters, descriptive statistics 
will include number of subjects, mean, standard deviation, median, minimum, and maximum. 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.will include number of subjects, mean, standard deviation, median, minimum, and maximum. 
Dec
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Dec
UCB   28 Mar 2019  
Statistical Analysis Plan  SP0982  
By-visit summaries will not include data from unscheduled clinic visits unless otherwise stated. 
Data provided at these visits will be included in subject data listings. A complete set of data 
listings containing all documented data and all calculated data (eg, change from Baseline) will be generated.  
3.2 General study level definitions 
3.2.1  Analysis time points 
The following study periods will be defined for analyses:  
 Historical Baseline Period: This period starts 84 days prior to Visit 1 and ends the day before 
Visit 1. This is expected to be 12 weeks in duration. 
 Prospective Baseline Period: This period starts the date of Visit 1 and ends the day before 
Visit 2. This is expected to be 4 weeks in duration. 
 Combined Baseline Period: combined Historical and Prospective Baseline Periods. This 
Period starts 84 days prior to Visit 1 and ends the day before Visit 2. This is expected to be 
16 weeks in duration. 
 Treatment Period: 24-week period following the 4-week Prospective Baseline. The Treatment Period is composed of the Titration Period and the Maintenance Period. 
 Titration Period: 6-week period following the 4-week Prospective Baseline. The Titration Period starts on the date of the Randomization Visit (Visit 2) and ends on the day before 
Visit 5 (or the date of the Early Termination (ET) visit in the situation where a subject 
discontinues prior to the last visit in the Titration Period). 
 Maintenance Period: 18-week period following the 6-week Titration Period. The 
Maintenance Period starts on the day of Visit 5 and continues until 1 of the following occurs (whichever occurs first): 
◦ Completion of ≥6 weeks of the Treatment Period, occurrence of ≥2 PGTC seizures 
and completion of the ET Visit 
◦ Completion of 18 weeks (Visit 10) of the Maintenance Period without occurrence of 2 PGTC seizures. 
 First 12 weeks: this is defined as the Titration Period + the first 6 weeks of the Maintenance Period. 
 Transition Period: up to 4-week period after the completion of Visit 10 (Week 24) or the ET 
Visit for subjects who choose to enter EP0012. The Transition Period starts the day after 
Visit 10 (Week 24) or the ET Visit and continues until 1 of the following occurs (whichever occurs first): 
◦ On the day before the first date that there is a dose decrease (subject enters Taper period) 
◦ On the date of the Final Clinic Visit (also date of EP0012 Visit 1). 
 Taper Period: up to 4-week period following either the Treatment Period for subjects who discontinue from the study at any time and are not eligible or choose not to enter EP0012 or REDACTED COPY eriod is composed of the Titration Period and the Maintenance Period.
REDACTED COPY eriod is composed of the Titration Period and the Maintenance Period.
week period following the 4
REDACTED COPY week period following the 4 -
REDACTED COPY -week Prospective Baseline. The Titration 
REDACTED COPY week Prospective Baseline. The Titration 
Period starts on the date of the Randomization Visit (Visit 2) and ends on the day before 
REDACTED COPY Period starts on the date of the Randomization Visit (Visit 2) and ends on the day before 
(or the date of the Early Termination (ET) visit in the situation where a subject 
REDACTED COPY (or the date of the Early Termination (ET) visit in the situation where a subject 
discontinues prior to the last visit in the Titration Period).
REDACTED COPY discontinues prior to the last visit in the Titration Period).
REDACTED COPY week period following the 6
REDACTED COPY week period following the 6
Maintenance Period starts on the REDACTED COPY Maintenance Period starts on the day of Visit 5 and continues until 1 of the following REDACTED COPY day of Visit 5 and continues until 1 of the following 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.ends the day before 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.ends the day before 
Prospective Baseline Period: This period starts the date of Visit 1 and ends the day before 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Prospective Baseline Period: This period starts the date of Visit 1 and ends the day before 
storical and Prospective Baseline Periods. This 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.storical and Prospective Baseline Periods. This 
Period starts 84 days prior to Visit 1 and ends the day before Visit 2. This is expected to be 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Period starts 84 days prior to Visit 1 and ends the day before Visit 2. This is expected to be 
week Prospective Baseline. The 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.week Prospective Baseline. The 
eriod is composed of the Titration Period and the Maintenance Period.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.eriod is composed of the Titration Period and the Maintenance Period.
week Prospective Baseline. The Titration 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.week Prospective Baseline. The Titration 
Period starts on the date of the Randomization Visit (Visit 2) and ends on the day before 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Period starts on the date of the Randomization Visit (Visit 2) and ends on the day before 
(or the date of the Early Termination (ET) visit in the situation where a subject 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.(or the date of the Early Termination (ET) visit in the situation where a subject 
discontinues prior to the last visit in the Titration Period).
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.discontinues prior to the last visit in the Titration Period).
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.week period following the 6
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.week period following the 6
day of Visit 5 and continues until 1 of the following 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.day of Visit 5 and continues until 1 of the following 
occurs (whichever occurs first):
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.occurs (whichever occurs first):
Completion of ≥6 weeks of the Treatment Period, occurrence of ≥2 PGTC seizures 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Completion of ≥6 weeks of the Treatment Period, occurrence of ≥2 PGTC seizures 
and completion of the ET Visit
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.and completion of the ET Visit
Completion of 18 weeks (Visit 10) of the Maintenance Perio
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Completion of 18 weeks (Visit 10) of the Maintenance Perio
2 PGTC seizures.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.2 PGTC seizures.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.First 12 weeks: this is defined as the Titration Period + the first 6 weeks of the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.First 12 weeks: this is defined as the Titration Period + the first 6 weeks of the 
Maintenance Period.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Maintenance Period.
Transition Period: up to 4
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Transition Period: up to 4
Visit for subjects w
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Visit for subjects w
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Visit 10 (Week 24) or the ET Visit and continues until 1 of the following occurs (whichever 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Visit 10 (Week 24) or the ET Visit and continues until 1 of the following occurs (whichever 
occurs first):
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.occurs first):
UCB   28 Mar 2019  
Statistical Analysis Plan  SP0982  
following the Transition Period for subjects that discontinue from the study during the 
Transition Period. The Taper Period starts the first date that there is a dose decrease or the 
day after the ET Visit for subjects that choose not to enter EP0012 and continues until the date of last dose of study medication.  
 Safety Follow-up Period: period following the Taper Period for subjects who complete the Taper Period. The Safety Follow-up Period starts the day after the last dose of study 
medication and continues until the Final Clinic Visit date or the Safety Follow-up telephone 
contact date, whichever is later. 
3.2.2  Seizure cluster  
If a seizure cluster is reported, it will be assigned to the International League Against Epilepsy (ILAE) seizure type reported and the frequency will be set to 2 times the number of clusters 
reported. 
3.2.3  Event  
In the primary efficacy analysis, an event for analysis purposes is: 
 The 2
nd PGTCS  
While keeping in mind the definition of seizure clusters in Section 3.2.2. 
For the primary and secondary efficacy analyses, these endpoints will be assessed using the at 
most the first 166 days, which is the 24-week Treatment Period minus a protocol-allowed 2 day 
window.  For all other efficacy parameters, all data reported during the Treatment Period will be used in the analysis. 
The primary efficacy endpoint, time to event, is defined as the “stop date” - the date of first dose 
of study drug + 1 day where the “stop date” is the first of the following to occur: 
 date of the event,  
 date of the premature discontinuation,  
 date of last dose of study medication in the Treatment Period, 
 date of the completion of the Treatment Period,  
 date of the 125
th event,  
 Day 166 
The same algorithm applies for the other secondary endpoint, where time to event, is replaced by 
time to 1st PGTCS.  
3.2.4  Censoring 
For the primary and secondary efficacy analyses, a Treatment Period of 166 days will be utilized. 
The censoring for the primary efficacy analysis will be as follows: 
 Subjects who complete the Treatment Period without having an event during the Treatment 
Period will be censored as of Day 167.  REDACTED COPY these endpoints will be assessed using the at 
REDACTED COPY these endpoints will be assessed using the at 
week Treatment Period minus a protocol
REDACTED COPY week Treatment Period minus a protocol
For all other efficacy parameters, all data report
REDACTED COPY For all other efficacy parameters, all data report
The primary efficacy endpoint, time to event, is defined as the “stop date” 
REDACTED COPY The primary efficacy endpoint, time to event, is defined as the “stop date” 
of study drug + 1 day where the “stop date” is the first of the following to occur:REDACTED COPY of study drug + 1 day where the “stop date” is the first of the following to occur:
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.up telephone 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.up telephone 
If a seizure cluster is reported, it will be assigned to the International League Against Epilepsy 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.If a seizure cluster is reported, it will be assigned to the International League Against Epilepsy 
(ILAE) seizure type reported and the frequency will be set to 2 times the number of clusters 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.(ILAE) seizure type reported and the frequency will be set to 2 times the number of clusters 
in Section
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.in Section 3.2.2
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.3.2.2
these endpoints will be assessed using the at 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.these endpoints will be assessed using the at 
week Treatment Period minus a protocol
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.week Treatment Period minus a protocol
For all other efficacy parameters, all data report
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.For all other efficacy parameters, all data report ed during the Treatment Period will be 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.ed during the Treatment Period will be 
The primary efficacy endpoint, time to event, is defined as the “stop date” 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.The primary efficacy endpoint, time to event, is defined as the “stop date” 
of study drug + 1 day where the “stop date” is the first of the following to occur:
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.of study drug + 1 day where the “stop date” is the first of the following to occur:
date of the premature discontinuation, 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.date of the premature discontinuation, 
ose of study medication in the T
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.ose of study medication in the T
date of the completion of the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.date of the completion of the 
event, 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.event, 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.The same algorithm applies for the other secondary
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.The same algorithm applies for the other secondary
PGTCS.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.PGTCS.
3.2.4
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.3.2.4
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.For the primary and secondary efficacy analyses, a Treatment Period of 166 days will be utilized. 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.For the primary and secondary efficacy analyses, a Treatment Period of 166 days will be utilized. 
The censoring for the primary efficacy analysis will be as follows:
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.The censoring for the primary efficacy analysis will be as follows:
UCB   28 Mar 2019  
Statistical Analysis Plan  SP0982  
 If the subject’s Treatment Period participation is less than or equal to 166 days (premature 
discontinuation), their PGTCS information will be censored on the date after the last dose of study drug.  
 If the subject’s Treatment Period participation is greater than 166 days, their PGTCS information will be censored as of Day 167.  
 For the subjects who are ongoing in the study when the 125
th event occurs, their PGTCS 
information for the primary efficacy endpoint analysis will be censored as of the day after the 125
th event, even if the subjects experience an event after the date of the 125th event but 
before 166 days of treatment is completed. 
 Only 125 events will be included in the primary efficacy endpoint analyses. In case of ties on 
the same date in reporting the 125th event, the first event reported to IRT will be deemed the 
125th event.  Data after the 125th event will be censored. 
Censoring for time to 1st PGTCS  will be calculated in a similar manner, except using the date of 
the 1st PGTCS instead of the date of the event. For subjects who are ongoing in the study when 
the 125th event occurs, the time to 1st PGTCS information will be censored in the same manner 
as the time to event information (ie., censor all PGTCS information beyond the date of the 125th 
event). 
3.2.5  AEDs and benzodiazepines 
AEDs and benzodiazepines (medications used for rescue) will be collected on the concomitant 
and prior medication case report form (CRF) for AEDs. At study entry, a subject should be 
taking a stable dose of 1 to 2 non-benzodiazepines marketed AEDs or 2 to 3 AEDs (with only 1 
of the AEDs is identified as a benzodiazepine). This dosing regimen must be stable for at least 28 
days prior to Visit 1. The subject must maintain this AED dosing regimen throughout the 
Prospective Baseline and the Treatment Period with or without additional concurrent stable 
VNS. Vagus nerve stimulation must have been in place for at least 6 months prior to Visit 1 with constant settings for at least 28 days prior to Visit 1 and must remain unchanged during the Treatment Period. 
AEDs at study entry are defined as AEDs where the start date is on or before 28 days prior to 
Visit 1 and the medication was still ongoing on the date of Visit 1. Lifetime AEDs are defined as AEDs taken in the subject’s history and stopped at least 28 days prior to Visit 1. 
Benzodiazepines taken for rescue will be flagged with “RESCUE” in the indication field on the 
CRF, although rescue AEDs  will also be identified programmatically as any AED taken 
intermittently for 1 or 2 days, at any frequency, with an epilepsy or seizure related indication. 
Rescue medication is defined as the intermittent use of benzodiazepines (limited to 2 doses per 
28 days) for epilepsy indications if established at least 28 days prior to Visit 1.  Lifetime 
benzodiazepines are defined as benzodiazepines taken in the subject’s history and stopped at 
least 28 days prior to Visit 1. 
3.2.5.1 Prohibited concomitant treatments (medications and therapies) 
The following medications/therapies are prohibited during the Treatment Period: 
 Clozapine REDACTED COPY AEDs and benzodiazepines (medications used for rescue) will be collected on the concomitant 
REDACTED COPY AEDs and benzodiazepines (medications used for rescue) will be collected on the concomitant 
tion case report form (CRF) for AEDs. At study entry, a subject should be 
REDACTED COPY tion case report form (CRF) for AEDs. At study entry, a subject should be 
benzodiazepines marketed AEDs or 2 to 3 AEDs (with only 1 
REDACTED COPY benzodiazepines marketed AEDs or 2 to 3 AEDs (with only 1 
of the AEDs is identified as a benzodiazepine). This dosing regimen must be stable for at
REDACTED COPY of the AEDs is identified as a benzodiazepine). This dosing regimen must be stable for at
days prior to Visit 1. The subject must maintain this AED dosing regimen throughout the REDACTED COPY days prior to Visit 1. The subject must maintain this AED dosing regimen throughout the 
Prospective Baseline and the Treatment Period with or without additional concurrent stable REDACTED COPY Prospective Baseline and the Treatment Period with or without additional concurrent stable 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.will be censored as of the day after the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.will be censored as of the day after the 
125 events will be included in the primary efficacy endpoint analyses. In case of ties on 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.125 events will be included in the primary efficacy endpoint analyses. In case of ties on 
event, the first event reported to IRT will be deemed the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.event, the first event reported to IRT will be deemed the 
will be calculated in a similar manner, except using the date of 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.will be calculated in a similar manner, except using the date of 
For subjects who are ongoing in the study when 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.For subjects who are ongoing in the study when 
PGTCS information will be censored i
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.PGTCS information will be censored i
as the time to event information (ie., censor all PGTCS information beyond the date of the 125
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.as the time to event information (ie., censor all PGTCS information beyond the date of the 125
AEDs and benzodiazepines (medications used for rescue) will be collected on the concomitant 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.AEDs and benzodiazepines (medications used for rescue) will be collected on the concomitant 
tion case report form (CRF) for AEDs. At study entry, a subject should be 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.tion case report form (CRF) for AEDs. At study entry, a subject should be 
benzodiazepines marketed AEDs or 2 to 3 AEDs (with only 1 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.benzodiazepines marketed AEDs or 2 to 3 AEDs (with only 1 
of the AEDs is identified as a benzodiazepine). This dosing regimen must be stable for at
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.of the AEDs is identified as a benzodiazepine). This dosing regimen must be stable for at
days prior to Visit 1. The subject must maintain this AED dosing regimen throughout the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.days prior to Visit 1. The subject must maintain this AED dosing regimen throughout the 
Prospective Baseline and the Treatment Period with or without additional concurrent stable 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Prospective Baseline and the Treatment Period with or without additional concurrent stable 
VNS. Vagus nerve stimulation must have been in place for at least 6
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.VNS. Vagus nerve stimulation must have been in place for at least 6
constant settings for at least 28 days prior to Visit 1 and must remain unchanged during the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.constant settings for at least 28 days prior to Visit 1 and must remain unchanged during the 
AEDs at study entry are defined as AEDs where the start date is on or before 28 days prior to 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.AEDs at study entry are defined as AEDs where the start date is on or before 28 days prior to 
ation was still ongoing on the date of Visit 1. Lifetime AEDs are defined as 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.ation was still ongoing on the date of Visit 1. Lifetime AEDs are defined as 
AEDs taken in the subject’s history and stopped at least 28 days prior to Visit 1.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.AEDs taken in the subject’s history and stopped at least 28 days prior to Visit 1.
Benzodiazepines 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Benzodiazepines taken for rescue 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.taken for rescue 
F, although rescue 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.F, although rescue 
intermittently for 1 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.intermittently for 1 
Rescue medication is defined as the intermittent use of benzodiazepines (lim
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Rescue medication is defined as the intermittent use of benzodiazepines (lim
28 days) for epilepsy indications if established at least 28 days prior to Visit 1.  Lifetime 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.28 days) for epilepsy indications if established at least 28 days prior to Visit 1.  Lifetime 
benzodiazepines are defined as benzodiazepines taken in the subject’s history and stopped at 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.benzodiazepines are defined as benzodiazepines taken in the subject’s history and stopped at 
least 28 days prior to Visit 1.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.least 28 days prior to Visit 1.
3.2.5.1
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.3.2.5.1
UCB   28 Mar 2019  
Statistical Analysis Plan  SP0982  
 Any MAO inhibitors 
 Barbiturates (except as antiepileptic medications) 
 Unstable dosing of non-benzodiazepine anxiolytics or once-daily hypnotics 
 Herbal medicines for epilepsy 
The study physician will review the concomitant medications and flag prohibited medications. 
3.2.6  Relative day 
Relative day will be presented in most subject data listings. Relative day will be calculated as 
follows: 
 If the start/stop date occurred prior to the first dose of study medication, the relative day is 
calculated as start/stop date minus first study medication dose date. In subject data listings, 
relative days based on this situation will be preceded by a ‘ -’. 
 If the start/stop date occurred on or after the first dose of study medication but prior to the last dose of study medication, the relative day is calculated as start/stop date minus first study medication dose date + 1. 
 If the start/stop date occurred after the date of last dose of study medication, the relative day 
is calculated as start/stop date minus date of last dose of study medication. In subject data 
listings, relative days based on this situation will be preceded by a ‘+’. 
Subjects with missing or incomplete dates will also have a missing relative day. 
3.2.7  Last Visit 
Last Visit is defined as the last post-Baseline non-missing visit (including unscheduled visits) during the Treatment Period.  
3.2.8  Month 
A month is defined as 28 days. 
3.3 Definition of Baseline values  
Data collected at Visit 2 prior to the first dose of study medication (physical examination, 
neurological examination, ECG, vital signs, laboratory tests) will be used as Baseline values. 
Data collected on the date of first dose of study medication will be assumed to be prior to the 
first dose. For quantitative ECG assessments, if repeat measurements pre-dose, then the average value is used as the Baseline value. For data not collected at Visit 2 prior to the first dose of 
study medication, the last data collected prior to the first dose of study medication will be used as 
Baseline values.  
For PGTCS efficacy analyses, the data used for Baseline calculations come from the Combined 
Baseline Period. For absence and myoclonic seizure analyses, the data used for Baseline 
calculations come from the Prospective Baseline Period only.  
3.4 Protocol deviations  
Important protocol deviations are deviations from the protocol which potentially could have a meaningful impact on either primary efficacy outcome or key safety outcomes for an individual REDACTED COPY ccurred after the date of last dose of study medication, the relative day 
REDACTED COPY ccurred after the date of last dose of study medication, the relative day 
is calculated as start/stop date minus date of last dose of study medication. In subject data 
REDACTED COPY is calculated as start/stop date minus date of last dose of study medication. In subject data 
listings, relative days based on this situation will be preceded by a ‘+’.
REDACTED COPY listings, relative days based on this situation will be preceded by a ‘+’.
missing or incomplete dates will also have a missing relative day.
REDACTED COPY missing or incomplete dates will also have a missing relative day.
Baseline non
REDACTED COPY Baseline non
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Relative day will be presented in most subject data listings. Relative day will be calculated as 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Relative day will be presented in most subject data listings. Relative day will be calculated as 
If the start/stop date occurred prior to the first dose of study medication, the relative day is 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.If the start/stop date occurred prior to the first dose of study medication, the relative day is 
calculated as start/stop date minus first study medication dose date. In subject data listings, 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.calculated as start/stop date minus first study medication dose date. In subject data listings, 
If the start/stop date occurred on or after the first dose of study medication but prior to the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.If the start/stop date occurred on or after the first dose of study medication but prior to the 
last dose of study medication, the relative day is calculated as start/stop date minus first study 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.last dose of study medication, the relative day is calculated as start/stop date minus first study 
ccurred after the date of last dose of study medication, the relative day 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.ccurred after the date of last dose of study medication, the relative day 
is calculated as start/stop date minus date of last dose of study medication. In subject data 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.is calculated as start/stop date minus date of last dose of study medication. In subject data 
listings, relative days based on this situation will be preceded by a ‘+’.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.listings, relative days based on this situation will be preceded by a ‘+’.
missing or incomplete dates will also have a missing relative day.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.missing or incomplete dates will also have a missing relative day.
Baseline non
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Baseline non
Definition of
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Definition of Baseline values
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Baseline values
Data collected at Visit 2 prior to the first dose of study medication (physical examination, 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Data collected at Visit 2 prior to the first dose of study medication (physical examination, 
neurological examination, ECG, vital signs, laboratory tests) will be used as Baseline values. 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.neurological examination, ECG, vital signs, laboratory tests) will be used as Baseline values. 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Data collected on the date of first dose of study m
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Data collected on the date of first dose of study m
first dose. For quantitative ECG assessments, if repeat measurements pre
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.first dose. For quantitative ECG assessments, if repeat measurements pre
value is used as the Baseline value. For data not collected at Visit 2 prior to the first dose of 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.value is used as the Baseline value. For data not collected at Visit 2 prior to the first dose of 
study medication,
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.study medication,
Baseline values. 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Baseline values. 
For PGTCS efficacy analyses, the data used for Baseline calculations come from the Combined 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.For PGTCS efficacy analyses, the data used for Baseline calculations come from the Combined 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Baseline Period. For absence and myoclonic seizure analyses, 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Baseline Period. For absence and myoclonic seizure analyses, 
calculations come from the Prospective Baseline Period only. 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.calculations come from the Prospective Baseline Period only. 
UCB   28 Mar 2019  
Statistical Analysis Plan  SP0982  
subject. The criteria for identifying important protocol deviations and the classification of 
important protocol deviations will be defined within the project Data Cleaning Plan. To the 
extent feasible, rules for identifying protocol deviations will be defined without review of the data and without consideration of the frequency of occurrence of such deviations. Whenever 
possible, criteria for identifying important protocol deviations will be implemented 
algorithmically to ensure consistency in the classification of important protocol deviations across all subjects. 
Important protocol deviations will be reviewed in a blinded manner as part of the ongoing data 
cleaning process prior to database lock to confirm exclusion from the Per Protocol Set (PPS). 
3.5 Analysis sets 
The Safety Set (SS) will serve as the primary population for assessing safety endpoints. The Full 
Analysis Set (FAS) will serve as the primary population for assessing efficacy endpoints. 
3.5.1  Screened Set 
The Screened Set (ScS) consists of all subjects who have entered screening at Visit 1, have a 
signed Informed Consent/Assent Form, and have at least basic demographic data available. 
3.5.2  Randomized Set 
The Randomized Set (RS) is a subset of the ScS and consists of all subjects who were 
randomized at the Randomization Visit (Visit 2). 
3.5.3  Safety Set 
The SS is a subset of the RS and consists of all subjects who have been treated with at least 1 
dose of study drug, either LCM or placebo. This population will serve as the primary population 
for assessing safety endpoints. 
3.5.4  Full Analysis Set 
The FAS is a subset of the SS consisting of all subjects with at least 1 seizure diary assessment 
during the Treatment Period. This population will serve as the primary population for assessing efficacy endpoints. 
3.5.5  Per Protocol Set 
The PPS is a subset of the FAS excluding subjects who completed fewer than 6 weeks of 
treatment or subjects with important protocol deviations affecting the interpretation of the primary efficacy analysis. Important protocol deviations will be determined prior to database 
lock and unblinding. 
3.6 Treatment assignment and treatment groups 
Safety data summaries will be presented by randomized treatment and sometimes by overall, 
while efficacy data summaries will be presented by randomized treatment. Treatments will be reported as LCM and placebo, and in some cases, by all subjects.  
If a subject receives a treatment other than the randomized treatment, an evaluation of the mis-treatment will be made to determine if the subject should be summarized under a different 
treatment arm for safety assessments. Data obtained from subjects who receive an incorrect kit REDACTED COPY The Randomized Set (RS) is a subset of the ScS and consists of a
REDACTED COPY The Randomized Set (RS) is a subset of the ScS and consists of a
The SS is a subset of the RS and consists of all subjects who have been treated with at least 1 
REDACTED COPY The SS is a subset of the RS and consists of all subjects who have been treated with at least 1 
dose of study drug, either LCM or placebo. This population will serve as the pr
REDACTED COPY dose of study drug, either LCM or placebo. This population will serve as the pr
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Important protocol deviations will be reviewed in a blinded manner as part of the ongoing data 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Important protocol deviations will be reviewed in a blinded manner as part of the ongoing data 
n from the Per Protocol Set (PPS).
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.n from the Per Protocol Set (PPS).
The Safety Set (SS) will serve as the primary population for assessing safety endpoints. The Full 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.The Safety Set (SS) will serve as the primary population for assessing safety endpoints. The Full 
Analysis Set (FAS) will serve as the primary population for assessing efficacy endpoints.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Analysis Set (FAS) will serve as the primary population for assessing efficacy endpoints.
reened Set (ScS) consists of all subjects who have entered screening at Visit 1, have a 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.reened Set (ScS) consists of all subjects who have entered screening at Visit 1, have a 
signed Informed Consent/Assent Form, and have at least basic demographic data available.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.signed Informed Consent/Assent Form, and have at least basic demographic data available.
The Randomized Set (RS) is a subset of the ScS and consists of a
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.The Randomized Set (RS) is a subset of the ScS and consists of a ll subjects who were 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.ll subjects who were 
The SS is a subset of the RS and consists of all subjects who have been treated with at least 1 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.The SS is a subset of the RS and consists of all subjects who have been treated with at least 1 
dose of study drug, either LCM or placebo. This population will serve as the pr
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.dose of study drug, either LCM or placebo. This population will serve as the pr
The FAS is a subset of the SS consisting of all subjects with at least 1 seizure diary assessment 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.The FAS is a subset of the SS consisting of all subjects with at least 1 seizure diary assessment 
during the Treatment Period. This population will serve as the primary population for asses
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.during the Treatment Period. This population will serve as the primary population for asses
Per Protocol Set
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Per Protocol Set
The PPS is a subset of the FAS excluding subjects who completed fewer than 6 weeks of 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.The PPS is a subset of the FAS excluding subjects who completed fewer than 6 weeks of 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.treatment or subjects with important protocol deviations affecting the interpretation of the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.treatment or subjects with important protocol deviations affecting the interpretation of the 
primary efficacy analysis. 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.primary efficacy analysis. 
lock and unblinding.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.lock and unblinding.
afety data summaries will be presented by randomized treatment and
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.afety data summaries will be presented by randomized treatment and
while efficacy data summaries will b
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.while efficacy data summaries will b
reported as LCM
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.reported as LCM
UCB   28 Mar 2019  
Statistical Analysis Plan  SP0982  
will be reviewed and the study team will determine how to handle such cases in the statistical 
analyses prior to database lock and unblinding. 
3.7 Center pooling strategy 
Refer to Section  4.4. 
3.8 Coding dictionaries 
Adverse events and medical history will be coded using the Medical Dictionary for Regulatory 
Activities (MedDRA) Version 16.1. Medications will be coded using the World Health 
Organization Drug Dictionary (WHO-DD, SEP/2013). All coding will be completed prior to database lock and unblinding. 
3.9 Changes to protocol-defined analyses 
For the key secondary efficacy variable, the Protocol Section 4.1.2 says that seizure freedom for PGTCS during the 24-week Treatment Period, will be estimated using Kaplan-Meier analysis. 
Also, Protocol Section 13.3.2.1 states that the key secondary efficacy variable will be analyzed in 
the same manner as the primary endpoint using the FAS and that the percentage of seizure- free 
subjects at 24 weeks will be estimated from the KM estimates of time to first seizure. The 
analysis of the key secondary endpoint has been clarified to assess the seizure-free rate at 24 
weeks using an extended Mantel-Haenszel technique which combines Kaplan-Meier estimates 
within each stratum. The extended Mantel-Haenszel technique is a randomization-based nonparametric method that provides a more robust method to assess seizure freedom. Thus, t he 
key secondary efficacy variable will not be analyzed in the same manner as the primary efficacy 
endpoint; the other secondary efficacy variable, time to first PGTCS, will be analyzed in the 
same manner as the primary efficacy endpoint. 
4 STATISTICAL/ANALYTIC AL ISSUES  
4.1 Adjustments for covariates 
Analyses of the primary efficacy variable and several other efficacy variables will be adjusted for 
the stratification variables Baseline PGTCS frequency (≤2 per 28 days vs >2 per 28 days for the 
16 week Combined Baseline Period prior to randomization) and age at informed consent (≥4 to <12 years of age vs ≥12 to <18 years of age, and ≥18 years of age). Stratification factors recorded at randomization in the interactive response technology (IRT) will be used. 
4.2 Handling of dropouts or missing data 
4.2.1  Missing seizure diary days 
For evaluations based on seizure diary data, imputation for missing data will not be performed. 
For the purpose of the derivation of the primary efficacy endpoint, secondary efficacy endpoints 
and for PGTC seizure-free status, if there are PGTCS counts reported as “not done” on a specific day, then the PGTCS count will be assumed to be zero on that date.  
The calculation of average 28-day PGTCS frequency accounts for missing data by only 
evaluating days for which data are available.  REDACTED COPY Haenszel technique which combines Kaplan
REDACTED COPY Haenszel technique which combines Kaplan
Haenszel technique is a randomization
REDACTED COPY Haenszel technique is a randomization
nonparametric method that provides a more robust method to assess seizure freedom.
REDACTED COPY nonparametric method that provides a more robust method to assess seizure freedom.
key secondary efficacy variable will not be analyzed in the same manner as the primary efficacy 
REDACTED COPY key secondary efficacy variable will not be analyzed in the same manner as the primary efficacy 
endpoint; the other secondary efficacy variable, time to first 
REDACTED COPY endpoint; the other secondary efficacy variable, time to first 
same manner as the primary efficacy endpoint.
REDACTED COPY same manner as the primary efficacy endpoint.
STATISTICAL/ANALYTIC REDACTED COPY STATISTICAL/ANALYTIC
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.using the Medical Dictionary for Regulatory 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.using the Medical Dictionary for Regulatory 
DD, SEP/2013). All coding will be completed prior to 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.DD, SEP/2013). All coding will be completed prior to 
For the key secondary efficacy variable, the Protocol Section 4.1.2 says that seizure freedom for 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.For the key secondary efficacy variable, the Protocol Section 4.1.2 says that seizure freedom for 
week Treatment Period, will be estimated using Kaplan
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.week Treatment Period, will be estimated using Kaplan -
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.-Meier analysis. 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Meier analysis. 
that the key secondary efficacy variable will be analyzed in 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.that the key secondary efficacy variable will be analyzed in 
the same manner as the primary endpoint using the FAS and that the percentage of seizure
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.the same manner as the primary endpoint using the FAS and that the percentage of seizure
om the KM estimates of time to first seizure. 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.om the KM estimates of time to first seizure. 
of the key secondary endpoint has been clarified to assess the seizure
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.of the key secondary endpoint has been clarified to assess the seizure
Haenszel technique which combines Kaplan
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Haenszel technique which combines Kaplan
Haenszel technique is a randomization
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Haenszel technique is a randomization
nonparametric method that provides a more robust method to assess seizure freedom.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.nonparametric method that provides a more robust method to assess seizure freedom.
key secondary efficacy variable will not be analyzed in the same manner as the primary efficacy 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.key secondary efficacy variable will not be analyzed in the same manner as the primary efficacy 
endpoint; the other secondary efficacy variable, time to first 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.endpoint; the other secondary efficacy variable, time to first 
same manner as the primary efficacy endpoint.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.same manner as the primary efficacy endpoint.
STATISTICAL/ANALYTIC
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.STATISTICAL/ANALYTIC
Adjustments for covariates
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Adjustments for covariates
Analyses of the primary efficacy variable and several other efficacy variables will be adjusted for 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Analyses of the primary efficacy variable and several other efficacy variables will be adjusted for 
iables Baseline PGTCS frequency (≤2 per 28 days vs >2 per 28 days for the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.iables Baseline PGTCS frequency (≤2 per 28 days vs >2 per 28 days for the 
16 week Combined Baseline Period prior to randomization) and age at informed consent (≥4 to 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.16 week Combined Baseline Period prior to randomization) and age at informed consent (≥4 to 
<12 years of age vs ≥12 to <18 years of age, and ≥18 years of age). Stratification factors
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.<12 years of age vs ≥12 to <18 years of age, and ≥18 years of age). Stratification factors
recorded at randomization in the interactive response technology (IRT) will be used.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.recorded at randomization in the interactive response technology (IRT) will be used.
Handling of dropouts or missing data
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Handling of dropouts or missing data
Missing seizure diary days
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Missing seizure diary days
For evaluations based on seizure diary data, imputation for missing data will not be performed.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.For evaluations based on seizure diary data, imputation for missing data will not be performed.
For the pu
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.For the pu
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.and for PGTC seizure
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.and for PGTC seizure
day, then the PGTCS count will be assumed to be zero on that date. 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.day, then the PGTCS count will be assumed to be zero on that date. 
The 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.The 
UCB   28 Mar 2019  
Statistical Analysis Plan  SP0982  
4.2.2  Incomplete dates for first epilepsy diagnosis 
To calculate the time since first epilepsy diagnosis, a complete date will be imputed for partially 
missing first diagnosis date. First diagnosis dates will be displayed as reported in the subject data 
listings (ie, no imputed values will be displayed in data listing). 
 Missing the day, but month and year present: 
Assign the 1st day of the month or the subject’s birthday (imputing 1st for the day if only month 
and year are collected), whichever is later. 
 Missing the day and month, but year present: 
Assign January 1st of the year or the subject’s birthday, whichever is later. 
 Missing the day, month and year: 
No imputation will be done. 
4.2.3  Incomplete dates for adverse events and concomitant medications 
The following rules are applied to impute partial start and stop dates for medications. The date as 
recorded on the CRF should be presented in subject data listings (no imputed dates should be 
included in subject data listings). 
Imputation of Partial Start Dates 
 If only the month and year are specified and the month and year of first dose is not the same 
as the month and year of the start date, then use the first day of the month. 
 If only the month and year are specified and the month and year of first dose is the same as 
the month and year of the start, then use the date of first dose. 
 If only the year is specified, and the year of first dose is not the same as the year of the start 
date, then use January 1st of the year of the start date. 
 If only the year is specified, and the year of first dose is the same as the year of the start date, 
then use the date of first dose. 
 If the start date is completely unknown and the stop date is unknown or not prior to the date of first dose, then use the date of first dose. 
Imputation of Partial Stop Dates 
 If only the month and year are specified, then use the last day of the month. 
 If only the year is specified, then the end day and month will be set to the maximum of the date of study termination or the date equivalent to 30 days after the last intake of LCM. 
However, if the study termination year and year for the date which is 30 days after last intake 
of LCM are greater than the concomitant medication year, then the day and month are to be set to December 31
st. 
 If the stop date is completely unknown, do not impute the stop date. 
In the event of ambiguity or incomplete data which makes it impossible to determine whether a medication was concomitant or not, the medication will be considered as concomitant. REDACTED COPY If only the month and year are specified and the month and year of first dose is not the same 
REDACTED COPY If only the month and year are specified and the month and year of first dose is not the same 
then use the first day of the month.
REDACTED COPY then use the first day of the month.
If only the month and year are specified and the month and year of first dose is the same as 
REDACTED COPY If only the month and year are specified and the month and year of first dose is the same as 
the month and year of the start, then use the date of first dose.
REDACTED COPY the month and year of the start, then use the date of first dose.
If only the year is specified, and the year of first dose is REDACTED COPY If only the year is specified, and the year of first dose is
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Incomplete dates for adverse events and concomitant medications
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Incomplete dates for adverse events and concomitant medications
The following rules are applied to impute partial start and stop dates for medications. The date as 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.The following rules are applied to impute partial start and stop dates for medications. The date as 
bject data listings (no imputed dates should be 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.bject data listings (no imputed dates should be 
If only the month and year are specified and the month and year of first dose is not the same 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.If only the month and year are specified and the month and year of first dose is not the same 
then use the first day of the month.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.then use the first day of the month.
If only the month and year are specified and the month and year of first dose is the same as 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.If only the month and year are specified and the month and year of first dose is the same as 
the month and year of the start, then use the date of first dose.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.the month and year of the start, then use the date of first dose.
If only the year is specified, and the year of first dose is
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.If only the year is specified, and the year of first dose is
of the year of the start date.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.of the year of the start date.
If only the year is specified, and the year of first dose is the same as the year of the start date, 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.If only the year is specified, and the year of first dose is the same as the year of the start date, 
then use the date of first dose.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.then use the date of first dose.
If the start date is comp
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.If the start date is comp letely unknown and the stop date is unknown or not prior to the date 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.letely unknown and the stop date is unknown or not prior to the date 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.of first dose, then use the date of first dose.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.of first dose, then use the date of first dose.
Imputation of Partial Stop Dates
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Imputation of Partial Stop Dates
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.If only the month and year are specified, then use the last day of the month.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.If only the month and year are specified, then use the last day of the month.
If only the year is specifie
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.If only the year is specifie
date of study termination or the date equivalent to 30 days after the last intake of LCM. 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.date of study termination or the date equivalent to 30 days after the last intake of LCM. 
However, if the study termination year and year for the date which is 30 days after last intake 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.However, if the study termination year and year for the date which is 30 days after last intake 
of LCM
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.of LCM
set to December 31
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.set to December 31
UCB   28 Mar 2019  
Statistical Analysis Plan  SP0982  
The following rules are applied to impute partial onset and resolution dates for AEs. AEs with 
partial onset date are classified as either non-treatment- or treatment-emergent based on the 
imputed onset date.  
Imputation of Partial Onset Dates 
 If only the month and year are specified and the month and year of first dose is not the same 
as the month and year of onset, then use the first day of the month. 
 If only the month and year are specified and the month and year of first dose is the same as the month and year of onset, then use the date of first dose. 
 If only the year is specified, and the year of first dose is not the same as the year of onset, 
then use January 1
st of the year of onset. 
 If only the year is specified, and the year of first dose is the same as the year of onset, then 
use the date of first dose. 
 If the AE onset date is completely unknown, then use the date of first dose. 
Imputation of Partial Resolution Dates  
 If only the month and year are specified, then use the last day of the month. 
 If only the year is specified, then the end day and month will be set to the maximum of the date of study termination or the date equivalent to 30 days after the last intake of LCM. However, if the study termination year and year for the date which is 30 days after last intake 
of LCM are greater than the event year, then the day and month are to be set to December 
31
st. 
 If the AE resolved and the resolution date is completely unknown, then do not impute the resolution date. 
4.2.4  Incomplete date for the last administration of study medication 
No imputation should be performed for missing study medication start dates. This field on the CRF should not be partial or missing. 
For partial or missing date of last dose of study medication, the following imputation rules will 
be applied for the purpose of calculating overall exposure: 
 If the day is missing (but month and year available), impute the last dose date as the 
minimum of the last day of the month or the date of last contact reported on the Study Termination CRF; if day and month are both missing (only year available), impute the last 
dose date as the minimum of the last day of the year or the date of last contact on the Study 
Termination CRF. 
 If a subject died and has a partial or missing last administration date, the date is set to the date of death. If there is a partial date of last dose and the month/year are prior to the month and year of the date of death, follow partial date imputation rules. 
 If the last dose date is completely missing and no information could be obtained from data cleaning exercises, the last dose date should be imputed as the date of last contact according 
to the Study Termination CRF. A review of the data for subjects with completely missing last REDACTED COPY If only the year is specified, then the end day and month will be set to the maximum of the 
REDACTED COPY If only the year is specified, then the end day and month will be set to the maximum of the 
date of study termination or the date equivalent to 30 days after the
REDACTED COPY date of study termination or the date equivalent to 30 days after the
However, if the study termination year and year for the date which is 30 days after last intake 
REDACTED COPY However, if the study termination year and year for the date which is 30 days after last intake 
of LCM are greater than the event year, then the day and month are to be set to December 
REDACTED COPY of LCM are greater than the event year, then the day and month are to be set to December 
If the AE resolved and the resolution date iREDACTED COPY If the AE resolved and the resolution date i
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.the month and year are specified and the month and year of first dose is the same as 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.the month and year are specified and the month and year of first dose is the same as 
If only the year is specified, and the year of first dose is not the same as the year of onset, 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.If only the year is specified, and the year of first dose is not the same as the year of onset, 
If only the year is specified, and the year of first dose is the same as the year of onset, then 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.If only the year is specified, and the year of first dose is the same as the year of onset, then 
If the AE onset date is completely unknown, then use the date of first dose.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.If the AE onset date is completely unknown, then use the date of first dose.
If only the month and year are specified, then use the last day of the month.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.If only the month and year are specified, then use the last day of the month.
If only the year is specified, then the end day and month will be set to the maximum of the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.If only the year is specified, then the end day and month will be set to the maximum of the 
date of study termination or the date equivalent to 30 days after the
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.date of study termination or the date equivalent to 30 days after the
However, if the study termination year and year for the date which is 30 days after last intake 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.However, if the study termination year and year for the date which is 30 days after last intake 
of LCM are greater than the event year, then the day and month are to be set to December 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.of LCM are greater than the event year, then the day and month are to be set to December 
If the AE resolved and the resolution date i
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.If the AE resolved and the resolution date i s completely unknown, then do not impute the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.s completely unknown, then do not impute the 
Incomplete date for the last administration of study medication
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Incomplete date for the last administration of study medication
No imputation should be performed for missing study medication start dates. This field on the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.No imputation should be performed for missing study medication start dates. This field on the 
CRF should not be partial or missing
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.CRF should not be partial or missing
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.For partial or missing date of last dose of study medication, the following imputation rules will 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.For partial or missing date of last dose of study medication, the following imputation rules will 
be applied for the purpose of calculating overall exposure:
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.be applied for the purpose of calculating overall exposure:
If the day is missing (but month and year available), impute the last dose date as the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.If the day is missing (but month and year available), impute the last dose date as the 
minimum o
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.minimum o f the last day of the month or the date of last contact reported on the Study 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.f the last day of the month or the date of last contact reported on the Study 
Termination CRF; if day and month are both missing (only year available), impute the last 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Termination CRF; if day and month are both missing (only year available), impute the last 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.dose date as the minimum of the last day of the year or the date of last contact on the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.dose date as the minimum of the last day of the year or the date of last contact on the 
Termination CRF.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Termination CRF.
If a subject died and has a partial or missing last administration date, the date is set to the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.If a subject died and has a partial or missing last administration date, the date is set to the 
date of death. If there is a partial date of last dose and the month/year are prior to the month 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.date of death. If there is a partial date of last dose and the month/year are prior to the month 
UCB   28 Mar 2019  
Statistical Analysis Plan  SP0982  
dose dates should be performed to ensure that the imputation does not result in an unrealistic 
value for duration of exposure.  
Imputed date of last dose dates should only be used for calculation of the duration of exposure. The date as recorded on the CRF should be presented in subject data listings (no imputed dates should be included in subject data listings). 
4.2.5  Missing adverse event intensity 
If the intensity of an AE is missing then it will be counted as severe for analysis purposes. 
4.2.6  Missing adverse event relationship to study medication 
If the AE relationship to study medication is missing then it will be counted as related for 
analysis purposes. 
4.3 Interim analyses and data monitoring 
To enhance safety monitoring, 3 interim analyses are planned when 25%, 50%, and 75% of 
subjects experience an event (31, 62, and 93 events, respectively) or 24 weeks after 50, 100, 
and 150 subjects have been randomized, respectively, whichever comes first. An event is defined 
as the occurrence of the second PGTCS during the Treatment Period. 
These interim reviews for safety will be performed using an Independent Data Monitoring 
Committee (IDMC), with a single futility assessment planned at the second interim analysis. The IDM C will oversee the safety of the study by reviewing safety data periodically. Details are 
provided in an IDMC charter. Both safety and futility will be assessed in a manner that ensures that blinding is not compromised for individuals involved with operational aspects of the study, nor individuals involved with the planning and conduct of the final statistical analyses. Analysis 
of the primary efficacy endpoint (time to second PGTCS) will only be examined at the planned 
futility assessment; an unblinded, descriptive review of safety and seizure data will be provided for all IDMC meetings. 
No consideration will be made for stopping due to early demonstration of efficacy; however, the 
significance level will be set using a Haybittle- Peto boundary at alpha=0.00 01 so as to require 
only a nominal alpha adjustment for the final analysis. Full details of the interim analysis are described in the Interim Analysis Statistical Analysis Plan. 
4.4 Multicenter studies 
Due to the small number of subjects per site, all sites will be pooled together for analysis. There will be no planned analyses for multi-center effects. 
4.5 Multiple comparisons/multiplicity 
A gatekeeping strategy (Marcus et al, 1996) will be used to test the key secondary efficacy variable provided that the primary efficacy endpoint is statistically significant (See Section  8.2.1 
for additional details). No additional adjustments for multiplicity are required as all additional inferences will be hypothesis-generating only. 
4.6 Use of an efficacy subset of subjects 
The PPS will be used to evaluate subjects who completed at least 6 weeks of treatment and have 
no important protocol deviations related to the primary efficacy variable. This analysis set will REDACTED COPY These interim reviews for safety will be performed using an Independent Data Monitoring 
REDACTED COPY These interim reviews for safety will be performed using an Independent Data Monitoring 
Committee (IDMC), with a single futility assessment planned at the second interim analysis. The 
REDACTED COPY Committee (IDMC), with a single futility assessment planned at the second interim analysis. The 
C will oversee the safety of the study by reviewing safety data periodically. Details are 
REDACTED COPY C will oversee the safety of the study by reviewing safety data periodically. Details are 
provided in an IDMC charter. Both safety and futility will be assessed in a manner that ensures 
REDACTED COPY provided in an IDMC charter. Both safety and futility will be assessed in a manner that ensures 
that blinding is not compromised for individuals involved with operati
REDACTED COPY that blinding is not compromised for individuals involved with operati
nor individuals involved with the planning and conduct of the final statistical analyses. Analysis 
REDACTED COPY nor individuals involved with the planning and conduct of the final statistical analyses. Analysis 
of the primary efficacy endpoint (time to second PGTCS) will only be examined at the planned 
REDACTED COPY of the primary efficacy endpoint (time to second PGTCS) will only be examined at the planned 
scriptive review of safety and seizure data will be provided REDACTED COPY scriptive review of safety and seizure data will be provided 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.If the AE relationship to study medication is missing then it will be counted as related for 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.If the AE relationship to study medication is missing then it will be counted as related for 
onitoring, 3 interim analyses are planned when 25%, 50%, and 75% of 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.onitoring, 3 interim analyses are planned when 25%, 50%, and 75% of 
subjects experience an event (31, 62, and 93 events, respectively) or 24 weeks after 50, 100, 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.subjects experience an event (31, 62, and 93 events, respectively) or 24 weeks after 50, 100, 
150 subjects have been randomized, respectively, whichever comes first. An event is define
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.150 subjects have been randomized, respectively, whichever comes first. An event is define
as the occurrence of the second PGTCS during the Treatment Period.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.as the occurrence of the second PGTCS during the Treatment Period.
These interim reviews for safety will be performed using an Independent Data Monitoring 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.These interim reviews for safety will be performed using an Independent Data Monitoring 
Committee (IDMC), with a single futility assessment planned at the second interim analysis. The 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Committee (IDMC), with a single futility assessment planned at the second interim analysis. The 
C will oversee the safety of the study by reviewing safety data periodically. Details are 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.C will oversee the safety of the study by reviewing safety data periodically. Details are 
provided in an IDMC charter. Both safety and futility will be assessed in a manner that ensures 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.provided in an IDMC charter. Both safety and futility will be assessed in a manner that ensures 
that blinding is not compromised for individuals involved with operati
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.that blinding is not compromised for individuals involved with operati
nor individuals involved with the planning and conduct of the final statistical analyses. Analysis 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.nor individuals involved with the planning and conduct of the final statistical analyses. Analysis 
of the primary efficacy endpoint (time to second PGTCS) will only be examined at the planned 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.of the primary efficacy endpoint (time to second PGTCS) will only be examined at the planned 
scriptive review of safety and seizure data will be provided 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.scriptive review of safety and seizure data will be provided 
No consideration will be made for stopping due to early demonstration of efficacy; however, the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.No consideration will be made for stopping due to early demonstration of efficacy; however, the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.significance level will be set using a Haybittle
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.significance level will be set using a Haybittle
only a nominal alpha adjustment for the final analysis. Full details of the interim analysis are 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.only a nominal alpha adjustment for the final analysis. Full details of the interim analysis are 
described in the Interim Analysis Statistical Analysis Plan.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.described in the Interim Analysis Statistical Analysis Plan.
Multicenter studies
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Multicenter studies
Due to the small number of subjects per site, all sites wi
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Due to the small number of subjects per site, all sites wi
will be no planned analyses for multi
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.will be no planned analyses for multi
Multiple comparisons/multiplicity
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Multiple comparisons/multiplicity
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.A gatekeeping strategy (Marcus et al, 1996) will be used to test the key secondary efficacy 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.A gatekeeping strategy (Marcus et al, 1996) will be used to test the key secondary efficacy 
variable provided that the primary
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.variable provided that the primary
for additional details). No additional adjustments for multiplicity are required 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.for additional details). No additional adjustments for multiplicity are required 
inferences will be hypothesis
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.inferences will be hypothesis
UCB   28 Mar 2019  
Statistical Analysis Plan  SP0982  
provide additional information on the analysis of the primary efficacy variable and will describe 
findings in a subset of subjects who more closely followed the intentions of the study protocol. 
Other than the planned analyses based on the PPS, no other efficacy subsets are defined for 
statistical analyses. 
4.7 Active -control studies intended to show equivalence 
This section is not applicable for this study. 
4.8 Examination of subgroups 
Descriptive statistics by all subgroups for the primary efficacy variable will be presented for the FAS.  Disposition will be presented by age subgroup for the SS and FAS.  Exposure will be 
presented by age and region subgroups for the SS.  Overall TEAE incidence will be presented by 
age subgroup for the SS.  Selected disposition and safety analyses will be presented by 
Development for the purpose of addressing requirements set in Article 46 of the European Pediatric Regulation (see Section  12.5 for further details). 
The subgroups to be examined include: 
 Age at enrollment (≥ 4 to <12 years of age, ≥12 to <18 years of age, 18 to <65, ≥65) 
 Development (Pediatric [≥4 to < 18 years old], Adult [≥18 years old]) 
 Racial group (white, non-white) 
 Gender (male, female) 
 Region  
 North America: United States, Puerto Rico 
 Latin America: Brazil, Mexico 
 Western/Central Europe: Belgium, Czech Republic, France, Germany, Hungary, Italy, 
Poland, Portugal, Slovakia, Spain 
 Eastern Europe: Bulgaria, Romania, Russia, Turkey 
 Asia/Pacific/Other: Australia, China, Israel, Japan, South Korea, Taiwan 
 Baseline PGTCS frequency (≤2 per 28 days and >2 per 28 days in the Combined Baselin e 
Period) 
 Concomitant AEDs at study entry, ie the total number of AEDs and benzodiazepines the 
subject is taking when enrolled into the study (1, 2, 3). 
Separate age sub-groupings are used for the purpose of summarizing the following scales:  
 PedsQL (4 years, ≥5 to ≤7 years, ≥8 to ≤12 years, and ≥13 to ≤18 years) 
 Achenbach CBCL (4 to 5 years, 6 to 18 years) 
 BRIEF -P/BRIEF (4 to <5 years, ≥5 years). REDACTED COPY ediatric [≥4 to < 18 years old], Adult [≥18 years old])
REDACTED COPY ediatric [≥4 to < 18 years old], Adult [≥18 years old])
North America: United States, Puerto Rico
REDACTED COPY North America: United States, Puerto Rico
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Descriptive statistics by all subgroups for the primary efficacy variable will be presented for the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Descriptive statistics by all subgroups for the primary efficacy variable will be presented for the 
FAS.  Disposition will be presented by age subgroup for the SS and FAS.  Exposure will be 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.FAS.  Disposition will be presented by age subgroup for the SS and FAS.  Exposure will be 
cidence will be presented by 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.cidence will be presented by 
age subgroup for the SS.  Selected disposition and safety analyses will be presented by 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.age subgroup for the SS.  Selected disposition and safety analyses will be presented by 
Development for the purpose of addressing requirements set in Article 46 of the European 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Development for the purpose of addressing requirements set in Article 46 of the European 
Age at enrollment (≥ 4 to <12 years of age, ≥12 to <18 years of age, 18 to <65, ≥65)
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Age at enrollment (≥ 4 to <12 years of age, ≥12 to <18 years of age, 18 to <65, ≥65)
ediatric [≥4 to < 18 years old], Adult [≥18 years old])
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.ediatric [≥4 to < 18 years old], Adult [≥18 years old])
North America: United States, Puerto Rico
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.North America: United States, Puerto Rico
Western/Central Europe: Belgium, Czech Republic, France, Germany, 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Western/Central Europe: Belgium, Czech Republic, France, Germany, 
Poland, Portugal, Slovakia, Spain
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Poland, Portugal, Slovakia, Spain
Eastern Europe: Bulgaria, Romania, Russia, 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Eastern Europe: Bulgaria, Romania, Russia, 
Asia/Pacific/Other: Australia, China, Israel, Japan, South Korea, Taiwan
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Asia/Pacific/Other: Australia, China, Israel, Japan, South Korea, Taiwan
Baseline PGTCS frequency (≤2 per 28 days and >2 per 28 days in the Combined Baselin
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Baseline PGTCS frequency (≤2 per 28 days and >2 per 28 days in the Combined Baselin
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Concomitant AEDs at study entry, ie the total number of AEDs and benzodiazepines the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Concomitant AEDs at study entry, ie the total number of AEDs and benzodiazepines the 
subject is taking when enrolled into the study (1, 2, 3).
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.subject is taking when enrolled into the study (1, 2, 3).
Separate age sub
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Separate age sub

This document cannot be used to support any marketing authorization application and any extensions or variations thereof.PedsQL (4 yea
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.PedsQL (4 yea

This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
UCB   28 Mar 2019  
Statistical Analysis Plan  SP0982  
4.9 Stratum Pooling  
The stratification factors for this study are Baseline PGTCS frequency (≤2 per 28 days vs >2 pe r 
28 days in the Combined Baseline Period) and age at informed consent (≥4 to <12 years of age, 
≥12 to <18 years of age vs ≥18 years of age). The analyses will use the stratification factors from IRT.  
To determine if strata pooling should occur for time to event (2
nd PGTCS) analysis: 
For the subjects with Baseline PGTCS frequency ≤2 per 28 days, the events for each of the 3 age 
at informed consent categories will be summed.  For categories with < 3 total events, the 
combining should occur as follows: 
 If 2 of the age at informed consent categories combined have < 3 total events, then all age 
categories are combined for the analysis.  
 If ≥4 to <12 years of age is the category with the smallest number of events that are 2 events 
or less, it should be combined with the ≥12 and <18 years of age category. 
 If ≥18 years of age is the category with the smallest number of events that are 2 events or less, it should be combined with the ≥12 and <18 years of age category. 
 If ≥12 and <18 years of age is the category with the smallest number of events that are 2 
events or less, it should be combined with the strata with the 2
nd smallest number of events. 
Repeat the algorithm for combining strata for the subjects who did not have events if there are 
categories with < 3 total non-events. 
For the subjects with Baseline PGTCS frequency >2 per 28 days, repeat the same exercise to 
determine stratum pooling for both events and non-events.  
For each  primary efficacy endpoint sensitivity analysis which us es stratum pooling, the pooling 
of the strata should be reassessed since the event distribution for the specific sensitivity may be 
different than the distribution in the primary efficacy endpoint analysis.  
Time to 1st PGTCS analyses: 
The prior algorithm for stratum pooling will be used to determine stratum pooling, except that 
“events” will now be in reference to subjects having only 1 PGTCS. Seizure freedom analyses: 
The prior algorithm for stratum pooling will be used to determine stratum pooling, except that 
“events” will now be in reference to subjects having 0 PGTCS. 
5 STUDY POPULATION CHA RACTERISTICS  
5.1 Subject disposition  
The number of subjects screened and the number and percentage of screen failures will be 
summarized overall. Screen failures are those subjects who are in the ScS and either met an exclusion criterion or did not meet an inclusion criterion. The reason for screen failure will be 
presented. The number and percentage of baseline failures due to PGTCS frequency during the 
Combined Baseline Period will also be summarized. The study eligibility criteria and those REDACTED COPY events or less, it should be combined with the strata with the 2
REDACTED COPY events or less, it should be combined with the strata with the 2
Repeat the algorithm for combining strata for the 
REDACTED COPY Repeat the algorithm for combining strata for the subjects
REDACTED COPY subjects
For the subjects with Baseline PGTCS frequency >2 per 28 days, repeat the same exercise to 
REDACTED COPY For the subjects with Baseline PGTCS frequency >2 per 28 days, repeat the same exercise to 
for both events and non
REDACTED COPY for both events and non
acy endpoint sensitivity analysi REDACTED COPY acy endpoint sensitivity analysi
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.For the subjects with Baseline PGTCS frequency ≤2 per 28 days, the events for each of the 3 age 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.For the subjects with Baseline PGTCS frequency ≤2 per 28 days, the events for each of the 3 age 
of the age at informed consent categories combined have < 3 total events, then all age 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.of the age at informed consent categories combined have < 3 total events, then all age 
If ≥4 to <12 years of age is the category with the smallest number of events that are 2 events 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.If ≥4 to <12 years of age is the category with the smallest number of events that are 2 events 
with the ≥12 and <18 years of age category.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.with the ≥12 and <18 years of age category.
If ≥18 years of age is the category with the smallest number of events that are 2 events or 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.If ≥18 years of age is the category with the smallest number of events that are 2 events or 
less, it should be combined with the ≥12 and <18 years of age category.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.less, it should be combined with the ≥12 and <18 years of age category.
the smallest number of events that are 2 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.the smallest number of events that are 2 
events or less, it should be combined with the strata with the 2
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.events or less, it should be combined with the strata with the 2
subjects
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.subjects who did
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.who did
For the subjects with Baseline PGTCS frequency >2 per 28 days, repeat the same exercise to 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.For the subjects with Baseline PGTCS frequency >2 per 28 days, repeat the same exercise to 
for both events and non
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.for both events and non
acy endpoint sensitivity analysi
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.acy endpoint sensitivity analysi
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.of the strata should be reassessed since
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.of the strata should be reassessed since the event distribution 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.the event distribution 
different than the distribution in the pri
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.different than the distribution in the pri mary efficacy endpoint analysis. 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.mary efficacy endpoint analysis. 
The prior algorithm for stratum pooling will
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.The prior algorithm for stratum pooling will
“events” will now be in reference to subjects having only 1 PGTCS.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.“events” will now be in reference to subjects having only 1 PGTCS.
Seizure freedom analyses:
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Seizure freedom analyses:
The prior algorithm for stratum pooling will be used
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.The prior algorithm for stratum pooling will be used
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.“events” will now
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.“events” will now
5.1
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.5.1
The number of subjects screened and the number and percentage of screen failures will be 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.The number of subjects screened and the number and percentage of screen failures will be 
summarized overall. Screen failures are those subjects who are in the
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.summarized overall. Screen failures are those subjects who are in the
UCB   28 Mar 2019  
Statistical Analysis Plan  SP0982  
subjects who did not meet it will be listed. All disposition data for the ScS will be presented in 
subject data listings. 
The number of subjects in the ScS, Randomized Set (RS), SS, FAS, and PPS will be presented 
by investigator; the date of first subject in and date of last subject out will also be included in this summary. The subject populations will be listed. 
The overall number and percentage of subjects who completed and discontinued from the study 
will be presented for the SS, FAS, and PPS including number and percentages for each reason 
for discontinuation. The completion of the study is defined as meeting any of the predetermined 
exit criteria (including when the 125
th event has occurred) or experiencing <2 PGTCS within the 
24-week treatment period. Discontinuation is defined as the completion of the ET Visit in all 
other cases.  This summary will be repeated for specific subgroups as detailed in Section  4.8 for 
the SS and FAS.  The study termination information will be presented in the subject data listings. 
A by-subject listing will be presented to show all visit dates and the associated relative day. 
5.2 Protocol deviations  
The number and percentage of subjects without any important protocol deviations and with at 
least 1 important protocol deviation in each of the categories defined in the prior to database lock and unblinding will be summarized overall for the RS. 
All important protocol deviations for subjects in the RS will be listed by site, subject number, 
and protocol deviation category. 
6 DEMOGRAPHICS AND OTHER BASELINE 
CHARACTERISTICS  
Unless otherwise specified, demographics and baseline characteristics will be summarized by 
treatment group and overall. 
6.1 Demographics 
6.1.1  Derivation of demographics variables 
6.1.1.1 BMI 
The body mass index (BMI) will be derived at Baseline only, from the Baseline height and weight values. BMI will be calculated using the following formula: 
   
22
(cm) height (kg) weight * 10000 ) (kg/m  BMI    REDACTED COPY All important protocol deviations for subjects in the RS will be listed by site, subject number, 
REDACTED COPY All important protocol deviations for subjects in the RS will be listed by site, subject number, 
DEMOGRAPHICS AND OTH
REDACTED COPY DEMOGRAPHICS AND OTH
REDACTED COPY CHARACTERISTICS
REDACTED COPY CHARACTERISTICS
Unless otherwise specified, demographics and baselineREDACTED COPY Unless otherwise specified, demographics and baseline
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.for discontinuation. The completion of the study is defined as meeting any of the predetermined 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.for discontinuation. The completion of the study is defined as meeting any of the predetermined 
iencing <2 PGTCS within the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.iencing <2 PGTCS within the 
week treatment period. Discontinuation is defined as the completion of the ET Visit
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.week treatment period. Discontinuation is defined as the completion of the ET Visit in all 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.in all 
Section
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Section 4.8
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.4.8
the SS and FAS.  The study termination information will be presented in the subject data listings.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.the SS and FAS.  The study termination information will be presented in the subject data listings.
subject listing will be presented to show all visit dates and the associated 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.subject listing will be presented to show all visit dates and the associated relative day.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.relative day.
The number and percentage of subjects without any important protocol deviations and with at 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.The number and percentage of subjects without any important protocol deviations and with at 
least 1 important protocol deviation in each of the categories defined in the prior to database lock 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.least 1 important protocol deviation in each of the categories defined in the prior to database lock 
All important protocol deviations for subjects in the RS will be listed by site, subject number, 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.All important protocol deviations for subjects in the RS will be listed by site, subject number, 
DEMOGRAPHICS AND OTH
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.DEMOGRAPHICS AND OTH
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.ER BASELINE 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.ER BASELINE 
Unless otherwise specified, demographics and baseline
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Unless otherwise specified, demographics and baseline
Derivation of demographics variables
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Derivation of demographics variables
The body mass index (BMI) will be derived at Baseline only, from the Baseline height and 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.The body mass index (BMI) will be derived at Baseline only, from the Baseline height and 
weight values. BMI will be calculated using t
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.weight values. BMI will be calculated using t
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.* 10000 ) (kg/m  BMI
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.* 10000 ) (kg/m  BMI
UCB   28 Mar 2019  
Statistical Analysis Plan  SP0982  
6.1.2  Analysis of demographics variables 
Baseline demographics will be summarized for the SS and include gender, race, ethnicity, age, 
age category, age strata from IRT, height (cm), weight (kg), BMI (kg/m2). Note age from the 
CRF will be summarized. 
Demographics will be listed for all subjects screened. 
6.2 Other Baseline characteristics 
6.2.1  Derivation of other Baseline characteristics 
6.2.1.1 Time since first diagnosis 
The time since first diagnosis of epilepsy is calculated as follows: 
the date of informed consent – the date of first epilepsy diagnosis/365.25.  
Imputation for partial dates of first epilepsy diagnosis will be imputed as described in 
Section  4.2.2. 
6.2.1.2 Age at diagnosis 
Age at diagnosis of epilepsy will be calculated using the first epilepsy diagnosis date and the date 
of birth. Imputation for partial dates of first epilepsy diagnosis will be imputed as described in 
Section  4.2.2. 
6.2.2  Analysis of other Baseline characteristics 
Combined Baseline PGTCS frequency, 12-week Historical Baseline PGTCS frequency, and 4-
week Prospective Baseline PGTCS frequency derived as frequencies per 28 days will be 
summarized as continuous data. Combined Baseline PGTCS frequency will also be summarized 
as categorical data (≤2 per 28 days and >2 per 28 days) from the CRF and IRT at randomization. 
The following Baseline characteristics will also be presented: 
 Time since first diagnosis at date of consent 
 Age at diagnosis of epilepsy 
 Number of lifetime AEDs and Benzodiazepines (0, 1-3, 4-6, ≥7)  
 Concomitant benzodiazepine use at study entry (yes, no) 
 ILAE (1989) Seizure classification history 
 Classification of epileptic syndrome 
 Etiology of epilepsy 
All Baseline characteristics will be presented in data listings. All reproductive potential and birth 
control information will be presented in data listings. 
6.3 Subgroups 
All subgroups detailed in Section  4.8 will be summarized in a table for the SS and FAS. 
Subgroup identification will also be listed. REDACTED COPY of birth. Imputation for partial dates of first epilepsy diagnosis will be imputed as described in 
REDACTED COPY of birth. Imputation for partial dates of first epilepsy diagnosis will be imputed as described in 
Analysis of other Baseline characteristics
REDACTED COPY Analysis of other Baseline characteristics
week Historical Baseline PGTCS frequency, and 4
REDACTED COPY week Historical Baseline PGTCS frequency, and 4
week Prospective Baseline PGTCS frequency derived as frequenc
REDACTED COPY week Prospective Baseline PGTCS frequency derived as frequenc
summarized as continuous data. Combined Baseline PGTCS frequency will also be summarized 
REDACTED COPY summarized as continuous data. Combined Baseline PGTCS frequency will also be summarized 
as categorical data (≤2 per 28 days and >2 per 28 days) from the CRF and IRT at randomization.REDACTED COPY as categorical data (≤2 per 28 days and >2 per 28 days) from the CRF and IRT at randomization.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Imputation for partial dates of first epilepsy diagnosis will be imputed as described in 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Imputation for partial dates of first epilepsy diagnosis will be imputed as described in 
Age at diagnosis of epilepsy will be calculated using the first epilepsy diagnosis date and the date 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Age at diagnosis of epilepsy will be calculated using the first epilepsy diagnosis date and the date 
of birth. Imputation for partial dates of first epilepsy diagnosis will be imputed as described in 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.of birth. Imputation for partial dates of first epilepsy diagnosis will be imputed as described in 
Analysis of other Baseline characteristics
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Analysis of other Baseline characteristics
week Historical Baseline PGTCS frequency, and 4
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.week Historical Baseline PGTCS frequency, and 4
week Prospective Baseline PGTCS frequency derived as frequenc
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.week Prospective Baseline PGTCS frequency derived as frequenc
summarized as continuous data. Combined Baseline PGTCS frequency will also be summarized 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.summarized as continuous data. Combined Baseline PGTCS frequency will also be summarized 
as categorical data (≤2 per 28 days and >2 per 28 days) from the CRF and IRT at randomization.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.as categorical data (≤2 per 28 days and >2 per 28 days) from the CRF and IRT at randomization.
The following Baseline characteristics will also
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.The following Baseline characteristics will also
Time since first diagnosis at date of consent
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Time since first diagnosis at date of consent
Age at diagnosis of epilepsy
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Age at diagnosis of epilepsy
Number of lifetime AEDs and Benzodiazepines (0, 1
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Number of lifetime AEDs and Benzodiazepines (0, 1
Concomitant benzodiazepine use at study entry (yes, no)
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Concomitant benzodiazepine use at study entry (yes, no)
ILAE (1989) Seizure classification history
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.ILAE (1989) Seizure classification history
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.sification of epileptic syndrome
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.sification of epileptic syndrome
Etiology of epilepsy
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Etiology of epilepsy
All Baseline characteristics will be presented in data listings. All reproductive potential and birth 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.All Baseline characteristics will be presented in data listings. All reproductive potential and birth 
control information will be presented in data listings.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.control information will be presented in data listings.
6.3
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.6.3
UCB   28 Mar 2019  
Statistical Analysis Plan  SP0982  
6.4 Medical history and concomitant diseases 
Previous and ongoing medical history conditions will be summarized by system organ class 
(SOC) and preferred term (PT) for the SS. A similar summary will be provided for concomitant diseases for the SS. Concomitant diseases are medical history events which are ongoing at the Screening Visit.  
The data, including the SOC, PT and verbatim reported term, will also be presented in data 
listings. A glossary of medical history SOC and PTs will also be completed. 
6.5 Procedure history 
All procedure history will be presented in data listings. 
6.6 Prior and concomitant medications 
Medications with a start date before the first dose of study medication will be considered prior medications. Medications taken on or after the date of the first dose of study medication will be 
considered concomitant medications. Medications with a missing start date whose stop date is 
either unknown or after the date of the first dose of study medication will be considered concomitant. Medications with a missing start date whose stop date is prior to the date of the first dose of study medication will be considered as prior medications.  
Details regarding imputation of incomplete dates are described in Section  4.2.3 . 
Medications will be summarized using the Anatomical Therapeutic Chemical (ATC) codes from 
the WHO-DD. All tabulations will be sorted by frequency of the higher-level ATC code and by 
frequency of the lower level ATC code within the higher-level ATC code. 
Medications (excluding AEDs and benzodiazepines) will be summarized separately for prior and 
concomitant medications by ATC level 1 (anatomical main group) and ATC level 2 (therapeutic 
subgroup) for the SS. 
Lifetime AEDs and benzodiazepines will be summarized separately by ATC level 4 (chemical 
subgroup) and PT for the SS. AEDs and benzodiazepines at study entry will also be summarized 
separately by ATC level 4 and PT for the SS.  
Concomitant AEDs will be defined by a manual medical review of all unique ATC codes and 
indications reported in the database to identify medications taken to treat epilepsy. Concomitant 
AEDs and benzodiazepines taken for any epilepsy indication during the Treatment Period will be summarized separately by ATC level 4 and PT for the SS. 
A glossary of ATC codes and associated investigator’s terms for all AEDs or benzodiazepines 
and all other medications (excluding AEDs and benzodiazepines) will be listed separately in data 
listings. The WHO-DD coding and other information for AEDs or benzodiazepines and all other 
medications (excluding AEDS and benzodiazepines) will be listed separately in subject data 
listings. AEDs flagged as rescue medications will also be list ed in subject data listings. 
7 MEASUREMENTS OF TREA TMENT COMPLIANCE  
Compliance data will be included in subject data listings. REDACTED COPY Details regarding imputation of incomplete dates are described in 
REDACTED COPY Details regarding imputation of incomplete dates are described in 
Medications will be summarized using the Anatomical Therapeutic Chemical (ATC) codes from 
REDACTED COPY Medications will be summarized using the Anatomical Therapeutic Chemical (ATC) codes from 
rted by frequency of the higher
REDACTED COPY rted by frequency of the higher
evel ATC code within the higher
REDACTED COPY evel ATC code within the higher
Medications (excluding AEDs and benzodiazepines) will be summarized separately for prior and 
REDACTED COPY Medications (excluding AEDs and benzodiazepines) will be summarized separately for prior and 
concomitant medications by ATC level 1 (anatomical main group) and ATC level 2 (therapeutic REDACTED COPY concomitant medications by ATC level 1 (anatomical main group) and ATC level 2 (therapeutic 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Medications with a start date before the first dose of study medication will be considered prior 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Medications with a start date before the first dose of study medication will be considered prior 
medications. Medications taken on or after the date of the first dose of study medication will be 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.medications. Medications taken on or after the date of the first dose of study medication will be 
concomitant medications. Medications with a missing start date whose stop date is 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.concomitant medications. Medications with a missing start date whose stop date is 
either unknown or after the date of the first dose of study medication will be considered 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.either unknown or after the date of the first dose of study medication will be considered 
concomitant. Medications with a missing start date whose stop date is prior to the d
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.concomitant. Medications with a missing start date whose stop date is prior to the d
dose of study medication will be considered as prior medications. 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.dose of study medication will be considered as prior medications. 
Details regarding imputation of incomplete dates are described in 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Details regarding imputation of incomplete dates are described in 
Medications will be summarized using the Anatomical Therapeutic Chemical (ATC) codes from 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Medications will be summarized using the Anatomical Therapeutic Chemical (ATC) codes from 
rted by frequency of the higher
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.rted by frequency of the higher
evel ATC code within the higher
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.evel ATC code within the higher
Medications (excluding AEDs and benzodiazepines) will be summarized separately for prior and 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Medications (excluding AEDs and benzodiazepines) will be summarized separately for prior and 
concomitant medications by ATC level 1 (anatomical main group) and ATC level 2 (therapeutic 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.concomitant medications by ATC level 1 (anatomical main group) and ATC level 2 (therapeutic 
Lifetime AEDs and benzodiazepines will be summarized separately by ATC level 4 (chemical 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Lifetime AEDs and benzodiazepines will be summarized separately by ATC level 4 (chemical 
subgroup) and PT for the SS. AEDs and benzodiazepines at study entry will also be summarized 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.subgroup) and PT for the SS. AEDs and benzodiazepines at study entry will also be summarized 
separately by ATC level 4 and PT for the SS. 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.separately by ATC level 4 and PT for the SS. 
EDs will be defined by a manual medical review of all unique ATC codes and 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.EDs will be defined by a manual medical review of all unique ATC codes and 
indications reported in the database to identify medications taken to treat epilepsy. Concomitant 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.indications reported in the database to identify medications taken to treat epilepsy. Concomitant 
AEDs and benzodiazepines taken for any epilepsy indication during the Treatment Per
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.AEDs and benzodiazepines taken for any epilepsy indication during the Treatment Per
summarized separately by ATC level 4 and PT for the SS.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.summarized separately by ATC level 4 and PT for the SS.
A glossary of ATC codes and associated investigator’s terms for all AEDs or benzodiazepines 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.A glossary of ATC codes and associated investigator’s terms for all AEDs or benzodiazepines 
and all other medications (excluding AEDs and benzodiazepines) will be listed separately in
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.and all other medications (excluding AEDs and benzodiazepines) will be listed separately in
listings. The WHO
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.listings. The WHO
medications (excluding AEDS and benzodiazepines) will be listed separately in subject data 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.medications (excluding AEDS and benzodiazepines) will be listed separately in subject data 
listings.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.listings.
7
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.7
UCB   28 Mar 2019  
Statistical Analysis Plan  SP0982  
8 EFFICACY ANALYSES  
Most efficacy analyses will be performed using the FAS population; in other cases, the 
population will be stated. 
For primary efficacy endpoint analyses, only data up to and including the day of the event, the 
Visit 10 date, last Treatment Period dose date, Day 166 or the date of the 125th event, whichever 
is earlier, will be included. For the secondary efficacy endpoint analyses, only data up to and including the day of the first PGTCS, the Visit 10 date, the last Treatment Period dose date, Day 166 or the date of the 125
th event, whichever is earlier, will be included. For all other exploratory 
efficacy variables, all appropriate seizure data during the Treatment Period, will be included. All seizure diary data will be listed including data not included in efficacy analyses. 
Testing for the primary efficacy endpoint will be done at the 5% level (2-sided). Provided that 
the primary efficacy endpoint is statistically significant, a gatekeeping strategy will be used to 
test the key secondary efficacy variable, seizure freedom. No additional adjustments for 
multiplicity are required as all additional inferences will be hypothesis-generating only. 
8.1 Statistical analysis of the primary efficacy variable 
8.1.1  Derivations of primary efficacy variable 
For the primary efficacy variable, an event and how time to event is calculated is described in Section  3.2.3, keeping in mind Section  3.2.2. Cens oring of subjects for this analysis will be as 
described in Section  3.2.4  . If a day is marked in the CRF as “not done”, it will be assumed that 
no seizures occurred on that day.  
8.1.2  Primary analysis of the primary efficacy variable 
The primary efficacy variable, time to event during the 166-day Treatment Period, will be 
evaluated using a Cox proportional hazards regression model (C ox, 1972), with an effect for 
treatment, stratifying for the subjects’ Baseline PGTCS frequency (≤2 per 28 days vs >2 per 28 
days in the Combined Baseline Period) and age at informed consent (≥ 4 to <12 years of age, 
≥12 to <18 years of age vs ≥18 years of age). The analysis will use the stratification factors from 
IRT and pooled as described in Section 4.9.   
The hypothesis for the assessment of primary efficacy variable (time to event) is as follows: 
H
0: β=0 
Versus 
H1: β≠0 
where β is the coefficient of an independent variable representing the treatment effect in the 
model. The hazard function is represented by 
ℎ(𝑡,𝑋)= ℎ0(𝑡)exp(∑𝛽 𝑗𝑋𝑗𝑝
𝑗=1) 
 
where xj is the collection of independent variables and h0(t) is the baseline hazard at time t. For 
the null hypothesis, the testing will be 2-sided with an α=0.05; the p -value will be presented. The REDACTED COPY and how time to event
REDACTED COPY and how time to event
oring of subjects for this analysis will be as 
REDACTED COPY oring of subjects for this analysis will be as 
. If a day is marked in the CRF as “not done”, it will be assumed that 
REDACTED COPY . If a day is marked in the CRF as “not done”, it will be assumed that 
Primary analysis of the primary efficacy variable
REDACTED COPY Primary analysis of the primary efficacy variable
e, time to event during the 166
REDACTED COPY e, time to event during the 166
evaluated using a Cox proportional hazards regression model REDACTED COPY evaluated using a Cox proportional hazards regression model
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.including the day of the first PGTCS, the Visit 10 date, the last Treatment Period dose date, Day 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.including the day of the first PGTCS, the Visit 10 date, the last Treatment Period dose date, Day 
For all other exploratory 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.For all other exploratory 
propriate seizure data during the Treatment Period, will be included. All 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.propriate seizure data during the Treatment Period, will be included. All 
sided). Provided that 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.sided). Provided that 
e primary efficacy endpoint is statistically significant, a gatekeeping strategy will be used to 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.e primary efficacy endpoint is statistically significant, a gatekeeping strategy will be used to 
. No additional adjustments for 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.. No additional adjustments for 
generating only.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.generating only.
Statistical analysis of the primary efficacy variable
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Statistical analysis of the primary efficacy variable
and how time to event
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.and how time to event is calculated is described in 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.is calculated is described in 
oring of subjects for this analysis will be as 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.oring of subjects for this analysis will be as 
. If a day is marked in the CRF as “not done”, it will be assumed that 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.. If a day is marked in the CRF as “not done”, it will be assumed that 
Primary analysis of the primary efficacy variable
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Primary analysis of the primary efficacy variable
e, time to event during the 166
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.e, time to event during the 166
evaluated using a Cox proportional hazards regression model
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.evaluated using a Cox proportional hazards regression model
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.treatment, stratifying for the subjects’ Baseline PGTCS frequency (≤2 per 28 days vs >2 per 28 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.treatment, stratifying for the subjects’ Baseline PGTCS frequency (≤2 per 28 days vs >2 per 28 
days in the Combined Baseline Period) and age at informed consent (≥ 4 to <12 years of age, 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.days in the Combined Baseline Period) and age at informed consent (≥ 4 to <12 years of age, 
≥12 to <18 years of age vs ≥18 yea
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.≥12 to <18 years of age vs ≥18 yea rs of age). The analysis will use the stratification factors from 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.rs of age). The analysis will use the stratification factors from 
IRT and pooled as described in Section
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.IRT and pooled as described in Section
The hypothesis for the assessment of primary efficacy variable (time to event) is as follows:
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.The hypothesis for the assessment of primary efficacy variable (time to event) is as follows:
here β is the coefficient of an independent variable representing the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.here β is the coefficient of an independent variable representing the 
model. 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.model. The hazard function is represented by
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.The hazard function is represented by
UCB   28 Mar 2019  
Statistical Analysis Plan  SP0982  
assumptions of proportional hazards will also be assessed graphically (e.g. log (log S) plot vs 
time, empirical score process) for any departure; non-proportionality is not expected when using 
a stratified Cox model. Depending on the departure from proportional hazards, a sensitivity analysis (e.g. piecewise proportional hazards, time-varying coefficient, restricted mean survival) 
may be performed.  
The stratified hazard ratio (HR) will be calculated using the placebo arm as the reference group. 
The 95% CI for the HR will also be reported.  
Additionally, a Kaplan-Meier (KM) plot for time to event as well as the KM estimate for the 
median time to event and 95% CI will be provided. If the median time is not estimable, then the 25
th percentile and 95% CI will be provided. The number of events will be reported by treatment 
group for the Titration Period, first 12 Weeks, and Treatment Period as well as the % of subjects 
who were censored in the analysis. 
8.1.3  Secondary analyses of the primary efficacy variable 
The summary of time to the event during the 166-day Treatment Period will be presented by all 
subgroup for the FAS. A KM plot for time to second PGTCS by all subgroups will also be 
provided.  8.1.4  Supportive and sensitivity analyses of the primary efficacy variable 
The following additional sensitivity analyses on the primary efficacy endpoint will be conducted 
in order to assess the effect of dropouts, important protocol deviations, and operational bias on 
the primary endpoint:   
 Repeat the primary efficacy analysis using the PPS. 
 Repeat the primary efficacy analysis using all PGTCS data (ie, all reported events after the 
date of the 125
th event ) through each subject’s first 166 days of treatment, on the FAS. 
 Repeat the primary efficacy analysis using the FAS, except all subjects who prematurely discontinue due to lack of efficacy, consent withdrawn, or lost to follow-up will be analyzed as treatment failures (ie, events at the time of discontinuation). 
 Repeat the primary efficacy analysis using the FAS, except all subjects who prematurely 
discontinue due to lack of efficacy or AEs only will be analyzed as treatment failures. 
 Repeat the primary efficacy analysis using the FAS, comparing the event rates prior to vs 
after each interim analysis to examine possible operational bias due to unblinding. 
 Repeat the primary efficacy analysis using the FAS, except all subjects who prematurely 
discontinue after their 1
st PGTC S will be analyzed as treatment failures. 
8.2 Statistical analysis of the secondary efficacy variables 
Provided that the primary efficacy endpoint is statistically significant, a gatekeeping strategy will 
be used to test the key secondary efficacy variable. Analyses of all other secondary efficacy variables will be descriptive in manner only. Any p-values or confidence limits provided other 
than those for the primary efficacy analysis of the primary efficacy variable (as described in 
Section 8.1.2) and the analysis of the key secondary efficacy variable will be exploratory only.  REDACTED COPY The following additional sensitivity analyses on the primary efficacy endpoint will be conducted 
REDACTED COPY The following additional sensitivity analyses on the primary efficacy endpoint will be conducted 
in order to assess the effect of dropouts, importan
REDACTED COPY in order to assess the effect of dropouts, importan t protocol deviations, and operational bias on 
REDACTED COPY t protocol deviations, and operational bias on 
Repeat the primary efficacy analysis using the PPS.
REDACTED COPY Repeat the primary efficacy analysis using the PPS.
Repeat the primary efficacy analysis using all PGTCS data (ie, all reported events
REDACTED COPY Repeat the primary efficacy analysis using all PGTCS data (ie, all reported events
) through each su REDACTED COPY ) through each su
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Meier (KM) plot for time to event as well as the KM estimate for the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Meier (KM) plot for time to event as well as the KM estimate for the 
nt and 95% CI will be provided. If the median time is not estimable, then the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.nt and 95% CI will be provided. If the median time is not estimable, then the 
percentile and 95% CI will be provided. The number of events will be reported by treatment 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.percentile and 95% CI will be provided. The number of events will be reported by treatment 
e % of subjects 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.e % of subjects 
Secondary analyses of the primary efficacy variable
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Secondary analyses of the primary efficacy variable
Treatment Period will be presented by 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Treatment Period will be presented by 
subgroups will also be 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.subgroups will also be 
Supportive and sensitivity analyses of the primary efficacy variable
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Supportive and sensitivity analyses of the primary efficacy variable
The following additional sensitivity analyses on the primary efficacy endpoint will be conducted 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.The following additional sensitivity analyses on the primary efficacy endpoint will be conducted 
t protocol deviations, and operational bias on 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.t protocol deviations, and operational bias on 
Repeat the primary efficacy analysis using the PPS.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Repeat the primary efficacy analysis using the PPS.
Repeat the primary efficacy analysis using all PGTCS data (ie, all reported events
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Repeat the primary efficacy analysis using all PGTCS data (ie, all reported events
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.) through each su
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.) through each su bject’s first 166 days of treatment, on the FAS.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.bject’s first 166 days of treatment, on the FAS.
Repeat the primary efficacy analysis using the FAS, except all subjects who prematurely 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Repeat the primary efficacy analysis using the FAS, except all subjects who prematurely 
discontinue due to lack of efficacy, consent withdrawn, or lost to follow
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.discontinue due to lack of efficacy, consent withdrawn, or lost to follow
, events at the time of discontinuation).
This document cannot be used to support any marketing authorization application and any extensions or variations thereof., events at the time of discontinuation).
Repeat the primary efficacy analysis using the FAS, except all subjects who prematurely 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Repeat the primary efficacy analysis using the FAS, except all subjects who prematurely 
discontinue due to lack of efficacy or AEs only will be analyzed as treatment failures.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.discontinue due to lack of efficacy or AEs only will be analyzed as treatment failures.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Repeat the primary efficacy analysis u
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Repeat the primary efficacy analysis u
after each interim analysis to examine possible operational bias due to unblinding.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.after each interim analysis to examine possible operational bias due to unblinding.
Repeat the primary efficacy analysis using the FAS, except all subjects who prematurely 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Repeat the primary efficacy analysis using the FAS, except all subjects who prematurely 
discontinue after their 1
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.discontinue after their 1
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Provided that the primary efficacy endpoint is statistically significant, a gatekeeping strategy will 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Provided that the primary efficacy endpoint is statistically significant, a gatekeeping strategy will 
be used to test the key secondary efficacy variable. An
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.be used to test the key secondary efficacy variable. An
variables will be descriptive in manner only. Any p
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.variables will be descriptive in manner only. Any p
UCB   28 Mar 2019  
Statistical Analysis Plan  SP0982  
8.2.1  Derivations of secondary efficacy variables 
8.2.1.1 Variable: Seizure freedom for PGTCS for the 166-day Treatment 
Period 
A seizure-free day from PGTCS will be defined as a day where no PGTCS were reported in the 
seizure diary and PGTCS were assessed. Days in the seizure diary which are marked as “not 
done” on the CRF will be counted as seizure- free days  from PGTCS. 
A subject will have seizure freedom from PGTCS for the 166-day Treatment Period if the 
subject completed the Treatment Period and reported zero PGTCS  or “not done” for all days 
during the 166-day Treatment Period. Ongoing subjects who are seizure- free from PGTCS on the 
date of the 125th event do not have seizure-freedom from PGTCS unless they are seizure- free 
from PGTCS for 166 days. 
8.2.1.2 Variable: Time to first PGTCS during the 166-day Treatment Period 
For PGTCS, how the time to first PGTCS is calculated is described in Section 3.2.3.  Censoring 
of subjects for this analysis will be as described in Section  3.2.4 . 
If a day is marked in the CRF as “not done”, it will be assumed that no seizures occurred on that 
seizure diary day. 
8.2.2  Analysis of secondary efficacy variables 
Analyses of secondary efficacy variables will be performed for the FAS. 8.2.2.1 Analysis: Seizure freedom for PGTCS for the 166-day Treatment 
Period 
Analysis of the key secondary efficacy variable, seizure freedom for PGTCS for the 166- day 
Treatment Period, will be evaluated using an extended Mantel-Haenszel testing procedure which 
takes into account that the subjects were initially stratified for the subjects’ Baseline PGTCS 
frequency (≤2 per 28 days vs >2 per 28 days in the Combined Baseline Period) and age at 
informed consent (≥ 4 to <12 years of age, ≥12 to <18 years of age vs ≥18 years of age). The analysis will use the stratification factors from IRT and pooled as described in Section 4.9.  
The hypothesis for the assessment of the key secondary efficacy (PGTC seizure-freedom) is as 
follows: 
H
0: S(t=166) LCM = S(t=166) PBO  
Versus 
H1: S(t=166) LCM ≠ S(t=166)PBO  
Where S(t=166) is the cumulative rate of subjects remaining seizure -free from PGTCS for 166 
days. 
Estimation of treatment difference: 
KM methods will be used to estimate the proportion of subjects remaining seizure- free from 
PGTCS  at Day 166. The estimate for the difference in Day 166 seizure-freedom from PGTCS 
will be adjusted for subjects’ Baseline PGTCS frequency (≤2 per 28 days vs >2 per 28 days in 
the Combined Baseline Period) and age at informed consent (≥ 4 to <12 years of age, ≥12 to <18 
years of age vs ≥18 years of age). The estimate for the stratified difference in proportion of REDACTED COPY secondary efficacy variables
REDACTED COPY secondary efficacy variables
Analyses of secondary efficacy variables will be performed for the FAS.
REDACTED COPY Analyses of secondary efficacy variables will be performed for the FAS.
Analysis: Seizure freedom for PGTCS for the 
REDACTED COPY Analysis: Seizure freedom for PGTCS for the 
Analysis of the key secondary efficacy variable, seizur
REDACTED COPY Analysis of the key secondary efficacy variable, seizur
Treatment Period, will be evaluated using an extended Mantel REDACTED COPY Treatment Period, will be evaluated using an extended Mantel
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.or “not done” for all days 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.or “not done” for all days 
from PGTCS 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.from PGTCS on the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.on the 
unless they are seizure
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.unless they are seizure -
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.-free 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.free 
Treatment Period
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Treatment Period
how the time to first PGTCS is calculated is described in Section
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.how the time to first PGTCS is calculated is described in Section 3.2.3
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.3.2.3
If a day is marked in the CRF as “not done”, it will be assumed that no seizures occurred on that 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.If a day is marked in the CRF as “not done”, it will be assumed that no seizures occurred on that 
secondary efficacy variables
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.secondary efficacy variables
Analyses of secondary efficacy variables will be performed for the FAS.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Analyses of secondary efficacy variables will be performed for the FAS.
Analysis: Seizure freedom for PGTCS for the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Analysis: Seizure freedom for PGTCS for the 
Analysis of the key secondary efficacy variable, seizur
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Analysis of the key secondary efficacy variable, seizur
Treatment Period, will be evaluated using an extended Mantel
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Treatment Period, will be evaluated using an extended Mantel
takes into account that the subjects were initially stratified for the subjects’ Baseline PGTCS 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.takes into account that the subjects were initially stratified for the subjects’ Baseline PGTCS 
frequency (≤2 per 28 days vs >2 per 28 days in the Combined B
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.frequency (≤2 per 28 days vs >2 per 28 days in the Combined B
informed consent (≥ 4 to <12 years of age, ≥12 to <18 years of age vs ≥18 years of age). The 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.informed consent (≥ 4 to <12 years of age, ≥12 to <18 years of age vs ≥18 years of age). The 
analysis will use the stratification factors from IRT and pooled as described in Section
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.analysis will use the stratification factors from IRT and pooled as described in Section
The hypothesis for the assessment of the key secondary efficacy (PGTC seizure
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.The hypothesis for the assessment of the key secondary efficacy (PGTC seizure
Where 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Where S
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.S(
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.(S(S
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.S(St
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.t=166) is the cumulative rate of subjects remaining seizure
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.=166) is the cumulative rate of subjects remaining seizure
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.days.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.days.
Estimation of treatment difference
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Estimation of treatment difference
KM methods will be used to estimate the proportion of subjects remaining seizure
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.KM methods will be used to estimate the proportion of subjects remaining seizure
UCB   28 Mar 2019  
Statistical Analysis Plan  SP0982  
subjects who are seizure- free from PGTCS on LCM vs PBO and a corresponding 95% two-sided 
confidence interval (CI LCM -PBO) will be produced using mantel Haenszel methods (LaVange et al, 
2005). The statistical methodology is expressed as follows: 
 d=∑wh(Sh1-Sh2)6
h=1  
Where Shi=KM estimate of 166-day seizure freedom from PGTCS for treatment i (1=LCM and 
2=PBO) in stratum h (1= ≤2 per 28 days Baseline PGTC S frequency and ≥ 4 to <12 years of age, 
2= ≤2 per 28 days Baseline PGTC S frequency and ≥12 to <18 years of age, 3= =≤2 per 28 days 
Baseline PGTCS frequency and ≥18 years of age, 4= >2 per 28 days Baseline PGTC S frequency 
and ≥ 4 to <12 years of age, 5= >2 per 28 days Baseline PGTC S frequency and ≥12 to <18 years 
of age and 6= >2 per 28 days Baseline PGTC S frequency and ≥18 years of age and 
wh={(nh1*nh2)/(nh1+nh2)}/∑{(nh1*nh2)6h=1/(nh1+nh2)}} 
where n hi is the number of subjects in I treatment group and stratum h.  The variance of d is 
calculated as Var(d)=∑wh2 6
h=1{Var(S h1)+Var(S h2)} where Var(S h1) and Var(S h2) are the 
Greenwood estimates of variance for Sh1 and S h2. 
The stratified proportion of subjects remaining seizure free from PGTCS for at least 166 days in 
each treatment group and the associated variance are derived as follows using Mantel Haneszel methods: 
The KM estimate for the LCM 166-day seizure-freedom from PGTCS rate is calculated as 
𝑆
1=∑𝑤ℎ6
ℎ=1𝑆ℎ1 
The KM estimate for the PBO 166-day seizure-freedom from PGTCS rate is calculated as 
𝑆2=∑𝑤ℎ6
ℎ=1𝑆ℎ2 
The variance is S1 is calculated as Var (𝑆1) =∑𝑤ℎ6 6
ℎ=1𝑉𝑎𝑟(𝑆ℎ1) 
The variance of S2 is calculated as Var (𝑆2) =∑𝑤ℎ6 6
ℎ=1𝑉𝑎𝑟(𝑆ℎ2) 
In order to assess superiority, 2-sided testi ng with α=0.05 will be used. The superiority test 
statistic, Q=d2/Var(d)  will be assessed by a chi-square distribution with 1 degree of freedom. 
This statistic is referred to as the “row mean score statistic” when using Proc Freq. 
The number and percentage of subjects who experience a PGTCS or censoring and the KM 
seizure-free rate from PGTCS (and 2-sided 95% CI) by Day 166 will be presented by treatment 
group for each stratum and overall. The stratified seizure-freedom rate from PGTCS (and 2-sided 
95% CI) at Day 166 for each treatment group and the difference between treatment groups will 
be presented. A Kaplan-Meier plot will be presented by treatment group for each stratum and 
overall. 
For the gatekeeping strategy, if the primary endpoint is statistically significant at the 5% level, 
then the key secondary efficacy endpoint will also be assessed at the 5% significance level. If the primary endpoint fails to reach statistical significance, then the key secondary efficacy endpoint will be exploratory only. 
8.2.2.2 Analysis: Time to first PGTCS during the 166-day Treatment Period 
Time to the first PGTCS during the 24-week Treatment Period will be evaluated using a Cox 
proportional hazards regression model (Cox, 1972), with an effect for treatment, stratifying for 
the subjects’ Baseline PGTCS frequency (≤2 per 28 days vs >2 per 28 days in the Combined REDACTED COPY freedom
REDACTED COPY freedom from PGTCS
REDACTED COPY from PGTCS
day seizure
REDACTED COPY day seizure -
REDACTED COPY -freedom
REDACTED COPY freedom
Var
REDACTED COPY Var(
REDACTED COPY (𝑆
REDACTED COPY 𝑆1
REDACTED COPY 1)
REDACTED COPY )
VarREDACTED COPY Var
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.frequency and ≥12 to <18 years of age, 3= =≤2 per 28 days 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.frequency and ≥12 to <18 years of age, 3= =≤2 per 28 days 
frequency 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.frequency 
cy and ≥12 to <18 years 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.cy and ≥12 to <18 years 
is the number of subjects in I treatment group and stratum h.  The variance of 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.is the number of subjects in I treatment group and stratum h.  The variance of 
Var(S
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Var(S h2
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.h2 Var(S h2 Var(S
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Var(S h2 Var(S )
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.)
from PGTCS
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.from PGTCS for at least 166 days in 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.for at least 166 days in 
each treatment group and the associated variance are derived as follows using Mantel Haneszel 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.each treatment group and the associated variance are derived as follows using Mantel Haneszel 
from PGTCS
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.from PGTCS
freedom
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.freedom from PGTCS
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.from PGTCS
=
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.=∑
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.∑6
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.6
ℎ
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.ℎ
(
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.(𝑆
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.𝑆2
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.2)
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.)=
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.=
sided testi
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.sided testi
will be assessed by a chi
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.will be assessed by a chi
This statistic is referred to as the “row mean score statistic” when using Proc Freq.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This statistic is referred to as the “row mean score statistic” when using Proc Freq.
The number and percentage
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.The number and percentage of subjects who experience a PGTCS or censoring and the KM 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.of subjects who experience a PGTCS or censoring and the KM 
from PGTCS
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.from PGTCS
group for each stratum and overall. The stratified seizure
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.group for each stratum and overall. The stratified seizure
at Day 166 for each treatment group and the difference between treatment groups will 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.at Day 166 for each treatment group and the difference between treatment groups will 
be presented. A Kaplan
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.be presented. A Kaplan
For the gatekeeping strategy, i
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.For the gatekeeping strategy, i
then the key secondary efficacy endpoint will also be assessed at the 5% significance level. If the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.then the key secondary efficacy endpoint will also be assessed at the 5% significance level. If the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.primary endpoint fails to reach statistical significance, then the key secondary efficacy endpoint 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.primary endpoint fails to reach statistical significance, then the key secondary efficacy endpoint 
will be exploratory only.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.will be exploratory only.
UCB   28 Mar 2019  
Statistical Analysis Plan  SP0982  
Baseline Period) and age at informed consent (≥ 4 to <12 years of age, ≥12 to <18 years of age 
vs ≥18 years of age). The analysis will use the stratification factors from IRT and pooled as 
described in Section 4.9.  
The hypothesis for the assessment of the time to first PGTCS is as follows: 
H0: β=0 
Versus 
H1: β≠0 
where β is the coefficient of an independent variable representing the treatment effect in the model. The hazard function is represented by 
ℎ(𝑡,𝑋)= ℎ
0(𝑡)exp(∑𝛽 𝑗𝑋𝑗𝑝
𝑗=1) 
where xj is the collection of independent variables and h0(t) is the baseline hazard at time t. For 
the null hypothesis, the testing will be 2-sided with an α =0.05. The assumptions of proportional 
hazards will also be checked using the same approach as for the primary efficacy endpoint.  
The stratified HR will be calculated using the placebo arm as the reference group. The 95% CI 
for the HR will also be reported.  
Additionally, a KM plot for time to 1st PGTCS  as well as the KM estimate for the median time to 
1st PGTCS and 95% CI will be provided. If the median time is not estimable, then the 25th 
percentile and 95% CI will be provided. The number of 1st PGTCS  will be reported by treatment 
group for the Titration Period, first 12 Weeks, and Treatment Period as well as the % of subjects 
who were censored. 
8.3 Analysis of seizure related other efficacy variables  
All seizure data recorded during the treatment period will be summarized and listed for the 
seizure related other efficacy variables. Analyses of seizure-related other efficacy variables wi ll 
be performed for the FAS. For absence seizure analyses, this analysis population will be further restricted to the subset of subjects who reported a history of absence seizures or reported absence seizures during baseline or the 24-week treatment period.  For myoclonic seizure analyses, this 
analysis population will be further restricted to the subset of subjects who reported a history of 
myoclonic seizures or reported myoclonic seizures during baseline or the 24-week treatment period. 
8.3.1  Derivations of seizure related other efficacy variables 
8.3.1.1 Variable: PGTCS frequency per 28 days  
In order to account for potential differences in the durations of the study periods for individuals, 
PGTCS  data will be normalized to 28 days. 
The 28-day PGTCS frequency (SF) will be calculated for the Combined Baseline and Treatment 
Periods as: 
SF =  
(# PGTCS in the relative period/# days in relative period with evaluable PGTCS data)*28 REDACTED COPY as well as the KM estimate for the median time to 
REDACTED COPY as well as the KM estimate for the median time to 
ovided. If the median time is not estimable, then the 25
REDACTED COPY ovided. If the median time is not estimable, then the 25
e provided. The number of 1
REDACTED COPY e provided. The number of 1
12 Weeks
REDACTED COPY 12 Weeks , and 
REDACTED COPY , and 
Analysis of seizure related other efficacy variablesREDACTED COPY Analysis of seizure related other efficacy variables
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.where β is the coefficient of an independent variable representing the treatment effect in the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.where β is the coefficient of an independent variable representing the treatment effect in the 
) is the baseline hazard at time 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.) is the baseline hazard at time 
=0.05. The assumptions of proportional 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.=0.05. The assumptions of proportional 
using the same approach as for the primary efficacy endpoint
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.using the same approach as for the primary efficacy endpoint
The stratified HR will be calculated using the placebo arm as the reference group. The 95% CI 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.The stratified HR will be calculated using the placebo arm as the reference group. The 95% CI 
as well as the KM estimate for the median time to 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.as well as the KM estimate for the median time to 
ovided. If the median time is not estimable, then the 25
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.ovided. If the median time is not estimable, then the 25
e provided. The number of 1
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.e provided. The number of 1
, and 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof., and Treatment Period
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Treatment Period
Analysis of seizure related other efficacy variables
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Analysis of seizure related other efficacy variables
All seizure data recorded during the treatment period will be summarized and listed for the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.All seizure data recorded during the treatment period will be summarized and listed for the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.seizure related other efficacy variables. Analyses of seizure
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.seizure related other efficacy variables. Analyses of seizure
For absence seizure analyses, this analysis population will be further 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.For absence seizure analyses, this analysis population will be further 
restricted to the subset of subjects who reported a history of absence seizures or reported absence 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.restricted to the subset of subjects who reported a history of absence seizures or reported absence 
seizures during baseline or the 24
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.seizures during baseline or the 24
analysis population will be further restricted to the subset of subjects who reported a history of 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.analysis population will be further restricted to the subset of subjects who reported a history of 
myoclonic seizures or reported myoclonic seizures during baseline or the 24
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.myoclonic seizures or reported myoclonic seizures during baseline or the 24
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Derivations of sei
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Derivations of sei
8.3.1.1
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.8.3.1.1
In order to account for potential differences in the durations of the study periods for individuals, 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.In order to account for potential differences in the durations of the study periods for individuals, 
PGTCS
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.PGTCS
The 28
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.The 28
UCB   28 Mar 2019  
Statistical Analysis Plan  SP0982  
The percent change (PCH) in PGTCS frequency per 28 days from the Combined Baseline (CB) 
to the appropriate analysis period (T) is defined as: 
PCH = [(SFT – SFCB) / SFCB] x 100 
where SFT corresponds to the 28-day PGTCS frequency during the relative period and SFCB 
corresponds to the 28-day Combined Baseline PGTCS frequency. PCH is calculated for 6- week 
Titration Period, first 12 weeks of the Treatment Period and the 24-week Treatment Period. 
 8.3.1.2 Variable: Days with seizures per 28 days 
The number of days with absence seizures per 28 days will be calculated separately for the 
Prospective Baseline and the Treatment Period as:  
D = ([# days with absence seizures in the relative period] / [# days in relative period with 
evaluable seizure data]) * 28. 
Similarly, the number of days with myoclonic seizures per 28 days will be calculated. 
The percent change (PCH) in days with absence seizures per 28 days from the Prospective 
Baseline (B) to the appropriate analysis period (T) is defined as: 
PCH = [(DT – DB) / DB] x 100 
where DT corresponds to the number of days with absence seizures per 28 days during the 
relative period and DB corresponds to the number of days with absence seizures per 28 days 
during the Prospective Baseline Period. If DB is zero, then PCH will be missing and any such subjects will be excluded from the percent change summary. PCH will be calculated for the 6-
week Titration Period, first 12 weeks of the Treatment Period and the 24-week Treatment Period. 
Similarly, the percent change in the number of days with myoclonic seizures per 28 days from the Prospective Baseline Period will be calculated. 
8.3.1.3 Variable: Seizure-free status 
A subject will have seizure-free status for PGTCS =yes for the Treatment Period if the subject 
completed the Treatment Period (with a minimum 166 days) and reported zero PGTCS or “not 
done” for all days during the Treatment Period. If the subject is exited from the study due to the 
125
th event occurring reporting zero PGTCS or “not done” for all days and duration of the 
Treatment Period is < 166 days, then the subject has not achieved seizure-free status for PGTCS.  
A subject will have seizure free status=yes for all generalized seizure types for the applicable 
Treatment Period if the subject completed the Treatment Period and reported zero generalized 
seizures for all days during the Treatment Period when the number of generalized seizures was 
available, and had <10% of days during the Treatment Period with seizure data reported as “not done”. 
Seizure-free statuses will be calculated for 6-week Titration Period, first 12 weeks of the 
Treatment Period and the 24-week Treatment Period. 
8.3.1.4 Variable: Responder status – reduction in PGTCS frequency   
Response to treatment will be based on the percent change in PGTCS frequency, calculated as 
described in  Section  8.3.1.1  . A 50% responder is defined as a subject experiencing ≥50% REDACTED COPY where DT corresponds to the number of days with absence seizures per 28 
REDACTED COPY where DT corresponds to the number of days with absence seizures per 28 
relative period and DB corresponds to the number of days with absence seizures per 28 days 
REDACTED COPY relative period and DB corresponds to the number of days with absence seizures per 28 days 
Baseline Period. If DB is zero, then PCH will be missing and any such 
REDACTED COPY Baseline Period. If DB is zero, then PCH will be missing and any such 
subjects will be excluded from the percent change summar
REDACTED COPY subjects will be excluded from the percent change summar
week Titration Period, first 12 weeks of the Treatment Period and the 24
REDACTED COPY week Titration Period, first 12 weeks of the Treatment Period and the 24
Similarly, the percent change in the number of days with myoclonic seizures per 28 days from REDACTED COPY Similarly, the percent change in the number of days with myoclonic seizures per 28 days from 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.The number of days with absence seizures per 28 days will be calculated separately for the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.The number of days with absence seizures per 28 days will be calculated separately for the 
D = ([# days with absence seizures in the relative period] / [# days in relative period with 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.D = ([# days with absence seizures in the relative period] / [# days in relative period with 
Similarly, the number of days with myoclonic seizures per 28 days will be calculated.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Similarly, the number of days with myoclonic seizures per 28 days will be calculated.
The percent change (PCH) in days with absence seizures per 28 days from the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.The percent change (PCH) in days with absence seizures per 28 days from the 
Baseline (B) to the appropriate analysis period (T) is defined as:
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Baseline (B) to the appropriate analysis period (T) is defined as:
where DT corresponds to the number of days with absence seizures per 28 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.where DT corresponds to the number of days with absence seizures per 28 
relative period and DB corresponds to the number of days with absence seizures per 28 days 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.relative period and DB corresponds to the number of days with absence seizures per 28 days 
Baseline Period. If DB is zero, then PCH will be missing and any such 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Baseline Period. If DB is zero, then PCH will be missing and any such 
subjects will be excluded from the percent change summar
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.subjects will be excluded from the percent change summar
week Titration Period, first 12 weeks of the Treatment Period and the 24
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.week Titration Period, first 12 weeks of the Treatment Period and the 24
Similarly, the percent change in the number of days with myoclonic seizures per 28 days from 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Similarly, the percent change in the number of days with myoclonic seizures per 28 days from 
will be calculated.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.will be calculated.
Variable: Seizure
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Variable: Seizure -
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.-free status
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.free status
free status
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.free status
completed the Treatment Period
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.completed the Treatment Period
done” for all days during the Treatment Period.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.done” for all days during the Treatment Period.
event occurring
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.event occurring reporting zero PGTCS or “not done” for all days
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.reporting zero PGTCS or “not done” for all days
Treatment Period is < 166 days, th
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Treatment Period is < 166 days, th
A subject will have seizure free status=yes for all 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.A subject will have seizure free status=yes for all 
Treatment Period if the subject completed the Treatment Period and reported zero 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Treatment Period if the subject completed the Treatment Period and reported zero 
izures for all days during the Treatment Period when the number of 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.izures for all days during the Treatment Period when the number of 
available, and had <10% of days during the Treatment Period with seizure data reported as “not 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.available, and had <10% of days during the Treatment Period with seizure data reported as “not 
done”.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.done”.
Seizure
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Seizure
Treatment Period and the 24
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Treatment Period and the 24
UCB   28 Mar 2019  
Statistical Analysis Plan  SP0982  
reduction in PGTCS frequency per 28 days from the Combined Baseline to the period of interest 
(6-week Titration Period, first 12 weeks of the Treatment Period or the 24-week Treatment 
Period). A 75% responder is defined as a subject experiencing ≥75% reduction in PGTCS 
frequency per 28 days from Combined Baseline to the period of interest (6 -week Titration 
Period, first 12 weeks of the Treatment Period or the 24-week Treatment Period). 
8.3.1.5 Variable: PG TCS frequency - worsening 
Seizure worsening is defined as a subject experiencing ≥50% increase in PGTCS frequency per 28 days from Combined Baseline to the period of interest (6-week Titration Period, first 12 weeks of the Treatment Period or the 24-week Treatment Period).  
8.3.1.6 Variable: Responder status – reduction in days with absence 
seizures   
Response to treatment for absence seizures per 28 days will be based on the percent change in 
days with absence seizures, calculated as described in  Section  8.3.1.2. A 50% responder is 
defined as a subject experiencing ≥50% reduction in days with absence seizures per 28 days from the Prospective Baseline to the period of interest (6-week Titration Period, first 12 weeks of 
the Treatment Period or the 24-week Treatment Period). A 75% responder is defined as a subject 
experiencing ≥75% reduction in days with absence seizures per 28 days from the Prospective 
Baseline to the period of interest (6-week Titration Period, first 12 weeks of the Treatment Period or the 24-week Treatment Period). 
8.3.1.7 Variable: Responder status – reduction in days with myoclonic 
seizures 
Response to treatment for myoclonic seizures per 28 days will be based on the percent change in 
days with myoclonic seizures, calculated as described in  Section  8.3.1.2. A 50% responder is 
defined as a subject experiencing ≥50% reduction in days with myoclonic seizures per 28 days 
from the Prospective Baseline to the period of interest (6-week Titration Period, first 12 weeks of 
the Treatment Period or the 24-week Treatment Period). A 75% responder is defined as a subject experiencing ≥75% reduction in days with myoclonic seizures per 28 days from the Prospective 
Baseline to the period of interest (6-week Titration Period, first 12 weeks of the Treatment 
Period or the 24-week Treatment Period). 
8.3.1.8 Variable: Days with absence and myoclonic seizures – worse ning 
Safety of the LCM treatment will be based on the percent change in days with absence seizure 
per 28 days and days with myoclonic seizure per 28 days. The increase in days with absence 
seizures per 28 days from Prospective Baseline will be categorized as >0 to 25%, >25 to 50%, 
>50 to 75%, and >75% for the Treatment Period. The increase in days with myoclonic seizures 
per 28 days from Prospective Baseline will be categorized as >0 to 25%, >25 to 50%, >50 to 
75%, and >75% for the Treatment Period. 
8.3.1.9 Variable: Absence and myoclonic seizure frequencies per 28 days  
In order to account for potential differences in the durations of the study periods for individuals, 
absence and myoclonic seizure data will be normalized to 28 days. 
The 28-day absence SF will be calculated for the Prospective Baseline and Treatment Periods as: 
SF =  REDACTED COPY on Period, first 12 weeks of the Treatment 
REDACTED COPY on Period, first 12 weeks of the Treatment 
–
REDACTED COPY –reduction in days with myoclonic 
REDACTED COPY reduction in days with myoclonic 
Response to treatment for myoclonic seizures per 28 days will be based on the percent change in 
REDACTED COPY Response to treatment for myoclonic seizures per 28 days will be based on the percent change in 
with myoclonic seizures, calculated as described in
REDACTED COPY with myoclonic seizures, calculated as described in
defined as a subject experiencing ≥50% reduction in days with REDACTED COPY defined as a subject experiencing ≥50% reduction in days with
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Seizure worsening is defined as a subject experiencing ≥50% increase in PGTCS frequency per 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Seizure worsening is defined as a subject experiencing ≥50% increase in PGTCS frequency per 
reduction in days with absence 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.reduction in days with absence 
s will be based on the percent change in 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.s will be based on the percent change in 
. A 50% responder is 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.. A 50% responder is 
defined as a subject experiencing ≥50% reduction in days with absence seizures per 28 days 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.defined as a subject experiencing ≥50% reduction in days with absence seizures per 28 days 
week Titration Period
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.week Titration Period
week Treatment Period). A 75% responder is defined as a subject 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.week Treatment Period). A 75% responder is defined as a subject 
experiencing ≥75% reduction in days with absence seizures per 28 days from the Prospective 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.experiencing ≥75% reduction in days with absence seizures per 28 days from the Prospective 
on Period, first 12 weeks of the Treatment 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.on Period, first 12 weeks of the Treatment 
reduction in days with myoclonic 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.reduction in days with myoclonic 
Response to treatment for myoclonic seizures per 28 days will be based on the percent change in 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Response to treatment for myoclonic seizures per 28 days will be based on the percent change in 
with myoclonic seizures, calculated as described in
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.with myoclonic seizures, calculated as described in
defined as a subject experiencing ≥50% reduction in days with
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.defined as a subject experiencing ≥50% reduction in days with
from the Prospective Baseline to the period of interest (6
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.from the Prospective Baseline to the period of interest (6
week Treatment Period). A 75% responder is defined as a subject 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.week Treatment Period). A 75% responder is defined as a subject 
n days with myoclonic seizures per 28 days from the Prospective 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.n days with myoclonic seizures per 28 days from the Prospective 
Baseline to the period of interest (6
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Baseline to the period of interest (6
week Treatment Period).
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.week Treatment Period).
Variable: Days with absence and myoclonic seizures 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Variable: Days with absence and myoclonic seizures 
Safety of the LCM treatment will be based on the percent change in days with absence seizure 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Safety of the LCM treatment will be based on the percent change in days with absence seizure 
per 28 days and days with myoclonic seizure per 28 days. The increase in days with absence 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.per 28 days and days with myoclonic seizure per 28 days. The increase in days with absence 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.seizures per 28 days from Prospective Baseline will be categorized 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.seizures per 28 days from Prospective Baseline will be categorized 
>50 to 75%, and >75% for the Treatment Period. The increase in days with
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.>50 to 75%, and >75% for the Treatment Period. The increase in days with
per 28 days from Prospective Baseline will be categorized as >0 to 25%, >25 to 50%, >50 to 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.per 28 days from Prospective Baseline will be categorized as >0 to 25%, >25 to 50%, >50 to 
75%, and >75% for the Treatment Period.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.75%, and >75% for the Treatment Period.
8.3.1.9
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.8.3.1.9
In order to account for potential differences in the durations of the study periods for individuals, 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.In order to account for potential differences in the durations of the study periods for individuals, 
UCB   28 Mar 2019  
Statistical Analysis Plan  SP0982  
(# absence seizures in the relative period/# days in relative period with evaluable absence seizure 
data)*28 
The PCH in Absence seizure frequency per 28 days from the Prospective Baseline (PB) to the 
appropriate analysis period (T) is defined as: 
PCH = [(SFT – SFPB) / SFPB] x 100 
where SFT corresponds to the 28-day absence seizure frequency during the relative period and 
SFPB corresponds to the 28-day Prospective Baseline absence frequency; if subjects had no 
absence seizures in Prospective Baseline, then PCH cannot be calculated. PCH is calculated for 
6-week Titration Period, first 12 weeks of the Treatment Period and the 24-week Treatment Period. 
SF and PCH are calculated for subjects with myoclonic seizures using the same algorithm 
described above. 
8.3.1.10 Variable: Respo nder status – reduction in absence and myoclonic 
seizure freque ncies    
Response to treatment will be based on the percent change in absence and myoclonic seizure 
frequencies, calculated as described in  Section  8.3.1.9 . A 50% responder is defined as a subject 
experiencing ≥50% reduction in absence (or myoclonic) seizure frequency per 28 days from the 
Prospective Baseline to the period of interest (6-week Titration Period, first 12 weeks of the 
Treatment Period or the 24-week Treatment Period). A 75% responder is defined as a subject expe riencing ≥75% reduction in absence (or myoclonic) seizure frequency per 28 days from 
Prospective Baseline to the period of interest (6-week Titration Period, first 12 weeks of the 
Treatment Period or the 24-week Treatment Period). 
8.3.1.11 Variable: Absence and myoclonic seizure frequency - worsening 
Safety of the LCM treatment will be based on the percent change in absence seizure frequ ency 
per 28 days and myoclonic seizure frequency per 28 days. The increase in absence seizure 
frequency per 28 days from Prospective Baseline will be categorized as >0 to 25%, >25 to 50%, 
>50 to 75%, and >75% for the Treatment Period. The increase in myoclonic seizure frequency per 28 days from Prospective Baseline will be categorized as >0 to 25%, >25 to 50%, >50 to 75%, and >75% for the Treatment Period. 
8.3.2  Analysis of seizure related other efficacy variables 
8.3.2.1 Analysis: Percent change in PGTCS frequency per 28 days from 
Combined Baseline  
Descriptive statistics will be provided on the percent change in PGTCS frequency for the first 6 
weeks of (entire Titration Period), first 12 weeks of, and the entire Treatment Period.   
All PGTCS frequency per 28 days data will be listed. 
8.3.2.2 Analysis: Reduction in days with seizures per 28 days 
The following data will be summarized with descriptive statistics only: 
 Change in days with absence seizures per 28 days during the Treatment Period relative to the 
Prospective Baseline REDACTED COPY n absence (or myoclonic) seizure
REDACTED COPY n absence (or myoclonic) seizure
week Titr
REDACTED COPY week Titr
week Treatment Period). A 75% responder is defined as a subject 
REDACTED COPY week Treatment Period). A 75% responder is defined as a subject 
riencing ≥75% reduction in absence (or myoclonic) seizure
REDACTED COPY riencing ≥75% reduction in absence (or myoclonic) seizure
terest (6
REDACTED COPY terest (6 -
REDACTED COPY -week Titration Period, first 12 weeks of the 
REDACTED COPY week Titration Period, first 12 weeks of the 
week Treatment Period).
REDACTED COPY week Treatment Period).
Variable: Absence and myoclonic seizure REDACTED COPY Variable: Absence and myoclonic seizure 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.absence seizures in Prospective Baseline, then PCH cannot be calculated. PCH is calculated for 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.absence seizures in Prospective Baseline, then PCH cannot be calculated. PCH is calculated for 
week Treatment 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.week Treatment 
ith myoclonic seizures using the same algorithm 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.ith myoclonic seizures using the same algorithm 
reduction in absence and myoclonic 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.reduction in absence and myoclonic 
d on the percent change in absence and myoclonic seizure 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.d on the percent change in absence and myoclonic seizure 
. A 50% responder is defined as a subject 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.. A 50% responder is defined as a subject 
n absence (or myoclonic) seizure
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.n absence (or myoclonic) seizure frequen
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.frequen
ation Period, first 12 weeks of the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.ation Period, first 12 weeks of the 
week Treatment Period). A 75% responder is defined as a subject 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.week Treatment Period). A 75% responder is defined as a subject 
riencing ≥75% reduction in absence (or myoclonic) seizure
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.riencing ≥75% reduction in absence (or myoclonic) seizure
week Titration Period, first 12 weeks of the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.week Titration Period, first 12 weeks of the 
week Treatment Period).
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.week Treatment Period).
Variable: Absence and myoclonic seizure 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Variable: Absence and myoclonic seizure 
LCM treatment will be based on the percent change in absence 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.LCM treatment will be based on the percent change in absence 
frequency 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.frequency 
er 28 days from Prospective Baseline will be categorized as >0 to 25%, >25 to 50%, 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.er 28 days from Prospective Baseline will be categorized as >0 to 25%, >25 to 50%, 
>50 to 75%, and >75% for the Treatment Period. The increase in myocl
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.>50 to 75%, and >75% for the Treatment Period. The increase in myocl
28 days from Prospective Baseline will be categorized as >0 to 25%, >25 to 50%, >50 to 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.28 days from Prospective Baseline will be categorized as >0 to 25%, >25 to 50%, >50 to 
75%, and >75% for the Treatment
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.75%, and >75% for the Treatment
Analysis of seizure related other efficacy variables
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Analysis of seizure related other efficacy variables
Analysis: Percent change in PGTCS frequency per 2
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Analysis: Percent change in PGTCS frequency per 2
Combined Baseline 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Combined Baseline 
Descriptive statistics will be provided on the percent change in PGTCS frequency for the first 6 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Descriptive statistics will be provided on the percent change in PGTCS frequency for the first 6 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.weeks of
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.weeks of (entire 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.(entire 
All PGTCS frequency per 28 days data 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.All PGTCS frequency per 28 days data 
8.3.2.2
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.8.3.2.2
UCB   28 Mar 2019  
Statistical Analysis Plan  SP0982  
 Percent change in days with absence seizures per 28 days during the first 6 weeks of the 
Treatment Period (Titration Period) relative to the Prospective Baseline 
 Percent change in days with absence seizures per 28 days during the first 12 weeks of the Treatment Period relative to the Prospective Baseline 
 Percent change in days with absence seizures per 28 days during the Treatment Period relative to the Prospective Baseline 
 Change in days with myoclonic seizures per 28 days during the Treatment Period relative to the Prospective Baseline 
 Percent change in days with myoclonic seizures per 28 days during the first 6 weeks of the 
Treatment Period (Titration Period) relative to the Prospective Baseline 
 Percent change in days with myoclonic seizures per 28 days during the first 12 weeks of the 
Treatment Period relative to the Prospective Baseline 
 Percent change in days with myoclonic seizures per 28 days during the Treatment Period relative to the Prospective Baseline 
All seizure days data for absence and myoclonic seizures will be listed. 
8.3.2.3 Analysis: Seizure-free status 
The following seizure-free status (yes/no) summaries will be provided: 
 Seizure-free status (yes, no) for PGTCS for the first 6 weeks of the Treatment Period 
(Titration Period) 
 Seizure-free status (yes, no) for PGTCS for the first 12 weeks of the Treatment Period  
 Seizure-free status (yes, no) for PGTCS for the 24-week Treatment Period  
 Seizure-free status (yes, no) for all generalized seizure types for the first 6 weeks of the 
Treatment Period (Titration Period) 
 Seizure-free status (yes, no) for all generalized seizure types for the first 12 weeks of the 
Treatment Period  
 Seizure-free status (yes, no) for all generalized seizure types for the 24-week Treatment 
Period  
8.3.2.4 Analysis: Responder st atus – reduction in PGTCS  frequency 
The following data will be summarized with descriptive statistics only: 
 Percentage of subjects with at least a 50% reduction in PGTCS frequency during the first 
6 weeks (Titration Period) compared to the Combined Baseline 
 Percentage of subjects with at least a 50% reduction in PGTCS frequency during the first 
12 weeks of the Treatment Period compared to the Combined Baseline 
 Percentage of subjects with at least a 50% reduction in PGTCS frequency during the 
Treatment Period compared to the Combined Baseline REDACTED COPY free status (yes/no) summaries will be provided:
REDACTED COPY free status (yes/no) summaries will be provided:
free status (yes, no) for PGTCS for the first 6 weeks of the Treatment Period
REDACTED COPY free status (yes, no) for PGTCS for the first 6 weeks of the Treatment Period
s, no) for PGTCS for the first 12 weeks of the Treatment Period 
REDACTED COPY s, no) for PGTCS for the first 12 weeks of the Treatment Period 
free status (yes, no) for PGTCS for the 24 REDACTED COPY free status (yes, no) for PGTCS for the 24
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.ive to 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.ive to 
Percent change in days with myoclonic seizures per 28 days during the first 6 weeks of the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Percent change in days with myoclonic seizures per 28 days during the first 6 weeks of the 
uring the first 12 weeks of the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.uring the first 12 weeks of the 
Percent change in days with myoclonic seizures per 28 days during the Treatment Period 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Percent change in days with myoclonic seizures per 28 days during the Treatment Period 
c seizures will be listed.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.c seizures will be listed.
free status (yes/no) summaries will be provided:
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.free status (yes/no) summaries will be provided:
free status (yes, no) for PGTCS for the first 6 weeks of the Treatment Period
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.free status (yes, no) for PGTCS for the first 6 weeks of the Treatment Period
s, no) for PGTCS for the first 12 weeks of the Treatment Period 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.s, no) for PGTCS for the first 12 weeks of the Treatment Period 
free status (yes, no) for PGTCS for the 24
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.free status (yes, no) for PGTCS for the 24
free status (yes, no) for all 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.free status (yes, no) for all generalized 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.generalized 
(Titration Period)
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.(Titration Period)
free status (yes, no) for all 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.free status (yes, no) for all 
free status (yes, no) for all 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.free status (yes, no) for all 
Analysis: Responder st
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Analysis: Responder st
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.The following data will be summarized with descriptive statistics only:
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.The following data will be summarized with descriptive statistics only:
Percentage of subjects with at least a 50% reduction in PGTCS frequency during the first 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Percentage of subjects with at least a 50% reduction in PGTCS frequency during the first 
6 weeks (Titration Period) compared to the Combined Baseline
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.6 weeks (Titration Period) compared to the Combined Baseline

This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
UCB   28 Mar 2019  
Statistical Analysis Plan  SP0982  
 Percentage of subjects with at least a 75% reduction in PGTCS frequency during the first 
6 weeks (Titration Period) compared to the Combined Baseline 
 Percentage of subjects with at least a 75% reduction in PGTCS frequency during the first 12 weeks of the Treatment Period compared to the Combined Baseline 
 Percentage of subjects with at least a 75% reduction in PGTCS frequency during the Treatment Period compared to the Combined Baseline 
A histogram of ≥50%, ≥75%, and 100% (seizure freedom) responder status for PGTCS frequency during the first 6 weeks (Titration Period), first 12 weeks, and the 24-week Treatment 
Period by treatment group will be provided. 
8.3.2.5 Analysis: Responder status – reduction in days with absence 
seizures   
The following data will be summarized with descriptive statistics only: 
 Percentage of subjects with at least a 50% reduction in absence seizure days during the first 6 
weeks of the Treatment Period (Titration Period) compared to the Prospective Baseline 
 Perce ntage of subjects with at least a 50% reduction in absence seizure days during the first 
12 weeks of the Treatment Period compared to the Prospective Baseline 
 Percentage of subjects with at least a 50% reduction in absence seizure days during the Treatment  Period compared to the Prospective Baseline 
 Percentage of subjects with at least a 75% reduction in absence seizure days during the first 6 weeks of the Treatment Period (Titration Period) compared to the Prospective Baseline 
 Percentage of subjects with at least a 75% reduction in absence seizure days during the first 
12 weeks of the Treatment Period compared to the Prospective Baseline 
 Percentage of subjects with at least a 75% reduction in absence seizure days during the 
Treatment Period compared to the Prospective Baseline 
 A histogram of ≥50% and  ≥75% responder status for reduction in days with absence seizures 
during the first 6 weeks (Titration Period), first 12 weeks, and the 24-week Treatment Period by treatment group will be provided. 
8.3.2.6 Analysis: Res ponder status – reduction in days with myoclonic 
seizures 
The following data will be summarized with descriptive statistics only: 
 Percentage of subjects with at least a 50% reduction in myoclonic seizure days during the 
first 6 weeks of the Treatment Period (Titration Period) compared to the Prospective Baseline  
 Percentage of subjects with at least a 50% reduction in myoclonic seizure days during the first 12 weeks of the Treatment Period compared to the Prospective Baseline  
 Percentage of subjects with at least a 50% reduction in myoclonic seizure days during the Treatment Period compared to the Prospective Baseline  REDACTED COPY 12 weeks of the Treatment Period compared to the Prospective Baseline
REDACTED COPY 12 weeks of the Treatment Period compared to the Prospective Baseline
Percentage of subjects with at least a 50% reduction in absence seizure days during the 
REDACTED COPY Percentage of subjects with at least a 50% reduction in absence seizure days during the 
Period compared to the Prospective Baseline
REDACTED COPY Period compared to the Prospective Baseline
Percentage of subjects with at least a 75% reduction in absence seizure days during the first 6 
REDACTED COPY Percentage of subjects with at least a 75% reduction in absence seizure days during the first 6 
(Titration Period)
REDACTED COPY (Titration Period)
at least a 75% reduction in absence seizure days during the first 
REDACTED COPY at least a 75% reduction in absence seizure days during the first 
12 weeks of the Treatment Period compared to the Prospective Baseline REDACTED COPY 12 weeks of the Treatment Period compared to the Prospective Baseline
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.week Treatment 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.week Treatment 
reduction in days with absence 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.reduction in days with absence 
Percentage of subjects with at least a 50% reduction in absence seizure days during the first 6 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Percentage of subjects with at least a 50% reduction in absence seizure days during the first 6 
compared to the Prospective Baseline
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.compared to the Prospective Baseline
ntage of subjects with at least a 50% reduction in absence seizure days during the first 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.ntage of subjects with at least a 50% reduction in absence seizure days during the first 
12 weeks of the Treatment Period compared to the Prospective Baseline
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.12 weeks of the Treatment Period compared to the Prospective Baseline
Percentage of subjects with at least a 50% reduction in absence seizure days during the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Percentage of subjects with at least a 50% reduction in absence seizure days during the 
Period compared to the Prospective Baseline
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Period compared to the Prospective Baseline
Percentage of subjects with at least a 75% reduction in absence seizure days during the first 6 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Percentage of subjects with at least a 75% reduction in absence seizure days during the first 6 
(Titration Period)
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.(Titration Period) compared to the Prospective Baseline
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.compared to the Prospective Baseline
at least a 75% reduction in absence seizure days during the first 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.at least a 75% reduction in absence seizure days during the first 
12 weeks of the Treatment Period compared to the Prospective Baseline
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.12 weeks of the Treatment Period compared to the Prospective Baseline
Percentage of subjects with at least a 75% reduction in absence seizure days during the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Percentage of subjects with at least a 75% reduction in absence seizure days during the 
Treatment Period compared to the
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Treatment Period compared to the Prospective Baseline
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Prospective Baseline
and
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.and≥75% responder status for reduction in days with absence seizures 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.≥75% responder status for reduction in days with absence seizures 
during the first 6 weeks
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.during the first 6 weeks (Titration Period)
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.(Titration Period)
by treatment group will be provided.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.by treatment group will be provided.
Analysis: Res
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Analysis: Res
seizures
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.seizures
The following data will be summarized with descriptive statistics only:
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.The following data will be summarized with descriptive statistics only:
Percentage of subjects with at least a 50% reduction in myoclonic seizure days during the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Percentage of subjects with at least a 50% reduction in myoclonic seizure days during the 
first 6 weeks of the Treatment Perio
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.first 6 weeks of the Treatment Perio

This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Percentage of subjects with at least a 50% reduction in myoclonic seizure days during the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Percentage of subjects with at least a 50% reduction in myoclonic seizure days during the 
UCB   28 Mar 2019  
Statistical Analysis Plan  SP0982  
 Percentage of subjects with at least a 75% reduction in myoclonic seizure days during the 
first 6 weeks of the Treatment Period (Titration Period) compared to the Prospective Baseline 
 Percentage of subjects with at least a 75% reduction in myoclonic seizure days during the first 12 weeks of the Treatment Period compared to the Prospective Baseline 
 Percentage of subjects with at least a 75% reduction in myoclonic seizure days during the Treatment Period compared to the Prospective Baseline 
 A histogram of ≥50% and ≥75% responder status for reduction in days with myoclonic 
seizures during the first 6 weeks (Titration Period), first 12 weeks, and the 24-week 
Treatment Period by treatment group will be provided. 
8.3.2.7 Analysis: Percent change in absence and myoclonic seizure 
frequency per 28 days from Prospective Baseline  
Descriptive statistics will be provided on the percent change in absence and myoclonic seizure frequencies for the first 6 weeks of (entire Titration Period), first 12 weeks of, and the entire 
Treatment Period.   
All absence and myoclonic seizure frequency per 28 days data will be listed. 8.3.2.8 Analysis: Responder status – reduction in absen ce and myoclonic 
seizure frequency 
The following data will be summarized with descriptive statistics only: 
 Percentage of subjects with at least a 50% reduction in absence seizure frequency during 
the first 6 weeks (Titration Period) compared to the Prospective Baseline 
 Percentage of subjects with at least a 50% reduction in myoclonic seizure frequency during the first 6 weeks (Titration Period) compared to the Prospective Baseline 
 Percentage of subjects with at least a 50% reduction in absence seizure frequency during the first 12 weeks of the Treatment Period compared to the Prospective Baseline 
 Percentage of subjects with at least a 50% reduction in myoclonic seizure frequency during the first 12 weeks of the Treatment Period compared to the Prospective Baseline 
 Percentage of subjects with at least a 50% reduction in absence seizure frequency during the Treatment Period compared to the Prospective Baseline 
 Percentage of subjects with at least a 50% reduction in myoclonic seizure frequency 
during the Treatment Period compared to the Prospective Baseline 
 Percentage of subjects with at least a 75% reduction in absence seizure frequency during 
the first 6 weeks (Titration Period) compared to the Prospective Baseline 
 Percentage of subjects with at least a 75% reduction in myoclonic seizure frequency 
during the first 6 weeks (Titration Period) compared to the Prospective Baseline 
 Percentage of subjects with at least a 75% reduction in absence seizure frequency during the first 12 weeks of the Treatment Period compared to the Prospective Baseline  REDACTED COPY The following data will be summarized with descriptive statistics only:
REDACTED COPY The following data will be summarized with descriptive statistics only:
Percentage of subjects with at least a 50% reduction in absence seizure frequency during 
REDACTED COPY Percentage of subjects with at least a 50% reduction in absence seizure frequency during 
the first 6 weeks (Titration Period) compared to the Prospec
REDACTED COPY the first 6 weeks (Titration Period) compared to the Prospec
Percentage of subjects with at least a 50% reduction in myoclonic seizure frequency 
REDACTED COPY Percentage of subjects with at least a 50% reduction in myoclonic seizure frequency 
during the first 6 weeks (Titration Period) compared to the Prospective Baseline REDACTED COPY during the first 6 weeks (Titration Period) compared to the Prospective Baseline
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.absence and myoclonic seizure
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.absence and myoclonic seizure
absence and myoc
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.absence and myoc lonic seizure 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.lonic seizure 
for the first 6 weeks of (entire Titration Period), first 12 weeks of, and the entire 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.for the first 6 weeks of (entire Titration Period), first 12 weeks of, and the entire 
frequency per 28 days data will be listed.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.frequency per 28 days data will be listed.
reduction in absen
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.reduction in absen
The following data will be summarized with descriptive statistics only:
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.The following data will be summarized with descriptive statistics only:
Percentage of subjects with at least a 50% reduction in absence seizure frequency during 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Percentage of subjects with at least a 50% reduction in absence seizure frequency during 
the first 6 weeks (Titration Period) compared to the Prospec
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.the first 6 weeks (Titration Period) compared to the Prospec
Percentage of subjects with at least a 50% reduction in myoclonic seizure frequency 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Percentage of subjects with at least a 50% reduction in myoclonic seizure frequency 
during the first 6 weeks (Titration Period) compared to the Prospective Baseline
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.during the first 6 weeks (Titration Period) compared to the Prospective Baseline
Percentage of subjects with at least a 50% reduction in absence seizure frequ
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Percentage of subjects with at least a 50% reduction in absence seizure frequ
the first 12 weeks of the Treatment Period compared to the Prospective Baseline
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.the first 12 weeks of the Treatment Period compared to the Prospective Baseline
Percentage of subjects with at least a 50% reduction in myoclonic seizure frequency 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Percentage of subjects with at least a 50% reduction in myoclonic seizure frequency 
during the first 12 weeks of the Treatment Period compared to the Prospective Ba
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.during the first 12 weeks of the Treatment Period compared to the Prospective Ba
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Percentage of subjects with at least a 50% reduction in absence seizure frequency during 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Percentage of subjects with at least a 50% reduction in absence seizure frequency during 
the Treatment Period compared to the Prospective Baseline
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.the Treatment Period compared to the Prospective Baseline
Percentage of subjects with at least a 50% reduction in myoclonic seizure frequency 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Percentage of subjects with at least a 50% reduction in myoclonic seizure frequency 
during the Treatme
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.during the Treatme
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Percentage of subjects with at least a 75% reduc
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Percentage of subjects with at least a 75% reduc
the first 6 weeks (Titration 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.the first 6 weeks (Titration 

This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
UCB   28 Mar 2019  
Statistical Analysis Plan  SP0982  
 Percentage of subjects with at least a 75% reduction in myoclonic seizure frequency 
during the first 12 weeks of the Treatment Period compared to the Prospective Baseline 
 Percentage of subjects with at least a 75% reduction in absence seizure frequency during the Treatment Period compared to the Prospective Baseline  
 Percentage of subjects with at least a 75% reduction in myoclonic seizure frequency during the Treatment Period compared to the Prospective Baseline 
8.4 Analysis of h ealth outcome other efficacy variables  
8.4.1  Derivations of health outcome other efficacy variables 
8.4.1.1 QOLIE- 31-P variables 
The Patient Weighted Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) Version 2 
will be used to evaluate the health-related quality of life (HRQoL) of study subjects ≥18 years of age. 
The QOLIE‑31‑P total score, subscale scores, and health status item score are calculated 
according to the scoring algorithm defined in Section  12.1 which accounts for the possibility of 
missing values. Scores range from 0 to 100 and higher scores indicating better functioning. 
QOLIE- 31-P data that are completely missing will not be replaced. 
Subscale scores 
As a first step to calculating the subscale scores, the individual responses for the 30 subscale 
items are rescaled to a 0 to 100 scale with higher scores reflecting better functioning; the rescaled values for each item are defined in Section 12.1. Each subscale score is then calculated by 
summing the rescaled responses for that subscale and dividing by the number of items with a 
non-missing response. A subscale score will be calculated only if at least 50% of the items within the subscale are present. 
Total score  
Total score is calculated as a weighted sum of the subscale scores based on the weighting in 
Section 12.1. Total score will be missing if at least 1 subscale score is missing. Total score will range from 0 to 100 with a higher score reflecting better functioning. 
Health status item 
The response for the health status item is a multiple of 10 ranging from 0 to 100 with a higher 
score corresponding to a better health status. The health status item response is analyzed without 
rescaling. 
Distress items 
Each subscale includes 1 distress item. The response for each distress item is an integer ranging 
from 1 to 5. The response for each distress item will be converted to a 0 to 100 scale (ie, 0, 25, 50, 75, and 100) with a higher score corresponding to greater distress. 
Prioritization item 
The response for each subscale for the prioritization item is an integer ranging from 1 to 7. The 
prioritization ranking is analyzed without rescaling. REDACTED COPY P data that are completely missing will not be replaced.
REDACTED COPY P data that are completely missing will not be replaced.
As a first step to calculating the subscale scores, the individual responses for the 30 subscale 
REDACTED COPY As a first step to calculating the subscale scores, the individual responses for the 30 subscale 
items are rescaled to a 0 to 100 scale with higher scores reflecting better functioning; the rescaled 
REDACTED COPY items are rescaled to a 0 to 100 scale with higher scores reflecting better functioning; the rescaled 
values for each item are defined in Section 12.
REDACTED COPY values for each item are defined in Section 12.
REDACTED COPY 1. Each subscale score is then calculated by 
REDACTED COPY 1. Each subscale score is then calculated by 
summing the rescaled responses for that subscale and dividing by the number of items with a 
REDACTED COPY summing the rescaled responses for that subscale and dividing by the number of items with a 
missing response. A subscale score will be calculated only if at least 50% of the items REDACTED COPY missing response. A subscale score will be calculated only if at least 50% of the items 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.31
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.31-
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.-P) Version 2 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.P) Version 2 
of life (HRQoL) of study subjects ≥18 years of 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.of life (HRQoL) of study subjects ≥18 years of 
P total score, subscale scores, and health status item score are calculated 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.P total score, subscale scores, and health status item score are calculated 
which accounts for the possibility of 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.which accounts for the possibility of 
missing values. Scores range from 0 to 100 and higher scores indicating better functioning. 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.missing values. Scores range from 0 to 100 and higher scores indicating better functioning. 
P data that are completely missing will not be replaced.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.P data that are completely missing will not be replaced.
As a first step to calculating the subscale scores, the individual responses for the 30 subscale 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.As a first step to calculating the subscale scores, the individual responses for the 30 subscale 
items are rescaled to a 0 to 100 scale with higher scores reflecting better functioning; the rescaled 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.items are rescaled to a 0 to 100 scale with higher scores reflecting better functioning; the rescaled 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.1. Each subscale score is then calculated by 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.1. Each subscale score is then calculated by 
summing the rescaled responses for that subscale and dividing by the number of items with a 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.summing the rescaled responses for that subscale and dividing by the number of items with a 
missing response. A subscale score will be calculated only if at least 50% of the items 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.missing response. A subscale score will be calculated only if at least 50% of the items 
Total score is calculated as a weighted sum of the subscale scores based on the weighting in 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Total score is calculated as a weighted sum of the subscale scores based on the weighting in 
Section 12.1. Total score will be missing if at least 1 subscale score is missing. Total score will 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Section 12.1. Total score will be missing if at least 1 subscale score is missing. Total score will 
range from 0 to 100 with a higher score refle
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.range from 0 to 100 with a higher score refle
Health status item
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Health status item
The response for the health status item is a multiple of 10 ranging from 0 to 100 with a higher 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.The response for the health status item is a multiple of 10 ranging from 0 to 100 with a higher 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.score corresponding to a better health status. The health status item response is analyzed without 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.score corresponding to a better health status. The health status item response is analyzed without 
ess items
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.ess items
Each subscale includes 1 distress item. The response for each distress item is an integer ranging 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Each subscale includes 1 distress item. The response for each distress item is an integer ranging 
from 1 to 5. The response for each distress item will be converted to a 0 to 100 scale (ie, 0, 25, 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.from 1 to 5. The response for each distress item will be converted to a 0 to 100 scale (ie, 0, 25, 
50, 75, and 100) with a higher score correspondin
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.50, 75, and 100) with a higher score correspondin
UCB   28 Mar 2019  
Statistical Analysis Plan  SP0982  
8.4.1.2 PedsQL variables  
The PedsQL is a validated instrument that consists of generic core scales suitable for use with 
pediatric populations (<18 years), including those with acute or chronic health conditions.  
PedsQL generic core scale scores will be calculated for each of the following 4 PedsQL scales: 
Physical Functioning, Emotional Functioning, Social Functioning, and School Functioning. The 
PedsQL assessment is retrospective to the prior 4 weeks, and individual items are scored using a 
5-point Likert scale (0 to 4 representing responses of: never, almost never, sometimes, often, or almost always). These scores of 0 to 4 will be transformed by the function: 100 – (response x 25) 
in order to generate scores of 0, 25, 50, 75, and 100, where a higher value represents a better 
HRQoL.  
Each scale score is then calculated as the mean of the non-missing categorized items if 50% or 
more of the items are non-missing.     
The above algorithm will also be used to calculate an overall total scale score (all scales) for 
each subject. To create the Total Scale Score, the mean is computed over the number of items answered on all the Scales 
8.4.1.3 EQ-5D-3L quality of life variables 
The 3-Level EuroQol-5 Dimensional Quality of Life Assessment (EQ-5D-3L) is a self-
administered questionnaire designed to measure health status in subjects ≥12 years of age.  
The EQ-5D-3L defines health in terms of 5 dimensions (mobility, self-care, usual activities, 
pain/discomfort, and anxiety/depression). Each dimension is divided into 3 levels: 
 No problem=1  
 Some or moderate problems=2 
 Extreme problems=3  
The EQ-5D-3L also captures a self-rating of health status on a 20cm vertical visual analog scale, 
anchored at 100 (best imaginable health state) at the top and 0 (worst imaginable health state) at 
the bottom. 
At each time point, an EQ-5D-3L utility value will be mapped to each subject’s health state. 
Health state is derived from the subject’s numerical ratings of the 5 EQ- 5D-3L Dimensions.  The 
order of the ratings is Mobility, Self-Care, Usual Activities, Pain/Discomfort, Anxiety/Depression.  Health state is derived by concatenating the numerical ratings of the 5 dimensions. For example, a health state may be derived as 11111, indicating best possible health. 
A utility value will then be mapped to the derived health states, using the UK EQ-5D-3L value 
set. This set is available to Global Statistical Programming in excel format. 
The mapped utility values will make up the utility variable. 8.4.1.4 Hospital stays 
An event logged on the Hospitalization/Emergency Room (ER) Visit form of the eCRF where 
“Emergency room” is marked as initial entry point will be defined as an ER visit. An ER visit with a subject transfer to an inpatient general ward will also be counted as a hospitalization. REDACTED COPY 5 Dimensional Quality of Life Assessment (EQ
REDACTED COPY 5 Dimensional Quality of Life Assessment (EQ
administered questionnaire designed to measure health status in subjects ≥12 years
REDACTED COPY administered questionnaire designed to measure health status in subjects ≥12 years
3L defines health in terms of 5 dimensions (mobility, self
REDACTED COPY 3L defines health in terms of 5 dimensions (mobility, self
pain/discomfort, and anxiety/depression). Each dimension is divided into 3 levels:
REDACTED COPY pain/discomfort, and anxiety/depression). Each dimension is divided into 3 levels:
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.imes, often, or 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.imes, often, or 
(response x 25) 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.(response x 25) 
in order to generate scores of 0, 25, 50, 75, and 100, where a higher value represents a better 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.in order to generate scores of 0, 25, 50, 75, and 100, where a higher value represents a better 
missing categorized items if 50% or 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.missing categorized items if 50% or 
The above algorithm will also be used to calculate an overall total scale score (all scales) for 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.The above algorithm will also be used to calculate an overall total scale score (all scales) for 
uted over the number of items 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.uted over the number of items 
5 Dimensional Quality of Life Assessment (EQ
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.5 Dimensional Quality of Life Assessment (EQ
administered questionnaire designed to measure health status in subjects ≥12 years
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.administered questionnaire designed to measure health status in subjects ≥12 years
3L defines health in terms of 5 dimensions (mobility, self
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.3L defines health in terms of 5 dimensions (mobility, self
pain/discomfort, and anxiety/depression). Each dimension is divided into 3 levels:
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.pain/discomfort, and anxiety/depression). Each dimension is divided into 3 levels:
3L also captures a self
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.3L also captures a self -
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.- 3L also captures a self - 3L also captures a self
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.3L also captures a self - 3L also captures a self rating of health status on a 20cm vertical visual analog scale, 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.rating of health status on a 20cm vertical visual analog scale, 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.anchored at 100 (best imaginable health state) at the top and 0 (worst imaginable health state) at 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.anchored at 100 (best imaginable health state) at the top and 0 (worst imaginable health state) at 
At each time point, an EQ
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.At each time point, an EQ -
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.-5D
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.5D
Health state is derived from the subject’s numerical ratings of the 5 EQ
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Health state is derived from the subject’s numerical ratings of the 5 EQ
order of the ratings is Mobility, Self
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.order of the ratings is Mobility, Self
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Anxiety/Depression.  Health state is derived
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Anxiety/Depression.  Health state is derived
dimensions. For example, a health state may be derived as 11111, indicating best possible health.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.dimensions. For example, a health state may be derived as 11111, indicating best possible health.
A utility value will then be mapped to the derived health states, using the UK EQ
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.A utility value will then be mapped to the derived health states, using the UK EQ
set. This set i
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.set. This set i
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.The mapped utility values will make up the utility variable.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.The mapped utility values will make up the utility variable.
8.4.1.4
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.8.4.1.4
UCB   28 Mar 2019  
Statistical Analysis Plan  SP0982  
However, all other instances of ER visits (where subject transfer is not to an inpatient general 
ward) will not be counted as hospitalizations.   
For hospital stays with a discharge date, the duration of each hospital stay will be calculated as 
the discharge date minus the admission date (Hospitalization/ER Visit Date on the eCRF) plus 1 
day. For hospitalizations with either a partial admission or discharge date, the duration of 
hospital stay will be set to missing.  The non-missing durations of hospital stays will be summed within each of the study periods (Baseline, Titration, and Maintenance, respectively). Should 
distinct records for hospital stays overlap, then the days during the overlap will only be counted 
once. Subjects with no hospital stays within a study period will have duration of 0 days for that period.  For subjects with hospital stays but no calculable hospital duration, the duration of hospitalization in the respective study period will be missing. 
8.4.2  Analysis of health outcome other efficacy variables 
8.4.2.1 QOLIE- 31-P variables 
QOLIE-31-P data, for a specific visit may have a status of Abandoned if the subject doesn’t 
complete the questionnaire. If the subject has duplicate QOLIE-31-P data for the same visit, 
where one record is deemed as Abandoned and one record is deemed as Completed, the 
Completed data will be used in the analysis and not the Abandoned record. All recorded QOLIE-31-P data will be listed. 
The observed values and change from Baseline will be summarized descriptively for the total 
score, the subscale scores, health score and the distress items for each visit and Last Visit. The mean observed values for the prioritization items will laso be summarized for each visit and Last 
Visit. They will all be summarized for both Visit 10 and Visit 10/ET.  The scores for individual 
subscales will only be analyzed when a total score can be calculated (ie, all subscales have a non-
missing score). Individual questions will not be summarized. Individual questions, subscale 
scores, and total scores will be presented in subject data listings. The means of the QOLIE-31- P 
total score, subscale scores and health status item score will be plotted by visit. 
8.4.2.2 PedsQL variables  
The observed values and change from Baseline for the total scale score and each of the 4 scale 
scores will be summarized for each visit and Last Visit by treatment group. They will be 
summarized for both Visit 10 and Visit 10/ET.  Subgroup summaries by age will be performed using the age groupings for which different questionnaires were entered: 4 years, ≥5 to ≤7 years, ≥8 to ≤12 years, and ≥13 to ≤18 years. 
All PedsQL data will be listed. The means of the PedsQL subscale scores and total score will be 
plotted by visit. 
8.4.2.3 EQ-5D-3L quality of life variables 
The observed values for each dimension and the mapped utility values will be summarized for 
each visit and Last Visit.  They will be summarized for both Visit 10 and Visit 10/ET.   
Observed values and the change from Baseline for the VAS score for general health state will 
also be summarized. REDACTED COPY The observed values and change from Baseline will be summarized 
REDACTED COPY The observed values and change from Baseline will be summarized 
score, the subscale scores, health score and the distress items for each visit and Last Visit. The 
REDACTED COPY score, the subscale scores, health score and the distress items for each visit and Last Visit. The 
mean observed values for the prioritization items will laso be summarized for each visit and Last 
REDACTED COPY mean observed values for the prioritization items will laso be summarized for each visit and Last 
zed for both Visit 10 and Visit 10/ET.  The scores for individual 
REDACTED COPY zed for both Visit 10 and Visit 10/ET.  The scores for individual 
subscales will only be analyzed when a total score can be calculated (ie, all subscales have a non
REDACTED COPY subscales will only be analyzed when a total score can be calculated (ie, all subscales have a non
missing score). Individual questions will not be summarized. Individual questions, subscaleREDACTED COPY missing score). Individual questions will not be summarized. Individual questions, subscale
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.distinct records for hospital stays overlap, then the days during the overlap will only be counted 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.distinct records for hospital stays overlap, then the days during the overlap will only be counted 
hospital stays within a study period will have duration of 0 days for that 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.hospital stays within a study period will have duration of 0 days for that 
period.  For subjects with hospital stays but no calculable hospital duration, the duration of 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.period.  For subjects with hospital stays but no calculable hospital duration, the duration of 
P data, for a specific visit may have a status of Abandoned if the subject doesn’t 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.P data, for a specific visit may have a status of Abandoned if the subject doesn’t 
P data for the same visit, 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.P data for the same visit, 
deemed as Abandoned and one record is deemed as Completed, the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.deemed as Abandoned and one record is deemed as Completed, the 
Completed data will be used in the analysis and not the Abandoned record. All recorded QOLIE
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Completed data will be used in the analysis and not the Abandoned record. All recorded QOLIE
The observed values and change from Baseline will be summarized 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.The observed values and change from Baseline will be summarized 
score, the subscale scores, health score and the distress items for each visit and Last Visit. The 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.score, the subscale scores, health score and the distress items for each visit and Last Visit. The 
mean observed values for the prioritization items will laso be summarized for each visit and Last 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.mean observed values for the prioritization items will laso be summarized for each visit and Last 
zed for both Visit 10 and Visit 10/ET.  The scores for individual 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.zed for both Visit 10 and Visit 10/ET.  The scores for individual 
subscales will only be analyzed when a total score can be calculated (ie, all subscales have a non
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.subscales will only be analyzed when a total score can be calculated (ie, all subscales have a non
missing score). Individual questions will not be summarized. Individual questions, subscale
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.missing score). Individual questions will not be summarized. Individual questions, subscale
scores, and total scores will be presented in subject data listings. The means of the QOLIE
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.scores, and total scores will be presented in subject data listings. The means of the QOLIE
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.total score, subscale scores and health status item score will be plotted by visit.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.total score, subscale scores and health status item score will be plotted by visit.
PedsQL variables
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.PedsQL variables
The observed values and change from Baseline for the tota
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.The observed values and change from Baseline for the tota
scores will be summarized for each visit and Last Visit by treatment group. They will be 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.scores will be summarized for each visit and Last Visit by treatment group. They will be 
summarized for both Visit 10 and Visit 10/ET.  Subgroup summaries by age will be performed 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.summarized for both Visit 10 and Visit 10/ET.  Subgroup summaries by age will be performed 
using the age groupings for which diff
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.using the age groupings for which diff
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.≥8 to ≤12 years, and ≥13 to ≤18 years.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.≥8 to ≤12 years, and ≥13 to ≤18 years.
All PedsQL data will be listed. The means of the PedsQL subscale scores and total score will be 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.All PedsQL data will be listed. The means of the PedsQL subscale scores and total score will be 
plotted by visit.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.plotted by visit.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.8.4.2.3
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.8.4.2.3
The obse
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.The obse
each visit and Last Visit.  They will be summarized for both Visit 10 and Visit 10/ET.  
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.each visit and Last Visit.  They will be summarized for both Visit 10 and Visit 10/ET.  
UCB   28 Mar 2019  
Statistical Analysis Plan  SP0982  
All EQ-5D-3L data will be presented in subject data listings. The mean of the EQ-5D- 3L VAS 
will be plotted by visit.  For the EQ-5D-3L, the percentage of subjects reporting a level within 
each dimension will be plotted in a histogram. 
8.4.2.4 Concomitant medical procedures 
Subjects who had any concomitant medical procedures during the course of the study based on 
the Concomitant Medical Procedures eCRF will be listed. Additionally, subjects who had any 
procedures or surgeries prior to study entry based on the Procedure History eCRF will also be listed. 
8.4.2.5 Healthcare provider consultations 
All healthcare provider consultations data will be listed. 
8.4.2.6 Hospital stays 
All hospitalization/ER data will be listed. 
8.4.2.7 Number of working or school days lost due to epilepsy 
All working or school days lost data will be listed. 8.4.2.8 Number of days with help from a paid caregiver due to epilepsy 
All data regarding help from a paid caregiver will be listed. 
8.4.2.9 Socio- professional data  
The number and percentage of subjects by each response level for highest level of education, 
housing status, current professional status, regular assistance in usual activities, and driving 
status will be summarized for each visit and Last Visit for the FAS. Percentages will be relative 
to the number of subjects with a response to each item. No statistical comparisons will be carried out for socio-professional data. 
All socio-professional data will be listed. 
9 PHARMACOKINETICS  
LCM plasma concentration will be summarized using the SS. Descriptive statistics of LCM 
plasma concentrations will be presented by visit and actual dose. The actual dose is defined as 
the most recent dose administrated prior to PK sampling.  
The following parameters will be calculated for each of the sampling points: n, nLOQ (number 
of measurements above or equal to the lower limit of quantification [LOQ]), arithmetic mean, 
standard deviation (SD) and coefficient of variation (CV), median, minimum, and maximum 
value.  
Values below LOQ will be replaced by 0 in calculations of mean, SD, CV(%) and median.  
Mean, SD and CV(%) will only be calculated if at least 2/3 of the data are above LOQ at the 
respective time point. In tables showing mean values, where values below LOQ are included in the calculation of mean values, these mean values will be marked.   
A listing of LCM plasma concentration data by subject and visit will include actual doses, date 
and time of the most recent administration, date and time of sampling, time interval between REDACTED COPY All data regarding help from a paid caregiver will be listed.
REDACTED COPY All data regarding help from a paid caregiver will be listed.
ts by each response level for highest level of education, 
REDACTED COPY ts by each response level for highest level of education, 
housing status, current professional status, regular assistance in usual activities, and driving 
REDACTED COPY housing status, current professional status, regular assistance in usual activities, and driving 
status will be summarized for each visit and Last Visit for the FAS. Percentages will be relative 
REDACTED COPY status will be summarized for each visit and Last Visit for the FAS. Percentages will be relative 
the number of subjects with a response to each item. No statistical comparisons will be carried REDACTED COPY the number of subjects with a response to each item. No statistical comparisons will be carried 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.st due to epilepsy
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.st due to epilepsy
Number of days with help from a paid caregiver due to epilepsy
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Number of days with help from a paid caregiver due to epilepsy
All data regarding help from a paid caregiver will be listed.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.All data regarding help from a paid caregiver will be listed.
ts by each response level for highest level of education, 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.ts by each response level for highest level of education, 
housing status, current professional status, regular assistance in usual activities, and driving 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.housing status, current professional status, regular assistance in usual activities, and driving 
status will be summarized for each visit and Last Visit for the FAS. Percentages will be relative 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.status will be summarized for each visit and Last Visit for the FAS. Percentages will be relative 
the number of subjects with a response to each item. No statistical comparisons will be carried 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.the number of subjects with a response to each item. No statistical comparisons will be carried 
professional data will be listed.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.professional data will be listed.
PHARMACOKINETICS 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.PHARMACOKINETICS 
plasma concentration will be summarized using the SS. Descrip
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.plasma concentration will be summarized using the SS. Descrip
plasma concentrations will be presented by visit and actual dose. The actual dose is defined as 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.plasma concentrations will be presented by visit and actual dose. The actual dose is defined as 
the most recent dose administrated prior to PK sampling. 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.the most recent dose administrated prior to PK sampling. 
The following parameters will be calculated for each of the sampling points: n, nLOQ (number 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.The following parameters will be calculated for each of the sampling points: n, nLOQ (number 
of measurements above or equal to the lower limit of quantification [LOQ]), arithmetic mean, 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.of measurements above or equal to the lower limit of quantification [LOQ]), arithmetic mean, 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.standard deviation (SD) and coefficient of variation (CV), median, min
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.standard deviation (SD) and coefficient of variation (CV), median, min
Values below LOQ will be replaced by 0 in calculations of mean, SD, CV(%) and median.  
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Values below LOQ will be replaced by 0 in calculations of mean, SD, CV(%) and median.  
Mean, SD and CV(%) will only be calculated if at least 2/3 of the data are above LOQ at the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Mean, SD and CV(%) will only be calculated if at least 2/3 of the data are above LOQ at the 
respective time point. In tables showing mean value
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.respective time point. In tables showing mean value
the calculation of mean values, these mean values will be marked.  
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.the calculation of mean values, these mean values will be marked.  
UCB   28 Mar 2019  
Statistical Analysis Plan  SP0982  
plasma sample and the most recent administration (in hours), visit, relative day, and the kit 
number. Samples that were excluded from the descriptive statistics will be marked in the listing. 
10 SAFETY ANALYSES  
10.1 Extent of exposure 
10.1.1 Derivation of exposure variables 
Study medication treatment duration will be calculated as ([last study medication dose during the 
Treatment Period – first study medication dose] + 1 day). Subject-years of exposure is the total 
treatment duration in days divided by 365.25. 
The mean exposure per day for an analysis period is calculated as the total exposure in 
milligrams during the analysis period (based on the randomized treatment group or protocol 
defined treatment regimen incorporating any scheduled dose changes) divided by the duration of 
exposure (days). Days during an analysis period with unknown dosing are to be excluded from both the numerator and the denominator for the calculation of mean exposure per day. 
10.1.2 Analysis of exposure variables 
Total duration of exposure (days) for each treatment group during the Titration Period, 
Maintenance Period, and Treatment Period will be summarized by region for the SS using 
descriptive statistics. The number of days of exposure in the Treatment Period will be calculated 
as the last dose date minus the first dose date +1. Study medication taken during the Taper and Transition Periods will not be included in these calculations. 
Treatment duration will be summarized with the number and percentage of subjects with 
treatment duration by 3 Week categories: 1 to 21 days, 22 to 42 days, 43 to 63 days, 64 to 84 
days, 85 to 105 days, 106 to 126 days, 127 to 147 days, 148 to 168 days, and > 168 days. Furthermore, the subject years exposed will be presented for the entire Treatment Period. 
If actual dosing information is presented, the LCM dose categories for oral solution are as follows: 0mg/kg/day/Unknown, >0 to <4mg/kg/day, ≥4mg/kg/day to <8mg/kg/day, and ≥8mg/kg 
day.  The LCM dose categories for tablets are as follows: 0mg/day/Unknown, >0 to 
<200mg/day, ≥200 to <400mg/day, ≥400 to <600mg/day, ≥600 to 800mg/day, and ≥800mg/day. 
The mean dose per day will be presented for the 3 different weight categories: <30kg 
(mg/kg/day), ≥30kg to <50kg (mg/kg/day) and ≥50kg (mg/day).  
This analysis will be repeated for each subgroup as detailed in Section  4.8.  
Detailed LCM exposure, LCM dosing, and drug accountability will be presented in subject data 
listings. 
10.2 Adverse events 
Adverse events will be coded using MedDRA, and tabulated by SOC and PT for each treatment 
group for the SS and will include the number and percentage of subjects experiencing each event 
at least once. All summaries will be sorted alphabetically by SOC and by frequency of events within each SOC, starting with the most frequent event for the LCM arm.  
Adverse events will be considered treatment-emergent if the event had onset on or after the date 
of the first study medication dose and within 30 days following the last study medication dose or REDACTED COPY Maintenance Period, and Treatment Period will be summarized by region for the SS using 
REDACTED COPY Maintenance Period, and Treatment Period will be summarized by region for the SS using 
descriptive statistics. The number of days of exposure in the Treatment Period 
REDACTED COPY descriptive statistics. The number of days of exposure in the Treatment Period 
as the last dose date minus the first dose date +1. Study medication taken during the Taper and 
REDACTED COPY as the last dose date minus the first dose date +1. Study medication taken during the Taper and 
Transition Periods will not be included in these calculations.
REDACTED COPY Transition Periods will not be included in these calculations.
Treatment duration will be summarized with the number and percentage of subjec
REDACTED COPY Treatment duration will be summarized with the number and percentage of subjec
treatment duration by 3 Week categories: 1 to 21 days, 22 to 42 days, 43 to 63 days, 64 to 84 
REDACTED COPY treatment duration by 3 Week categories: 1 to 21 days, 22 to 42 days, 43 to 63 days, 64 to 84 
days, 85 to 105 days, 106 to 126 days, 127 to 147 days, 148 to 168 days, and > 168 days. 
REDACTED COPY days, 85 to 105 days, 106 to 126 days, 127 to 147 days, 148 to 168 days, and > 168 days. 
Furthermore, the subject years exposed will be presented for the REDACTED COPY Furthermore, the subject years exposed will be presented for the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Study medication treatment duration will be calculated as ([last study medication dose during the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Study medication treatment duration will be calculated as ([last study medication dose during the 
years of exposure is the total 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.years of exposure is the total 
The mean exposure per day for an analysis period is calculated as the total exposure in 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.The mean exposure per day for an analysis period is calculated as the total exposure in 
milligrams during the analysis period (based on the randomized treatment group or protocol 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.milligrams during the analysis period (based on the randomized treatment group or protocol 
cheduled dose changes) divided by the duration of 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.cheduled dose changes) divided by the duration of 
exposure (days). Days during an analysis period with unknown dosing are to be excluded from 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.exposure (days). Days during an analysis period with unknown dosing are to be excluded from 
both the numerator and the denominator for the calculation of mean exposure per day.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.both the numerator and the denominator for the calculation of mean exposure per day.
Total duration of exposure (days) for each treatment group during the Titration Period, 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Total duration of exposure (days) for each treatment group during the Titration Period, 
Maintenance Period, and Treatment Period will be summarized by region for the SS using 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Maintenance Period, and Treatment Period will be summarized by region for the SS using 
descriptive statistics. The number of days of exposure in the Treatment Period 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.descriptive statistics. The number of days of exposure in the Treatment Period 
as the last dose date minus the first dose date +1. Study medication taken during the Taper and 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.as the last dose date minus the first dose date +1. Study medication taken during the Taper and 
Transition Periods will not be included in these calculations.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Transition Periods will not be included in these calculations.
Treatment duration will be summarized with the number and percentage of subjec
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Treatment duration will be summarized with the number and percentage of subjec
treatment duration by 3 Week categories: 1 to 21 days, 22 to 42 days, 43 to 63 days, 64 to 84 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.treatment duration by 3 Week categories: 1 to 21 days, 22 to 42 days, 43 to 63 days, 64 to 84 
days, 85 to 105 days, 106 to 126 days, 127 to 147 days, 148 to 168 days, and > 168 days. 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.days, 85 to 105 days, 106 to 126 days, 127 to 147 days, 148 to 168 days, and > 168 days. 
Furthermore, the subject years exposed will be presented for the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Furthermore, the subject years exposed will be presented for the 
If actual dosing information is presented, the LCM dose categories for oral solution are as 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.If actual dosing information is presented, the LCM dose categories for oral solution are as 
follows: 0mg/kg/day/Unknown, >0 to <4mg/kg/day, ≥4mg/kg/day to <8mg/kg/day, and ≥8mg/kg 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.follows: 0mg/kg/day/Unknown, >0 to <4mg/kg/day, ≥4mg/kg/day to <8mg/kg/day, and ≥8mg/kg 
day.  The LCM dose categories for tablets are as fo
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.day.  The LCM dose categories for tablets are as fo
<200mg/day, ≥200 to <400mg/day, ≥400 to <600mg/day, ≥600 to 800mg/day, and ≥800mg/day.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.<200mg/day, ≥200 to <400mg/day, ≥400 to <600mg/day, ≥600 to 800mg/day, and ≥800mg/day.
The mean dose per day will be presented for the 3 different weight categories: <30kg 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.The mean dose per day will be presented for the 3 different weight categories: <30kg 
(mg/kg/day), ≥30kg to <50kg (mg/kg/day) and ≥50kg (mg/
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.(mg/kg/day), ≥30kg to <50kg (mg/kg/day) and ≥50kg (mg/
This analysis will be repeated for each subgroup as detailed in 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This analysis will be repeated for each subgroup as detailed in 
Detailed LCM exposure, LCM dosing, and drug accountability will
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Detailed LCM exposure, LCM dosing, and drug accountability will
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.10.2
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.10.2
Adverse events will be coded using MedDRA, and tabulated by SOC and PT for each treatment 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Adverse events will be coded using MedDRA, and tabulated by SOC and PT for each treatment 
group for the SS and will include the number and percentage of subjects experiencing each event 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.group for the SS and will include the number and percentage of subjects experiencing each event 
at least once. 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.at least once. 
UCB   28 Mar 2019  
Statistical Analysis Plan  SP0982  
events whose intensity worsened on or after the date of first study medication dose and within 
30 days following the date of last study medication administration. 
If the last dose of study medication administration is unknown, any event occurring after the first 
study medication dose will be considered treatment-emergent. If the start date of an AE is 
completely missing and the stop date is either unknown or after the date of the first dose of study 
medication, the AE will be considered as treatment-emergent. Incomplete dates for AEs will be handled as described in Section  4.2.3. 
Treatment emergent adverse events (TEAEs) during the Treatment Period, Maintenance Period and Taper/Safety Follow-Up Period, respectively, are TEAEs with an onset date during the respective period. 
The following summaries will be presented by randomized treatment group: 
 Overview of TEAEs  
 Overview of TEAEs by subgroup as detailed in Section 4.8  
 Incidence of TEAEs  
 Incidence of TEAEs by subgroup as detailed in Section 4.8 
 Incidence of TEAEs in the Titration Period 
 Incidence of TEAEs in the Maintenance Period 
 Incidence of TEAEs in the Taper Period 
 Incidence of TEAEs in the Transition Period 
 Incidence of TEAEs by intensity  
 Incidence of common TEAEs for US labeling (above or equal to reporting threshold of 2% 
(prior to rounding) of subjects in the total LCM group)  
 Incidence of common drug-associated TEAEs (TEAEs occurring in ≥5% of subjects in the LCM group and occurring twice as often as in the placebo group) 
 Incidence of common TEAEs for EU labeling (above or equal to reporting threshold of 1% 
(prior to rounding) of subjects in the total LCM group) and occurring > 1% than in the 
placebo group 
 Incidence of serious TEAEs  
 Incidence of serious TEAEs – Subject numbers 
 Incidence of TEAEs leading to discontinuation  
 Incidence in TEAEs leading to discontinuation in the Titration Period 
 Incidence in TEAEs leading to discontinuation in the Maintenance Period 
 Incidence in TEAEs leading to discontinuation – Subject numbers 
 Incidence of other significant TEAEs (See Section  12.2.1  for details) REDACTED COPY Incidence of TEAEs in the Maintenance Period
REDACTED COPY Incidence of TEAEs in the Maintenance Period
Incidence of TEAEs in the Transition Period
REDACTED COPY Incidence of TEAEs in the Transition Period
Incidence of common TEAEs for US labeling (above or equal to reporting threshold of 2% REDACTED COPY Incidence of common TEAEs for US labeling (above or equal to reporting threshold of 2% 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Treatment emergent adverse events (TEAEs) during the Treatment Period, Maintenance Period 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Treatment emergent adverse events (TEAEs) during the Treatment Period, Maintenance Period 
Up Period, respectively, are TEAEs with an onset date during the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Up Period, respectively, are TEAEs with an onset date during the 
Incidence of TEAEs in the Transition Period
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Incidence of TEAEs in the Transition Period
Incidence of common TEAEs for US labeling (above or equal to reporting threshold of 2% 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Incidence of common TEAEs for US labeling (above or equal to reporting threshold of 2% 
(prior to rounding) of subjects in the total LCM group) 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.(prior to rounding) of subjects in the total LCM group) 
associated TEAEs (TEAEs occurring in ≥5% of subjects in the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.associated TEAEs (TEAEs occurring in ≥5% of subjects in the 
LCM group and occurring twice as often as in the placebo group)
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.LCM group and occurring twice as often as in the placebo group)
Incidence of common TEAEs for EU labeling (above or equal to reporting threshold of 1% 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Incidence of common TEAEs for EU labeling (above or equal to reporting threshold of 1% 
(prior to rounding) of subjects in the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.(prior to rounding) of subjects in the 
Incidence of serious TEAEs 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Incidence of serious TEAEs 
Incidence of serious TEAEs 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Incidence of serious TEAEs 
Incidence of TEAEs leading to discontinuation 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Incidence of TEAEs leading to discontinuation 
Incidence in TEAEs leading to discontinuation in the Titration Period
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Incidence in TEAEs leading to discontinuation in the Titration Period

This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
UCB   28 Mar 2019  
Statistical Analysis Plan  SP0982  
 Incidence of TEAEs for potential drug-induced liver injury (PDILI) (See Section  12.2.2 for 
details) 
To assess TEAEs related to epilepsy, PTs will be identified by ongoing manual medical review.  
The following PTs (including those identified from continuing medical review) will be 
summarized: petit mal epilepsy, myoclonus, and myoclonic epilepsy. 
 Incidence of TEAEs related to epilepsy by 3-month exposure period of TEAE onset 
The dose at onset TEAE summaries will be presented by the LCM dosing categories presented in 
Section  10.1.2. AEs of unknown dosing are those with no known dose or known dosing and 
partial AE start or stop dates. 
 Incidence of TEAEs by actual dose at onset  
Subject data listings will be presented for the following:  Subjects experiencing adverse events on the ES 
 Subjects experiencing Serious TEAEs on the SS 
 Subjects experiencing TEAEs leading to discontinuation on the SS 
A glossary of AEs will be presented showing the mapping of investigator terms to coded SOC 
and PTs. 
A list of further AE tables required for EudraCT and clinicaltrials.gov is provided in 
Section  12.5. 
10.3 Clinical laboratory evaluations  
Measurement and change from Baseline in continuous laboratory parameters, including hematology, clinical chemistry, endocrinology, and urinalysis will be summarized using descriptive statistics for the scheduled visits. When analyzing categorical data, the number and 
percentage of subjects in each category will be presented. In addition, summary statistics for the 
actual value and change from Baseline will be presented for Last Visit, minimum, and maximum post-Baseline values obtained during the Treatment Period. Repeated or unscheduled laboratory 
assessments during the study will not be presented in by-visit summaries, but will be considered 
when determining the last visit, minimum, and maximum post-Baseline values during the Treatment Period. 
Shifts based on the normal range (ie, low, normal, high, and missing) for each hematology and 
clinical chemistry lab parameter will be presented by maximum value during the Treatment 
Period relative to Baseline by treatment group. Similar shift tables for Baseline versus minimum 
value during the Treatment Period will also be presented. Unscheduled visits will be considered 
when determining the maximum and minimum value during the defined treatment period.  
Treatment -emergent markedly abnormal (TEMA) values indicate significant deviations from the 
expected range of age-appropriate values. TEMA laboratory abnormalities results are those that 
are observed post-Baseline during the Treatment Period but are not present at Baseline. TEMA values for serum chemistry and hematology laboratory parameters are provided in UCB 
conventional (traditional) and standard units. The definition of MA values for hematology and 
chemistry values can be found in Section 12.3. The number and percentage of subjects with at REDACTED COPY A glossary of AEs will be presented showing the mapping of investigator terms to coded SOC 
REDACTED COPY A glossary of AEs will be presented showing the mapping of investigator terms to coded SOC 
of further AE tables required for EudraCT and clinicaltrials.gov is provided in 
REDACTED COPY of further AE tables required for EudraCT and clinicaltrials.gov is provided in 
Clinical laboratory evaluations
REDACTED COPY Clinical laboratory evaluations
from Baseline in continuous laboratory parameters, including 
REDACTED COPY from Baseline in continuous laboratory parameters, including 
hematology, clinical chemistry, endocrinology, and urinalysis will be summarized using REDACTED COPY hematology, clinical chemistry, endocrinology, and urinalysis will be summarized using 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.The dose at onset TEAE summaries will be presented by the LCM dosing categories presented in 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.The dose at onset TEAE summaries will be presented by the LCM dosing categories presented in 
. AEs of unknown dosing are those with no known dose or known dosing and 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.. AEs of unknown dosing are those with no known dose or known dosing and 
Subjects experiencing TEAEs leading to discontinuation on the SS
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Subjects experiencing TEAEs leading to discontinuation on the SS
A glossary of AEs will be presented showing the mapping of investigator terms to coded SOC 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.A glossary of AEs will be presented showing the mapping of investigator terms to coded SOC 
of further AE tables required for EudraCT and clinicaltrials.gov is provided in 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.of further AE tables required for EudraCT and clinicaltrials.gov is provided in 
Clinical laboratory evaluations
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Clinical laboratory evaluations
from Baseline in continuous laboratory parameters, including 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.from Baseline in continuous laboratory parameters, including 
hematology, clinical chemistry, endocrinology, and urinalysis will be summarized using 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.hematology, clinical chemistry, endocrinology, and urinalysis will be summarized using 
descriptive statistics for the scheduled visits. When analyzing categorical data, the number and 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.descriptive statistics for the scheduled visits. When analyzing categorical data, the number and 
of subjects in each category will be presented. In addition, summary statistics for the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.of subjects in each category will be presented. In addition, summary statistics for the 
actual value and change from Baseline will be presented for Last Visit, minimum, and maximum 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.actual value and change from Baseline will be presented for Last Visit, minimum, and maximum 
Baseline values obtained during the Treatment Period. Repeated or uns
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Baseline values obtained during the Treatment Period. Repeated or uns
assessments during the study will not be presented in by
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.assessments during the study will not be presented in by
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.when determining the last visit, minimum, and maximum post
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.when determining the last visit, minimum, and maximum post
Shifts based on the normal range (i
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Shifts based on the normal range (i
clinical chemistry lab parameter will be presented by maximum value during the Treatment 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.clinical chemistry lab parameter will be presented by maximum value during the Treatment 
Period relative to Baseline by treatment group. Similar shift tables for Baseline versus minimum 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Period relative to Baseline by treatment group. Similar shift tables for Baseline versus minimum 
value durin
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.value durin g the Treatment Period will also be presented. Unscheduled visits will be considered 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.g the Treatment Period will also be presented. Unscheduled visits will be considered 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.when determining the maximum and minimum value during the defined treatment period. 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.when determining the maximum and minimum value during the defined treatment period. 
Treatment
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Treatment
expected range of age
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.expected range of age
are observed post
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.are observed post
UCB   28 Mar 2019  
Statistical Analysis Plan  SP0982  
least 1 TEMA value will be summarized by scheduled visit, Last Visit, minimum and maximum 
post-Baseline values obtained during the Treatment Period for each laboratory parameter 
(hematology and clinical chemistry) with markedly abnormal criteria specified. TEMA values are those that are observed during the defined treatment period at scheduled or unscheduled visits and were not observed at any visit during the Baseline period.  
A table summarizing the number of subjects meeting the potential drug induced liver injury 
criteria will also be presented. 
The National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTC) 
can be found in Section 12.4 . The number and percentage of subjects with treatment emergent 
laboratory abnormalities of NCI CTC grade 2 or higher (hematology and clinical chemistry) will be summarized by treatment group, laboratory parameter, and visit for the Treatment Period. 
Treatment emergent abnormalities of grade 2 or higher are those that were observed during the 
Treatment Period at scheduled visits and not reporting a grade 2 or higher abnormality during t he 
Baseline Period. All treatment emergent laboratory abnormalities of NCI CTC grade 2 or higher 
will be presented in a subject number listing. 
Subject data listings of all laboratory data will also be presented. Within the listings TEMA 
values will be identified. Separate tables will also be provided to show the subject numbers of those who meet any of the TEMA and NCI CTC grade 2 or higher criteria. 
Any additional lab data will be listed, including positive pregnancy test results listed by subject. 
10.4 Vital signs, physical findings, and other observations related to 
safety 
10.4.1 Vital signs 
Observed values and changes from Baseline in vital sign parameters will be summarized using 
descriptive statistics for the scheduled visits. In addition, summary statistics for the observed 
value and change from Baseline will be presented for Last Visit, minimum, and maximum post-
Baseline values obtained during the Treatment Period. Repeated or unscheduled assessments during the study will not be presented in by-visit summaries, but will be considered when determining the minimum, and maximum post-Baseline values during the Treatment Period. 
The number and percentage of subjects with a TEMA value, TEMA low value, and TEMA high 
value, at each post-Baseline visit, for which systolic blood pressure, diastolic blood pressure, pulse rate, and body weight were scheduled to be assessed, and Last Visit, will be presented. Percentages will be relative to the number of subjects with a value at each time point. All TEMA results summarized will be presented in a subject number listing. The abnormal vital sign criteria 
are defined in Section  12.3.3 . 
A subject data listing of all vital signs data will be created, indicating any abnormal value s. 
10.4.2 Electrocardiograms 
ECGs will be performed locally and no standardization techniques will be employed. The data 
will be analyzed as reported. 
10.4.2.1 Derivation of corrected QT values 
The Bazett corrected QT (QTcB) will be calculated as REDACTED COPY those who meet any of the TEMA and NCI CTC grade 2 or higher criteria.
REDACTED COPY those who meet any of the TEMA and NCI CTC grade 2 or higher criteria.
Any additional lab data will be listed, including positive pregnancy test results listed by subject.
REDACTED COPY Any additional lab data will be listed, including positive pregnancy test results listed by subject.
signs, physical findings, and other observations related to 
REDACTED COPY signs, physical findings, and other observations related to 
Observed values and changes from Baseline in vital sign parameters will be summarized using REDACTED COPY Observed values and changes from Baseline in vital sign parameters will be summarized using 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.NCI CTC
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.NCI CTC )
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.)
. The number and percentage of subjects with treatment emergent 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.. The number and percentage of subjects with treatment emergent 
laboratory abnormalities of NCI CTC grade 2 or higher (hematology and clinical chemistry) will 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.laboratory abnormalities of NCI CTC grade 2 or higher (hematology and clinical chemistry) will 
t group, laboratory parameter, and visit for the Treatment Period. 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.t group, laboratory parameter, and visit for the Treatment Period. 
Treatment emergent abnormalities of grade 2 or higher are those that were observed during the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Treatment emergent abnormalities of grade 2 or higher are those that were observed during the 
Treatment Period at scheduled visits and not reporting a grade 2 or higher abnormality during t
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Treatment Period at scheduled visits and not reporting a grade 2 or higher abnormality during t
Baseline Period. All treatment emergent laboratory abnormalities of NCI CTC grade 2 or higher 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Baseline Period. All treatment emergent laboratory abnormalities of NCI CTC grade 2 or higher 
Subject data listings of all laboratory data will also be presented. Within the listings TEMA 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Subject data listings of all laboratory data will also be presented. Within the listings TEMA 
ntified. Separate tables will also be provided to show the subject numbers of 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.ntified. Separate tables will also be provided to show the subject numbers of 
those who meet any of the TEMA and NCI CTC grade 2 or higher criteria.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.those who meet any of the TEMA and NCI CTC grade 2 or higher criteria.
Any additional lab data will be listed, including positive pregnancy test results listed by subject.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Any additional lab data will be listed, including positive pregnancy test results listed by subject.
signs, physical findings, and other observations related to 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.signs, physical findings, and other observations related to 
Observed values and changes from Baseline in vital sign parameters will be summarized using 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Observed values and changes from Baseline in vital sign parameters will be summarized using 
descriptive statistics for the scheduled visits. In addition, summary statistics for 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.descriptive statistics for the scheduled visits. In addition, summary statistics for 
value and change from Baseline will be presented for Last Visit, minimum, and maximum post
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.value and change from Baseline will be presented for Last Visit, minimum, and maximum post
Baseline values obtained during the Treatment Period. Repeated or unscheduled assessments 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Baseline values obtained during the Treatment Period. Repeated or unscheduled assessments 
during the study will not be presented in by
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.during the study will not be presented in by
determining the minimum, and maximum post
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.determining the minimum, and maximum post
The number and percentage of subjects with a TEMA value, TEMA low value, and TEMA high 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.The number and percentage of subjects with a TEMA value, TEMA low value, and TEMA high 
Baseline visit, for which systolic
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Baseline visit, for which systolic
pulse rate, and body weight were scheduled to be assessed, and Last Visit, will be presented. 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.pulse rate, and body weight were scheduled to be assessed, and Last Visit, will be presented. 
Percentages will be relative to the number of subjects with a value at each time point. All TEMA 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Percentages will be relative to the number of subjects with a value at each time point. All TEMA 
results summarized wil
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.results summarized wil
are defined in 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.are defined in Section
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Section
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.A subject data listing of all vital sign
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.A subject data listing of all vital sign
10.4.2
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.10.4.2
ECGs will be performed locally and no standardization techniques will be employed. The data 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.ECGs will be performed locally and no standardization techniques will be employed. The data 
UCB   28 Mar 2019  
Statistical Analysis Plan  SP0982  
QT/√𝑅𝑅, where RR = 60/heart rate.  
The Fridericia corrected QT (QTcF) will be calculated as 
QT/√𝑅𝑅3, where RR = 60/heart rate.  
10.4.2.2 Analysis of ECG parameters 
For quantitative ECG measurements (heart rate, PR interval, QRS interval, QT interval, RR 
Interval and corrected QT intervals using Bazett and Fridiricia correction methods), summary 
statistics of the actual values and change from Baseline will be summarized using descriptive 
statistics for the scheduled visits, overall, Last Visit, minimum and maximum post-Baseline values obtained during the Treatment Period, and in each of the TEMA ECG criteria age 
categories. Last visit is the value from the last post baseline visit during the Treatment Period. 
Repeated or unscheduled ECG assessments during the study will not be presented in by-visit 
summaries, but will be considered when determining the last visit, minimum, and maximum 
post-Baseline values during the Treatment Period. If repeat measurements are taken at a 
particular visit, then the average value is used in summaries and the original values are listed. 
The number and percentage of subjects who met each of the TEMA criteria specified in 
Section  12.3.4 will be presented within the specified age groups. For each parameter, the number 
and percentage of subjects with an abnormality (ie subjects who met any of the criteria specific 
to their age) will be summarized for heart rate, PR interval, QRS interval, QT interval and 
corrected QT intervals by scheduled visit and Last Visit during the Treatment Period. Repeated 
or unscheduled ECG assessments during the study will not be presented in by-visit summaries, but will be considered when determining the last visit values during the Treatment Period. 
Subject numbers for those with TEMA ECG values will be listed by abnormality criteria. TEMA 
results for a subject are those that are observed during the defined treatment period at scheduled 
or unscheduled visits and were not observed at any visit during the Baseline period. 
Detailed information on the quantitative and qualitative ECG findings will be presented in 
subject data listings. 
10.4.3 Physical examination  
A listing of abnormal physical examination findings will be provided. 10.4.4 Safety Seizure Information 
10.4.4.1 New Seizure Type 
The number and percentage of subjects with seizure types present or absent in the Treatment 
Period vs whether the seizure type was present or absent in Combined Baseline will be tabulated. 
The number and percentage of subjects with seizure types present or absent in the Treatment 
Period vs whether the seizure type was present or absent in Seizure History (including Combined 
Baseline) will be tabulated. 
The number and percentage of subjects with new absence or myoclonic seizure types 
experienced in the Treatment Period with absence or myoclonic seizure type, respectively, 
indicated by the Seizure History Classification but not experienced in the Combined Baseline as recorded in the diary will be summarized.  REDACTED COPY and percentage of subjects with an abnormality (ie subjects who met any of the criteria specific 
REDACTED COPY and percentage of subjects with an abnormality (ie subjects who met any of the criteria specific 
PR interval, QRS interval, QT interval and 
REDACTED COPY PR interval, QRS interval, QT interval and 
corrected QT intervals by scheduled visit and Last Visit during the Treatment Period. Repeated 
REDACTED COPY corrected QT intervals by scheduled visit and Last Visit during the Treatment Period. Repeated 
or unscheduled ECG assessments during the study will not be presented in by
REDACTED COPY or unscheduled ECG assessments during the study will not be presented in by
hen determining the last visit values during the Treatment Period. 
REDACTED COPY hen determining the last visit values during the Treatment Period. 
ECG values will be listed by abnormality criteria.
REDACTED COPY ECG values will be listed by abnormality criteria.
results for a subject are those that are observed during the defined treatment period at schedule
REDACTED COPY results for a subject are those that are observed during the defined treatment period at schedule
or unscheduled visits and were not observed at any visit during the Baseline period. REDACTED COPY or unscheduled visits and were not observed at any visit during the Baseline period.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.statistics of the actual values and change from Baseline will be summarized using descriptive 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.statistics of the actual values and change from Baseline will be summarized using descriptive 
Baseline 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Baseline 
values obtained during the Treatment Period, and in each of the TEMA ECG criteria age 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.values obtained during the Treatment Period, and in each of the TEMA ECG criteria age 
categories. Last visit is the value from the last post baseline visit during the Treatment Period. 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.categories. Last visit is the value from the last post baseline visit during the Treatment Period. 
essments during the study will not be presented in by
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.essments during the study will not be presented in by
summaries, but will be considered when determining the last visit, minimum, and maximum 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.summaries, but will be considered when determining the last visit, minimum, and maximum 
Baseline values during the Treatment Period. If repeat measurements are taken at a 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Baseline values during the Treatment Period. If repeat measurements are taken at a 
en the average value is used in summaries and the original values are listed.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.en the average value is used in summaries and the original values are listed.
The number and percentage of subjects who met each of the TEMA criteria specified in 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.The number and percentage of subjects who met each of the TEMA criteria specified in 
will be presented within the specified age groups. For each parameter, the number 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.will be presented within the specified age groups. For each parameter, the number 
and percentage of subjects with an abnormality (ie subjects who met any of the criteria specific 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.and percentage of subjects with an abnormality (ie subjects who met any of the criteria specific 
PR interval, QRS interval, QT interval and 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.PR interval, QRS interval, QT interval and 
corrected QT intervals by scheduled visit and Last Visit during the Treatment Period. Repeated 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.corrected QT intervals by scheduled visit and Last Visit during the Treatment Period. Repeated 
or unscheduled ECG assessments during the study will not be presented in by
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.or unscheduled ECG assessments during the study will not be presented in by
hen determining the last visit values during the Treatment Period. 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.hen determining the last visit values during the Treatment Period. 
ECG values will be listed by abnormality criteria.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.ECG values will be listed by abnormality criteria.
results for a subject are those that are observed during the defined treatment period at schedule
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.results for a subject are those that are observed during the defined treatment period at schedule
or unscheduled visits and were not observed at any visit during the Baseline period.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.or unscheduled visits and were not observed at any visit during the Baseline period.
Detailed information on the quantitative and qualitative ECG findings will be presented in 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Detailed information on the quantitative and qualitative ECG findings will be presented in 
Physical examination
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Physical examination
A listing of abnormal physical exa
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.A listing of abnormal physical exa
Safety Seizure Information
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Safety Seizure Information
New Seizure Type
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.New Seizure Type
The number and percentage of subjects with seizure types present or absent in the Treatment 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.The number and percentage of subjects with seizure types present or absent in the Treatment 
Period vs whether the seizure type was present or absent in Combined Baseline will b
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Period vs whether the seizure type was present or absent in Combined Baseline will b
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.The number and percentage of subjects with seizure types present or absent in the Treatment 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.The number and percentage of subjects with seizure types present or absent in the Treatment 
Period vs whether the seizure type was present or absent in Seizure History (including Combined 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Period vs whether the seizure type was present or absent in Seizure History (including Combined 
Baseline) will be tabulated.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Baseline) will be tabulated.
The number and percentage 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.The number and percentage 
experienced in the Treatment Period with absence or myoclonic seizure type, respectively, 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.experienced in the Treatment Period with absence or myoclonic seizure type, respectively, 
UCB   28 Mar 2019  
Statistical Analysis Plan  SP0982  
The number and percentage of subjects with new absence or myoclonic seizure types 
experienced in the Treatment Period but not experienced in the Combined Baseline or indicated 
in Seizure History Classification will also be summarized. 
The number and percentage of subjects with new absence or myoclonic seizure types in the 
Treatment Period, with absence or myoclonic, respectively, indicated by the Seizure History 
Classification but not experienced in the Combined Baseline Period or subjects with ≥50% worsening in days with absence or myoclonic seizures, respectively, will be summarized.  
10.4.4.2 Increase in days with absence seizures   
Response to treatment regarding absence seizures will be based on the percent change in the 
number of days with absence seizures per 28 days, calculated as described in Section  8.3.1.2. 
The number and percentage of subjects experiencing an increase of up to 25%, >25% to 50%, 
>50% to 75%, and >75% in the number of days with absence seizures per 28 days during the 
Treatment Period compared to the Prospective Baseline Period will be presented.  
10.4.4.3 Increase in days with myoclonic seizures   
Response to treatment regarding myoclonic seizures will be based on the percent change in the 
number of days with myoclonic seizures per 28 days, calculated as described in Section  8.3.1.2. 
The number and percentage of subjects experiencing an increase of up to 25%, >25% to 50%, 
>50% to 75%, and >75% in the number of days with myoclonic seizures per 28 days during the Treatment  Period compared to the Prospective Baseline Period will be presented.  
10.4.4.4 Increase in absence seizure frequency   
Response to treatment regarding absence seizures will also be based on the percent change in the 
absence seizure frequency per 28 days, calculated as described in Section 8.3.1.9 . The number 
and percentage of subjects experiencing an increase of up to 25%, >25% to 50%, >50% to 75%, 
and >75% in absence seizure frequency per 28 days during the Treatment Period compared to the 
Prospective Baseline Period will be presented.  
10.4.4.5 Increase in myoclonic seizure frequency   
Response to treatment regarding myoclonic seizures will also be based on the percent change in 
the myoclonic seizure frequency per 28 days, calculated as described in Section 8.3.1.9. The 
number and percentage of subjects experiencing an increase of up to 25%, >25% to 50%, >50% 
to 75%, and >75% in myoclonic seizure frequency per 28 days during the Treatment Period 
compared to the Prospective Baseline Period will be presented.  
10.4.5 Tanner stage assessment 
The investigator will evaluate the subject’s sexual development using the 3-item Tanner scale 
(ie, for females: breasts, pubic hair, and overall stage; and for males: genitals, pubic hair, and 
overall stage). The investigator should use clinical judgment in deciding which subjects are selected for evaluation of Tanner stage (ie, those subjects who are pubescent at Visit 2 or who will enter puberty during the course of the study). 
A listing of Tanner stage assessments will be provided. REDACTED COPY >50% to 75%, and >75% in the number of days with myoclonic seizures per 28 days during the 
REDACTED COPY >50% to 75%, and >75% in the number of days with myoclonic seizures per 28 days during the 
Period compared to the Prospective Baseline Period will be presented. 
REDACTED COPY Period compared to the Prospective Baseline Period will be presented. 
Increase in absence seizure frequency  
REDACTED COPY Increase in absence seizure frequency  
nce seizures will also be 
REDACTED COPY nce seizures will also be 
per 28 days, calculat
REDACTED COPY per 28 days, calculat
and percentage of subjects experiencing an increase of up to 25%, >25% to 50%, >50% to 75%, REDACTED COPY and percentage of subjects experiencing an increase of up to 25%, >25% to 50%, >50% to 75%, 
bsence seizure frequencyREDACTED COPY bsence seizure frequency
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Response to treatment regarding absence seizures will be based on the percent change in the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Response to treatment regarding absence seizures will be based on the percent change in the 
8.3.1.2
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.8.3.1.2
%, >25% to 50%, 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.%, >25% to 50%, 
>50% to 75%, and >75% in the number of days with absence seizures per 28 days during the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.>50% to 75%, and >75% in the number of days with absence seizures per 28 days during the 
Treatment Period compared to the Prospective Baseline Period will be presented. 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Treatment Period compared to the Prospective Baseline Period will be presented. 
ding myoclonic seizures will be based on the percent change in the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.ding myoclonic seizures will be based on the percent change in the 
number of days with myoclonic seizures per 28 days, calculated as described in 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.number of days with myoclonic seizures per 28 days, calculated as described in 
The number and percentage of subjects experiencing an increase of up to 25%, >25% to 50%, 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.The number and percentage of subjects experiencing an increase of up to 25%, >25% to 50%, 
>50% to 75%, and >75% in the number of days with myoclonic seizures per 28 days during the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.>50% to 75%, and >75% in the number of days with myoclonic seizures per 28 days during the 
Period compared to the Prospective Baseline Period will be presented. 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Period compared to the Prospective Baseline Period will be presented. 
Increase in absence seizure frequency  
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Increase in absence seizure frequency  
nce seizures will also be 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.nce seizures will also be 
per 28 days, calculat
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.per 28 days, calculat ed as described in 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.ed as described in 
and percentage of subjects experiencing an increase of up to 25%, >25% to 50%, >50% to 75%, 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.and percentage of subjects experiencing an increase of up to 25%, >25% to 50%, >50% to 75%, 
bsence seizure frequency
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.bsence seizure frequency per 28 days during the Treatment Period compared to the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.per 28 days during the Treatment Period compared to the 
Prospective Baseline Period will be presented. 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Prospective Baseline Period will be presented. 
Increase in myoclonic seizure frequency  
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Increase in myoclonic seizure frequency  
Response to treatment regarding myoclonic seizures will 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Response to treatment regarding myoclonic seizures will 
myoclonic seizure frequency
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.myoclonic seizure frequency
number and percentage of subjects experiencing an 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.number and percentage of subjects experiencing an 
to 75%, and >75% in 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.to 75%, and >75% in myoclonic seizure frequency
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.myoclonic seizure frequency
compared to the Prospective Baseline Period will be presented. 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.compared to the Prospective Baseline Period will be presented. 
Tanner stage assessment
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Tanner stage assessment
The investigator will evaluate the subj
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.The investigator will evaluate the subj
(ie, for females: breasts, pubic hair, and overall stage; and for males: genitals, pubic hair, and 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.(ie, for females: breasts, pubic hair, and overall stage; and for males: genitals, pubic hair, and 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.overall stage). The investigator should use clinical judgment in deciding which subjects are 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.overall stage). The investigator should use clinical judgment in deciding which subjects are 
selected 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.selected 
will enter puberty during the course of the study).
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.will enter puberty during the course of the study).
UCB   28 Mar 2019  
Statistical Analysis Plan  SP0982  
10.4.6 Neurological examination 
Summaries of shift from Baseline to Last Visit will be provided by major neurological category 
and treatment group based on categories normal, abnormal, not clinically significant, and 
abnormal, clinically significant. The major neurological categories collected on the CRF are General, Cranial Nerves, Reflexes, Motor System (including General, Muscle Strength and 
Muscle Tone), Coordination/Cerebellar Function and Sensation (including Upper and Lower 
Extremities). A listing of abnormal neurological examination findings will also be provided.  
10.4.7 Assessment of suicidality 
Suicidality will be assessed using the Columbia-Suicide Severity Rating Scale (C-SSRS). This 
scale will be used for screening as well as to assess suicide ideation and behavior that may occur 
during the study. All subjects who are ≥6 years of age will complete the “Baseline/Screening” 
version of the C-SSRS at the first visit and will complete the “Since Last Visit” version at 
subsequent visits. If a subject becomes 6 years of age during the study, the “Already Enrolled” 
version of the C-SSRS should be used at the first visit at which the subject is 6 years of age and the “Since Last Visit” version should be used at subsequent visits. The C-SSRS is not validated for subjects <6 years of age and will not be used for this population.  
Subject data listings of the data for the C-SSRS will be provided. No summaries of the C- SSRS 
data are planned. 
10.4.8 Achenbach Child Behavior Checklist 
The Achenbach CBCL form is a questionnaire intended to evaluate a child’s competencies and 
behavioral/emotional problems. Depending on the subject’s age, 1 of 2 versions of the Achenbach CBCL is used. The CBCL/1½-5 is intended for use in children 4 years to 5 years and 
11 months of age. For subjects ≥6 years to <17 years, the CBCL/6-18 will be used. For each 
subject, the same version (CBCL/1½-5 or CBCL/6-18) that is used at Visit 2 (Baseline) should be used at all following visits, even if the subject passes the applicable age range during the study, and should be completed by the same parent/legal representative.  
10.4.8.1 Derivation of Achenbach variables 
The CBCL/1 ½-5 will be grouped according to syndrome scales in Table 2 and the CBCL/6-18 
will be grouped according to empirically based syndrome scales in Table 3. The Achenbach 
CBCL has a 6 month recall. If a subject leaves the study early, and has been in the study for less than 6 months, this subject’s data will not be included in the analysis and will be listed only. 
Table 2: CBCL/1½- 5  
Syndrome scale Questions 
Aggressive behavior 8, 15, 16, 18, 20, 27, 29, 35, 40, 42, 44, 53, 58, 66, 
69, 81, 85, 88, 96 
Anxious/depressed 10, 33, 37, 43, 47, 68, 87, 90 
Attention problems 5, 6, 56, 59, 95 
Emotionally reactive 21, 46, 51, 79, 82, 83, 92, 97, 99 REDACTED COPY Achenbach Child Behavior Checklist
REDACTED COPY Achenbach Child Behavior Checklist
The Achenbach CBCL form is a questionnaire intended to evaluate a child’s competencies and 
REDACTED COPY The Achenbach CBCL form is a questionnaire intended to evaluate a child’s competencies and 
al problems. Depending on the subject’s age, 1 of 2 versions of the 
REDACTED COPY al problems. Depending on the subject’s age, 1 of 2 versions of the 
Achenbach CBCL is used. The CBCL/1½
REDACTED COPY Achenbach CBCL is used. The CBCL/1½ -
REDACTED COPY -5 is intended for use in children 4 years to 5 years and 
REDACTED COPY 5 is intended for use in children 4 years to 5 years and 
11 months of age. For subjects ≥6 years to <17 years, the CBCL/6
REDACTED COPY 11 months of age. For subjects ≥6 years to <17 years, the CBCL/6
5 or CBCL/6REDACTED COPY 5 or CBCL/6
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.SSRS). This 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.SSRS). This 
scale will be used for screening as well as to assess suicide ideation and behavior that may occur 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.scale will be used for screening as well as to assess suicide ideation and behavior that may occur 
≥6 years of age will complete the “Baseline/Screening” 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.≥6 years of age will complete the “Baseline/Screening” 
SSRS at the first visit and will complete the “Since Last Visit” version at 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.SSRS at the first visit and will complete the “Since Last Visit” version at 
subsequent visits. If a subject becomes 6 years of age during the study, the “Already Enrolled” 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.subsequent visits. If a subject becomes 6 years of age during the study, the “Already Enrolled” 
SSRS should be used at the first visit at which the subject is 6 years of age and 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.SSRS should be used at the first visit at which the subject is 6 years of age and 
the “Since Last Visit” version should be used at subsequent visits. The C
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.the “Since Last Visit” version should be used at subsequent visits. The C -
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.-SSRS is not validated 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.SSRS is not validated 
for subjects <6 years of age and will not be used for this population. 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.for subjects <6 years of age and will not be used for this population. 
SSRS will be provided. No summaries of the C
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.SSRS will be provided. No summaries of the C
Achenbach Child Behavior Checklist
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Achenbach Child Behavior Checklist
The Achenbach CBCL form is a questionnaire intended to evaluate a child’s competencies and 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.The Achenbach CBCL form is a questionnaire intended to evaluate a child’s competencies and 
al problems. Depending on the subject’s age, 1 of 2 versions of the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.al problems. Depending on the subject’s age, 1 of 2 versions of the 
5 is intended for use in children 4 years to 5 years and 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.5 is intended for use in children 4 years to 5 years and 
11 months of age. For subjects ≥6 years to <17 years, the CBCL/6
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.11 months of age. For subjects ≥6 years to <17 years, the CBCL/6
5 or CBCL/6
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.5 or CBCL/6
be used at all following visits, even if the subject passes the applicable age range during the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.be used at all following visits, even if the subject passes the applicable age range during the 
study, and should be completed by the same parent/legal representative.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.study, and should be completed by the same parent/legal representative.
Derivation of Achenbach variables
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Derivation of Achenbach variables
5 will be grouped according to syndrome scales in 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.5 will be grouped according to syndrome scales in 
will be grouped according to empirically based syndrome scales in
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.will be grouped according to empirically based syndrome scales in
CBCL has a 6 month recall. If a subject leaves the study early, and has been in the study for less 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.CBCL has a 6 month recall. If a subject leaves the study early, and has been in the study for less 
than 6 months, this subject’s data will not be included in the analysis and will be listed only.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.than 6 months, this subject’s data will not be included in the analysis and will be listed only.
CBCL/1½
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.CBCL/1½
Syndrome scale
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Syndrome scale
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Aggressive behavior
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Aggressive behavior
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Anxious/depressed
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Anxious/depressed
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
UCB   28 Mar 2019  
Statistical Analysis Plan  SP0982  
Table 2: CBCL/1½- 5  
Syndrome scale Questions 
Sleep problems 22, 38, 48, 64, 74, 84, 94 
Somatic complaints 1, 7, 12, 19, 24, 39, 45, 52, 78, 86, 93 
Withdrawn 2, 4, 23, 62, 67, 70, 71, 98 
Other problems 3, 9, 11, 13, 14, 17, 25, 26, 28, 30, 31, 32, 34, 36, 
41, 49, 50, 54, 55, 57, 60, 61, 63, 65, 72, 73, 75, 76, 77, 80, 89, 91, 100 
CBCL=  Child Behavior Checklist 
 
Table 3 :  CBCL/6-18 
Syndrome scale Questions 
Aggressive behavior 3, 16, 19, 20, 21, 22, 23, 37, 57, 68, 86, 87, 88, 89, 
94, 95, 97, 104 
Anxious/depressed 14, 29, 30, 31, 32, 33, 35, 45, 50, 52, 71, 91, 112 
Attention problems 1, 4, 8, 10, 13, 17, 41, 61, 78, 80 
Rule -breaking behavior 2, 26, 28, 39, 43, 63, 67, 72, 73, 81, 82, 90, 96, 99, 
101, 105, 106 
Social problems 11, 12, 25, 27, 34, 36, 38, 48, 62, 64, 79 
Somatic complaints 47, 49, 51, 54, 56a, 56b, 56c, 56d, 56e, 56f, 56g 
Thought problems 9, 18, 40, 46, 58, 59, 60, 66, 70, 76, 83, 84, 85, 92, 100 
Withdrawn/depressed 5, 42, 65, 69, 75, 102, 103, 111 
CBCL= Child Behavior Checklist  
The Syndrome scale scores are calculated as the sum of the associated individual items scores. 
Each individual item score has the response options of:  
0=not true (as far as known)  
1=somewhat or sometimes true  
2=very true or often true.  
Missing data will not be replaced. Standardized T-scores are determined for each subject’s raw syndrome and overall scores based on the subject’s age and gender. Tables mapping each raw 
score to the appropriate T-score are provided in the CBCL Professional Manual and will be 
reproduced programmatically.  
10.4.8.2 Analysis of Achenbach variables 
Calculated T-score values and change from Baseline for each CBCL/1½ -5 syndrome (aggressive 
behavior, anxious/depressed, attention problems, emotionally reactive, other problems, sleep REDACTED COPY 1, 4, 8, 10, 13, 17, 41, 61, 78, 80
REDACTED COPY 1, 4, 8, 10, 13, 17, 41, 61, 78, 80
REDACTED COPY 2, 26, 28, 39, 43, 63, 67, 72, 73, 81, 82, 90, 96, 99, 
REDACTED COPY 2, 26, 28, 39, 43, 63, 67, 72, 73, 81, 82, 90, 96, 99, 
101, 105, 106
REDACTED COPY 101, 105, 106
REDACTED COPY REDACTED COPY REDACTED COPY REDACTED COPY REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.3, 9, 11, 13, 14, 17, 25, 26, 28, 30, 31, 32, 34, 36, 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.3, 9, 11, 13, 14, 17, 25, 26, 28, 30, 31, 32, 34, 36, 
63, 65, 72, 73, 75, 76, 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.63, 65, 72, 73, 75, 76, 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.3, 16, 19, 20, 21, 22, 23, 37, 57, 68, 86, 87, 88, 89, 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.3, 16, 19, 20, 21, 22, 23, 37, 57, 68, 86, 87, 88, 89, 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.14, 29, 30, 31, 32, 33, 35, 45, 50, 52, 71, 91, 112
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.14, 29, 30, 31, 32, 33, 35, 45, 50, 52, 71, 91, 112
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.1, 4, 8, 10, 13, 17, 41, 61, 78, 80
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.1, 4, 8, 10, 13, 17, 41, 61, 78, 80
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.2, 26, 28, 39, 43, 63, 67, 72, 73, 81, 82, 90, 96, 99, 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.2, 26, 28, 39, 43, 63, 67, 72, 73, 81, 82, 90, 96, 99, 
101, 105, 106
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.101, 105, 106
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.11, 12, 25, 27, 34, 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.11, 12, 25, 27, 34, 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.The Syndrome scale scores are calculated as the sum of the associated individual items scores. 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.The Syndrome scale scores are calculated as the sum of the associated individual items scores. 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Each individual item score has the response options of: 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Each individual item score has the response options of: 
0=not true (as far as known)
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.0=not true (as far as known)
1=somewhat or sometimes true
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.1=somewhat or sometimes true
2=very true or often true.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.2=very true or often true.
Missing data will not be replaced. Standardized T
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Missing data will not be replaced. Standardized T
syndrome and overall scores based on the subject’s age and gender. Tables mapping each raw 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.syndrome and overall scores based on the subject’s age and gender. Tables mapping each raw 
score to the appropriate T
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.score to the appropriate T
reproduced programmatically. 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.reproduced programmatically. 
UCB   28 Mar 2019  
Statistical Analysis Plan  SP0982  
problems, somatic complaints, and withdrawn) will be summarized for each visit, and Last Visit, 
by treatment group. 
Calculated T-score values and change from Baseline for each CBCL/6-18 syndrome (aggressive 
behavior, anxious/depressed, attention problems, rule-breaking behavior, social problems, 
somatic complaints, thought problems, and withdrawn/depressed) will be summarized for each 
visit, and Last Visit, by treatment group. 
Subject data listings of the data for the Achenbach CBCL will be provided. The means of the 
calculated T-score will be plotted by visit. 
10.4.9 BRIEF-P and BRIEF assessment 
The BRIEF-P and BRIEF are validated tools that will be used for the evaluation of subjects ≥4 to 
<5 years of age, and ≥5 years of age, respectively. The BRIEF- P and BRIEF will be used only in 
countries where a translated scale is available. For each subject, the same version (BRIEF-P or 
BRIEF) that is used at Visit 2 (Baseline) should be used at all following visits, even if the subject passes the applicable age range during the study. The BRIEF-P and BRIEF have a 6 month 
recall. If a subject leaves the study early, and has been in the study for less than 6 months, this 
subject’s data will not be included in the analysis and will be listed only. 
10.4.9.1 BRIEF-P scores 
The BRIEF -P form comprises of 63 questions which can be answered Never (scored as 1 point), 
Sometimes (scored as 2 points), and Often (scored as 3 points).  
The 63 items are included in the raw Global Executive Composite (GEC) score which ranges 
from 63 to 189, with higher scores reflecting poorer functioning. 
The 3 subscale scores and 5 individual component scores that make up these subscale scores are 
outlined in Table 4 . 
Table 4: BRIEF-P questionnaire scoring 
 
Scale/Index Questions 
Inhibit 3, 8, 13, 18, 23, 28, 33, 38, 43, 48, 52, 54, 56, 58, 
60, 62 
Shift 5,10, 15, 20, 25, 30, 35, 40, 45, 50 
Emotional Control 1, 6, 11, 16, 21, 26, 31, 36, 41, 46 
Inhibitory self-control All from {Inhibit and Emotional Control} 
Flexibility All from {Shift and Emotional Control} 
Working Memory 2, 7, 12, 17, 22, 27, 32, 37, 42, 47, 51, 53, 55, 57, 59, 61, 63 
Plan/Organize 4, 9, 14, 19, 24, 29, 34, 39, 44, 49 
Emergent metacognition All from {Working Memory and Plan/Organize} REDACTED COPY P form comprises of 63 questions which can be answered Never (scored as 1 point), 
REDACTED COPY P form comprises of 63 questions which can be answered Never (scored as 1 point), 
Sometimes (scored as 2 points), and Often (scored as 3 points). 
REDACTED COPY Sometimes (scored as 2 points), and Often (scored as 3 points). 
The 63 items are included in the raw Global Executive Composite (GEC) score which ranges 
REDACTED COPY The 63 items are included in the raw Global Executive Composite (GEC) score which ranges 
, with higher scores reflecting poorer functioning.
REDACTED COPY , with higher scores reflecting poorer functioning.
The 3 subscale scores and 5 individual component scores that make up these subscale scores are 
REDACTED COPY The 3 subscale scores and 5 individual component scores that make up these subscale scores are 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.P and BRIEF are validated tools that will be used for the evaluation of subjects ≥4 to 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.P and BRIEF are validated tools that will be used for the evaluation of subjects ≥4 to 
and BRIEF will be used only in 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.and BRIEF will be used only in 
countries where a translated scale is available. For each subject, the same version (BRIEF
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.countries where a translated scale is available. For each subject, the same version (BRIEF
BRIEF) that is used at Visit 2 (Baseline) should be used at all following visits, even if the subject 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.BRIEF) that is used at Visit 2 (Baseline) should be used at all following visits, even if the subject 
P and BRIEF have a 6 month 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.P and BRIEF have a 6 month 
recall. If a subject leaves the study early, and has been in the study for less than 6 months, this 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.recall. If a subject leaves the study early, and has been in the study for less than 6 months, this 
subject’s data will not be included in the analysis and will be listed only.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.subject’s data will not be included in the analysis and will be listed only.
P form comprises of 63 questions which can be answered Never (scored as 1 point), 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.P form comprises of 63 questions which can be answered Never (scored as 1 point), 
Sometimes (scored as 2 points), and Often (scored as 3 points). 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Sometimes (scored as 2 points), and Often (scored as 3 points). 
The 63 items are included in the raw Global Executive Composite (GEC) score which ranges 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.The 63 items are included in the raw Global Executive Composite (GEC) score which ranges 
, with higher scores reflecting poorer functioning.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof., with higher scores reflecting poorer functioning.
The 3 subscale scores and 5 individual component scores that make up these subscale scores are 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.The 3 subscale scores and 5 individual component scores that make up these subscale scores are 
P questionnaire scoring
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.P questionnaire scoring
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Emotional Control
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Emotional Control
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Inhibitory self
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Inhibitory self
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Flexibility
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Flexibility
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Working Memory
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Working Memory
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
UCB   28 Mar 2019  
Statistical Analysis Plan  SP0982  
Table 4: BRIEF-P questionnaire scoring 
 
Scale/Index Questions 
GEC Score 1-63 
GEC=Global Executive Composite 
Standardized T-scores are determined from each subject’s raw GEC, inhibitory self-control, 
flexibility, emergent metacognition, and component scores based on the subject’s age and 
gender. Tables that map each raw score to the appropriate T-score are provided in the BRIEF- P 
Professional Manual and will be reproduced progr ammatically.  
Two validity scales will also be derived: Negativity to assess the extent to which the respondent answers selected BRIEF-P items in an unusually negative manner and Inconsistency to assess the 
extent to which the respondent answers similar BRI EF-P items in an inconsistent manner. The 
Negativity scale is the number of items in 30, 44, 46, 47, 53, 55, 56, 57, 59 and 63 with a score of 3, and so has a range of 0 to10. A score of 2 or less is considered acceptable, 3 as elevated and 4 or more highly elevated. 
For the Inconsistency scale, there are 10 item pairs of related questions. The Inconsistency scale is the sum of the absolute values of the difference in scores for the items in each item pair, and so ranges from 0 to 20. The item pairs are questions 1 and 11, 3 and 33, 5 and 45, 10 and 20, 
11 and  26, 16 and 21, 18 and 52, 33 and 38, 43 and 52, and 48 and 54. A score of 7 or less is 
acceptable and 8 or more inconsistent.  
Calculated T-score values and change from Baseline for the 2 indexed scores (BRI and MI), and 
GEC for the BRIEF-P questionnaire will be summarized at each visit, and Last Visit, by 
treatment group.  
All BRIEF-P assessment data will be listed. The means of the BRIEF-P assessment data will be 
plotted by visit. 
10.4.9.2 BRIEF scores 
The BRIEF form comprises of 86 questions which can be answered as Never (scored as 1 point), 
Sometimes (scored as 2 points), and Often (scored as 3 points).  
The first 72 items are included in the GEC score which ranges from 72 to 216, with higher scores 
reflecting poorer functioning. 
The 2 subscale scores and 8 individual component scores that make up these subscale scores are outlined in Table 5 . 
Table 5: BRIEF questionnaire scoring  
Scale/Index Questions 
Inhibit 38, 41, 43, 44, 49, 54, 55, 56, 59, 65 
Shift 5, 6, 8, 12, 13, 23, 30, 39 
Emotional Control 1, 7, 20, 25, 26, 45, 50, 62, 64, 70 REDACTED COPY For the Inconsistency scale, there are 10 item pairs of related questions. The Inconsistency scale 
REDACTED COPY For the Inconsistency scale, there are 10 item pairs of related questions. The Inconsistency scale 
is the sum of the absolute values of the difference in scores for the items in each item pair, and so 
REDACTED COPY is the sum of the absolute values of the difference in scores for the items in each item pair, and so 
stions 1 and 11, 3 and 33, 5 and 45, 10 and 20, 
REDACTED COPY stions 1 and 11, 3 and 33, 5 and 45, 10 and 20, 
26, 16 and 21, 18 and 52, 33 and 38, 43 and 52, and 48 and 54. A score of 7 or less is 
REDACTED COPY 26, 16 and 21, 18 and 52, 33 and 38, 43 and 52, and 48 and 54. A score of 7 or less is 
score values and change from Baseline for the 2 indexed score
REDACTED COPY score values and change from Baseline for the 2 indexed score
P questionnaire will be summarized at each visit, and Last Visit, by REDACTED COPY P questionnaire will be summarized at each visit, and Last Visit, by 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.control, 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.control, 
and component scores based on the subject’s age and 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.and component scores based on the subject’s age and 
score are provided in the BRIEF
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.score are provided in the BRIEF
Two validity scales will also be derived: Negativity to assess the extent to which the respondent 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Two validity scales will also be derived: Negativity to assess the extent to which the respondent 
P items in an unusually negative manner and Inconsistency to assess the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.P items in an unusually negative manner and Inconsistency to assess the 
P items in an inconsistent manner. The 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.P items in an inconsistent manner. The 
Negativity scale is the number of items in 30, 44, 46, 47, 53, 55, 56, 57, 59 and 63 with a score 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Negativity scale is the number of items in 30, 44, 46, 47, 53, 55, 56, 57, 59 and 63 with a score 
of 3, and so has a range of 0 to10. A score of 2 or less is considered acceptable, 3 as elevated 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.of 3, and so has a range of 0 to10. A score of 2 or less is considered acceptable, 3 as elevated 
For the Inconsistency scale, there are 10 item pairs of related questions. The Inconsistency scale 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.For the Inconsistency scale, there are 10 item pairs of related questions. The Inconsistency scale 
is the sum of the absolute values of the difference in scores for the items in each item pair, and so 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.is the sum of the absolute values of the difference in scores for the items in each item pair, and so 
stions 1 and 11, 3 and 33, 5 and 45, 10 and 20, 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.stions 1 and 11, 3 and 33, 5 and 45, 10 and 20, 
26, 16 and 21, 18 and 52, 33 and 38, 43 and 52, and 48 and 54. A score of 7 or less is 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.26, 16 and 21, 18 and 52, 33 and 38, 43 and 52, and 48 and 54. A score of 7 or less is 
score values and change from Baseline for the 2 indexed score
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.score values and change from Baseline for the 2 indexed score
P questionnaire will be summarized at each visit, and Last Visit, by 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.P questionnaire will be summarized at each visit, and Last Visit, by 
P assessment data will be listed. The means of the BRIEF
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.P assessment data will be listed. The means of the BRIEF
BRIEF scores
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.BRIEF scores
EF form comprises of 86 questions which can be answered as Never (scored as 1 point), 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.EF form comprises of 86 questions which can be answered as Never (scored as 1 point), 
Sometimes (scored as 2 points), and Often (scored as 3 points). 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Sometimes (scored as 2 points), and Often (scored as 3 points). 
The first 72 items are included in the GEC score which ranges from 72 to 216, with higher scores 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.The first 72 items are included in the GEC score which ranges from 72 to 216, with higher scores 
ng poorer functioning.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.ng poorer functioning.
The 2 subscale scores and 8 individual component scores that make up these subscale scores are 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.The 2 subscale scores and 8 individual component scores that make up these subscale scores are 
outlined in 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.outlined in Table
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Table
Table
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Table
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Scale/Index
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Scale/Index
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
UCB   28 Mar 2019  
Statistical Analysis Plan  SP0982  
Table 5: BRIEF questionnaire scoring  
Scale/Index Questions 
BRI All from {Inhibit, Shift, and Emotional Control} 
Initiate  3, 10, 16, 47, 48, 61, 66, 71 
Working Memory 2, 9, 17, 19, 24, 27, 32, 33, 37, 57 
Plan/Organize 11, 15, 18, 22, 35, 36, 40, 46, 51, 53, 58 
Organization of Materials 4, 29, 67, 68, 69, 72 
Monitor 14, 21, 31, 34, 42, 52, 60, 63 
MI All from {Initiate, Working Memory, 
Plan/Organize, Organization of Materials, and Monitor}  
GEC Score 1-72 
BRI=Behavioral Regulation Index, MI=Metacognition Index, GEC=Global Executive Composite 
The BRI score is the total of 28 items and ranges from 28-84. The MI score is the total of 
44 items and ranges from 44 to 132. 
Standardized T-scores are determined from each subject’s raw GEC, BRI, MI, and component 
scores based on the subject’s age and gender. Tables that map each raw score to the appropriate T-score are provided in the BRIEF Professional Manual and will be reproduced programmatically. 
Two validity scales will also be derived: Negativity to assess the extent to which the respondent 
answers selected BRIEF items in an unusually negative manner, and Inconsistency to assess the 
extent to which the respondent answers similar BRIEF items in an inconsistent manner. The 
Negativity scale is the number of items in 8, 13, 23, 30, 62, 71, 80, 83, and 85 with a score of 3, and so has a range of 0 to 9. A score of 4 or less is considered acceptable, 5 and 6 elevated, and 7 or more highly elevated. 
For the Inconsistency scale, there are 10 item pairs of related questions. The Inconsistency scale 
is the sum of the absolute values of the difference in scores for the items in each item pair, and so 
ranges from 0 to 20. The item pairs are questions 7 and 25, 11 and 22, 27 and 17, 33 and 32, 38 
and 59, 41 and 65, 42 and 63, 44 and 54, 43 and 60, and 55 and 44. A score of 6 or less is acceptable, 7 and 8 questionable, and 9 or more inconsistent. 
Calculated T-score values and change from Baseline for the 2 indexed scores (BRI and MI), and 
GEC for the BRIEF questionnaire will be summarized at each visit, and Last Visit, by treatment group.  
All BRIEF assessment data will be listed. The means of the BRIEF assessment data will be 
plotted by visit. 
10.4.10 Vagus nerve stimulation 
Vagus nerve stimulation (VNS) status is recorded only for subjects with an implanted VNS 
device.  REDACTED COPY scores are determined from each subject’s raw GEC, BRI, MI, and component 
REDACTED COPY scores are determined from each subject’s raw GEC, BRI, MI, and component 
scores based on the subject’s age and gender. Tables that map each raw score to the appropriate
REDACTED COPY scores based on the subject’s age and gender. Tables that map each raw score to the appropriate
score are provided in the BRIEF Professional Manual and will be reproduced 
REDACTED COPY score are provided in the BRIEF Professional Manual and will be reproduced 
Two validity scales will also be derived: Negativity to assess the extent to which the respondent 
REDACTED COPY Two validity scales will also be derived: Negativity to assess the extent to which the respondent 
answers selected BRIEF items in an unusually negative manner, REDACTED COPY answers selected BRIEF items in an unusually negative manner, 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.All from {Initiate, Working Memory, 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.All from {Initiate, Working Memory, 
Plan/Organize, Organization of Materials, and 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Plan/Organize, Organization of Materials, and 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.BRI=Behavioral Regulation Index, MI=Metacognition Index, GEC=Global Executive Composite
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.BRI=Behavioral Regulation Index, MI=Metacognition Index, GEC=Global Executive Composite
84. The MI score is the total of 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.84. The MI score is the total of 
scores are determined from each subject’s raw GEC, BRI, MI, and component 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.scores are determined from each subject’s raw GEC, BRI, MI, and component 
scores based on the subject’s age and gender. Tables that map each raw score to the appropriate
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.scores based on the subject’s age and gender. Tables that map each raw score to the appropriate
score are provided in the BRIEF Professional Manual and will be reproduced 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.score are provided in the BRIEF Professional Manual and will be reproduced 
Two validity scales will also be derived: Negativity to assess the extent to which the respondent 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Two validity scales will also be derived: Negativity to assess the extent to which the respondent 
answers selected BRIEF items in an unusually negative manner, 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.answers selected BRIEF items in an unusually negative manner, 
extent to which the respondent answers similar BRIEF items in an inconsistent manner. The 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.extent to which the respondent answers similar BRIEF items in an inconsistent manner. The 
Negativity scale is the number of items in 8, 13, 23, 30, 62, 71, 80, 83, and 85 with a score of 3, 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Negativity scale is the number of items in 8, 13, 23, 30, 62, 71, 80, 83, and 85 with a score of 3, 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.and so has a range of 0 to 9. A sc
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.and so has a range of 0 to 9. A sc
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.ore of 4 or less is considered acceptable, 5 and 6 elevated, and 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.ore of 4 or less is considered acceptable, 5 and 6 elevated, and 
For the Inconsistency scale, there are 10 item pairs of related questions. The Inconsistency scale 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.For the Inconsistency scale, there are 10 item pairs of related questions. The Inconsistency scale 
is the sum of the absolute values of the difference in scores for
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.is the sum of the absolute values of the difference in scores for
ranges from 0 to 20. The item pairs are questions 7 and 25, 11 and 22, 27 and 17, 33 and 32, 38 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.ranges from 0 to 20. The item pairs are questions 7 and 25, 11 and 22, 27 and 17, 33 and 32, 38 
and 59, 41 and 65, 42 and 63, 44 and 54, 43 and 60, and 55 and 44. A score of 6 or less is 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.and 59, 41 and 65, 42 and 63, 44 and 54, 43 and 60, and 55 and 44. A score of 6 or less is 
acceptable, 7 and 8 questionable
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.acceptable, 7 and 8 questionable
Calculated T
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Calculated T -
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.-score values and change from Baseline for the 2 indexed scores (BRI and MI), and 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.score values and change from Baseline for the 2 indexed scores (BRI and MI), and 
GEC for the BRIEF questionnaire will be summarized at each visit, and Last Visit, by treatment 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.GEC for the BRIEF questionnaire will be summarized at each visit, and Last Visit, by treatment 
group. 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.group. 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.All BRIEF assessment data wil
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.All BRIEF assessment data wil
plotted by visit.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.plotted by visit.
UCB   28 Mar 2019  
Statistical Analysis Plan  SP0982  
A listing of VNS status data will be provided only for those subjects with an implanted VNS 
device. No summaries of VNS data are planned. 
10.4.11 Ketogenic diet 
A listing of ketogenic diet findings will be provided. 
 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
UCB   28 Mar 2019  
Statistical Analysis Plan  SP0982  
11 REFERENCES  
Allison, PD. Survival Analysis Using SAS®: A Practical Guide. 2nd ed. Cary: SAS Institute; 
2010 
Biton V, Di Memmo J, Shukla R, Lee YY, Poverennova I, Demchenko V, et al. Adjunctive 
lamotrigine XR for primary generalized tonic-clonic seizures in a randomized, placebo-controlled study. Epilepsy & Behavior. 2010; 19: 352-8. 
Collett D. Modelling survival data in medical research. 3
rd ed. London: CRC Press; 2015 
Cox DR. Regression models and life-tables. J R Stat Soc Series B Methodol. 
1972;34(2):187-220.  
French JA, Temkin NR, Hammer AE, VanLandingham KE. Time to nth seizure analysis of 
lamotrigine as adjunctive therapy in subjects with primary generalized tonic-clonic seizures. 
Epilepsia. 2007;48(S6):77-78.  
LaVange LM, Durham TA, Koch GG. Randomization-based nonparametric methods for the 
analysis of multicentre trials. Stat Methods Med Res. 2005;14:281-301. 
Marcus R, Peritz E, Gabriel KR. On closed testing procedure with special reference to ordered 
analysis of variance. Biometrika. 1976;63:655-60. 
SAS®/Stat 9.4: User’s Guide. Cary: SAS Institute Inc; 2015 
 
REDACTED COPY /Stat 9.4: User’s Guide. Cary: SAS Institute Inc; 20
REDACTED COPY /Stat 9.4: User’s Guide. Cary: SAS Institute Inc; 20 15
REDACTED COPY 15
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.French JA, Temkin NR, Hammer AE, VanLandingham KE. Time to nth seizure analysis of 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.French JA, Temkin NR, Hammer AE, VanLandingham KE. Time to nth seizure analysis of 
clonic seizures. 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.clonic seizures. 
based nonparametric methods for the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.based nonparametric methods for the 
301.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.301.
Marcus R, Peritz E, Gabriel KR. On closed testing procedure with special reference to ordered 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Marcus R, Peritz E, Gabriel KR. On closed testing procedure with special reference to ordered 
15
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.15
UCB   28 Mar 2019  
Statistical Analysis Plan  SP0982  
12 APPE NDICES  
12.1 Appendix 1: QOLIE- 31-P total and subscale score calculations 
The following outlines the calculation of the subscale scores for the QOLIE ‑31‑P. The rescaled 
responses are provided for each item. The subscale scores are calculated by summing the 
rescaled responses for that subscale and dividing by the number of items with a non-missing 
response. Note that the divisors shown assume that all items for each subscale have a response; 
the divisor will differ if there are missing responses. A subscale score will be calculated only if at least 50% of the items within the subscale are present. 
  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.will be calculated only if at 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.will be calculated only if at 
UCB   28 Mar 2019  
Statistical Analysis Plan  SP0982  
Response Final Score  
 
                                                                         Response                                                               Final Score 
Scale/Item Numbers      1             2             3             4             5            6           Subtotal        0-100 point scale  
Seizure Worry  
      30.                               0            20           40           60           80        100           _____  
      31.                               0          33.3       66.7        100           ––          ––            _____  
      32.                               0            50          100                        ––          ––            _____  
      33.                               0          33.3       66.7        100           ––          ––            _____  
      34.                             100         75           50           25            0           ––            _____  
  
                                                                                                              TOTAL :      _____         ÷ 5 = _____  
Overall Quality of Life  
      1.                                Multiply each response by 10                                           _____  
      36.                             100         75           50           25            0          ––             _____  
  
                                                                                                              TOTAL :      _____         ÷ 2 = _____  
Emotional Well-Being  
      7.                                 0            20           40           60           80        100           _____  
      8.                                 0            20           40           60           80        100           _____  
      9.                               100         80           60           40           20           0             _____  
      10.                               0            20           40           60           80        100           _____  
      11.                             100         80           60           40           20           0             _____  
  
                                                                                                              TOTAL :      _____         ÷ 5 = _____  REDACTED COPY                                                                                                              
REDACTED COPY                                                                                                              
response by 10
REDACTED COPY response by 10
50REDACTED COPY 50
This document cannot be used to support any marketing authorization application and any extensions or variations thereof._____
This document cannot be used to support any marketing authorization application and any extensions or variations thereof._____
           
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.           _____
This document cannot be used to support any marketing authorization application and any extensions or variations thereof._____
TOTAL :
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.TOTAL :
response by 10
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.response by 10                                    
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.                                   
          
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.          25
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.25
                                                                                                             
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.                                                                                                             
                                
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.                                0
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.0           
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.           
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.                                
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.                                
                              
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.                              
10.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.10.                              
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.                              
     
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.     
UCB   28 Mar 2019  
Statistical Analysis Plan  SP0982  
Energy/Fatigue  
      2.                               100         80           60           40           20           0             _____  
      3.                               100         80           60           40           20           0             _____  
      4.                                 0            20           40           60           80        100           _____  
      5.                                 0            20           40           60           80        100           _____  
  
                                                                                                              TOTAL :      _____         ÷ 4 =   _____  
Cognitive Functioning  
      19.                               0            20           40           60           80        100           _____  
      20.                               0          33.3       66.7        100            ––         ––            _____  
      21.                               0            20           40           60           80        100           _____  
      22.                               0            20           40           60           80        100           _____  
      23.                               0            20           40           60           80        100           _____  
      24.                             100         75           50           25            0            ––           _____  
  
                                                                                                              TOTAL :      _____         ÷ 6 =   _____  
Medication Effects  
      28.                               0          33.3       66.7        100           ––           ––          _____  
      26.                             100         75           50           25            0          ––            _____ 
      27.                             100         75           50           25            0          ––            _____  
  
                                                                                               TOTAL : _____           ÷ 3 =        _____  
 
 
 REDACTED COPY 80
REDACTED COPY 80       
REDACTED COPY        
          
REDACTED COPY           
          
REDACTED COPY           60
REDACTED COPY 60
50
REDACTED COPY 50          
REDACTED COPY           
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.÷ 4 =
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.÷ 4 = _____ 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof._____ 
_____
This document cannot be used to support any marketing authorization application and any extensions or variations thereof._____
          
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.            
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.  
100
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.100          
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.          
80
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.80       
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.       
          
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.          80
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.80
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.          
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.          25
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.25
                                                                                                             
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.                                                                                                             
                              
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.                              0
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.0         
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.         
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.                            
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.                            
                            
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.                            
                                                                                              
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.                                                                                              
UCB   28 Mar 2019  
Statistical Analysis Plan  SP0982  
Daily Activities/Social Functioning  
      13.                               0            20           40           60           80        100           _____  
      14.                               0            25           50           75          100        ––            _____  
      15.                               0            25           50           75          100        ––            _____  
      16.                             100          75           50           25            0          ––            _____  
      17.                             100          75           50           25            0          ––            _____  
  
                                                                                                              TOTAL :      _____         ÷ 5 = _____  
 
Total score is calculated as a weighted sum of the subscale scores based on the weighting shown 
below. Total score will be missing if at least 1 subscale score is missing. Total score will range from 0 to 100 with a higher score reflecting better functioning. 
  
QOLIE -31-P Scale    Final Scale 
Score      
Weight      
Subtotal  
              
Seizure worry  (a) ____   0.08 = ____  
Overall quality of life  (b) ____   0.14 = ____  
Emotional well -being  (c) ____   0.15 = ____  
Energy/fatigue  (d) ____   0.12 = ____  
Cognitive functioning  (e) ____   0.27 = ____  
Medication effects  (f) ____   0.03 = ____  
Daily activities/Social functioning  (g) ____   0.21 = ____  
              
TOTAL SCORE : Sum subtotals (a) through (g)  
  
  ____  
 
  REDACTED COPY Final Scale 
REDACTED COPY Final Scale 
Score
REDACTED COPY Score
REDACTED COPY (b)
REDACTED COPY (b)
(c)
REDACTED COPY (c)
(d)REDACTED COPY (d)
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.       
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.       ÷ 5 = _____
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.÷ 5 = _____
Total score is calculated as a weighted sum of the subscale scores based on the weighting shown 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Total score is calculated as a weighted sum of the subscale scores based on the weighting shown 
al score will be missing if at least 1 subscale score is missing. Total score will range 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.al score will be missing if at least 1 subscale score is missing. Total score will range 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.____
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.____
____
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.____
(d)
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.(d)
(e)
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.(e)
(f)
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.(f)
activities/Social functioning
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.activities/Social functioning
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.TOTAL SCORE : Sum subtotals (a) through (g)
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.TOTAL SCORE : Sum subtotals (a) through (g)
UCB   28 Mar 2019  
Statistical Analysis Plan  SP0982  
12.2 Appendix 2: Adverse Events 
12.2.1 Other Significant AEs 
Table 6 :  Other Significant AEs 
MedDRA Preferred Term  
CARDIAC AND ECG RELATED TERMS 
Atrioventricular block third degree               
Atrioventricular block second degree 
Bradyarrhythmia* 
Bradycardia* 
Cardiac pacemaker insertion 
Atrial fibrillation 
Atrial flutter 
Sinus bradycardia* 
Ventricular tachycardia  
Ventricular fibrillation 
Heart Rate decreased* 
Sick sinus syndrome 
Atrial conduction time prolongation 
Atrioventricular dissociation 
Conduction disorder 
Cardiac fibrillation 
Cardiac flutter 
Sinus arrest 
Torsade de pointes 
Ventricular asystole REDACTED COPY REDACTED COPY REDACTED COPY tachycardia
REDACTED COPY tachycardia
REDACTED COPY Ventricular fibrillation REDACTED COPY Ventricular fibrillation REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.tachycardia
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.tachycardia
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Ventricular fibrillation
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Ventricular fibrillation
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Heart Rate decreased*
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Heart Rate decreased*
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Sick sinus syndrome
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Sick sinus syndrome
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Atrial conduction time prolongation
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Atrial conduction time prolongation
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Atrioventricular dissociation
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Atrioventricular dissociation
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
UCB   28 Mar 2019  
Statistical Analysis Plan  SP0982  
MedDRA Preferred Term  
Ventricular flutter 
Ventricular tachyarrhythmia 
Implantable defibrillator insertion 
SUICIDALITY RELATED TERMS  
Completed suicide 
Depression suicidal 
Suicidal behavior 
Suicidal ideation 
Suicide attempt 
Intentional self-injury 
Self injurious behavior 
Self-injurious ideation 
Intentional overdose 
Multiple drug overdose intentional 
Poisoning deliberate 
ADDITIONAL TERMS 
Loss of consciousness 
Syncope 
Appetite disorder 
Decreased appetite 
Diet refusal 
Hypophagia 
Food allergy REDACTED COPY REDACTED COPY injurious ideation
REDACTED COPY injurious ideation
REDACTED COPY Intentional overdoseREDACTED COPY Intentional overdoseREDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Intentional overdose
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Intentional overdose
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Multiple drug overdose intentional
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Multiple drug overdose intentional
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Poisoning deliberate
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Poisoning deliberate
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.ADDITIONAL TERMS
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.ADDITIONAL TERMS
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Loss of consciousness
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Loss of consciousness
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
UCB   28 Mar 2019  
Statistical Analysis Plan  SP0982  
MedDRA Preferred Term  
Abnormal behavior 
  *All cases with reported reduced heart rate will be reviewed and only cases with marked bradycardia (marked 
reduction in heart rate) with heart rate <45 bpm will be listed as ‘Other Significant AEs’. 
 
12.2.2 List of AEs for Potentially Drug Induced Liver Injury (PDILI) 
Table 7 :  AEs for PDILI 
MedDRA Preferred Term for PDILI  
Cholestasis 
Cholestatic liver injury 
Cholestatic pruritus 
Drug -induced liver injury 
Hepatitis cholestatic 
Hyperbilirubinaemia 
Icterus index increased 
Jaundice 
Jaundice cholestatic 
Jaundice hepatocellular 
Mixed liver injury 
Ocular icterus 
Acute hepatic failure 
Asterixis 
Cholestatic liver injury 
Coma hepatic 
Cryptogenic cirrhosis REDACTED COPY induced liver injury
REDACTED COPY induced liver injury
Hepatitis cholestatic
REDACTED COPY Hepatitis cholestatic
REDACTED COPY Hyperbilirubinaemia
REDACTED COPY Hyperbilirubinaemia
REDACTED COPY Icterus index 
REDACTED COPY Icterus index 
REDACTED COPY REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.induced liver injury
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.induced liver injury
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Hepatitis cholestatic
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Hepatitis cholestatic
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Hyperbilirubinaemia
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Hyperbilirubinaemia
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Icterus index 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Icterus index 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
UCB   28 Mar 2019  
Statistical Analysis Plan  SP0982  
Drug -induced liver injury 
Hepatic cirrhosis 
Hepatic encephalopathy 
Hepatic failure 
Hepatic infiltration eosinophilic 
Hepatic necrosis 
Hepatic steatosis 
Hepatitis fulminant 
Hepatobiliary disease 
Hepatocellular foamy cell syndrome 
Hepatocellular injury 
Hepatotoxicity 
Liver disorder 
Liver injury 
Mixed liver injury 
Non-alcoholic steatohepatitis 
Subacute hepatic failure 
Allergic hepatitis 
Chronic hepatitis 
Hepatitis 
Hepatitis acute 
Hepatitis cholestatic 
Hepatitis chronic active 
Hepatitis chronic persistent REDACTED COPY Hepatocellular injury
REDACTED COPY Hepatocellular injury
Hepatotoxicity
REDACTED COPY Hepatotoxicity
REDACTED COPY Liver disorder
REDACTED COPY Liver disorder
REDACTED COPY REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Hepatocellular foamy cell syndrome
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Hepatocellular foamy cell syndrome
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Hepatocellular injury
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Hepatocellular injury
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Hepatotoxicity
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Hepatotoxicity
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Liver disorder
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Liver disorder
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Liver injury
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Liver injury
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Mixed liver injury
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Mixed liver injury
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Non
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Non
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
UCB   28 Mar 2019  
Statistical Analysis Plan  SP0982  
Hepatitis fulminant 
Hepatitis toxic 
Non-alcoholic steatohepatitis 
Blood bilirubin abnormal 
Blood bilirubin increased 
Hyperbilirubinaemia 
 
 
 
  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
UCB   28 Mar 2019  
Statistical Analysis Plan  SP0982  
12.3 Appendix 3: Markedly abnormal values 
12.3.1 Hematology 
Table 8 :  Hematology - Markedly Abnormal Values  
Parameter Age 
Range UNIT 
(conventional) Abnormality Criteria (conventional unit) Unit 
(standard) Abnormality Criteria (standard unit) 
Hematocrit  2y - <17y  % 
 ≤29 
>47 % ≤29 
>47 
≥17y ≤85% of LLN  
≥115%  of ULN  ≤85% of LLN  
≥115%  of ULN  
Hemoglobin  2y - <17y  g/dL  
 ≤9.5 
>16.0 g/L ≤95 
>160 
≥17y ≤85% of LLN  
≥115%  of ULN  ≤85% of LLN  
≥115%  of ULN  
WBC/ 
Leukocytes  All 109/L ≤3.0 
≥16.0  G/L ≤3.0 
≥16.0  
Lymphocytes 
Absolute  2y - <6y 109/L <0.7 
>6.9 G/L <0.7 
>6.9 
≥6y <0.6 
>5.0 <0.6 
>5.0 
Basophils  >1m % ≥5.0 % ≥5.0 
Basophils 
Absolute  >1m 109/L ≥0.4 G/L ≥0.4 
Eosinophils  >1m % ≥10 % ≥10 
Eosinophils 
Absolute  >1m 109/L ≥1.0 G/L ≥1.0 
Monocytes  >1m % ≥20.0  % ≥20.0  
Monocytes 
Absolute  >1m 109/L ≥2.0 G/L ≥2.0 
Neutrophils 
Absolute  >1m 109/L <1.5 
 G/L <1.5 
Platelets  >1m 109/L ≤100  
≥600  G/L ≤100  
≥600  
RBC/ 
Erythrocytes  ≥2y 1012/L <3.5 T/L <3.5 
Abbreviations: ANC = absolute neutrophil count; LLN = lower limit of normal; m  = month; ULN = 
upper limit of normal; y = year.  
A month is defined as 30 days; a year is defined as 365.25 days. 
 
  REDACTED COPY >5.0
REDACTED COPY >5.0
REDACTED COPY ≥5.0
REDACTED COPY ≥5.0
REDACTED COPY REDACTED COPY REDACTED COPY REDACTED COPY REDACTED COPY REDACTED COPY REDACTED COPY REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.85%
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.85% of LLN
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.of LLN
115%
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.115% of ULN
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.of ULN
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.≤95
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.≤95
>160
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.>160
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.G/L
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.G/L
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.G/L
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.G/L
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.≥0.4
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.≥0.4
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.%
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.%
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.10
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.10
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.>1m
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.>1m
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.>1m
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.>1m
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Erythrocytes
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Erythrocytes
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Abbreviations: ANC = absolute neutrophil count
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Abbreviations: ANC = absolute neutrophil count
upper limit of normal; y = year. 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.upper limit of normal; y = year. 
UCB   28 Mar 2019  
Statistical Analysis Plan  SP0982  
12.3.2 Chemistry 
Table 9 :  Chemistry: Markedly Abnormal Values 
PARAMETE
R AGE 
RANG
E UNIT 
(conventional
) ABNORMALIT
Y CRITERIA 
(conventional)  UNIT  
(standard
) ABNORMALIT
Y CRITERIA 
(standard)  
AST (SGOT)  All U/L ≥3.0 x ULN  
≥5.0 x ULN 
≥10.0 x ULN U/L ≥3.0 x ULN  
≥5.0 x ULN 
≥10.0 x ULN  
ALT (SGPT)  All U/L ≥3.0 x ULN  
≥5.0 x ULN 
≥10.0 x ULN U/L ≥3.0 x ULN  
≥5.0 x ULN 
≥10.0 x ULN  
Alkaline 
Phosphatase 4y - <10y  U/L ≥834 U/L ≥834 
10y - 
<17y  ≥1761  ≥1761  
≥17y ≥3.0 x ULN  ≥3.0 x ULN  
GGT  1y - <13y  U/L ≥66 U/L ≥66 
13y - 
<17y  ≥126 ≥126 
≥17y ≥3.0 x ULN  ≥3.0 x ULN  
Total Bilirubin  >1m mg/dL  ≥2.0 umol/L  ≥34.208  
Total Protein  1y - <17y  g/dL  <4.3 
>12.0 g/L <43 
>120 
≥17y <4.3 
>13.0 <43 
>130 
Albumin  ≥1y - 
<17y g/dL  <2.4 
>8.4 g/L <24 
>84 
≥17y <2.6 <26 
BUN  1y - <17y  mg/dL  ≥36 mmol/L  ≥12.852  
≥17y ≥40 ≥14.28  
Urea  ≥1y mg/dL  >60 mmol/L  >10.02  
Creatinine  1y - <10y  mg/dL  >1.2 umol/L  >106.8  
10y - 
<16y  >1.8 >159.12  
≥16y ≥2.0 ≥176.8  
Creatinine 
Clearance* All mL/min  <50 mL/s  <0.835  REDACTED COPY 3.0
REDACTED COPY 3.0x ULN
REDACTED COPY x ULN
REDACTED COPY ≥2.0
REDACTED COPY ≥2.0
REDACTED COPY REDACTED COPY REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.x ULN
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.x ULN
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.≥3.0 x ULN
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.≥3.0 x ULN
≥5.0 x ULN
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.≥5.0 x ULN
10.0
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.10.0 x ULN
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.x ULN
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.≥
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.≥834
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.834
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.≥
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.≥
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.U/L
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.U/L
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.x ULN
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.x ULN
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.≥2.0
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.≥2.0
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.<4.3
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.<4.3
>12.0
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.>12.0
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.g/dL
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.g/dL
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.<17y
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.<17y
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.≥
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.≥17y
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.17y
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.≥
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.≥
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Creatinine
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Creatinine
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
UCB   28 Mar 2019  
Statistical Analysis Plan  SP0982  
PARAMETE
R AGE 
RANG
E UNIT 
(conventional
) ABNORMALIT
Y CRITERIA 
(conventional)  UNIT  
(standard
) ABNORMALIT
Y CRITERIA 
(standard)  
Bicarbonate  >1m - 
<17y mEq/L  <15 
>38 mmol/L  <15 
>38 
≥17y <18 
>38 <18 
>38 
Calcium  1y - <17y  mg/dL  <7.4 
>11.7 mmol/L  <1.85  
>2.925 
≥17y ≤7.6 
≥11.0 ≤1.9 
≥2.75 
Chloride  >1m mEq/L  ≤90 
≥112 mmol/L  ≤90 
≥112 
Phosphorous  1y - <17y  mg/dL  <1.8 
>7.4 mmol/L  <0.5814  
>2.3902 
≥17y ≤2.0 
≥6.0 ≤0.646  
≥1.938  
Potassium  ≥1y mEq/L  ≤3.0 
≥6.0 mmol/L  ≤3.0 
≥6.0 
Sodium  >1m mEq/L  <127  
>151 mmol/L  <127  
>151 
Glucose  >1m - 
<17y mg/dL  <50 
≥180 mmol/L  <2.775  
≥9.99 
≥17y <50 
≥200 <2.775  
≥11.1 
Total 
Cholesterol ≥1y mg/dL  >250  mmol/L  >6.475  
LDL 
(calculated) 1y - <17y  mg/dL  >140  mmol/L  >3.626  
≥17y >200  >5.18  
HDL  >2y mg/dL  <20 mmol/L  <0.518  
Triglycerides  ≥1y mg/dL  >300  mmol/L  >3.39  
Uric Acid  1y - <13y  mg/dL  >6.5 umol/L  >386.62  
13y - 
<17y  >8.6 >511.528  
≥17y >9.5 >565.06  
Thyroxine (T4)  ≥1y ug/dL  ≤3.8 
≥13.5 nmol/L  ≤48.9098  
≥173.7585 
Globulin  ≥1y g/dL  <1.2 
>5.3 g/L <12 
>53 REDACTED COPY >151
REDACTED COPY >151
REDACTED COPY <50
REDACTED COPY <50
≥
REDACTED COPY ≥180
REDACTED COPY 180
REDACTED COPY REDACTED COPY REDACTED COPY REDACTED COPY REDACTED COPY REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.2.75
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.2.75
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.≤90
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.≤90
≥112
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.≥112
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.<0.5814
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.<0.5814
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.mmol/L
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.mmol/L
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.180
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.180
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.<50
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.<50
≥
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.≥200
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.200
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.mg/dL
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.mg/dL
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.mg/dL
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.mg/dL
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.1y
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.1y
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.1y 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.1y -
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.-<13y
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.<13y
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.13y 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.13y 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Thyroxine (T4)
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Thyroxine (T4)
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Globulin
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Globulin
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
UCB   28 Mar 2019  
Statistical Analysis Plan  SP0982  
Abbreviations: ALT = alanine aminotransferase; AST = aspartate aminotransferase; BUN = blood urea nitrogen; 
dL = deciliter; GGT: gamma-glutamyltransferase; L = liter; LLN = lower limit of normal; m = month; mg = 
milligram; mmol = millimoles; μg = microgram; U = unit; ULN = upper limit of normal; y = year.  
*Cr Cl ml/min = [Height (cm) * 0.55] / serum creatinine   Cockroft equation (subjects >12); 
Male: Cr Cl ml/min  =  [(140 -age) x body weight (kg)] / (72 x serum creatinine); 
Female: Cr Cl ml/min  = [(140 -age) x body  weight (kg)] / (72 x serum creatinine)] x 0.85.  
 
12.3.3 Vital signs 
Abnormality criteria to be applied in the assessment of vital signs parameter values are given 
below: 
Table 10:  Vital Signs - Abnormality Criteria 
Parameter  Age Range  Abnormality Criteria  
Pulse Rate 
(beats/minute)  
 
 3y - <12y  <60 
>130  
12y - <17y  <50 
>120 
≥17y  <50 and a decrease from Baseline of ≥15  
>120 and an increase from Baseline of ≥15 
<60a 
>100a 
Systolic Blood Pressure 
(mmHg)  3y - <12y  <80 
>140  
12y - <17y  <90 
>160  
≥17y  ≤ 90 and a decrease from Baseline of ≥20  
≥ 180 and an increase from Baseline of ≥20 <90
a 
>140a 
>160a 
Diastolic Blood 
Pressure (mmHg) 3y - <12y  <50 
>80 
12y - <17y  <50 
>105 
≥17y  <50 and a decrease from Baseline of ≥15  
>105 and an increase from Baseline of ≥ 15 
<50a 
>90a 
>100a 
Body Weight  1m - <17y  <3% or 97% of the normal body weight growth curve 
ranges based on gender and the age of subject on date of 
weight assessmenta 
≥17y  ≥ 10% change from Baseline (an increase or a decrease)b 
≥7% change from Baseline (an increase or a decrease)a 
Abbreviations: y = year.  REDACTED COPY 50 and a decrease from Baseline of ≥15
REDACTED COPY 50 and a decrease from Baseline of ≥15
120 and an increase from Baseline of ≥15
REDACTED COPY 120 and an increase from Baseline of ≥15
>100
REDACTED COPY >100a
REDACTED COPY a
<80
REDACTED COPY <80
>140
REDACTED COPY >140
REDACTED COPY REDACTED COPY REDACTED COPY REDACTED COPY REDACTED COPY REDACTED COPY REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Abnormality criteria to be applied in the assessment of vital signs parameter values are given 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Abnormality criteria to be applied in the assessment of vital signs parameter values are given 
Abnormality Criteria
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Abnormality Criteria
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.50 and a decrease from Baseline of ≥15
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.50 and a decrease from Baseline of ≥15
120 and an increase from Baseline of ≥15
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.120 and an increase from Baseline of ≥15
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.>140
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.>140
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.<90
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.<90
>160
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.>160
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.≤ 90 and a decrease from Baseline of ≥20
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.≤ 90 and a decrease from Baseline of ≥20
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.3y 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.3y -
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.-<12y
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.<12y
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Body Weight
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Body Weight
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
UCB   28 Mar 2019  
Statistical Analysis Plan  SP0982  
A month is defined as 30 days; a year is defined as 365.25 days.  
a Type C Meeting Written Response Dated 4 Mar 2019 (Response to the Type C Meeting Request submitted on Dec 
12, 2018 to IND 057939 Sequence No. 1268 cross -reference IND 068407 and IND 073809)  
bsource: http://www.cdc.gov/growthcharts/ 
 
  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
UCB   28 Mar 2019  
Statistical Analysis Plan  SP0982  
12.3.4 ECGs 
Abnormality criteria to be applied in the assessment of ECG parameter values are given below: 
Table 11:  ECGs - Abnormality Criteria  
Parameter  Age Abnormality Criteria  
QT interval (ms)  1m-<12y  >500 
>12y <450, 450 -<480, 480 -<500, > 500 or <30,  30-<60, ≥60 
increase from Baseline  
QTc(F) (ms)   
 
3y-<12y   
 
>440, or >15% increase from Baseline  
>12y- <17y  >440, or >15% increase from Baseline  
≥17y  <450, 450 -<480, 480 -<500, > 500 or <30, 30 -<60, ≥60 
increase from Baseline 
>450, >480a 
QTc(B) (ms)   
 
3y-<12y   
 
>450, or >15% increase from Baseline  
>12y- <17y  >450, or >15% increase from Baseline  
≥17y  <450, 450 -<480, 480 -<500, > 500 or <30, 30 -<60, ≥60 
increase from Baseline 
>450, >480a 
PR interval (ms)   
 
3y-<12y   
 
>180, or  >25% increase from Baseline  
>12y - <17y  >200, or  >25% increase from Baseline  
≥17y  Treatment -emergent value >200, >220, >250  
QRS interval (ms)  
3y-<12y   
 
>100, or  >25% increase from Baseline  
>12y - <17y  >110, or >25% increase from Baseline  
≥17y  Treatment -emergent value >100, >120, >140  
Heart rate (bpm)  
3y-<12y  <60, >130  
>12y <50, >120  
a Type C M eeting Written Response dat ed 4 Mar 2019 (Response to the Type C Meeting Request submitted on Dec 
12, 2018 to IND 057939 Sequence No. 1268 cross -reference IND 068407 and IND 073809)  
Abbreviations: bpm = beats per minute; m = month; ms = milliseconds; QTc = corrected QT interval; y = years.  
A month is defined as 30 days; a year is defined as 365.25 days.  
Note: Treatment-emergent is defined as meeting the criteria at any post-Baseline visit during the Treatment Period 
(including unscheduled visits) and not meeting the same criteria during Baseline. 
  REDACTED COPY <480, 480
REDACTED COPY <480, 480
REDACTED COPY increase from Baseline
REDACTED COPY increase from Baseline
>450, >480
REDACTED COPY >450, >480a
REDACTED COPY a
>180, or
REDACTED COPY >180, or
REDACTED COPY REDACTED COPY >200, or
REDACTED COPY >200, or
REDACTED COPY REDACTED COPY REDACTED COPY REDACTED COPY REDACTED COPY REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.500 or <30, 30
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.500 or <30, 30 -
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.-<60, ≥60 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.<60, ≥60 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.>450, or >15% increase from Baseline
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.>450, or >15% increase from Baseline
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.>450, or >15% increase from Baseline
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.>450, or >15% increase from Baseline
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.<480, 480
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.<480, 480 -
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.-<500, >
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.<500, >
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.increase from Baseline
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.increase from Baseline
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.>180, or
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.>180, or >
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.>25% increase from Baseline
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.25% increase from Baseline
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.>200, or
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.>200, or
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Treatment
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Treatment
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.<17y
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.<17y
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.≥17y
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.≥17y
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.3y
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.3y
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.eeting Written Response dat
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.eeting Written Response dat
IND 057939 Sequence No. 1268 cross
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.IND 057939 Sequence No. 1268 cross
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Abbreviations: bpm = beats per minute; m = month; ms = milliseconds; QTc = corrected QT interval; y = years. 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Abbreviations: bpm = beats per minute; m = month; ms = milliseconds; QTc = corrected QT interval; y = years. 
A month is defined as 30 days; a year is defined as 365.25 days. 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.A month is defined as 30 days; a year is defined as 365.25 days. 
Note: Treatment
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Note: Treatment
(including unscheduled visits) and not meeting the same criteria during Baseline.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.(including unscheduled visits) and not meeting the same criteria during Baseline.
UCB   28 Mar 2019  
Statistical Analysis Plan  SP0982  
12.4 Appendix 4: NCI CTC 
Table 12:  NCI CTC  
Medical Term  Lab 
parameter  Grade 1  Grade 2  Grade 3  Grade 4  
Blood/bone marrow  
Anemia  Hemoglobin  <LLN - 10.0 g/dL 
(C) 
<LLN - 6.2 mmol/L  
 <LLN -100 g/L (S)   <10.0 - 8.0 g/dL 
(C) <6.2 - 4.9mmol/L 
<100 - 80g/L (S)   <8.0 g/dL (C)  
<4.9 mmol/L  
<80 g/L (S) * 
Neutrophil count 
decreased   Neutrophil 
count  <LLN - 1500/mm3  
 <LLN - 1.5 x10e9 
/L (C) 
<LLN – 1.5G/L (S) 
 <1500 - 1000/mm3  
<1.5 - 1.0 x10e9/L 
(C) <1.5 - 1.0G/L (S) 
 <1000 - 500/mm3  
 <1.0 - 0.5 
x10e9/L (C) <1.0 - 0.5G/L (S) 
 <500/mm3  
<0.5 x 10e9/L 
(C) 
<0.5G/L (S) 
White blood cell 
decreased  
 White blood 
cell (WBC) <LLN - 3000/mm3  
<LLN - 3.0x10e9/L 
(C) 
<LLN - 3.0G/L (S) 
 <3000 - 2000/mm3  
<3.0 - 2.0x10e9/L 
(C) <3.0 - 2.0G/L (S) 
 <2000 -
1000/mm3  
<2.0 - 1.0x10e9/L 
(C) <2.0 - 1.0G/L (S) 
 <1000/mm3  
<1.0 x 10e9/L 
(C) 
<1.0G/L (S) 
Platelet count 
decreased  Platelet count  <LLN - 75,000/mm3  
<LLN -75.0 x 10e9/L(C) 
<LLN -75.0G/L (S) 
 <75,000 - 
50,000/mm3  
<75.0 -50.0 x 
10e9/L(C) <75.0 -50.0G/L (S) 
 <50,000 -
25,000/mm3  
<50.0 -25.0 x 
10e9/L(C) 
<50.0 -25.0G/L (S) 
 <25,000/mm3  
<25.0 x 10e9/L(C) 
<25.0G/L (S) 
Lymphocyte count 
decreased  Lymphocyte 
count  <LLN -800/mm3  
<LLN -0.8x10e9/L 
(C) 
<LLN -0.8G/L (S)  <800 -500/mm3  
<0.8 – 0.5x10e9/L 
(C) 
<0.8 – 0.5G /L (S)  <500 - 200/mm3  
<0.5 – 
0.2x10e9/L (C)  
<0.5 – 0.2G/L (S)  <200mm3  
<0.2x10e9/L 
(C) 
<0.2G/L (S)  
Metabolic/chemistry  
GGT increased  Gamma 
glutaryl 
transferase  >ULN - 2.5 x ULN  >2.5 - 5.0 x ULN  >5.0 - 20.0 x 
ULN  >20.0 x ULN  
Hypercalcemia  Calcium, 
corrected serum >ULN - 11.5 mg/dL 
(C) >ULN - 2.9mmol/L 
(S) >11.5 - 12.5 mg/dL 
(C) >2.9 - 3.1mmol/L 
(S) >12.5 - 13.5 
mg/dL (C) >3.1 - 3.4mmol/L 
(S) >13.5 mg/dL 
(C) >3.4 mmol/L 
(S) 
Hypocalcemia  Calcium, 
corrected serum <LLN - 8.0 mg/dL 
(C) <LLN - 2.0mmol/L 
(S) <8.0 - 7.0 mg/dL 
(C) <2.0 - 1.75 mmol/L 
(S) <7.0 - 6.0 mg/dL 
(C) <1.75 - 
1.5mmol/L (S)  <6.0 mg/dL 
(C)  <1.5 mmol/L 
(S) 
Hyperglycemia  Glucose, 
fasting >ULN -160 mg/dL 
(C) 
>ULN - 8.9 mmol/L 
(S) >160 -250 mg/dL 
(C) >8.9 - 13.9 mmol/L 
(S) >250 - 500 
mg/dL (C) >13.9 - 
27.8mmol/L (S)  >500 mg/dL 
(C) >27.8 mmol/L 
(S) 
Hypoglycemia  Glucose  <LLN - 55 mg/dL 
(C) 
<LLN - 3.0mmol/L 
(S) <55 - 40 mg/dL (C)  
 <3.0 - 2.2mmol/L 
(S) <40 - 30 mg/dL 
(C)  <2.2 - 
1.7mmol/L (S)  <30 mg/dL (C)  
 <1.7 mmol/L 
(S) 
Hyperkalemia  Potassium  >ULN - 5.5 mmol/L 
(S) >5.5 - 6.0 mmol/L 
(S) >6.0 - 7.0 
mmol/L (S)  >7.0 mmol/L 
(S) 
Hypokalemia  Potassium  <LLN - 3.0 mmol/L 
(S)  * <3.0 - 2.5 
mmol/L (S)  <2.5 mmol/L 
(S) 
Hypernatremia  Sodium  >ULN - 150 mmol/L 
(S) >150 - 155 mmol/L 
(S) >155 - 160 
mmol/L (S)  >160 mmol/L 
(S) REDACTED COPY 10e9/L(C)
REDACTED COPY 10e9/L(C)
<75.0 
REDACTED COPY <75.0 
REDACTED COPY 800/mm3
REDACTED COPY 800/mm3
0.8x10e9/L 
REDACTED COPY 0.8x10e9/L 
0.8G/L (S)
REDACTED COPY 0.8G/L (S)
REDACTED COPY REDACTED COPY REDACTED COPY REDACTED COPY REDACTED COPY Metabolic/chemistryREDACTED COPY Metabolic/chemistryREDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.<500/mm3
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.<500/mm3
<0.5 x 10e9/L 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.<0.5 x 10e9/L 
(C)
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.(C)
<0.5G/L (S)
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.<0.5G/L (S)
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.1000/mm3
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.1000/mm3
1.0x10e9/L 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.1.0x10e9/L 
<2.0 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.<2.0 -
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.-1.0G/L (S)
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.1.0G/L (S)
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.50.0G/L (S)
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.50.0G/L (S)<50,000 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.<50,000 
25,000/mm3
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.25,000/mm3
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.0.8G/L (S)
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.0.8G/L (S)<800 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.<800 500/mm3
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.500/mm3
<0.8 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.<0.8 
(C)
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.(C)
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Metabolic/chemistry
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Metabolic/chemistry
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.-
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.-2.5 x ULN
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.2.5 x ULN
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.>ULN 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.>ULN 
(C)
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.(C)
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Calcium, 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Calcium, 
corrected 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.corrected 
serum
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.serum
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Glucose, 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Glucose, 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Hypoglycemia
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Hypoglycemia
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Hyperkalemia
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Hyperkalemia
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
UCB   28 Mar 2019  
Statistical Analysis Plan  SP0982  
Medical Term  Lab 
parameter  Grade 1  Grade 2  Grade 3  Grade 4  
Hyponatremia  Sodium  <LLN - 130 mmol/L 
(S)  Not defined  <130 - 120 
mmol/L (S)  <120 mmol/L  
(S) 
Hyper -
triglyceridemia Triglycerides  150 - 300 mg/dL (C)  
1.71 - 3.42 mmol/L 
(S) 
 >300 - 500 mg/dL 
(C)  >3.42 - 5.7 mmol/L 
(S) 
 >500 - 1000 
mg/dL (C)  >5.7 - 11.4 
mmol/L (S) 
 >1000 mg/dL 
(C)  >11.4 mmol/L 
(S) 
Hyperuricemia  Uric acid   
 >ULN - 10 mg/dL 
(C) 
>ULN - 0.5948 
mmol/La  
>ULN – 594.8 
umol/L (S)  Not defined  * 
 >10 mg/dL (C)  
>0.5948 mmol/L
a  
>594.8 umol/L 
(S)  
Hypoalbuminemia  Albumin  <LLN - 3 g/dL (C)  
<LLN - 30 g/L (S) 
  
 <3 - 2 g/dL (C)  
<30 - 20 g/L (S) <2 g/dL (C)  
<20 g/L (S)  
 * 
Hypo -
phosphatemia  Phosphorus  <LLN - 2.5 mg/dL 
(C)  <LLN - 0.8mmol/L 
(S) 
 <2.5 - 2.0 mg/dL 
(C) <0.8 - 0.6mmol/L 
(S) 
 <2.0 - 1.0 mg/dL 
(C) <0.6 - 0.3mmol/L 
(S) 
 <1.0 mg/dL 
(C) <0.3 mmol/L 
(S) 
Alanine 
aminotransferase 
increased  Alanine amino -
transferase 
(ALT)  >ULN - 3.0 x ULN  >3.0 - 5.0 x ULN  >5.0 - 20.0 x 
ULN  >20.0 x ULN  
Alkaline 
phosphatase 
increased  Alkaline 
phosphatase  >ULN - 2.5 x ULN  >2.5 - 5.0 x ULN  >5.0 - 20.0 x 
ULN  >20.0 x ULN  
Aspartate 
aminotransferase 
increased  Aspartate 
amino -
transferase 
(AST)  >ULN - 3.0 x ULN  >3.0 - 5.0 x ULN  >5.0 - 20.0 x 
ULN  >20.0 x ULN  
Blood bilirubin 
increased  Bilirubin  >ULN - 1.5 x ULN   >1.5 - 3.0 x ULN  >3.0 - 10.0 x 
ULN  >10.0 x ULN  
Cholesterol high  Cholesterol, 
total >ULN - 300 mg/dL 
(C) 
>ULN - 7.75mmol/L 
(S) 
 >300 - 400 mg/dL 
(C) >7.75 -10.34 
mmol/L (S) 
 >400 - 500 
mg/dL (C) >10.34 -12.92 
mmol/L (S) 
 >500 mg/dL 
(C) >12.92 mmol/L (S) 
Creatinine 
increased  Creatinine  >ULN - 1.5x ULN  
 >1.5 - 3.0x ULN  
  >3.0 - 6.0 x ULN  >6.0 x ULN  
Abbreviations: LLN = lower limit of normal; ULN = upper limit of normal. 
The cutoffs are according to the Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0 
Published: May 28, 2009 (v4.03: June 14, 2010)  
(C)=Conventional units, (S)=Standard units 
  REDACTED COPY >2.5 
REDACTED COPY >2.5 
REDACTED COPY REDACTED COPY 3.0 x ULN 
REDACTED COPY 3.0 x ULN 
REDACTED COPY REDACTED COPY >ULN REDACTED COPY >ULN -REDACTED COPY -1.5 x ULNREDACTED COPY 1.5 x ULNREDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.>10 mg/dL (C)
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.>10 mg/dL (C)
>594.8 umol/L 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.>594.8 umol/L 
(S) 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.(S) 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.*
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.*
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.1.0 mg/dL 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.1.0 mg/dL 
(C)
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.(C)
<0.6 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.<0.6 -
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.-0.3mmol/L 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.0.3mmol/L 
(S)
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.(S)
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.5.0 x ULN
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.5.0 x ULN
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.5.0 x ULN
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.5.0 x ULN
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.>3.0 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.>3.0 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.1.5 x ULN
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.1.5 x ULN
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.>ULN 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.>ULN -
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.-300 mg/dL 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.300 mg/dL 
(C)
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.(C)
>ULN 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.>ULN 
(S)
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.(S)
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Creatinine
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Creatinine
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Abbreviations: LLN = lower limit 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Abbreviations: LLN = lower limit 
The cutoffs are according to the Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.The cutoffs are according to the Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0 
Published: May 28, 2009 (v4.03: June 14, 2010)
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Published: May 28, 2009 (v4.03: June 14, 2010)
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.(C)=Conventional units, (S)=Standard units
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.(C)=Conventional units, (S)=Standard units
UCB   28 Mar 2019  
Statistical Analysis Plan  SP0982  
12.5 Appendix 5: Registry Required Tables 
The following is the list of tables required for Article 41 (EudraCT), clinicaltrials.gov and/or 
Article 46 (European Pediatric Regulation). These tables will be produced at the same time as the CSR required Tables. 
Disposition and Discontinuation Reasons by Development 
Discontinuation due to AEs 
Demographics by Development Baseline Characteristics by Development 
ILAE Seizure Classification History by Development 
Classification of Epileptic Syndrome by Development 
AEDs and Benzodiazepines at Study Entry by Development 
Summary of Time to Second PGTCS by Development 
Proportion of Subjects with Seizure Freedom at Day 166 by Development 
PGTCS Frequency Observed Results and Percent Changes from Combined Baseline by 
Development 
Absence Seizure Frequ ency Observed Results and Percent Changes from Prospective Baseline 
by Development 
Myoclonic Seizure Frequency Observed Results and Percent Changes from Prospective Baseline 
by Development 
Responder Status for PGCTS by Development 
Responder Status for Absence Seizure Frequency by Development 
Responder Status for Myoclonic Seizure Frequency by Development Seizure-free Status for PGTCS by Development 
Days with Absence Seizures Observed Results and Percent Changes from Prospective Baseline 
by Development 
Incre ase in Days with Absence Seizures During the Treatment Period Compared to Prospective 
Baseline by Development 
Increase in Absence Seizure Frequency During the Treatment Period Compared to Prospective 
Baseline by Development 
Responder Status and Seizure Worsening for Days with Absence Seizures by Development 
Days with Myoclonic Seizures Observed Results and Percent Changes from Prospective 
Baseline by Development 
Increase in Days with Myoclonic Seizures During the Treatment Period Compared to 
Prospective Baseline by Development REDACTED COPY ency Observed Results and Percent Changes from Prospective Baseline 
REDACTED COPY ency Observed Results and Percent Changes from Prospective Baseline 
Myoclonic Seizure Frequency Observed Results and Percent Changes from Prospective Baseline 
REDACTED COPY Myoclonic Seizure Frequency Observed Results and Percent Changes from Prospective Baseline 
Responder Status for PGCTS by DevelopmentREDACTED COPY Responder Status for PGCTS by Development
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Proportion of Subjects with Seizure Freedom at Day 166 by Development
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Proportion of Subjects with Seizure Freedom at Day 166 by Development
PGTCS Frequency Observed Results and Percent Changes from Combined Baseline by 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.PGTCS Frequency Observed Results and Percent Changes from Combined Baseline by 
ency Observed Results and Percent Changes from Prospective Baseline 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.ency Observed Results and Percent Changes from Prospective Baseline 
Myoclonic Seizure Frequency Observed Results and Percent Changes from Prospective Baseline 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Myoclonic Seizure Frequency Observed Results and Percent Changes from Prospective Baseline 
Responder Status for PGCTS by Development
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Responder Status for PGCTS by Development
nce Seizure Frequency by Development
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.nce Seizure Frequency by Development
Responder Status for Myoclonic Seizure Frequency by Development
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Responder Status for Myoclonic Seizure Frequency by Development
free Status for PGTCS by Development
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.free Status for PGTCS by Development
Days with Absence Seizures Observed Results and Percent Changes from Prospective Baseline 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Days with Absence Seizures Observed Results and Percent Changes from Prospective Baseline 
ase in Days with Absence Seizures During the Treatment Period Compared to Prospective 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.ase in Days with Absence Seizures During the Treatment Period Compared to Prospective 
Baseline by Development
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Baseline by Development
Increase in Absence Seizure Frequency During the Treatment Period Compared to Prospective 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Increase in Absence Seizure Frequency During the Treatment Period Compared to Prospective 
Baseline by Development
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Baseline by Development
Responder Status and Seizure Wor
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Responder Status and Seizure Wor
Days with Myoclonic Seizures Observed Results and Percent Changes from Prospective 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Days with Myoclonic Seizures Observed Results and Percent Changes from Prospective 
Baseline by Development
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Baseline by Development
UCB   28 Mar 2019  
Statistical Analysis Plan  SP0982  
Increase in Myoclonic Seizure Frequency During the Treatment Period Compared to Prospective 
Baseline by Development 
Responder Status and Seizure Worsening for Days with Myoclonic Seizures by Development 
Incidence of Absence Seizure Emergence or Worsening by Development Incidence of Myoclonic Seizure Emergence or Worsening by Development 
Seizure-free Status for All Generalized Seizure Types by Development 
Study Medication Duration by Development Cumulative Study Medication Duration by Development 
Study Medication Daily Dosing by Development 
Incidence of TEAEs by Development – Overview 
Incidence of TEAEs by Development 
Incidence of Serious TEAEs by Development 
Incidence of Non-serious TEAEs  
Incidence of TEAEs by Relationship and Development 
Incidence of TEAEs Leading to Discontinuation by Development 
Incidence of Serious TEAEs by Relationship  Incidence of Non-serious TEAEs by Relationship  
Incidence of Fatal TEAEs by Relationship  
Incidence of Non-serious TEAEs Above Reporting Threshold of 5% of Subjects 
Incidence of Non-serious TEAEs Above Reporting Threshold of 5% of Subjects by Relationship 
12-Lead ECG Summary by Development Treatment -Emergent Abnormal 12-Lead ECG Findings for Subjects by Development 
 
12.6 Additional Subgroups to be programmed in ADSL 
The following subgroup variable will also be programmed: Subjects enrolled at Japanese study sites (Japanese, non- Japanese)  
Subjects enrolled at Asian study sites (Asian, non-Asian) – Asian sites are those in Taiwan, 
South Korea, Chin a and Japan  
 REDACTED COPY Incidence of TEAEs Leading to Discontinuation by Development
REDACTED COPY Incidence of TEAEs Leading to Discontinuation by Development
serious TEAEs by Relationship 
REDACTED COPY serious TEAEs by Relationship 
Incidence of Fatal TEAEs by Relationship 
REDACTED COPY Incidence of Fatal TEAEs by Relationship 
serious TEAEs Above Reporting REDACTED COPY serious TEAEs Above Reporting 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Incidence of TEAEs Leading to Discontinuation by Development
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Incidence of TEAEs Leading to Discontinuation by Development
serious TEAEs by Relationship 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.serious TEAEs by Relationship 
serious TEAEs Above Reporting 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.serious TEAEs Above Reporting 
serious TEAEs Above Reporting Threshold of 5% of Subjects by Relationship
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.serious TEAEs Above Reporting Threshold of 5% of Subjects by Relationship
Lead ECG Summary by Development
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Lead ECG Summary by Development
Emergent Abnormal 12
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Emergent Abnormal 12
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Additional Subgroups to 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Additional Subgroups to 
The following subgroup
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.The following subgroup
enrolled at Japanese study sites
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.enrolled at Japanese study sites
Subjects enrolled at Asian study sites (Asian, non
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Subjects enrolled at Asian study sites (Asian, non
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.South Korea, Chin
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.South Korea, Chin
UCB   28 Mar 2019  
Statistical Analysis Plan  SP0982  
13 AMENDMENT(S) TO THE STATISTICAL ANALYSIS  PLAN 
(SAP)  
13.1 Amendment 1 
13.1.1 Rationale for the amendment 
The SAP was amended to reflect changes adopted in Protocol Amendment 5 v1.0 which affected 
the definition of the titration and maintenance periods and the rules for pooling strata with low 
numbers of events in the SAP. The compliance derivation was also updated to allow for subjects that take more than 2 tablets as they titrate to a higher dose. 
13.1.2 Modification and changes 
13.1.2.1 Specific changes 
The information below was revised: 
SAP/Amendment Number  Date  
Final SAP  09 Aug 2016  
Has been changed to: 
SAP/Amendment Number  Date  
Final SAP  09 Aug 2016  
Amendment #1  24 Feb 2017  
Section 3.2.1, the following text was changed from: 
 Treatment Period: 24-week period following the 4-week Prospective Baseline. The 
Treatment Period is composed of the Titration Period and the Maintenance Period. 
 Titration Period: 6-week period following the 4-week Prospective Baseline. The Titration 
Period starts on the date of the Randomization Visit (Visit 2) and ends on the day before Visit 6 (or the date of the Early Termination (ET) visit in the situation where a subject discontinues prior to the last visit in the Titration Period). 
 Maintenance Period: 18-week period following the 6-week Titration Period. The 
Maintenance Period starts on the day of Visit 6 and continues until 1 of the following occurs (whichever occurs first): 
◦ Completion of ≥6 weeks of the Treatment Period, occurrence of ≥2 PGTC seizures 
and completion of the ET Visit 
◦ Completion of 18 weeks (Visit 10) of the Maintenance Period without occurrence of 2 PGTC seizures. 
And revised as follows: 
 Treatment Period: 24-week period following the 4-week Prospective Baseline. The 
Treatment Period is composed of the Titration Period and the Maintenance Period. 
 Titration Period: 6-week period following the 4-week Prospective Baseline. The Titration 
Period starts on the date of the Randomization Visit (Visit 2) and ends on the day before REDACTED COPY Section 3.2.1, the following text was changed from:
REDACTED COPY Section 3.2.1, the following text was changed from:
following the 4
REDACTED COPY following the 4
Treatment Period is composed of the Titration Period and the Maintenance Period.
REDACTED COPY Treatment Period is composed of the Titration Period and the Maintenance Period.
week period following the 4 REDACTED COPY week period following the 4
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.numbers of events in the SAP. The compliance derivation was also updated to allow for subjects 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.numbers of events in the SAP. The compliance derivation was also updated to allow for subjects 
Section 3.2.1, the following text was changed from:
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Section 3.2.1, the following text was changed from:
following the 4
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.following the 4
Treatment Period is composed of the Titration Period and the Maintenance Period.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Treatment Period is composed of the Titration Period and the Maintenance Period.
week period following the 4
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.week period following the 4
Period starts on the date of the Random
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Period starts on the date of the Random
Visit 6 (or the date of the Early Termination (ET) visit in the situation where a subject 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Visit 6 (or the date of the Early Termination (ET) visit in the situation where a subject 
discontinues prior to the last visit in the Titration Period).
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.discontinues prior to the last visit in the Titration Period).
Maintenance Period: 18
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Maintenance Period: 18 -
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.-week period following the 6
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.week period following the 6
Maintenance Period starts on the day of Visit 6 and continues until 1 of the following 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Maintenance Period starts on the day of Visit 6 and continues until 1 of the following 
occurs (whichever occurs first):
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.occurs (whichever occurs first):
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Completion of ≥6 weeks of the Treatment Period, occurrence of ≥2 PGTC seizures 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Completion of ≥6 weeks of the Treatment Period, occurrence of ≥2 PGTC seizures 
and completion of the ET Visit
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.and completion of the ET Visit
Completion of 18 weeks (Visit 10) of the Maintenance Period without occurrence of 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Completion of 18 weeks (Visit 10) of the Maintenance Period without occurrence of 
2 PGTC seizures.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.2 PGTC seizures.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.And revised as follows:
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.And revised as follows:

This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Treatment Period: 24
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Treatment Period: 24
UCB   28 Mar 2019  
Statistical Analysis Plan  SP0982  
Visit 5 (or the date of the Early Termination (ET) visit in the situation where a subject 
discontinues prior to the last visit in the Titration Period). 
 Maintenance Period: 18-week period following the 6-week Titration Period. The 
Maintenance Period starts on the day of Visit 5 and  continues until 1 of the following occurs (whichever occurs first): 
◦ Completion of ≥6 weeks of the Treatment Period, occurrence of ≥2 PGTC seizures 
and completion of the ET Visit 
◦ Completion of 18 weeks (Visit 10) of the Maintenance Period without occurrence of 2 PGTC seizures. 
Section 7, the following bullet point was changed from: 
 Compliance (%) = (Number of tablets dispensed – Number of tablets returned) / (Number of 
tablets prescribed per day (2 tablets) x Number of days between x 100. 
And revised as follows: 
 Compliance (%) = (Number of tablets dispensed – Number of tablets returned) / (Number of 
tablets prescribed per day x Number of days between x 100. 
Section 8.1.2, the following text was changed from: 
If no events (ie, no subjects who had a second PGTC seizure) occur in a stratum, then data will 
be pooled by Baseline PGTC seizure frequency for analysis as follows:  
 If no events occur in the group of subjects who are ≥12 and <18 years of age with ≤2 
Baseline PGTC seizures per 28 days, then this group will be combined for analysis with 
either the group of subjects who are ≥4 to <12 years of age with ≤2 Baseline PGTC seizures 
per 28 days or the group of subjects who are ≥18 years of age with ≤2 Baseline PGTC seizures per 28 days, whichever has the smallest number of events. 
 If no events occur in the group of subjects who are ≥4 to <12 years of age with ≤2 Baseline 
PGTC seizures per 28 days, then this group will be combined for analysis with the group of subjects who are ≥12 to <18 years of age with ≤2 Baseline PGTC seizures per 28 days. 
 If no events occur in the group of subjects who are ≥18 years of age with ≤2 Baseline PGTC seizures per 28 days, then this group will be combined for analysis with the group of subjects who are ≥12 to <18 years of age with ≤2 Baseline PGTC seizures per 28 days.  
 Similarly, rules 1 to 3 apply to those age groups within subjects with > 2 Baseline PGTC 
seizures per 28 days. 
And revised as follows: 
If 5 events or less (ie, less than 6 subjects who had a second PGTC seizure) occur in a stratum, 
then data will be pooled by Baseline PGTC seizure frequency for analysis as follows:  
 If 5 events or less occur in the group of subjects who are ≥12 and <18 years of age with ≤2 Baseline PGTC seizures per 28 days, then this group will be combined for analysis with either the group of subjects who are ≥4 to <12 years of age with ≤2 Baseline PGTC seizures 
per 28 days or the group of subjects who are ≥18 years of age with ≤2 Baseline PGTC 
seizures per 28 days, whichever has the smallest number of events. REDACTED COPY If no events (ie, no subjects who had a second PGTC seizure) occur in a 
REDACTED COPY If no events (ie, no subjects who had a second PGTC seizure) occur in a 
be pooled by Baseline PGTC seizure frequency for analysis as follows: 
REDACTED COPY be pooled by Baseline PGTC seizure frequency for analysis as follows: 
If no events occur in the group of subjects who are ≥12 and <18 years of age with ≤2 
REDACTED COPY If no events occur in the group of subjects who are ≥12 and <18 years of age with ≤2 
Baseline PGTC seizures per 28 days, then this group will be combined for ana
REDACTED COPY Baseline PGTC seizures per 28 days, then this group will be combined for ana
either the group of subjects who are ≥4 to <12 years of age with ≤2 Baseline PGTC seizures 
REDACTED COPY either the group of subjects who are ≥4 to <12 years of age with ≤2 Baseline PGTC seizures 
per 28 days or the group of subjects who are ≥18 years of age with ≤2 Baseline PGTC REDACTED COPY per 28 days or the group of subjects who are ≥18 years of age with ≤2 Baseline PGTC 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Completion of 18 weeks (Visit 10) of the Maintenance Period without occurrence of 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Completion of 18 weeks (Visit 10) of the Maintenance Period without occurrence of 
Number of tablets returned) / (Number of 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Number of tablets returned) / (Number of 
Number of tablets returned) / (Number of 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Number of tablets returned) / (Number of 
If no events (ie, no subjects who had a second PGTC seizure) occur in a 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.If no events (ie, no subjects who had a second PGTC seizure) occur in a 
be pooled by Baseline PGTC seizure frequency for analysis as follows: 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.be pooled by Baseline PGTC seizure frequency for analysis as follows: 
If no events occur in the group of subjects who are ≥12 and <18 years of age with ≤2 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.If no events occur in the group of subjects who are ≥12 and <18 years of age with ≤2 
Baseline PGTC seizures per 28 days, then this group will be combined for ana
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Baseline PGTC seizures per 28 days, then this group will be combined for ana
either the group of subjects who are ≥4 to <12 years of age with ≤2 Baseline PGTC seizures 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.either the group of subjects who are ≥4 to <12 years of age with ≤2 Baseline PGTC seizures 
per 28 days or the group of subjects who are ≥18 years of age with ≤2 Baseline PGTC 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.per 28 days or the group of subjects who are ≥18 years of age with ≤2 Baseline PGTC 
seizures per 28 days, whichever has the smallest number of events.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.seizures per 28 days, whichever has the smallest number of events.
no events occur in the group of subjects who are ≥4 to <12 years of age with ≤2 Baseline 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.no events occur in the group of subjects who are ≥4 to <12 years of age with ≤2 Baseline 
PGTC seizures per 28 days, then this group will be combined for analysis with the group of 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.PGTC seizures per 28 days, then this group will be combined for analysis with the group of 
subjects who are ≥12 to <18 years of age with ≤2 Baseline PGTC seizures per 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.subjects who are ≥12 to <18 years of age with ≤2 Baseline PGTC seizures per 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.If no events occur in the group of subjects who are ≥18 years of age with ≤2 Baseline PGTC 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.If no events occur in the group of subjects who are ≥18 years of age with ≤2 Baseline PGTC 
seizures per 28 days, then this group will be combined for analysis with the group of subjects 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.seizures per 28 days, then this group will be combined for analysis with the group of subjects 
who are ≥12 to <18 years of age with ≤2 Baseline PGTC seizure
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.who are ≥12 to <18 years of age with ≤2 Baseline PGTC seizure
Similarly, rules 1 to 3 apply to those age groups within subjects with > 2 Baseline PGTC 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Similarly, rules 1 to 3 apply to those age groups within subjects with > 2 Baseline PGTC 
seizures per 28 days.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.seizures per 28 days.
And revised as follows:
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.And revised as follows:
If 5 events or less (ie, less than 6 subjects who had a second PGTC seizure) occur in a stratum, 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.If 5 events or less (ie, less than 6 subjects who had a second PGTC seizure) occur in a stratum, 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.then dat
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.then dat

This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
UCB   28 Mar 2019  
Statistical Analysis Plan  SP0982  
 If 5 events or less occur in the group of subjects who are ≥4 to <12 years of age with ≤2 
Baseline PGTC seizures per 28 days, then this group will be combined for analysis with the group of subjects who are ≥12 to <18 years of age with ≤2 Baseline PGTC seizures per 28 days. 
 If 5 events or less occur in the group of subjects who are ≥18 years of age with ≤2 Baseline PGTC seizures per 28 days, then this group will be combined for analysis with the group of subjects who are ≥12 to <18 years of age with ≤2 Baseline PGTC seizures per 28 days.  
 Similarly, rules 1 to 3 apply to those age groups within subjects with > 2 Baseline PGTC seizures per 28 days. 
Section 8.2.2.1, the following text was changed from: 
If no events (ie, no subjects who had a second PGTC seizure) occur in a stratum, then data will 
be pooled by Baseline PGTC seizure frequency for analysis as follows:  
 If no events occur in the group of subjects who are ≥12 and <18 years of age with ≤2 
Baseline PGTC seizures per 28 days, then this group will be combined for analysis with 
either the group of subjects who are ≥4 to <12 years of age with ≤2 Baseline PGTC seizures per 28 days or the group of subjects who are ≥18 years of age with ≤2 Baseline PGTC seizures per 28 days, whichever has the smallest number of events. 
 If no events occur in the group of subjects who are ≥4 to <12 years of age with ≤2 Baseline 
PGTC seizures per 28 days, then this group will be combined for analysis with the group of subjects who are ≥12 to <18 years of age with ≤2 Baseline PGTC seizures per 28 days. 
 If no events occur in the group of subjects who are ≥18 years of age with ≤2 Baseline PGTC 
seizures per 28 days, then this group will be combined for analysis with the group of subjects 
who are ≥12 to <18 years of age with ≤2 Baseline PGTC seizures per 28 days.  
 Similarly, rules 1 to 3 apply to those age groups within subjects with > 2 Baseline PGTC 
seizures per 28 days. 
And revised as follows: 
If 5 events or less (ie, less than 6 subjects who had a second PGTC seizure) occur in a stratum, 
then data will be pooled by Baseline PGTC seizure frequency for analysis as follows:  
 If 5 events or less occur in the group of subjects who are ≥12 and <18 years of age with ≤2 
Baseline PGTC seizures per 28 days, then this group will be combined for analysis with either the group of subjects who are ≥4 to <12 years of age with ≤2 Baseline PGTC seizures 
per 28 days or the group of subjects who are ≥18 years of age with ≤2 Baseline PGTC 
seizures per 28 days, whichever has the smallest number of events. 
 If 5 events or less occur in the group of subjects who are ≥4 to <12 years of age with ≤2 Baseline PGTC seizures per 28 days, then this group will be combined for analysis with the group of subjects who are ≥12 to <18 years of age with ≤2 Baseline PGTC seizures per 28 days. 
 If 5 events or less occur in the group of subjects who are ≥18 years of age with ≤2 Baseline PGTC seizures per 28 days, then this group will be combined for analysis with the group of subjects who are ≥12 to <18 years of age with ≤2 Baseline PGTC seizures per 28 days.  REDACTED COPY seizures per 28 days, whichever has the smallest number of events.
REDACTED COPY seizures per 28 days, whichever has the smallest number of events.
no events occur in the group of subjects who are ≥4 to <12 years of age with ≤2 Baseline 
REDACTED COPY no events occur in the group of subjects who are ≥4 to <12 years of age with ≤2 Baseline 
PGTC seizures per 28 days, then this group will be combined for analysis with the group of 
REDACTED COPY PGTC seizures per 28 days, then this group will be combined for analysis with the group of 
subjects who are ≥12 to <18 years of age with ≤2 Baseline PGTC seizures per
REDACTED COPY subjects who are ≥12 to <18 years of age with ≤2 Baseline PGTC seizures per
If no events occur in the group of subjects who are ≥18 years of age with ≤2 Baseline PGTC 
REDACTED COPY If no events occur in the group of subjects who are ≥18 years of age with ≤2 Baseline PGTC 
seizures per 28 days, then this group will be combined for analysis with the group of subjects 
REDACTED COPY seizures per 28 days, then this group will be combined for analysis with the group of subjects 
who are ≥12 to <18 years of age with ≤2 Baseline PGTC seizur REDACTED COPY who are ≥12 to <18 years of age with ≤2 Baseline PGTC seizur
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Similarly, rules 1 to 3 apply to those age groups within subjects with > 2 Baseline PGTC 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Similarly, rules 1 to 3 apply to those age groups within subjects with > 2 Baseline PGTC 
stratum, then data will 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.stratum, then data will 
If no events occur in the group of subjects who are ≥12 and <18 years of age with ≤2 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.If no events occur in the group of subjects who are ≥12 and <18 years of age with ≤2 
Baseline PGTC seizures per 28 days, then this group will be combined for an
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Baseline PGTC seizures per 28 days, then this group will be combined for an
either the group of subjects who are ≥4 to <12 years of age with ≤2 Baseline PGTC seizures 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.either the group of subjects who are ≥4 to <12 years of age with ≤2 Baseline PGTC seizures 
per 28 days or the group of subjects who are ≥18 years of age with ≤2 Baseline PGTC 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.per 28 days or the group of subjects who are ≥18 years of age with ≤2 Baseline PGTC 
seizures per 28 days, whichever has the smallest number of events.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.seizures per 28 days, whichever has the smallest number of events.
no events occur in the group of subjects who are ≥4 to <12 years of age with ≤2 Baseline 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.no events occur in the group of subjects who are ≥4 to <12 years of age with ≤2 Baseline 
PGTC seizures per 28 days, then this group will be combined for analysis with the group of 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.PGTC seizures per 28 days, then this group will be combined for analysis with the group of 
subjects who are ≥12 to <18 years of age with ≤2 Baseline PGTC seizures per
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.subjects who are ≥12 to <18 years of age with ≤2 Baseline PGTC seizures per
If no events occur in the group of subjects who are ≥18 years of age with ≤2 Baseline PGTC 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.If no events occur in the group of subjects who are ≥18 years of age with ≤2 Baseline PGTC 
seizures per 28 days, then this group will be combined for analysis with the group of subjects 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.seizures per 28 days, then this group will be combined for analysis with the group of subjects 
who are ≥12 to <18 years of age with ≤2 Baseline PGTC seizur
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.who are ≥12 to <18 years of age with ≤2 Baseline PGTC seizur
Similarly, rules 1 to 3 apply to those age groups within subjects with > 2 Baseline PGTC 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Similarly, rules 1 to 3 apply to those age groups within subjects with > 2 Baseline PGTC 
If 5 events or less (ie, less than 6 subjects who had a second PGTC seizure) occur in a stratum, 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.If 5 events or less (ie, less than 6 subjects who had a second PGTC seizure) occur in a stratum, 
then data will be pooled by Baseline PGTC seizure frequency for analysis as follows: 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.then data will be pooled by Baseline PGTC seizure frequency for analysis as follows: 
If 5 events or less occur in the group of subjects who are ≥12 and <18 ye
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.If 5 events or less occur in the group of subjects who are ≥12 and <18 ye
Baseline PGTC seizures per 28 days, then this group will be combined for analysis with 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Baseline PGTC seizures per 28 days, then this group will be combined for analysis with 
either the group of subjects who are ≥4 to <12 years of age with ≤2 Baseline PGTC seizures 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.either the group of subjects who are ≥4 to <12 years of age with ≤2 Baseline PGTC seizures 
per 28 days or the group of subjects who are ≥18 years of a
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.per 28 days or the group of subjects who are ≥18 years of a
seizures per 28 days, whichever has the smallest number of events.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.seizures per 28 days, whichever has the smallest number of events.
If 5 events or less occur in the group of subjects who are ≥4 to <12 years of age with ≤2 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.If 5 events or less occur in the group of subjects who are ≥4 to <12 years of age with ≤2 
Baseline PGTC seizures per 28 days, then this group will be combined for a
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Baseline PGTC seizures per 28 days, then this group will be combined for a
UCB   28 Mar 2019  
Statistical Analysis Plan  SP0982  
 Similarly, rules 1 to 3 apply to those age groups within subjects with > 2 Baseline PGTC 
seizures per 28 days. 
Section 8.2.2.3, the following text was changed from: 
If no events (ie, no subjects who had a PGTC seizure) occur in a stratum, then data will be 
pooled by Baseline PGTC seizure frequency for analysis as follows:  
 If no events occur in the group of subjects who are ≥12 and <18 years of age with ≤2 
Baseline PGTC seizures per 28 days, then this group will be combined for analysis with 
either the group of subjects who are ≥4 to <12 years of age with ≤2 Baseline PGTC seizures 
per 28 days or the group of subjects who are ≥18 years of age with ≤2 Baseline PGTC seizures per 28 days, whichever has the smallest number of events. 
 If no events occur in the group of subjects who are ≥4 to <12 years of age with ≤2 Baseline PGTC seizures per 28 days, then this group will be combined for analysis with the group of subjects who are ≥12 to <18 years of age with ≤2 Baseline PGTC seizures per 28 days. 
 If no events occur in the group of subjects who are ≥18 years of age with ≤2 Baseline PGTC seizures per 28 days, then this group will be combined for analysis with the group of subjects who are ≥12 to <18 years of age with ≤2 Baseline PGTC seizures per 28 days.  
 Similarly, rules 1 to 3 apply to those age groups within subjects with > 2 Baseline PGTC seizures per 28 days. 
And revised as follows: 
If 5 events or less (ie, less than 6 subjects who had a PGTC seizure) occur in a stratum, then data 
will be pooled by Baseline PGTC seizure frequency for analysis as follows:  
 If 5 events or less occur in the group of subjects who are ≥12 and <18 years of age with ≤2 
Baseline PGTC seizures per 28 days, then this group will be combined for analysis with 
either the group of subjects who are ≥4 to <12 years of age with ≤2 Baseline PGTC seizures per 28 days or the group of subjects who are ≥18 years of age with ≤2 Baseline PGTC seizures per 28 days, whichever has the smallest number of events. 
 If 5 events or less occur in the group of subjects who are ≥4 to <12 years of age with ≤2 Baseline PGTC seizures per 28 days, then this group will be combined for analysis with the group of subjects who are ≥12 to <18 years of age with ≤2 Baseline PGTC seizures per 28 days. 
 If 5 events or less occur in the group of subjects who are ≥18 years of age with ≤2 Baseline 
PGTC seizures per 28 days, then this group will be combined for analysis with the group of 
subjects who are ≥12 to <18 years of age with ≤2 Baseline PGTC seizures per 28 days.  
 Similarly, rules 1 to 3 apply to those age groups within subjects with > 2 Baseline PGTC seizures per 28 days. 
13.2 Amendment 2 
13.2.1 Rationale for the amendment 
The SAP was amended to include flexibility as an index for BRIEF- P. REDACTED COPY Similarly, rules 1 to 3 apply to those age groups within subjects with > 2 Baseline PGTC 
REDACTED COPY Similarly, rules 1 to 3 apply to those age groups within subjects with > 2 Baseline PGTC 
vents or less (ie, less than 6 subjects who had a PGTC seizure) occur in a stratum, then data 
REDACTED COPY vents or less (ie, less than 6 subjects who had a PGTC seizure) occur in a stratum, then data 
will be pooled by Baseline PGTC seizure frequency for analysis as follows: 
REDACTED COPY will be pooled by Baseline PGTC seizure frequency for analysis as follows: 
If 5 events or less occur in the group of subjects who are ≥12 and <18 years of age wiREDACTED COPY If 5 events or less occur in the group of subjects who are ≥12 and <18 years of age wi
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.either the group of subjects who are ≥4 to <12 years of age with ≤2 Baseline PGTC seizures 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.either the group of subjects who are ≥4 to <12 years of age with ≤2 Baseline PGTC seizures 
of age with ≤2 Baseline PGTC 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.of age with ≤2 Baseline PGTC 
If no events occur in the group of subjects who are ≥4 to <12 years of age with ≤2 Baseline 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.If no events occur in the group of subjects who are ≥4 to <12 years of age with ≤2 Baseline 
ysis with the group of 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.ysis with the group of 
subjects who are ≥12 to <18 years of age with ≤2 Baseline PGTC seizures per 28 days.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.subjects who are ≥12 to <18 years of age with ≤2 Baseline PGTC seizures per 28 days.
If no events occur in the group of subjects who are ≥18 years of age with ≤2 Baseline PGTC 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.If no events occur in the group of subjects who are ≥18 years of age with ≤2 Baseline PGTC 
r analysis with the group of subjects 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.r analysis with the group of subjects 
who are ≥12 to <18 years of age with ≤2 Baseline PGTC seizures per 28 days. 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.who are ≥12 to <18 years of age with ≤2 Baseline PGTC seizures per 28 days. 
Similarly, rules 1 to 3 apply to those age groups within subjects with > 2 Baseline PGTC 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Similarly, rules 1 to 3 apply to those age groups within subjects with > 2 Baseline PGTC 
vents or less (ie, less than 6 subjects who had a PGTC seizure) occur in a stratum, then data 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.vents or less (ie, less than 6 subjects who had a PGTC seizure) occur in a stratum, then data 
will be pooled by Baseline PGTC seizure frequency for analysis as follows: 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.will be pooled by Baseline PGTC seizure frequency for analysis as follows: 
If 5 events or less occur in the group of subjects who are ≥12 and <18 years of age wi
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.If 5 events or less occur in the group of subjects who are ≥12 and <18 years of age wi
Baseline PGTC seizures per 28 days, then this group will be combined for analysis with 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Baseline PGTC seizures per 28 days, then this group will be combined for analysis with 
either the group of subjects who are ≥4 to <12 years of age with ≤2 Baseline PGTC seizures 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.either the group of subjects who are ≥4 to <12 years of age with ≤2 Baseline PGTC seizures 
per 28 days or the group of subjects who are ≥18 years of age with ≤2 Ba
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.per 28 days or the group of subjects who are ≥18 years of age with ≤2 Ba
seizures per 28 days, whichever has the smallest number of events.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.seizures per 28 days, whichever has the smallest number of events.
If 5 events or less occur in the group of subjects who are ≥4 to <12 years of age with ≤2 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.If 5 events or less occur in the group of subjects who are ≥4 to <12 years of age with ≤2 
Baseline PGTC seizures per 28 days, then this group will be combined for analysis with 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Baseline PGTC seizures per 28 days, then this group will be combined for analysis with 
group of subjects who are ≥12 to <18 years of age with ≤2 Baseline PGTC seizures per 28 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.group of subjects who are ≥12 to <18 years of age with ≤2 Baseline PGTC seizures per 28 
If 5 events or less occur in the group of subjects who are ≥18 years of age with ≤2 Baseline 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.If 5 events or less occur in the group of subjects who are ≥18 years of age with ≤2 Baseline 
PGTC seizures per 28 days, then this group will be combined for a
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.PGTC seizures per 28 days, then this group will be combined for a
subjects who are ≥12 to <18 years of age with ≤2 Baseline PGTC seizures per 28 days. 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.subjects who are ≥12 to <18 years of age with ≤2 Baseline PGTC seizures per 28 days. 
Similarly, rules 1 to 3 apply to those age groups within subjects with > 2 Baseline PGTC 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Similarly, rules 1 to 3 apply to those age groups within subjects with > 2 Baseline PGTC 
seizures per 28 days.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.seizures per 28 days.
13.2
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.13.2
UCB   28 Mar 2019  
Statistical Analysis Plan  SP0982  
13.2.2 Modification and changes 
13.2.2.1 Specific changes 
The information below was revised: 
SAP/Amendment Number  Date  
Final SAP  09 Aug 2016  
Amendment #1  24 Feb 2017  
Has been changed to: 
SAP/Amendment Number  Date  
Final SAP  09 Aug 2016  
Amendment #1  24 Feb 2017  
Amendment #2  14 Mar 2017  
Section 10.4.9.1, the following text was changed from: 
The BRIEF-P form comprises of 63 questions which can be answered Never (scored as 1 point), 
Sometimes (scored as 2 points), and Often (scored as 3 points).  
The 63 items are included in the raw Global Executive Composite (GEC) score which ranges 
from 63 to 189, with higher scores reflecting poorer functioning. 
The 2 subscale scores and 5 individual component scores that make up these subscale scores are 
outlined in Table 4 . 
Table 4: BRIEF-P questionnaire scoring 
Scale/Index Questions 
Inhibit 3, 8, 13, 18, 23, 28, 33, 38, 43, 48, 52, 54, 56, 58, 
60, 62 
Shift 5,10, 15, 20, 25, 30, 35, 40, 45, 50 
Emotional Control 1, 6, 11, 16, 21, 26, 31, 36, 41, 46 
BRI All from {Inhibit, Shift, and Emotional Control} 
Working Memory 2, 7, 12, 17, 22, 27, 32, 37, 42, 47, 51, 53, 55, 57, 59, 61, 63 
Plan/Organize 4, 9, 14, 19, 24, 29, 34, 39, 44, 49 
MI All from {Working Memory and Plan/Organize} 
GEC Score 1-63 
BRI=Behavioral Regulation Index, MI=Metacognition Index, GEC=Global Executive Composite 
Standardized T-scores are determined from each subject’s raw GEC, BRI, MI, and component 
scores based on the subject’s age and gender. Tables that map each raw score to the appropriate 
T-score are provided in the BRIEF-P Professional Manual and will be reproduced 
programmatically. 
And revised as follows: REDACTED COPY from 63 to 189, with higher scores reflecting poorer functioning.
REDACTED COPY from 63 to 189, with higher scores reflecting poorer functioning.
The 2 subscale scores and 5 individual component scores that make up these subscale scores are 
REDACTED COPY The 2 subscale scores and 5 individual component scores that make up these subscale scores are 
scoring
REDACTED COPY scoring
REDACTED COPY REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.P form comprises of 63 questions which can be answered Never (scored as 1 point), 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.P form comprises of 63 questions which can be answered Never (scored as 1 point), 
The 63 items are included in the raw Global Executive Composite (GEC) score which ranges 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.The 63 items are included in the raw Global Executive Composite (GEC) score which ranges 
from 63 to 189, with higher scores reflecting poorer functioning.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.from 63 to 189, with higher scores reflecting poorer functioning.
The 2 subscale scores and 5 individual component scores that make up these subscale scores are 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.The 2 subscale scores and 5 individual component scores that make up these subscale scores are 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.GEC Score
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.GEC Score
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.BRI=Behavioral Regulation Index, MI=Metacognition Index, GE
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.BRI=Behavioral Regulation Index, MI=Metacognition Index, GE
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Standardized T
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Standardized T
scores based on the subject’s age and gender. Tables that map each raw score to the appropriate 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.scores based on the subject’s age and gender. Tables that map each raw score to the appropriate 
UCB   28 Mar 2019  
Statistical Analysis Plan  SP0982  
The BRIEF-P form comprises of 63 questions which can be answered Never (scored as 1 point), 
Sometimes (scored as 2 points), and Often (scored as 3 points).  
The 63 items are included in the raw Global Executive Composite (GEC) score which ranges 
from 63 to 189, with higher scores reflecting poorer functioning. 
The 3 subscale scores and 5 individual component scores that make up these subscale scores are 
outlined in Table 4 . 
Table 4: BRIEF- P questionnaire scoring  
Scale/Index Questions 
Inhibit 3, 8, 13, 18, 23, 28, 33, 38, 43, 48, 52, 54, 56, 58, 
60, 62 
Shift 5,10, 15, 20, 25, 30, 35, 40, 45, 50 
Emotional Control 1, 6, 11, 16, 21, 26, 31, 36, 41, 46 
Inhibitory self-control All from {Inhibit and Emotional Control} 
Flexibility All from {Shift and Emotional Control} 
Working Memory 2, 7, 12, 17, 22, 27, 32, 37, 42, 47, 51, 53, 55, 57, 
59, 61, 63 
Plan/Organize 4, 9, 14, 19, 24, 29, 34, 39, 44, 49 
Emergent metacognition All from {Working Memory and Plan/Organize} 
GEC Score 1-63 
GEC=Global Executive Composite 
Standardized T-scores are determined from each subject’s raw GEC, inhibitory self-control, 
flexibility, emergent metacognition, and component scores based on the subject’s age and 
gender. Tables that map each raw score to the appropriate T-score are provided in the BRIEF- P 
Professional Manual and will be reproduced progr ammatically.  
13.3 Amendment 3 
13.3.1 Rationale for the amendment 
The SAP was amended to reflect changes adopted in Protocol Amendment 5 v4.0. The primary purpose of Protocol Amendment 5 v4.0 was to stop the subjects’ study participation once 125 
events are observed to avoid exposing subjects to placebo unnecessarily.  This SAP amendment 
provides more detail in how PGTCS data will be analyzed for the primary and secondary 
efficacy endpoints. In general, all variables and all statistical analyses are more clarified. 
13.3.2 Modification and changes 
13.3.2.1 Specific changes 
The information below was revised from:  
SAP/Amendment Number  Date  
Final SAP  09 Aug 2016  
Amendment #1  24 Feb 2017  REDACTED COPY 59, 61, 63
REDACTED COPY 59, 61, 63
4, 9, 14, 19, 24, 29, 34, 39, 44, 49
REDACTED COPY 4, 9, 14, 19, 24, 29, 34, 39, 44, 49
REDACTED COPY REDACTED COPY REDACTED COPY REDACTED COPY REDACTED COPY REDACTED COPY REDACTED COPY REDACTED COPY REDACTED COPY scores are determined from each subject’s raw GEC, REDACTED COPY scores are determined from each subject’s raw GEC, 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.3, 8, 13, 18, 23, 28, 33, 38, 43, 48, 52, 54, 56, 58, 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.3, 8, 13, 18, 23, 28, 33, 38, 43, 48, 52, 54, 56, 58, 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.30, 35, 40, 45, 50
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.30, 35, 40, 45, 50
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.1, 6, 11, 16, 21, 26, 31, 36, 41, 46
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.1, 6, 11, 16, 21, 26, 31, 36, 41, 46
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.All from {Inhibit and Emotional Control}
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.All from {Inhibit and Emotional Control}
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.All from {Shift and Emotional Control}
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.All from {Shift and Emotional Control}
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.2, 7, 12, 17, 22, 27, 32, 37, 42, 47, 51, 53, 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.2, 7, 12, 17, 22, 27, 32, 37, 42, 47, 51, 53, 
59, 61, 63
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.59, 61, 63
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.4, 9, 14, 19, 24, 29, 34, 39, 44, 49
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.4, 9, 14, 19, 24, 29, 34, 39, 44, 49
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.All from {Working Memory and Plan/Organize}
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.All from {Working Memory and Plan/Organize}
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.1
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.1-
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.-63
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.63
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.This document cannot be used to support any marketing authorization application and any extensions or variations thereof.scores are determined from each subject’s raw GEC, 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.scores are determined from each subject’s raw GEC, 
and component scores based on the subject’s age and 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.and component scores based on the subject’s age and 
gender. Tables that map each raw score to the appropriate T
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.gender. Tables that map each raw score to the appropriate T
Professional Manual and will be reproduced progr
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Professional Manual and will be reproduced progr
Amendment 3
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Amendment 3
Rationale for the amendment
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Rationale for the amendment
The SAP was amended to reflect changes adopted in Protocol Amendment 5 v4.0. The primary 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.The SAP was amended to reflect changes adopted in Protocol Amendment 5 v4.0. The primary 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.purpose of Protocol Amendment 5 v4.0 was to stop the subjects’ study participation once 125 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.purpose of Protocol Amendment 5 v4.0 was to stop the subjects’ study participation once 125 
events are observed to
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.events are observed to
provides more detail in how PGTC
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.provides more detail in how PGTC
efficacy endpoints. In general, all variables and all statistical analyses are more clarified.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.efficacy endpoints. In general, all variables and all statistical analyses are more clarified.
13.3.2
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.13.3.2
13.3.2.1
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.13.3.2.1
The information below was revised from:
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.The information below was revised from:
UCB   28 Mar 2019  
Statistical Analysis Plan  SP0982  
Amendment #2  14 Mar 2017  
has been revised to:  
SAP/Amendment Number  Date  
Final SAP  09 Aug 2016  
Amendment #1  24 Feb 2017  
Amendment #2  14 Mar 2017  
Amendment #3  4 Jan 2019  
The following abbreviations were revised from:  
IGE idiopathic generalized epilepsy 
ILAE  International League Against Epilepsy 
IRT Interactive response technology 
LCM  lacosamide 
LLN  lower limit of normal 
MedDRA Medical Dictionary for Regulatory Activities 
MI Metacognition Index 
PCH  percent change 
PedsQL Pediatric Quality of Life Inventory  
PGTC  primary generalized tonic-clonic 
Has been revised to:  
IGE idiopathic generalized epilepsy 
IIA Absence seizures 
IIB Myoclonic seizures 
IIC Clonic seizures 
IID Tonic seizures 
IIE (primary generalized) tonic-clonic seizures 
IIF Atonic seizures 
III Unclassified seizures 
ILAE  International League Against Epilepsy 
IRT Interactive response technology 
KM Kaplan- Meier  
LCM  Lacosamide 
LLN  lower limit of normal 
MedDRA Medical Dictionary for Regulatory Activities 
MI Metacognition Index REDACTED COPY Pediatric Quality of Life Inventory 
REDACTED COPY Pediatric Quality of Life Inventory 
primary generalized tonic
REDACTED COPY primary generalized tonic
idiopathic REDACTED COPY idiopathic 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Medical Dictionary for Regulatory Activities
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Medical Dictionary for Regulatory Activities
Pediatric Quality of Life Inventory 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Pediatric Quality of Life Inventory 
primary generalized tonic
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.primary generalized tonic
idiopathic 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.idiopathic generalized epilepsy
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.generalized epilepsy
Absence seizures
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Absence seizures
Myoclonic seizures
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Myoclonic seizures
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.IRT
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.IRT
KM
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.KM
LCM
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.LCM
UCB   28 Mar 2019  
Statistical Analysis Plan  SP0982  
NCI CTC  National Cancer Institute Common Terminology Criteria 
for Adverse Events 
PCH  percent change 
PedsQL Pediatric Quality of Life Inventory  
PGTC  primary generalized tonic-clonic 
PGTCS  Primary generalized tonic-clonic seizure 
Section 2.2.1.2 Secondary efficacy variables were changed from:  
The key secondary efficacy variable is: 
 Seizure freedom for during the 24-week Treatment Period, estimated using Kaplan-Meier 
analysis 
The other secondary efficacy variables are: 
 The percent change in PGTC seizure frequency per 28 days during the first 6 weeks of the 
Treatment Period (Titration Period) relative to the Combined Baseline (combined 12-week Historical and 4-week Prospective Baseline) 
 The percent change in PGTC seizure frequency per 28 days during the Treatment Period relative to the Combined Baseline  
 Time to the first PGTC seizure during the 24-week Treatment Period 
And revised as follows: 
The key secondary efficacy variable is: 
 Seizure freedom for PGTCS during the 24-week Treatment Period, estimated using Kaplan-
Meier analysis 
The other secondary efficacy variable is: 
  Time to first seizure during the 24-week Treatment Period 
Section 2.2.1.3 Other efficacy variables were changed from:  
Other efficacy variables are:  Change in days with absence seizures per 28 days during the Treatment Period relative to the 
Prospective Baseline 
 Percent change in days with absence seizures per 28 days during the first 6 weeks of the Treatment Period (Titration Period) relative to the Prospective Baseline 
 Percent change in days with absence seizures per 28 days during the Treatment Period relative to the Prospective Baseline 
 Percentage of subjects with at least a 50% reduction in absence seizure days compared to Prospective Baseline 
 Change in days with myoclonic seizures per 28 days during the Treatment Period relative to 
the Prospective Baseline REDACTED COPY The percent change in PGTC seizure frequency per 28 days 
REDACTED COPY The percent change in PGTC seizure frequency per 28 days 
week Treatment Period
REDACTED COPY week Treatment Period
Seizure freedom for PGTCS during the 24REDACTED COPY Seizure freedom for PGTCS during the 24
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.week Treatment Period, estimated using Kaplan
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.week Treatment Period, estimated using Kaplan -
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.-Meier 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Meier 
during the first 6 weeks of the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.during the first 6 weeks of the 
the Combined Baseline (combined 12
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.the Combined Baseline (combined 12
The percent change in PGTC seizure frequency per 28 days 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.The percent change in PGTC seizure frequency per 28 days during the Treatment Period 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.during the Treatment Period 
week Treatment Period
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.week Treatment Period
Seizure freedom for PGTCS during the 24
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Seizure freedom for PGTCS during the 24 -
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.-week Treatment Period, estimated using Kaplan
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.week Treatment Period, estimated using Kaplan
The other secondary efficacy variable is:
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.The other secondary efficacy variable is:
Time to first seizure during the 24
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Time to first seizure during the 24
Section 2.2.1.3 Other efficacy variables were changed from:
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Section 2.2.1.3 Other efficacy variables were changed from:
Other efficacy variables are:
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Other efficacy variables are:
Change in days with absence seizures per 28 days during the Treatment Period relative to the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Change in days with absence seizures per 28 days during the Treatment Period relative to the 
Prospective Ba
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Prospective Ba seline
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.seline
Percent change in days with absence seizures per 28 days 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Percent change in days with absence seizures per 28 days 
Treatment Period (Titration Period) relative to the Prospective Baseline
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Treatment Period (Titration Period) relative to the Prospective Baseline
Percent change in days with absence seizures per 28 days 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Percent change in days with absence seizures per 28 days 
re
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.relative to the Prospective Baseline
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.lative to the Prospective Baseline

This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
UCB   28 Mar 2019  
Statistical Analysis Plan  SP0982  
 Percent change in days with myoclonic seizures per 28 days during the first 6 weeks of the 
Treatment Period (Titration Period) relative to the Prospective Baseline 
 Percent change in days with myoclonic seizures per 28 days during the Treatment Period 
relative to the Prospective Baseline 
 Percentage of subjects with at least a 50% reduction in myoclonic seizure days compared to Prospective Baseline 
 Seizure-free status (yes, no) for PGTC seizures for the first 12 weeks of the Treatment Period  
 Seizure-free status (yes, no) for PGTC seizures for the 24-week Treatment Period 
 Percentage of subjects with at least a 50% reduction in PGTC seizure frequency during the first 12 weeks of the Treatment Period compared to Combined Baseline 
 Percentage of subjects with at least a 50% reduction in PGTC seizure frequency during the Treatment Period compared to Combined Baseline 
 Seizure-free status (yes, no) for all generalized seizure types for the first 12 weeks of the 
Treatment Period  
 Seizure-free status (yes, no) for all generalized seizure types for the 24-week Treatment 
Period  
 Change from Baseline in Patient-Weighted Quality of Life in Epilepsy Inventory-Form 31 
(QOLIE-31-P) subscale (Seizure Worry, Daily Activities/Social Functioning, Energy/Fatigue, Emotional Well-being, Mental Activity/Cognitive Functioning, Overall 
Quality of Life and Medication Effects) and total scores in subjects ≥18 years of age or 
change from Baseline in the Pediatric Quality of Life Inventory (PedsQL) subscale (Physical 
Functioning, Emotional Functioning, Social Functioning, and School Functioning) and total scores in subjects <18 years of age 
 Change from Baseline to end of treatment or early termination (ET) in the 3-Level EuroQol-5 Dimension Quality of Life Assessment (EQ-5D- 3L) visual analogue scale (VAS) score and 
change in utility as converted from the 5 dimensions (for subjects ≥12 years of age) 
 Healthcare resource use: medical procedures, hospitalizations, and healthcare provider visits 
 Number of working or school days lost by subject due to epilepsy 
 Number of days with help from a caregiver due to epilepsy 
And revised as follows: 
Other efficacy variables are: 
 The percent change in PGTCS frequency per 28 days during the first 6 weeks of the 
Treatment Period (Titration Period) relative to the Combined Baseline Period (combined 12-week Historical and 4-week Prospective Baseline Periods) 
 The percent change in PGTCS frequency per 28 days during the first 12 weeks of the Treatment Period relative to the Combined Baseline Period REDACTED COPY Weighted Qualit
REDACTED COPY Weighted Qualit y of Life in Epilepsy Inventory
REDACTED COPY y of Life in Epilepsy Inventory
P) subscale (Seizure Worry, Daily Activities/Social Functioning, 
REDACTED COPY P) subscale (Seizure Worry, Daily Activities/Social Functioning, 
being, Mental Activity/Cognitive Functioning, Overall 
REDACTED COPY being, Mental Activity/Cognitive Functioning, Overall 
Quality of Life and Medication Effects) and total scores in subjects ≥18 years of age or 
REDACTED COPY Quality of Life and Medication Effects) and total scores in subjects ≥18 years of age or 
change from Baseline in the Pediatric Quality of Life Inventory (PedsQL) subscale (Physical 
REDACTED COPY change from Baseline in the Pediatric Quality of Life Inventory (PedsQL) subscale (Physical 
ng, Emotional Functioning, Social Functioning, and School Functioning) and total REDACTED COPY ng, Emotional Functioning, Social Functioning, and School Functioning) and total 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.free status (yes, no) for PGTC seizures for the first 12 weeks of the Treatment Period 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.free status (yes, no) for PGTC seizures for the first 12 weeks of the Treatment Period 
Percentage of subjects with at least a 50% reduction in PGTC seizure frequency during the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Percentage of subjects with at least a 50% reduction in PGTC seizure frequency during the 
bjects with at least a 50% reduction in PGTC seizure frequency during the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.bjects with at least a 50% reduction in PGTC seizure frequency during the 
seizure types for the first 12 weeks of the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.seizure types for the first 12 weeks of the 
seizure types for the 24
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.seizure types for the 24
y of Life in Epilepsy Inventory
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.y of Life in Epilepsy Inventory
P) subscale (Seizure Worry, Daily Activities/Social Functioning, 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.P) subscale (Seizure Worry, Daily Activities/Social Functioning, 
being, Mental Activity/Cognitive Functioning, Overall 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.being, Mental Activity/Cognitive Functioning, Overall 
Quality of Life and Medication Effects) and total scores in subjects ≥18 years of age or 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Quality of Life and Medication Effects) and total scores in subjects ≥18 years of age or 
change from Baseline in the Pediatric Quality of Life Inventory (PedsQL) subscale (Physical 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.change from Baseline in the Pediatric Quality of Life Inventory (PedsQL) subscale (Physical 
ng, Emotional Functioning, Social Functioning, and School Functioning) and total 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.ng, Emotional Functioning, Social Functioning, and School Functioning) and total 
scores in subjects <18 years of age
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.scores in subjects <18 years of age
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Change from Baseline to end of treatment or early termination (ET) in the 3
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Change from Baseline to end of treatment or early termination (ET) in the 3
Dimension Quality of Life Assessment (EQ
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Dimension Quality of Life Assessment (EQ
change in utility as converted from the 5 dimensions (for subjects ≥12 years of age)
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.change in utility as converted from the 5 dimensions (for subjects ≥12 years of age)
Healthcare resource use: medical procedures, hospitalizations, and healthcare provider visits
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Healthcare resource use: medical procedures, hospitalizations, and healthcare provider visits
Number of working or school days lost 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Number of working or school days lost 
Number of days with help from a caregiver
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Number of days with help from a caregiver
And revised as follows:
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.And revised as follows:
Other efficacy variables are:
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Other efficacy variables are:
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.The percent change in PGTCS frequency per 28 days during the first 6 weeks of the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.The percent change in PGTCS frequency per 28 days during the first 6 weeks of the 
Treatment Period (Titration Period)
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Treatment Period (Titration Period)
UCB   28 Mar 2019  
Statistical Analysis Plan  SP0982  
 The percent change in PGTCS frequency per 28 days during the Treatment Period relative to 
the Combined Baseline Period 
 Change in days with absence seizures per 28 days during the Treatment Period relative to the Prospective Baseline Period 
 Percent change in days with absence seizures per 28 days during the first 6 weeks of the Treatment Period (Titration Period) relative to the Prospective Baseline Period 
 Percent change in days with absence seizures per 28 days during the Treatment Period relative to the Prospective Baseline Period 
 Percentage of subjects with at least a 50% reduction in absence seizure days compared to 
Prospective Baseline Period 
 Change in days with myoclonic seizures per 28 days during the Treatment Period relative to 
the Prospective Baseline Period 
 Percent change in days with myoclonic seizures per 28 days during the first 6 weeks of the Treatment Period (Titration Period) relative to the Prospective Baseline Period 
 Percent change in days with myoclonic seizures per 28 days during the Treatment Period relative to the Prospective Baseline Period 
 Percentage of subjects with at least a 50% reduction in myoclonic seizure days compared to Prospective Baseline Period 
 Seizure-free status (yes, no) for PGTCS for the first 12 weeks of the Treatment Period  
 Seizure-free status (yes, no) for PGTCS for the 24-week Treatment Period 
 Percentage of subjects with at least a 50% reduction in PGTCS frequency during the Titration Period compared to Combined Baseline Period 
 Percentage of subjects with at least a 50% reduction in PGTCS frequency during the first 12 weeks of the Treatment Period compared to Combined Baseline Period 
 Percentage of subjects with at least a 50% reduction in PGTCS frequency during the Treatment Period compared to Combined Baseline Period 
 Seizure-free status (yes, no) for all generalized seizure types for the first 12 weeks of the 
Treatment Period  
 Seizure-free status (yes, no) for all generalized seizure types for the 24-week Treatment 
Period  
 Change from Baseline in Patient-Weighted Quality of Life in Epilepsy Inventory-Form 31 
(QOLIE-31-P) subscale (Seizure Worry, Daily Activities/Social Functioning, 
Energy/Fatigue, Emotional Well-being, Mental Activity/Cognitive Functioning, Overall 
Quality of Life and Medication Effects) and total scores in subjects ≥18 years of age or 
change from Baseline in the Pediatric Quality of Life Inventory (PedsQL) subscale (Physical Functioning, Emotional Functioning, Social Functioning, and School Functioning) and total scores in subjects <18 years of age REDACTED COPY Percentage of subjects with at least a 50% reduction in myoclonic seizure days compared to 
REDACTED COPY Percentage of subjects with at least a 50% reduction in myoclonic seizure days compared to 
for the first 12 weeks of the Treatment Peri
REDACTED COPY for the first 12 weeks of the Treatment Peri
free status (yes, no) for PGTCS for the 24
REDACTED COPY free status (yes, no) for PGTCS for the 24
Percentage of subjects with at least a 50% reduction in PGTCS frequency during the REDACTED COPY Percentage of subjects with at least a 50% reduction in PGTCS frequency during the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Percentage of subjects with at least a 50% reduction in absence seizure days compared to 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Percentage of subjects with at least a 50% reduction in absence seizure days compared to 
Change in days with myoclonic seizures per 28 days during the Treatment Period relative to 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Change in days with myoclonic seizures per 28 days during the Treatment Period relative to 
Percent change in days with myoclonic seizures per 28 days during the first 6 weeks of the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Percent change in days with myoclonic seizures per 28 days during the first 6 weeks of the 
Treatment Period (Titration Period) relative to the Prospective Baseline Period
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Treatment Period (Titration Period) relative to the Prospective Baseline Period
Percent change in days with myoclonic seizures per 28 days during the Treatmen
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Percent change in days with myoclonic seizures per 28 days during the Treatmen
Percentage of subjects with at least a 50% reduction in myoclonic seizure days compared to 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Percentage of subjects with at least a 50% reduction in myoclonic seizure days compared to 
for the first 12 weeks of the Treatment Peri
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.for the first 12 weeks of the Treatment Peri
free status (yes, no) for PGTCS for the 24
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.free status (yes, no) for PGTCS for the 24
Percentage of subjects with at least a 50% reduction in PGTCS frequency during the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Percentage of subjects with at least a 50% reduction in PGTCS frequency during the 
Titration Period compared to Combined Baseline Period
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Titration Period compared to Combined Baseline Period
Percentage of subjects with at least a 50%
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Percentage of subjects with at least a 50%
weeks of the Treatment Period compared to Combined Baseline Period
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.weeks of the Treatment Period compared to Combined Baseline Period
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Percentage of subjects with at least a 50% reduction in PGTCS frequency during the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Percentage of subjects with at least a 50% reduction in PGTCS frequency during the 
Treatment Period compared to Combined Baseline Period
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Treatment Period compared to Combined Baseline Period
free status (yes, no) for all generalized seizure types for the f
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.free status (yes, no) for all generalized seizure types for the f
Treatment Period 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Treatment Period 
free status (yes, no) for all generalized seizure types for the 24
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.free status (yes, no) for all generalized seizure types for the 24
Period 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Period 
Change from Baseline in Patient
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Change from Baseline in Patient
(QOLIE
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.(QOLIE
Energy/Fatigue, Emotional Well
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Energy/Fatigue, Emotional Well
UCB   28 Mar 2019  
Statistical Analysis Plan  SP0982  
 Change from Baseline to end of treatment or early termination (ET) in the 3-Level EuroQol-5 
Dimension Quality of Life Assessment (EQ-5D-3L) visual analogue scale (VAS) score and 
change in utility as converted from the 5 dimensions (for subjects ≥12 years of age) 
 Healthcare resource use: medical procedures, hospitalizations, and healthcare provider visits 
 Number of working or school days lost by subject due to epilepsy 
 Number of days with help from a caregiver due to epilepsy 
Section 2.2.2 was revised from:  
The safety variables are: 
 Adverse events (AEs) as reported spontaneously by the subject and/or caregiver or observed 
by the investigator 
 Subject withdrawal due to AEs 
 Changes in hematology, chemistry, endocrinology, and urinalysis parameters 
 Changes in 12-lead electrocardiograms (ECGs) 
 Changes in vital sign measurements (ie, blood pressure [BP] and pulse rate) (including body 
weight and height) and physical and neurological examination findings 
 Incidence of new seizure types during the Treatment Period 
 Subjects with an increase of up to 25%, >25% to 50%, >50% to 75%, and >75% in the days with absence seizures per 28 days during the Treatment Period relative to the Prospective 
Baseline 
 Subjects with an increase of up to 25%, >25% to 50%, >50% to 75%, and >75% in the days 
with myoclonic seizures per 28 days during the Treatment Period relative to the Prospective Baseline 
And revised as follows: 
The safety variable is: 
 Adverse events (AEs) as reported spontaneously by the subject and/or caregiver or observed 
by the investigator 
Section 2.2.2.1 was revised from:  
Other safety variables are: 
 Behavioral assessment (Achenbach Child Behavior Checklist [CBCL]/1½-5 or CBCL/6-18) 
 Cognitive function assessment (Behavior Rating Inventory of Executive Function
®-Preschool 
Version [BRIEF -P] or Behavior Rating Inventory of Executive Function® [BRIEF])  
And revised as follows: 
Other safety variables are: 
 Subject withdrawal due to AEs 
 Incidence of new seizure types during the Treatment Period REDACTED COPY weight and height) and physical and neurological examination findings
REDACTED COPY weight and height) and physical and neurological examination findings
Incidence of new seizure types during the Treatment Period
REDACTED COPY Incidence of new seizure types during the Treatment Period
with an increase of up to 25%, >25% to 50%, >50% to 75%, and >75% in the days 
REDACTED COPY with an increase of up to 25%, >25% to 50%, >50% to 75%, and >75% in the days 
with absence seizures per 28 days during the Treatment Period relative to the Prospective 
REDACTED COPY with absence seizures per 28 days during the Treatment Period relative to the Prospective 
Subjects with an increase of up to 25%, >25% to 50%, >50% to 75%, and >75% in tREDACTED COPY Subjects with an increase of up to 25%, >25% to 50%, >50% to 75%, and >75% in t
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Adverse events (AEs) as reported spontaneously by the subject and/or caregiver 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Adverse events (AEs) as reported spontaneously by the subject and/or caregiver or observed 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.or observed 
Changes in hematology, chemistry, endocrinology, and urinalysis parameters
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Changes in hematology, chemistry, endocrinology, and urinalysis parameters
Changes in vital sign measurements (ie, blood pressure [BP] and pulse rate) (including body 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Changes in vital sign measurements (ie, blood pressure [BP] and pulse rate) (including body 
weight and height) and physical and neurological examination findings
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.weight and height) and physical and neurological examination findings
Incidence of new seizure types during the Treatment Period
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Incidence of new seizure types during the Treatment Period
with an increase of up to 25%, >25% to 50%, >50% to 75%, and >75% in the days 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.with an increase of up to 25%, >25% to 50%, >50% to 75%, and >75% in the days 
with absence seizures per 28 days during the Treatment Period relative to the Prospective 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.with absence seizures per 28 days during the Treatment Period relative to the Prospective 
Subjects with an increase of up to 25%, >25% to 50%, >50% to 75%, and >75% in t
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Subjects with an increase of up to 25%, >25% to 50%, >50% to 75%, and >75% in t
with myoclonic seizures per 28 days during the Treatment Period relative to the Prospective 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.with myoclonic seizures per 28 days during the Treatment Period relative to the Prospective 
Adverse events (AEs) as reported spontaneously by the subject and/or caregiver or observed 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Adverse events (AEs) as reported spontaneously by the subject and/or caregiver or observed 
nvestigator
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.nvestigator
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Section 2.2.2.1 was revised from:
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Section 2.2.2.1 was revised from:
Other safety variables are:
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Other safety variables are:
Behavioral assessment (Achenbach Child Behavior Checklist [CBCL]/1½
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Behavioral assessment (Achenbach Child Behavior Checklist [CBCL]/1½
Cognitive function assessment (Behavior Rating Inventory of Executive Function
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Cognitive function assessment (Behavior Rating Inventory of Executive Function
Version 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Version 
And revised as follows:
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.And revised as follows:
UCB   28 Mar 2019  
Statistical Analysis Plan  SP0982  
 Subjects with an increase of up to 25%, >25% to 50%, >50% to 75%, and >75% in the days 
with absence seizures per 28 days during the Treatment Period relative to the Prospective Baseline 
 Subjects with an increase of up to 25%, >25% to 50%, >50% to 75%, and >75% in the days 
with myoclonic seizures per 28 days during the Treatment Period relative to the Prospective 
Baseline 
 Changes in hematology, chemistry, endocrinology, and urinalysis parameters 
 Changes in 12-lead electrocardiograms (ECGs) 
 Changes in vital sign measurements (ie, blood pressure [BP] and pulse rate) (including body 
weight and height) and physical and neurological examination findings 
 Behavioral assessment (Achenbach Child Behavior Checklist [CBCL]/1½-5 or CBCL/6-18) 
 Cognitive function assessment (Behavior Rating Inventory of Executive Function
®-Preschool 
Version [BRIEF-P] or Behavior Rating Inventory of Executive Function® [BRIEF]) for 
pediatric subjects only 
Section 2.3.1, 2nd paragraph was revised from:  
Approximately 200 subjects (100 per treatment arm) will be randomized to achieve a total of 
125 events, where an event is defined as the occurrence of the second PGTC seizure. 
Has been revised to:  
Up to 250 subjects across 150 to 180 sites in the US, Europe, Asia, and Australia, with possible 
extension to other countries and regions, are planned to be randomized in this study to see 125 
events. An event is the occurrence of each subject’s second PGTCS. The maximum duration of 
study medication administration is 28 weeks. The study will last a maximum of 36 weeks per 
subject.  
Section 2.3.1, 5th paragraph, the following sentence was added:  
Seizures reported on the Historical Seizure Count CRF with incomplete dates will be assumed to 
have occurred with the 12-week Historical Baseline Period when checking eligibility for the study and inclusion in baseline PGTCS frequency per 28 days. 
Section 2.3.1, 2
nd paragraph from end, newly states:  
If the 125th event occurs while the subject is still participating in the study, the subject can: 
 Complete the Visit 10 (Week 24) or ET Visit (if the next scheduled visit is not Visit 10) and 
choose to continue in EP0012 by completing a blinded transition followed by a Final Clinic Visit. 
 Discontinue from the study by completing the Visit 10 (Week 24) or ET Visit (if the next scheduled visit is not Visit 10) and an up to 4-week blinded taper followed by an End of Taper visit.  
Section 2.4, 2
nd paragraph was revised from:  
This is an event-driven study. The study will be closed to enrollment once 125 events have been observed. If 125 events are observed prior to 200 randomized subjects, then enrollment will stop REDACTED COPY Approximately 200 subjects (100 per treatment arm) will be randomized to achieve a 
REDACTED COPY Approximately 200 subjects (100 per treatment arm) will be randomized to achieve a 
events, where an event is defined as the occurrence of the second PGTC seizure.
REDACTED COPY events, where an event is defined as the occurrence of the second PGTC seizure.
Up to 250 subjects across 150 to 180 sites in the US, Europe, Asia, and Australia, with possible 
REDACTED COPY Up to 250 subjects across 150 to 180 sites in the US, Europe, Asia, and Australia, with possible 
extension to other countries and regions, are
REDACTED COPY extension to other countries and regions, are planned to be randomized in this study to see 125 
REDACTED COPY planned to be randomized in this study to see 125 
events. An event is the occurrence of each subject’s second PGTCS. The maximum duration of 
REDACTED COPY events. An event is the occurrence of each subject’s second PGTCS. The maximum duration of 
study medication administration is 28 weeks. The study will last a maximum of 36 weeks per REDACTED COPY study medication administration is 28 weeks. The study will last a maximum of 36 weeks per 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.d pulse rate) (including body 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.d pulse rate) (including body 
5 or CBCL/6
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.5 or CBCL/6
Cognitive function assessment (Behavior Rating Inventory of Executive Fu
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Cognitive function assessment (Behavior Rating Inventory of Executive Fu nction
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.nction
P] or Behavior Rating Inventory of Executive Function
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.P] or Behavior Rating Inventory of Executive Function®
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.®
Approximately 200 subjects (100 per treatment arm) will be randomized to achieve a 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Approximately 200 subjects (100 per treatment arm) will be randomized to achieve a 
events, where an event is defined as the occurrence of the second PGTC seizure.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.events, where an event is defined as the occurrence of the second PGTC seizure.
Up to 250 subjects across 150 to 180 sites in the US, Europe, Asia, and Australia, with possible 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Up to 250 subjects across 150 to 180 sites in the US, Europe, Asia, and Australia, with possible 
planned to be randomized in this study to see 125 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.planned to be randomized in this study to see 125 
events. An event is the occurrence of each subject’s second PGTCS. The maximum duration of 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.events. An event is the occurrence of each subject’s second PGTCS. The maximum duration of 
study medication administration is 28 weeks. The study will last a maximum of 36 weeks per 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.study medication administration is 28 weeks. The study will last a maximum of 36 weeks per 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.paragraph, the following sentence was added:
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.paragraph, the following sentence was added:
Seizures reported on the Historical Seizure Count CRF with incomplete dates will be assumed to 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Seizures reported on the Historical Seizure Count CRF with incomplete dates will be assumed to 
week Historical Baseline Period when checking eligibility for the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.week Historical Baseline Period when checking eligibility for the 
inclusion in baseline PGTCS frequency per 28 days.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.inclusion in baseline PGTCS frequency per 28 days.
paragraph from end, newly states:
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.paragraph from end, newly states:
event occurs while the subject is still participating in the study, the subject can:
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.event occurs while the subject is still participating in the study, the subject can:
Complete the Visit 10 (Week 24) or ET Visit (if the ne
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Complete the Visit 10 (Week 24) or ET Visit (if the ne
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.choose to continue in EP0012 by completing a blinded transition followed by a Final Clinic 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.choose to continue in EP0012 by completing a blinded transition followed by a Final Clinic 
Visit.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Visit.

This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Discontinue from the study by completing the Visit 10 (Week 24) or ET Visit (if the next 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Discontinue from the study by completing the Visit 10 (Week 24) or ET Visit (if the next 
UCB   28 Mar 2019  
Statistical Analysis Plan  SP0982  
and fewer than 200 subjects will be randomized. However, if 125 events are not observed 
after 200 subjects are randomized, then the study will continue to enroll up to a maximum of 
250 subjects randomized or 125 events, whichever occurs first. 
Has been revised to:  
This is an event-driven study. Enrollment in the study will continue up to 125 events occurring 
or a maximum of 250 subjects randomized, whichever comes first. 
Section 3.1 was revised from:  
Statistical analysis and generation of tables, figures, subject data listings, and statistical output 
will be performed using SAS® Version 9.4 or higher.  
Descriptive statistics will be used to provide an overview of the primary, secondary, and other 
variable results. For categorical parameters, the number and percentage of subjects in each 
category will be presented. The denominator for percentages will be based on the number of subjects appropriate for the purpose of the analysis. Unless otherwise noted, all percentages will 
be displayed to 1 decimal place except 100% which will be displayed to 0 decimal places. For 
continuous parameters, descriptive statistics will include number of subjects, mean, standard deviation, median, minimum, and maximum.  
By-visit summaries will not include data from unscheduled clinic visits unless otherwise stated. 
Data provided at these visits will be included in subject data listings. Subject data listings will be 
provided and will present source data and key derived variables for statistical analyses. 
Was revised to:  
Statistical analysis and generation of tables, figures, subject data listings, and statistical output 
will be performed using SAS® Version 9.4 or higher. All tables and listings will use Courier 
New font size 9. 
Descriptive statistics will be used to provide an overview of the primary, secondary, and other 
variable results. For categorical parameters, the number and percentage of subjects in each 
category will be presented. The denominator for percentages will be based on the number of 
subjects appropriate for the purpose of the analysis. Unless otherwise noted, all percentages will be displayed to 1 decimal place. No percentage will be displayed for zero counts, and no decimal 
will be presented when the percentage is 100%. For continuous parameters, descriptive statistics 
will include number of subjects, mean, standard deviation, median, minimum, and maximum.  
Decimal places for descriptive statistics will always apply the following rules: 
 “n” will be an integer 
 Mean, SD and median will use 1 additional decimal place compared to the original data. 
 Minimum and maximum will have the same number of decimal places as the original value. 
By-visit summaries will not include data from unscheduled clinic visits unless otherwise stated. 
Data provided at these visits will be included in subject data listings. A complete set of data 
listings containing all documented data and all calculated data (eg, change from Baseline) will be 
generated.  
Section 3.2.1, Analysis Time Points, the following sentence was inserted:  REDACTED COPY t summaries will not include data from unscheduled clinic visits unless otherwise stated. 
REDACTED COPY t summaries will not include data from unscheduled clinic visits unless otherwise stated. 
Data provided at these visits will be included in subject data listings. Subject data listings will be 
REDACTED COPY Data provided at these visits will be included in subject data listings. Subject data listings will be 
provided and will present source data and key derived variables
REDACTED COPY provided and will present source data and key derived variables
Statistical analysis and generation of tables, figures, subject data listings, and statistical output 
REDACTED COPY Statistical analysis and generation of tables, figures, subject data listings, and statistical output 
will be performed using SAS® Version 9.4 or higher. All tables and listings will use Courier 
REDACTED COPY will be performed using SAS® Version 9.4 or higher. All tables and listings will use Courier 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.tatistical analysis and generation of tables, figures, subject data listings, and statistical output 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.tatistical analysis and generation of tables, figures, subject data listings, and statistical output 
Descriptive statistics will be used to provide an overview of the primary, secondary, and other 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Descriptive statistics will be used to provide an overview of the primary, secondary, and other 
le results. For categorical parameters, the number and percentage of subjects in each 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.le results. For categorical parameters, the number and percentage of subjects in each 
category will be presented. The denominator for percentages will be based on the number of 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.category will be presented. The denominator for percentages will be based on the number of 
subjects appropriate for the purpose of the analysis. Unless otherwise noted, a
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.subjects appropriate for the purpose of the analysis. Unless otherwise noted, a ll percentages will 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.ll percentages will 
be displayed to 1 decimal place except 100% which will be displayed to 0 decimal places. For 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.be displayed to 1 decimal place except 100% which will be displayed to 0 decimal places. For 
continuous parameters, descriptive statistics will include number of subjects, mean, standard 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.continuous parameters, descriptive statistics will include number of subjects, mean, standard 
t summaries will not include data from unscheduled clinic visits unless otherwise stated. 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.t summaries will not include data from unscheduled clinic visits unless otherwise stated. 
Data provided at these visits will be included in subject data listings. Subject data listings will be 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Data provided at these visits will be included in subject data listings. Subject data listings will be 
provided and will present source data and key derived variables
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.provided and will present source data and key derived variables
Statistical analysis and generation of tables, figures, subject data listings, and statistical output 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Statistical analysis and generation of tables, figures, subject data listings, and statistical output 
will be performed using SAS® Version 9.4 or higher. All tables and listings will use Courier 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.will be performed using SAS® Version 9.4 or higher. All tables and listings will use Courier 
escriptive statistics will be used to provide an overview of the primary, secondary, and other 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.escriptive statistics will be used to provide an overview of the primary, secondary, and other 
variable results. For categorical parameters, the number and percentage of subjects in each 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.variable results. For categorical parameters, the number and percentage of subjects in each 
category will be presented. The denominator for percentages will be b
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.category will be presented. The denominator for percentages will be b
subjects appropriate for the purpose of the analysis. Unless otherwise noted, all percentages will 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.subjects appropriate for the purpose of the analysis. Unless otherwise noted, all percentages will 
be displayed to 1 decimal place. No percentage will be displayed for zero counts, and no decimal 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.be displayed to 1 decimal place. No percentage will be displayed for zero counts, and no decimal 
will be presented when the percentage 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.will be presented when the percentage 
will include number of subjects, mean, standard deviation, median, minimum, and maximum. 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.will include number of subjects, mean, standard deviation, median, minimum, and maximum. 
Decimal places for descriptive statistics will always apply the following rules:
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Decimal places for descriptive statistics will always apply the following rules:
“n” will be an integer
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.“n” will be an integer
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Mea
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Mea
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.n, SD and median will use 1 additional decimal place compared to the original data.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.n, SD and median will use 1 additional decimal place compared to the original data.
Minimum and maximum will have the same number of decimal places as the original value.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Minimum and maximum will have the same number of decimal places as the original value.
By
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Byvisit summaries will not include data from unscheduled clinic visits unless otherw
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.visit summaries will not include data from unscheduled clinic visits unless otherw
Data provided at these visits will be included in subject data listings. A complete set of data 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Data provided at these visits will be included in subject data listings. A complete set of data 
UCB   28 Mar 2019  
Statistical Analysis Plan  SP0982  
First 12 weeks: this is defined as the Titration Period + the first 6 weeks of the Maintenance 
Period 
Section 3.2.2, Seizure cluster, this section was moved to occur earlier in Section 3 and the text 
was revised from:  
For PGTC seizures, if a seizure cluster is reported, it will be assigned to the most dominant ILAE seizure type and the frequency will be set to 2 times the number of clusters reported. 
Was revised to:  
If a seizure cluster is reported, it will be assigned to the International League Against Epilepsy 
(ILAE) seizure type reported and the frequency will be set to 2 times the number of clusters reported. 
Section 3.2.3, Event, was added:  
In the primary efficacy analysis, an event for analysis purposes is: 
 The 2
nd PGTCS  
While keeping in mind the definition of seizure clusters in Section 3.2.2. 
For the primary and secondary efficacy analyses, these endpoints will be assessed using the at 
most the first 166 days, which is the 24-week Treatment Period minus a protocol-allowed 2 day 
window.  For all other efficacy parameters, all data reported during the Treatment Period will be used in the analysis. 
The primary efficacy endpoint, time to event, is defined as the “stop date” - the date of first dose 
of study drug + 1 day where the “stop date” is the first of the following to occur: 
 date of the event,  
 date of the premature discontinuation,  
 date of last dose of study medication in the Treatment Period, 
 date of the completion of the Treatment Period,  
 date of the 125
th event,  
 Day 166 
The same algorithm applies for the other secondary endpoint, where time to event, is replaced by 
time to 1st PGTCS.  
Section 3.2.4, Censoring, was revised from:  
Subjects who complete the Treatment Period without having a second PGTC seizure during the 
Treatment Period will be censored. If the subject’s Treatment Period participation is less than 
24 weeks minus the visit window for Visit 10, they will be censored on the date of the last dose of study drug. If the subject’s Treatment Period participation is greater than 24 weeks minus the 
visit window for Visit 10, they will be censored as of 24 weeks minus the visit window for Visit 
10.  
Subjects who have important protocol deviations for inappropriate use of AEDs and 
benzodiazepines will be censored. The important protocol deviations and rules for censoring due REDACTED COPY week Treatment Period minus a protocol
REDACTED COPY week Treatment Period minus a protocol
window.  For all other efficacy parameters, all data reported during the Treatment Period will be 
REDACTED COPY window.  For all other efficacy parameters, all data reported during the Treatment Period will be 
fficacy endpoint, time to event, is defined as the “stop date” 
REDACTED COPY fficacy endpoint, time to event, is defined as the “stop date” 
of study drug + 1 day where the “stop date” is the first of the following to occur:
REDACTED COPY of study drug + 1 day where the “stop date” is the first of the following to occur:
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.o the International League Against Epilepsy 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.o the International League Against Epilepsy 
(ILAE) seizure type reported and the frequency will be set to 2 times the number of clusters 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.(ILAE) seizure type reported and the frequency will be set to 2 times the number of clusters 
3.2.2
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.3.2.2
For the primary and secondary efficacy analyses, these endpoints w
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.For the primary and secondary efficacy analyses, these endpoints w ill be assessed using the at 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.ill be assessed using the at 
week Treatment Period minus a protocol
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.week Treatment Period minus a protocol
window.  For all other efficacy parameters, all data reported during the Treatment Period will be 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.window.  For all other efficacy parameters, all data reported during the Treatment Period will be 
fficacy endpoint, time to event, is defined as the “stop date” 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.fficacy endpoint, time to event, is defined as the “stop date” 
of study drug + 1 day where the “stop date” is the first of the following to occur:
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.of study drug + 1 day where the “stop date” is the first of the following to occur:
date of the premature discontinuation, 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.date of the premature discontinuation, 
dy medication in the Treatment Period,
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.dy medication in the Treatment Period,
date of the completion of the Treatment Period, 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.date of the completion of the Treatment Period, 
event, 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.event, 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.The same algorithm applies for the other secondary endpoint, where time to event, is replaced by 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.The same algorithm applies for the other secondary endpoint, where time to event, is replaced by 
PGTCS.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.PGTCS.
Section 3.2.4, Cen
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Section 3.2.4, Cen
Subjects who complete the Treatment Period without having a second PGTC seizure during the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Subjects who complete the Treatment Period without having a second PGTC seizure during the 
Treatment Period will be censored. If the subject’s Treatment Period participation is less than 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Treatment Period will be censored. If the subject’s Treatment Period participation is less than 
24
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.24weeks minus the visit window for Visit 1
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.weeks minus the visit window for Visit 1
of study drug. If the subject’s Treatment Period participation is greater than 24 weeks minus the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.of study drug. If the subject’s Treatment Period participation is greater than 24 weeks minus the 
visit window for Visit 10, they will be censored as of 24 weeks minus the visit window for Visit 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.visit window for Visit 10, they will be censored as of 24 weeks minus the visit window for Visit 
UCB   28 Mar 2019  
Statistical Analysis Plan  SP0982  
to important protocol deviations will be determined and documented prior to the database lock 
and unblinding. 
Has been changed to:  
For the primary and secondary efficacy analyses, a Treatment Period of 166 days will be utilized. 
The censoring for the primary efficacy analysis will be as follows: 
 Subjects who complete the Treatment Period without having an event during the Treatment 
Period will be censored as of Day 167.  
 If the subject’s Treatment Period participation is less than or equal to 166 days (premature 
discontinuation), their PGTCS information will be censored on the date after the last dose of study drug.  
 If the subject’s Treatment Period participation is greater than 166 days, their PGTCS information will be censored as of Day 167.  
 For the subjects who are ongoing in the study when the 125
th event occurs, their PGTCS 
information for the primary efficacy endpoint analysis will be censored as of the day after the 125
th event, even if the subjects experience an event after the date of the 125th event but 
before 166 days of treatment is completed. 
 Only 125 events will be included in the primary efficacy endpoint analyses. In case of ties on the same date in reporting the 125
th event, the first event reported to IRT will be deemed the 
125th event.  Data after the 125th event will be censored. 
Censoring for time to 1st PGTCS  will be calculated in a similar manner, except using the date of 
the 1st PGTCS instead of the date of the event. For subjects who are ongoing in the study when 
the 125th event occurs, the time to 1st PGTCS information will be censored in the same manner 
as the time to event information (ie., censor all PGTCS information beyond the date of the 125th 
event). 
Section 3.2.5, AEDs and Benzodiazepines, the 1st paragraph has been revised from:  
Antiepileptic drugs and benzodiazepines (medications used for rescue) will be collected on the 
concomitant and prior medication case report form (CRF) for AEDs. At study entry, a subject 
should be taking 1 to 2 non-benzodiazepines or 1 to 3 AEDs where only 1 of the AEDs is 
identified as a benzodiazepine. This dosing regimen must be stable for at least 28 days prior to Visit 1. The subject must maintain this AED dosing regimen throughout the Prospective Baseline and the Treatment Period. 
Has been changed to:  
AEDs and benzodiazepines (medications used for rescue) will be collected on the concomitant 
and prior medication case report form (CRF) for AEDs. At study entry, a subject should be 
taking a stable dose of 1 to 2 non-benzodiazepines marketed AEDs or 2 to 3 AEDs (with only 1 of the AEDs is identified as a benzodiazepine). This dosing regimen must be stable for at least 28 
days prior to Visit 1. The subject must maintain this AED dosing regimen throughout the 
Prospective Baseline and the Treatment Period with or without additional concurrent stable VNS. Vagus nerve stimulation must have been in place for at least 6 months prior to Visit 1 with REDACTED COPY Only 125 events will be included in the primary efficacy endpoint analyses. In case of ties on 
REDACTED COPY Only 125 events will be included in the primary efficacy endpoint analyses. In case of ties on 
event, the first event reported to IRT will be deemed the 
REDACTED COPY event, the first event reported to IRT will be deemed the 
event will be censored.
REDACTED COPY event will be censored.
will be calculated in a similar manner, except using the date of 
REDACTED COPY will be calculated in a similar manner, except using the date of 
PGTCS instead of the date of the event. For subjects who are ongoing in the study when 
REDACTED COPY PGTCS instead of the date of the event. For subjects who are ongoing in the study when 
PGTCS information will be cenREDACTED COPY PGTCS information will be cen
as the time to event information (ie., censor all PGTCS information beyond the date of the 125 REDACTED COPY as the time to event information (ie., censor all PGTCS information beyond the date of the 125
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.If the subject’s Treatment Period participation is less than or equal to 166 days (premature 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.If the subject’s Treatment Period participation is less than or equal to 166 days (premature 
discontinuation), their PGTCS information will be censored on the date after the last dose of 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.discontinuation), their PGTCS information will be censored on the date after the last dose of 
er than 166 days, their PGTCS 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.er than 166 days, their PGTCS 
event occurs, their PGTCS 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.event occurs, their PGTCS 
information for the primary efficacy endpoint analysis will be censored as of the day after the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.information for the primary efficacy endpoint analysis will be censored as of the day after the 
event, even if the subjects experience an event after the date of the 125
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.event, even if the subjects experience an event after the date of the 125
Only 125 events will be included in the primary efficacy endpoint analyses. In case of ties on 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Only 125 events will be included in the primary efficacy endpoint analyses. In case of ties on 
event, the first event reported to IRT will be deemed the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.event, the first event reported to IRT will be deemed the 
event will be censored.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.event will be censored.
will be calculated in a similar manner, except using the date of 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.will be calculated in a similar manner, except using the date of 
PGTCS instead of the date of the event. For subjects who are ongoing in the study when 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.PGTCS instead of the date of the event. For subjects who are ongoing in the study when 
PGTCS information will be cen
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.PGTCS information will be cen
as the time to event information (ie., censor all PGTCS information beyond the date of the 125
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.as the time to event information (ie., censor all PGTCS information beyond the date of the 125
Section 3.2.5, AEDs and Benzodiazepines, the 1
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Section 3.2.5, AEDs and Benzodiazepines, the 1
Antiepileptic drugs and benzodiazepines (med
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Antiepileptic drugs and benzodiazepines (med
concomitant and prior medication case report form (CRF) for AEDs. At study entry, a subject 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.concomitant and prior medication case report form (CRF) for AEDs. At study entry, a subject 
should be taking 1 to 2 non
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.should be taking 1 to 2 non -
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.-benzodiazepines or 1 to 3 AEDs where only 1 of the AEDs is 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.benzodiazepines or 1 to 3 AEDs where only 1 of the AEDs is 
identified as a benzodiaze
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.identified as a benzodiaze pine. This dosing regimen must be stable for at least 28 days prior to 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.pine. This dosing regimen must be stable for at least 28 days prior to 
Visit 1. The subject must maintain this AED dosing regimen throughout the Prospective Baseline 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Visit 1. The subject must maintain this AED dosing regimen throughout the Prospective Baseline 
and the Treatment Period.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.and the Treatment Period.
Has been changed to:
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Has been changed to:
AEDs and benzodiazepines (medications used 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.AEDs and benzodiazepines (medications used 
and prior medication case report form (CRF) for AEDs. At study entry, a subject should be 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.and prior medication case report form (CRF) for AEDs. At study entry, a subject should be 
taking a stable dose of 1 to 2 non
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.taking a stable dose of 1 to 2 non
of the AEDs is identifie
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.of the AEDs is identifie
days prior to Visit 1. The subject must maintain this AED dosing regimen throughout the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.days prior to Visit 1. The subject must maintain this AED dosing regimen throughout the 
UCB   28 Mar 2019  
Statistical Analysis Plan  SP0982  
constant settings for at least 28 days prior to Visit 1 and must remain unchanged during the 
Treatment Period. 
Section 3.2.5.1, Prohibited concomitant treatments, has been added:  
The following medications/therapies are prohibited during the Treatment Period: 
 Clozapine 
 Any MAO inhibitors 
 Barbiturates (except as antiepileptic medications) 
 Unstable dosing of non-benzodiazepine anxiolytics or once-daily hypnotics 
 Herbal medicines for epilepsy 
The study physician will review the concomitant medications and flag prohibited medications. Section 3.2.8, Month, has been added:  
A month is defined as 28 days. 
Section 3.3, Definition of baseline values, the 2
nd paragraph had been revised from:  
Baseline values for seizure data will be based on data collected during the Combined Baseline 
Period, excluding data collected on the day of Visit 2. 
Has been revised to:  
For PGTCS efficacy analyses, the data used for Baseline calculations come from the Combined 
Baseline Period. For absence and myoclonic seizure analyses, the data used for Baseline 
calculations come from the Prospective Baseline Period only.  
Section 3.9, Changes to protocol-defined analyses, has been revised from:  
There are no changes to analyses specified in the protocol. 
Has been revised to:  
For the key secondary efficacy variable, the Protocol Section 4.1.2 says that seizure freedom for 
PGTCS during the 24-week Treatment Period, will be estimated using Kaplan-Meier analysis. 
The analysis of the key secondary endpoint has been clarified to assess the seizure-free rate using an extended Mantel-Haenszel technique which combines Kaplan-Meier estimates within each stratum. The extended Mantel-Haenszel technique is a randomization-based nonparametric method that provides a more robust method to assess seizure freedom. 
Section 4.2.1, Missing seizure diary days, 2
nd paragraph has been revised from:  
For the purpose of the derivation of the primary endpoint of time to second PGTC seizure and 
for PGTC seizure-free status, if there are seizure counts reported as “not done” on a specific day, 
then the seizure count will be assumed to be zero on that date.  
Has been changed to:  
For the purpose of the derivation of the primary efficacy endpoint, secondary efficacy endpoints 
and for PGTC seizure-free status, if there are PGTCS counts reported as “not done” on a specific day, then the PGTCS count will be assumed to be zero on that date.  REDACTED COPY Baseline values for seizure data will be based on data collected during the Combined Baseline 
REDACTED COPY Baseline values for seizure data will be based on data collected during the Combined Baseline 
Period, excluding data collected on the day of Visit 2.
REDACTED COPY Period, excluding data collected on the day of Visit 2.
For PGTCS efficacy analyses, the data used for Baseline calculations
REDACTED COPY For PGTCS efficacy analyses, the data used for Baseline calculations
Baseline Period. For absence and myoclonic seizure analyses, the data used for Baseline 
REDACTED COPY Baseline Period. For absence and myoclonic seizure analyses, the data used for Baseline 
calculations come from the Prospective Baseline Period only. 
REDACTED COPY calculations come from the Prospective Baseline Period only. 
defined analyses, has been revised from:REDACTED COPY defined analyses, has been revised from:
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.The study physician will review the concomitant medications and flag prohibited medications.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.The study physician will review the concomitant medications and flag prohibited medications.
paragraph had be
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.paragraph had be en revised from:
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.en revised from:
Baseline values for seizure data will be based on data collected during the Combined Baseline 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Baseline values for seizure data will be based on data collected during the Combined Baseline 
For PGTCS efficacy analyses, the data used for Baseline calculations
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.For PGTCS efficacy analyses, the data used for Baseline calculations
Baseline Period. For absence and myoclonic seizure analyses, the data used for Baseline 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Baseline Period. For absence and myoclonic seizure analyses, the data used for Baseline 
calculations come from the Prospective Baseline Period only. 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.calculations come from the Prospective Baseline Period only. 
defined analyses, has been revised from:
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.defined analyses, has been revised from:
are no changes to analyses specified in the protocol.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.are no changes to analyses specified in the protocol.
For the key secondary efficacy variable, the Protocol Section 4.1.2 says that seizure freedom for 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.For the key secondary efficacy variable, the Protocol Section 4.1.2 says that seizure freedom for 
week Treatment Period, will be estimated using Kaplan
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.week Treatment Period, will be estimated using Kaplan
The analysis of the key secondary endpoint has been clarified to assess the seizure
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.The analysis of the key secondary endpoint has been clarified to assess the seizure
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.an extended Mantel
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.an extended Mantel
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.-
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.-Haenszel technique which combines Kaplan
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Haenszel technique which combines Kaplan
stratum. The extended Mantel
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.stratum. The extended Mantel
method that provides a more robust method to assess seizure freedom.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.method that provides a more robust method to assess seizure freedom.
Section 4.2.1, Missing seizure diary days, 2
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Section 4.2.1, Missing seizure diary days, 2
For the purpose of the derivation of the primary endpoint of time to second PGTC 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.For the purpose of the derivation of the primary endpoint of time to second PGTC 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.for PGTC seizure
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.for PGTC seizure
then the seizure count will be assumed to be zero on that date. 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.then the seizure count will be assumed to be zero on that date. 
Has been changed to:
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Has been changed to:
UCB   28 Mar 2019  
Statistical Analysis Plan  SP0982  
Section 4.2.2, Incomplete dates for first epilepsy diagnosis, the following final imputation note 
was added:  
 Missing the day, month and year: 
No imputation will be done. 
Section 4.4, Multicenter studies, was revised from:  
Due to the small number of subjects per site, pooling the sites for statistical analysis will be 
necessary. All sites will be pooled together for analysis. 
has been changed to:  
Due to the small number of subjects per site, all sites will be pooled together for analysis. There 
will be no planned analyses for multi-center effects. 
Secti on 4.8, Examination of subgroups, was revised from:  
Descriptive statistics by all subgroups for the primary efficacy variable will be presented for the 
FAS.  Disposition will be presented by age subgroup for the SS and FAS.  Exposure will be 
presented by age and region subgroups for the SS.  Overall TEAE incidence will be presented by age subgroup for the SS.  Selected disposition and safety analyses will be presented by age at 
enrollment for the purpose of addressing requirements set in Article 46 of the European Pediatric 
Regulation (see Section  12.5  for further details). 
The subgroups to be examined include: 
 Age at enrollment (≥ 4 to <12 years of age, ≥12 to <18 years of age, 18 to <65, ≥65) 
 Racial group (white, non-white) 
 Gender (male, female) 
 Region   North America: United States 
 Latin America: Brazil, Mexico 
 Western Europe: Belgium, France, Germany, Italy, Portugal, Spain 
 Eastern Europe: Bulgaria, Czech Republic, Hungary, Poland, Romania, Russia, Slovakia, 
Turkey 
 Asia/Pacific/Other: Australia, Israel, Japan, South Korea, Taiwan 
 Baseline PGTC seizure frequency (≤2 per 28 days and >2 per 28 days in the Combined Baseline Period) 
 Concomitant AEDs at study entry, ie the total number of AEDs and benzodiazepines the subject is taking when enrolled into the study (1, 2, 3). 
Separate age sub-groupings are used for the purpose of summarizing the following scales:  
 PedsQL (4 years, ≥5 to ≤7 years, ≥8 to ≤12 years, and ≥13 to ≤18 years) 
 Achenbach CBCL (4 to 5 years, 6 to 18 years) REDACTED COPY enrollment for the purpose of addressing requirements set in Article 46 of the E
REDACTED COPY enrollment for the purpose of addressing requirements set in Article 46 of the E
Age at enrollment (≥ 4 to <12 years of ag
REDACTED COPY Age at enrollment (≥ 4 to <12 years of ag e, ≥12 to <18 years of age, 18 to <65, ≥65)
REDACTED COPY e, ≥12 to <18 years of age, 18 to <65, ≥65)
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Due to the small number of subjects per site, all sites will be pooled together for analysis. There 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Due to the small number of subjects per site, all sites will be pooled together for analysis. There 
Descriptive statistics by all subgroups for the primary efficacy variable will be presented for the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Descriptive statistics by all subgroups for the primary efficacy variable will be presented for the 
FAS.  Disposition will be presented by age subgroup for the SS and FAS.  Exposure will be 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.FAS.  Disposition will be presented by age subgroup for the SS and FAS.  Exposure will be 
ge and region subgroups for the SS.  Overall TEAE incidence will be presented by 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.ge and region subgroups for the SS.  Overall TEAE incidence will be presented by 
age subgroup for the SS.  Selected disposition and safety analyses will be presented by age at 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.age subgroup for the SS.  Selected disposition and safety analyses will be presented by age at 
enrollment for the purpose of addressing requirements set in Article 46 of the E
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.enrollment for the purpose of addressing requirements set in Article 46 of the E
e, ≥12 to <18 years of age, 18 to <65, ≥65)
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.e, ≥12 to <18 years of age, 18 to <65, ≥65)
North America: United States
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.North America: United States
Latin America: Brazil, Mexico
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Latin America: Brazil, Mexico
Western Europe: Belgium, France, Germany, Italy, Portugal, Spain
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Western Europe: Belgium, France, Germany, Italy, Portugal, Spain
Eastern Europe: Bulgaria, 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Eastern Europe: Bulgaria, 
Asia/Pacific/Other: Australia, Israel, Japan, South Korea, Taiwan
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Asia/Pacific/Other: Australia, Israel, Japan, South Korea, Taiwan
Baseline PGTC seizure frequency (≤2 per 28 days and >2 per 28 days in the Combined 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Baseline PGTC seizure frequency (≤2 per 28 days and >2 per 28 days in the Combined 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Baseline Period)
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Baseline Period)
Concomitant AEDs at stu
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Concomitant AEDs at stu
subject is taking when enrolled into the study (1, 2, 3).
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.subject is taking when enrolled into the study (1, 2, 3).
UCB   28 Mar 2019  
Statistical Analysis Plan  SP0982  
 BRIEF -P/BRIEF (4 to <5 years, ≥5 years). 
Has been changed to:  
Descriptive statistics by all subgroups for the primary efficacy variable will be presented for the 
FAS.  Disposition will be presented by age subgroup for the SS and FAS.  Exposure will be 
presented by age and region subgroups for the SS.  Overall TEAE incidence will be presented by age subgroup for the SS.  Selected disposition and safety analyses will be presented by 
Development for the purpose of addressing requirements set in Article 46 of the European 
Pediatric Regulation (see Section  12.5 for further details). 
The subgroups to be examined include: 
 Age at enrollment (≥ 4 to <12 years of age, ≥12 to <18 years of age, 18 to <65, ≥65) 
 Development (Pediatric [≥4 to < 18 years old], Adult [≥18 years old]) 
 Racial group (white, non-white) 
 Gender (male, female) 
 Region   North America: United States, Puerto Rico 
 Latin America: Brazil, Mexico 
 Western/Central Europe: Belgium, Czech Republic, France, Germany, Hungary, Italy, 
Poland, Portugal, Slovakia, Spain 
 Eastern Europe: Bulgaria,  Romania, Russia,  Turkey 
 Asia/Pacific/Other: Australia, China, Israel, Japan, South Korea, Taiwan 
 Baseline PGTCS frequency (≤2 per 28 days and >2 per 28 days in the Combined Baseline Period) 
 Concomitant AEDs at study entry, ie the total number of AEDs and benzodiazepines the subject is taking when enrolled into the study (1, 2, 3). 
Separate age sub-groupings are used for the purpose of summarizing the following scales:  
 PedsQL (4 years, ≥5 to ≤7 years, ≥8 to ≤12 years, and ≥13 to ≤18 years) 
 Achenbach CBCL (4 to 5 years, 6 to 18 years) 
 BRIEF -P/BRIEF (4 to <5 years, ≥5 years). 
Section 4.9, Stratum Pooling has been moved from a later section and the algorithm modified from saying:  
The analysis will use the stratification factors from IRT. If 5 events or less (ie, less than 6 
subjects who had a second PGTC seizure) occur in a stratum, then data will be pooled by 
Baseline PGTC seizure frequency for analysis as follows:  
1. If 5 events or less occur in the group of subjects who are ≥12 and <18 years of age with ≤2 
Baseline PGTC seizures per 28 days, then this group will be combined for analysis with 
either the group of subjects who are ≥4 to <12 years of age with ≤2 Baseline PGTC seizures REDACTED COPY Western/Central Europe: Belgium, Czech Republic, France, Germany, Hungary, Italy, 
REDACTED COPY Western/Central Europe: Belgium, Czech Republic, France, Germany, Hungary, Italy, 
Eastern Europe: Bulgaria,  Romania, Russia,  Turkey
REDACTED COPY Eastern Europe: Bulgaria,  Romania, Russia,  Turkey
stralia, China, Israel, Japan, South Korea, TaiwanREDACTED COPY stralia, China, Israel, Japan, South Korea, Taiwan
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Age at enrollment (≥ 4 to <12 years of age, ≥12 to <18 years of age, 18 to <65, ≥65)
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Age at enrollment (≥ 4 to <12 years of age, ≥12 to <18 years of age, 18 to <65, ≥65)
Western/Central Europe: Belgium, Czech Republic, France, Germany, Hungary, Italy, 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Western/Central Europe: Belgium, Czech Republic, France, Germany, Hungary, Italy, 
Eastern Europe: Bulgaria,  Romania, Russia,  Turkey
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Eastern Europe: Bulgaria,  Romania, Russia,  Turkey
stralia, China, Israel, Japan, South Korea, Taiwan
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.stralia, China, Israel, Japan, South Korea, Taiwan
Baseline PGTCS frequency (≤2 per 28 days and >2 per 28 days in the Combined Baseline 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Baseline PGTCS frequency (≤2 per 28 days and >2 per 28 days in the Combined Baseline 
Concomitant AEDs at study entry, ie the total number of AEDs and benzodiazepines the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Concomitant AEDs at study entry, ie the total number of AEDs and benzodiazepines the 
subject is taking when enro
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.subject is taking when enro lled into the study (1, 2, 3).
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.lled into the study (1, 2, 3).
groupings are used for the purpose of summarizing the following scales: 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.groupings are used for the purpose of summarizing the following scales: 
PedsQL (4 years, ≥5 to ≤7 years, ≥8 to ≤12 years, and ≥13 to ≤18 years)
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.PedsQL (4 years, ≥5 to ≤7 years, ≥8 to ≤12 years, and ≥13 to ≤18 years)
Achenbach CBCL (4 to 5 years, 6 to 18 years)
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Achenbach CBCL (4 to 5 years, 6 to 18 years)
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.BRIEF
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.BRIEF -
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.-
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.P/BRIEF (4 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.P/BRIEF (4 
Section 4.9, Stratum Pooling has been moved from a later section and the algorithm modified 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Section 4.9, Stratum Pooling has been moved from a later section and the algorithm modified 
from saying:
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.from saying:
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.The analysis will use the stratification factors from IRT. If 5 events or less (ie, less than 6 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.The analysis will use the stratification factors from IRT. If 5 events or less (ie, less than 6 
subjects who had a second PGTC 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.subjects who had a second PGTC 
UCB   28 Mar 2019  
Statistical Analysis Plan  SP0982  
per 28 days or the group of subjects who are ≥18 years of age with ≤2 Baseline PGTC 
seizures per 28 days, whichever has the smallest number of events. 
2. If 5 events or less occur in the group of subjects who are ≥4 to <12 years of age with ≤2 Baseline PGTC seizures per 28 days, then this group will be combined for analysis with the 
group of subjects who are ≥12 to <18 years of age with ≤2 Baseline PGTC seizures per 28 
days. 
3. If 5 events or less occur in the group of subjects who are ≥18 years of age with ≤2 Baseline 
PGTC seizures per 28 days, then this group will be combined for analysis with the group of 
subjects who are ≥12 to <18 years of age with ≤2 Baseline PGTC seizures per 28 days.  
4. Similarly, rules 1 to 3 apply to those age groups within subjects with > 2 Baseline PGTC seizures per 28 days. 
Has been revised to:  
The stratification factors for this study are Baseline PGTCS frequency (≤2 per 28 days vs >2 per 
28 days in the Combined Baseline Period) and age at informed consent (≥4 to <12 years of age, 
≥12 to <18 years of age vs ≥18 years of age). The analyses will use the stratification factors from IRT.  
To determine if strata pooling should occur for time to event (2
nd PGTCS) analysis: 
For the subjects with Baseline PGTCS frequency ≤2 per 28 days, the events for each of the 3 age 
at informed consent categories will be summed.   
 If 2 of the age at informed consent categories combined have < 3 total events, then all age 
categories are combined for the analysis.  
 If ≥4 to <12 years of age is the category with the smallest number of events that are 2 events or less, it should be combined with the ≥12 and <18 years of age category. 
 If ≥18 years of age is the category with the smallest number of events that are 2 events or 
less, it should be combined with the ≥12 and <18 years of age category. 
 If ≥12 and <18 years of age is the category with the smallest number of events that are 2 events or less, it should be combined with the strata with the 2
nd smallest number of events. 
For the subjects with Baseline PGTCS frequency >2 per 28 days, repeat the same exercise to determine stratum pooling.  
Time to 1
st PGTCS analyses: 
The prior algorithm for stratum pooling will be used to determine stratum pooling, except that 
“events” will now be in reference to subjects having only 1 PGTCS. 
Seizure freedom analyses: 
The prior algorithm for stratum pooling will be used to determine stratum pooling, except that 
“events” will now be in reference to subjects having 0 PGTCS. 
Section 5.1, Subject disposition, the 3rd paragraph was modified from: 
The overall number and percentage of subjects who completed and discontinued from the study 
will be presented for the SS, FAS and PPS including number and percentages for each reason for REDACTED COPY ling should occur for time to event (2
REDACTED COPY ling should occur for time to event (2
For the subjects with Baseline PGTCS frequency ≤2 per 28 days, the events for each of the 3 age 
REDACTED COPY For the subjects with Baseline PGTCS frequency ≤2 per 28 days, the events for each of the 3 age 
at informed consent categories will be summed.  
REDACTED COPY at informed consent categories will be summed.  
If 2 of the age at informed consent categories combin
REDACTED COPY If 2 of the age at informed consent categories combin
categories are combined for the analysis. 
REDACTED COPY categories are combined for the analysis. 
If ≥4 to <12 years of age is the category with the smallest number of events that are 2 events REDACTED COPY If ≥4 to <12 years of age is the category with the smallest number of events that are 2 events 
or less, it should be combined with the ≥12 and <18 years of age category.REDACTED COPY or less, it should be combined with the ≥12 and <18 years of age category.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.If 5 events or less occur in the group of subjects who are ≥18 years of age with ≤2 Baseline 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.If 5 events or less occur in the group of subjects who are ≥18 years of age with ≤2 Baseline 
PGTC seizures per 28 days, then this group will be combined for analysis with the group of 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.PGTC seizures per 28 days, then this group will be combined for analysis with the group of 
ears of age with ≤2 Baseline PGTC seizures per 28 days. 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.ears of age with ≤2 Baseline PGTC seizures per 28 days. 
Similarly, rules 1 to 3 apply to those age groups within subjects with > 2 Baseline PGTC 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Similarly, rules 1 to 3 apply to those age groups within subjects with > 2 Baseline PGTC 
ncy (≤2 per 28 days vs >2 per 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.ncy (≤2 per 28 days vs >2 per 
28 days in the Combined Baseline Period) and age at informed consent (≥4 to <12 years of age, 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.28 days in the Combined Baseline Period) and age at informed consent (≥4 to <12 years of age, 
≥12 to <18 years of age vs ≥18 years of age). The analyses will use the stratification factors from 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.≥12 to <18 years of age vs ≥18 years of age). The analyses will use the stratification factors from 
ling should occur for time to event (2
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.ling should occur for time to event (2nd
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.ndPGTCS) analysis:
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.PGTCS) analysis:
For the subjects with Baseline PGTCS frequency ≤2 per 28 days, the events for each of the 3 age 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.For the subjects with Baseline PGTCS frequency ≤2 per 28 days, the events for each of the 3 age 
If 2 of the age at informed consent categories combin
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.If 2 of the age at informed consent categories combin
If ≥4 to <12 years of age is the category with the smallest number of events that are 2 events 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.If ≥4 to <12 years of age is the category with the smallest number of events that are 2 events 
or less, it should be combined with the ≥12 and <18 years of age category.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.or less, it should be combined with the ≥12 and <18 years of age category.
18 years of age is the category with the smallest number of events that are 2 events or 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.18 years of age is the category with the smallest number of events that are 2 events or 
less, it should be combined with the ≥12 and <18 years of age category.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.less, it should be combined with the ≥12 and <18 years of age category.
If ≥12 and <18 years of age is the category with the smallest number of events that are 2 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.If ≥12 and <18 years of age is the category with the smallest number of events that are 2 
or less, it should be combined with the strata with the 2
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.or less, it should be combined with the strata with the 2
For the subjects with Baseline PGTCS frequency >2 per 28 days, repeat the same exercise to 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.For the subjects with Baseline PGTCS frequency >2 per 28 days, repeat the same exercise to 
determine stratum pooling. 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.determine stratum pooling. 
PGTCS analyses:
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.PGTCS analyses:
The prior algorithm f
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.The prior algorithm f
“events” will now be in reference to subjects having only 1 PGTCS.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.“events” will now be in reference to subjects having only 1 PGTCS.
Seizure freedom analyses:
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Seizure freedom analyses:
The prior algorithm for stratum pooling will be used to determine stratum pooling, except
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.The prior algorithm for stratum pooling will be used to determine stratum pooling, except
“events” will now be in reference to subjects having 0 PGTCS.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.“events” will now be in reference to subjects having 0 PGTCS.
UCB   28 Mar 2019  
Statistical Analysis Plan  SP0982  
discontinuation. The completion of the study is defined as meeting any of the predetermined exit 
criteria or experiencing <2 PGTC seizures within the 24-week treatment period. Discontinuation 
is defined as the completion of the ET Visit.  This summary will be repeated for specific subgroups as detailed in Section  4.8 for the SS and FAS.  The study termination information will 
be presented in the subject data listings. 
Has been changed to:  
The overall number and percentage of subjects who completed and discontinued from the study 
will be presented for the SS, FAS, and PPS including number and percentages for each reason 
for discontinuation. The completion of the study is defined as meeting any of the predetermined exit criteria (including when the 125
th event has occurred) or experiencing <2 PGTCS within the 
24-week treatment period. Discontinuation is defined as the completion of the ET Visit in all 
other cases.  This summary will be repeated for specific subgroups as detailed in Section  4.8 for 
the SS and FAS.  The study termination information will be presented in the subject data listings. 
Section 6.2.2, Analysis of baseline characteristics, the 2nd paragraph has been changed from:  
The following Baseline characteristics will also be presented: 
 Time since first diagnosis at date of consent 
 Age at diagnosis of the disease 
 International League Against Epilepsy (ILAE) Seizure classification history 
 Classification of epileptic syndrome 
 Etiology of epilepsy 
Has been changed to:  
The following Baseline characteristics will also be presented: 
 Time since first diagnosis at date of consent 
 Age at diagnosis of epilepsy 
 Number of lifetime AEDs and Benzodiazepines (0, 1-3, 4-6, ≥7)  
 Concomitant benzodiazepine use at study entry (yes, no) 
 ILAE (1989) Seizure classification history 
 Classification of epileptic syndrome 
 Etiology of epilepsy 
Section 7, Measurements of Treatment Compliance, the following text was removed:  
For oral solution, compliance will be calculated using the following formula:  
Compliance (%) = Actual weight of used oral solution (g) / Expected weight of used oral 
solution (g) x 100. 
For tablets, compliance will be calculated using the following formula:  REDACTED COPY International League Against Epilepsy (ILAE) Seizure classification history
REDACTED COPY International League Against Epilepsy (ILAE) Seizure classification history
following Baseline characteristics will also be presented:REDACTED COPY following Baseline characteristics will also be presented:
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.The overall number and percentage of subjects who completed and discontinued from the study 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.The overall number and percentage of subjects who completed and discontinued from the study 
number and percentages for each reason 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.number and percentages for each reason 
for discontinuation. The completion of the study is defined as meeting any of the predetermined 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.for discontinuation. The completion of the study is defined as meeting any of the predetermined 
event has occurred) or experiencing <2 PGTCS within the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.event has occurred) or experiencing <2 PGTCS within the 
Discontinuation is defined as the completion of the ET Visit in all 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Discontinuation is defined as the completion of the ET Visit in all 
other cases.  This summary will be repeated for specific subgroups as detailed in 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.other cases.  This summary will be repeated for specific subgroups as detailed in Section
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Section
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.the SS and FAS.  The study termination information will be presented in the subject data listings.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.the SS and FAS.  The study termination information will be presented in the subject data listings.
paragraph has been changed from:
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.paragraph has been changed from:
International League Against Epilepsy (ILAE) Seizure classification history
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.International League Against Epilepsy (ILAE) Seizure classification history
following Baseline characteristics will also be presented:
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.following Baseline characteristics will also be presented:
Time since first diagnosis at date of consent
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Time since first diagnosis at date of consent
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Age at diagnosis of epilepsy
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Age at diagnosis of epilepsy
Number of lifetime AEDs and Benzodiazepines (0, 1
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Number of lifetime AEDs and Benzodiazepines (0, 1
Concomitant benzodiazepine use at study entry (yes, no)
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Concomitant benzodiazepine use at study entry (yes, no)
E (1989) Seizure classification history
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.E (1989) Seizure classification history
Classification of epileptic syndrome
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Classification of epileptic syndrome
Etiology of epilepsy
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Etiology of epilepsy
Section 7, Measurements of Treatment Compliance, the following text was removed:
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Section 7, Measurements of Treatment Compliance, the following text was removed:
For oral solution, compliance will be calculated using the following formula:
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.For oral solution, compliance will be calculated using the following formula:
Compliance (%) = Actual weight of used oral solution (g) / Expected weight of used oral 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Compliance (%) = Actual weight of used oral solution (g) / Expected weight of used oral 
UCB   28 Mar 2019  
Statistical Analysis Plan  SP0982  
Compliance (%) = (Number of tablets dispensed – Number of tablets returned) / (Number of 
tablets prescribed per day x Number of days between x 100. 
Rates of compliance will be calculated and summarized by category: <75%, 75-125%, >125%. 
Section 8, Efficacy Analyses, were revised from:  
All efficacy analyses will be performed using the FAS population. 
For all efficacy analyses, only data up to and including the day of the second PGTC seizure, the 
Visit 10 date or the last maintenance dose date, whichever is earlier, will be included. All seizure diary data will be listed including data not included in the efficacy analyses. 
Testing for the primary endpoint will be done at the 5% level (2-sided). Provided that the 
primary endpoint is statistically significant, a gatekeeping strategy will be used to test the key 
secondary efficacy variable. No additional adjustments for multiplicity are required as all 
additional inferences will be hypothesis-generating only. 
Has been revised to:  
Most efficacy analyses will be performed using the FAS population; in other cases, the 
population will be stated. 
For primary efficacy endpoint analyses, only data up to and including the day of the event, the 
Visit 10 date, last Treatment Period dose date, Day 166 or the date of the 125
th event, whichever 
is earlier, will be included. For the secondary efficacy endpoint analyses, only data up to and 
including the day of the first PGTCS, the Visit 10 date, the last Treatment Period dose date, Day 
166 or the date of the 125th event, whichever is earlier, will be included. For all other exploratory 
efficacy variables, all appropriate seizure data during the Treatment Period, will be included. All 
seizure diary data will be listed including data not included in efficacy analyses. 
Testing for the primary efficacy endpoint will be done at the 5% level (2-sided). Provided that 
the primary efficacy endpoint is statistically significant, a gatekeeping strategy will be used to test the key secondary efficacy variable, seizure freedom. No additional adjustments for multiplicity are required as all additional inferences will be hypothesis-generating only. 
Section 8.1.1, Derivations of primary efficacy variable, has been revised from:  
For PGTC seizures, the number of days until the second seizure will be derived using the date of 
the second PGTC seizure – date of first dose of study medication +1. For subjects who 
prematurely discontinue or complete the 24-week Treatment Period prior to having a second PGTC seizure, time to censor will be calculated as the date of censoring - date of first dose of 
study medication + 1. Only data up to Week 24 will be included. Censoring of subjects for this 
analysis will be as described in Section  3.2.2.If a day is marked in the CRF as “not done”, it will 
be assumed that no seizures occurred on that day. 
Has been changed to:  
For the primary efficacy variable, an event and how time to event is calculated is described in 
Section  3.2.3, keeping in mind Section  3.2.2. Censoring of subjects for this analysis will be as 
described in Section  3.2.4  . If a day is marked in the CRF as “not done”, it will be assumed that 
no seizures occurred on that day. 
Section 8.1.2, Primary analysis of the primary efficacy variable, has been modified from:  REDACTED COPY For primary efficacy endpoint analyses, only data up to and including the day of the event, the 
REDACTED COPY For primary efficacy endpoint analyses, only data up to and including the day of the event, the 
Visit 10 date, last Treatment Period dose date, Day 166 or the date of the 125
REDACTED COPY Visit 10 date, last Treatment Period dose date, Day 166 or the date of the 125
is earlier, will be included. For the secondary effica
REDACTED COPY is earlier, will be included. For the secondary effica cy endpoint analyses, only data up to and 
REDACTED COPY cy endpoint analyses, only data up to and 
including the day of the first PGTCS, the Visit 10 date, the last Treatment Period dose date, Day 
REDACTED COPY including the day of the first PGTCS, the Visit 10 date, the last Treatment Period dose date, Day 
event, whichever is earlier, will be included. For all other exploratory 
REDACTED COPY event, whichever is earlier, will be included. For all other exploratory 
bles, all appropriate seizure data during the Treatment Period, will be included. All 
REDACTED COPY bles, all appropriate seizure data during the Treatment Period, will be included. All 
seizure diary data will be listed including data not included in efficacy analyses.
REDACTED COPY seizure diary data will be listed including data not included in efficacy analyses.
Testing for the primary efficacy endpoint will be done at the 5% level (2REDACTED COPY Testing for the primary efficacy endpoint will be done at the 5% level (2
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.For all efficacy analyses, only data up to and including the day of the second PGTC seizure, the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.For all efficacy analyses, only data up to and including the day of the second PGTC seizure, the 
Visit 10 date or the last maintenance dose date, whichever is earlier, will be included. All seizure 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Visit 10 date or the last maintenance dose date, whichever is earlier, will be included. All seizure 
sided). Provided that the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.sided). Provided that the 
primary endpoint is statistically significant, a gatekeeping strategy will be used to test the key 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.primary endpoint is statistically significant, a gatekeeping strategy will be used to test the key 
riable. No additional adjustments for multiplicity are required as all 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.riable. No additional adjustments for multiplicity are required as all 
; in other cases, the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.; in other cases, the 
For primary efficacy endpoint analyses, only data up to and including the day of the event, the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.For primary efficacy endpoint analyses, only data up to and including the day of the event, the 
Visit 10 date, last Treatment Period dose date, Day 166 or the date of the 125
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Visit 10 date, last Treatment Period dose date, Day 166 or the date of the 125
cy endpoint analyses, only data up to and 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.cy endpoint analyses, only data up to and 
including the day of the first PGTCS, the Visit 10 date, the last Treatment Period dose date, Day 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.including the day of the first PGTCS, the Visit 10 date, the last Treatment Period dose date, Day 
event, whichever is earlier, will be included. For all other exploratory 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.event, whichever is earlier, will be included. For all other exploratory 
bles, all appropriate seizure data during the Treatment Period, will be included. All 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.bles, all appropriate seizure data during the Treatment Period, will be included. All 
seizure diary data will be listed including data not included in efficacy analyses.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.seizure diary data will be listed including data not included in efficacy analyses.
Testing for the primary efficacy endpoint will be done at the 5% level (2
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Testing for the primary efficacy endpoint will be done at the 5% level (2
the primary efficacy endpoint is statistically significant, a gatekeeping strategy will be used to 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.the primary efficacy endpoint is statistically significant, a gatekeeping strategy will be used to 
test the key secondary efficacy variable, seizure freedom. No additional adjustments for 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.test the key secondary efficacy variable, seizure freedom. No additional adjustments for 
multiplicity are required as all additional inferences wil
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.multiplicity are required as all additional inferences wil
Section 8.1.1, Derivations of primary efficacy variable, has been revised from:
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Section 8.1.1, Derivations of primary efficacy variable, has been revised from:
For PGTC seizures, the number of days until the second seizure will be derived using the date of 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.For PGTC seizures, the number of days until the second seizure will be derived using the date of 
the second PGTC seizure 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.the second PGTC seizure 
prematurely discontinue or complete the 24
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.prematurely discontinue or complete the 24
PGTC seizure, time to censor will be calculated as the date of censoring 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.PGTC seizure, time to censor will be calculated as the date of censoring 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.study medication + 1. Only da
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.study medication + 1. Only da
analysis will be as described in 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.analysis will be as described in 
be assumed that no seizures occurred on that day.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.be assumed that no seizures occurred on that day.
Has been changed to:
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Has been changed to:
For the primary efficacy variable, an event and how time to event is calculated is described in 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.For the primary efficacy variable, an event and how time to event is calculated is described in 
UCB   28 Mar 2019  
Statistical Analysis Plan  SP0982  
The primary efficacy variable, time to second PGTC seizure during the 24-week Treatment 
Period, will be evaluated using a Cox proportional hazards regression model (Cox, 1972), with 
an effect for treatment, stratifying for the subjects’ Baseline PGTC seizure frequency (≤2 per 28 days vs >2 per 28 days in the Combined Baseline Period) and age at informed consent (≥ 4 to 
<12 years of age, ≥12 to <18 years of age vs ≥18 years of age). The analysis will use the 
stratification factors from IRT. If 5 events or less (ie, less than 6 subjects who had a second PGTC seizure) occur in a stratum, then data will be pooled by Baseline PGTC seizure frequency for analysis as follows:  
5. If 5 events or less occur in the group of subjects who are ≥12 and <18 years of age with ≤2 
Baseline PGTC seizures per 28 days, then this group will be combined for analysis with 
either the group of subjects who are ≥4 to <12 years of age with ≤2 Baseline PGTC seizures 
per 28 days or the group of subjects who are ≥18 years of age with ≤2 Baseline PGTC 
seizures per 28 days, whichever has the smallest number of events. 
6. If 5 events or less occur in the group of subjects who are ≥4 to <12 years of age with ≤2 
Baseline PGTC seizures per 28 days, then this group will be combined for analysis with the group of subjects who are ≥12 to <18 years of age with ≤2 Baseline PGTC seizures per 28 days. 
7. If 5 events or less occur in the group of subjects who are ≥18 years of age with ≤2 Baseline PGTC seizures per 28 days, then this group will be combined for analysis with the group of subjects who are ≥12 to <18 years of age with ≤2 Baseline PGTC seizures per 28 days.  
8. Similarly, rules 1 to 3 apply to those age groups within subjects with > 2 Baseline PGTC seizures per 28 days. 
 The stratified HR will be calculated using the placebo arm as the reference group. 
Additionally, a KM plot for time to second PGTC seizure as well as the KM estimate for the 
median time to second PGTC seizure will be provided. If the median time is not estimable, then the 25
th percentile will be provided.  
Has been changed to:  
The primary efficacy variable, time to event during the 166-day Treatment Period, will be 
evaluated using a Cox proportional hazards regression model (Cox, 1972), with an effect for 
treatment, stratifying for the subjects’ Baseline PGTCS frequency (≤2 per 28 days vs >2 per 28 days in the Combined Baseline Period) and age at informed consent (≥ 4 to <12 years of age, 
≥12 to <18 years of age vs ≥18 years of age). The analysis will use the stratification factors from 
IRT and pooled as described in Section 4.9.   
The hypothesis for the assessment of primary efficacy variable (time to event) is as follows: 
H
0: β=0  
Versus 
H1: β≠0 
where β is the coefficient of an independent variable representing the treatment effect in the 
model. The hazard function is represented by REDACTED COPY If 5 events or less occur in the group of subjects who are ≥18
REDACTED COPY If 5 events or less occur in the group of subjects who are ≥18
PGTC seizures per 28 days, then this group will be combined for analysis with the group of 
REDACTED COPY PGTC seizures per 28 days, then this group will be combined for analysis with the group of 
subjects who are ≥12 to <18 years of age with ≤2 Baseline PGTC seizures per 28 days. 
REDACTED COPY subjects who are ≥12 to <18 years of age with ≤2 Baseline PGTC seizures per 28 days. 
Similarly, rules 1 to 3 apply to those age group
REDACTED COPY Similarly, rules 1 to 3 apply to those age group s within subjects with > 2 Baseline PGTC 
REDACTED COPY s within subjects with > 2 Baseline PGTC 
The stratified HR will be calculated using the placebo arm as the reference group.
REDACTED COPY The stratified HR will be calculated using the placebo arm as the reference group.
Additionally, a KM plot for time to second PGTC seizure as well as the KM estimate for the REDACTED COPY Additionally, a KM plot for time to second PGTC seizure as well as the KM estimate for the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.If 5 events or less occur in the group of subjects who are ≥12 and <18 years of age with ≤2 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.If 5 events or less occur in the group of subjects who are ≥12 and <18 years of age with ≤2 
Baseline PGTC seizures per 28 days, then this group will be combined for analysis with 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Baseline PGTC seizures per 28 days, then this group will be combined for analysis with 
Baseline PGTC seizures 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Baseline PGTC seizures 
per 28 days or the group of subjects who are ≥18 years of age with ≤2 Baseline PGTC 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.per 28 days or the group of subjects who are ≥18 years of age with ≤2 Baseline PGTC 
If 5 events or less occur in the group of subjects who are ≥4 to <12 years of age
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.If 5 events or less occur in the group of subjects who are ≥4 to <12 years of age
Baseline PGTC seizures per 28 days, then this group will be combined for analysis with the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Baseline PGTC seizures per 28 days, then this group will be combined for analysis with the 
group of subjects who are ≥12 to <18 years of age with ≤2 Baseline PGTC seizures per 28 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.group of subjects who are ≥12 to <18 years of age with ≤2 Baseline PGTC seizures per 28 
If 5 events or less occur in the group of subjects who are ≥18
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.If 5 events or less occur in the group of subjects who are ≥18 years of age with ≤2 Baseline 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.years of age with ≤2 Baseline 
PGTC seizures per 28 days, then this group will be combined for analysis with the group of 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.PGTC seizures per 28 days, then this group will be combined for analysis with the group of 
subjects who are ≥12 to <18 years of age with ≤2 Baseline PGTC seizures per 28 days. 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.subjects who are ≥12 to <18 years of age with ≤2 Baseline PGTC seizures per 28 days. 
s within subjects with > 2 Baseline PGTC 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.s within subjects with > 2 Baseline PGTC 
The stratified HR will be calculated using the placebo arm as the reference group.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.The stratified HR will be calculated using the placebo arm as the reference group.
Additionally, a KM plot for time to second PGTC seizure as well as the KM estimate for the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Additionally, a KM plot for time to second PGTC seizure as well as the KM estimate for the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.ond PGTC seizure will be provided. If the median time is not estimable, then 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.ond PGTC seizure will be provided. If the median time is not estimable, then 
percentile will be provided. 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.percentile will be provided. 
The primary efficacy variable, time to event during the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.The primary efficacy variable, time to event during the 
evaluated using a Cox proport
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.evaluated using a Cox proport
treatment, stratifying for the subjects’ Baseline PGTCS frequency (≤2 per 28 days vs >2 per 28 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.treatment, stratifying for the subjects’ Baseline PGTCS frequency (≤2 per 28 days vs >2 per 28 
days in the Combined Baseline Period) and age at informed consent (≥ 4
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.days in the Combined Baseline Period) and age at informed consent (≥ 4
≥12 to <18 years of age vs ≥18 years of age). The analysis will use the stratification factors from 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.≥12 to <18 years of age vs ≥18 years of age). The analysis will use the stratification factors from 
IRT and pooled as described in Section
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.IRT and pooled as described in Section
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.The hypothesis for the assessment of primary efficacy variable (time to event) is as follows:
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.The hypothesis for the assessment of primary efficacy variable (time to event) is as follows:
Versus
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Versus
UCB   28 Mar 2019  
Statistical Analysis Plan  SP0982  
ℎ(𝑡,𝑋)= ℎ0(𝑡)exp(∑𝛽 𝑗𝑋𝑗𝑝
𝑗=1 
where xj is the collection of independent variables and h0(t) is the baseline hazard at time t. For 
the null hypothesis, the testing will be 2-sided with an α=0.05; the p -value will be presented. Th e 
assumptions of proportional hazards will also be checked.  
The stratified hazard ratio (HR) will be calculated using the placebo arm as the reference group. 
The SE and 95% CI for the HR will also be reported.  
Additionally, a Kaplan-Meier (KM) plot for time to event as well as the KM estimate for the 
median time to event and 95% CI will be provided. If the median time is not estimable, then the 
25th percentile and 95% CI will be provided. The number of events will be reported by treatment 
group for the Titration Period, first 12 Weeks, and Treatment Period as well as the % of subjects 
who were censored in the analysis. 
Section 8.1.3, Secondary analyses of the primary efficacy variable, has been changed from:  
The summary of time to the second PGTC seizure during the 24-week Treatment Period will be 
presented by subgroup for the FAS.  A KM plot for time to second PGTC seizure by selected subgroups will also be provided.  
Has been changed to:  
The summary of time to the event during the 166-day Treatment Period will be presented by all 
subgroup for the FAS. A KM plot for time to second PGTCS by all subgroups will also be 
provided.  
Section 8.1.4, Supportive and sensitivity analyses of the primary efficacy variable, has been 
changed from:  
The following additional sensitivity analyses on the primary efficacy endpoint will be conducted in order to assess the effect of dropouts, important protocol deviations, and operational bias on the primary endpoint:   
 Repeat the primary analysis using the PPS. 
 Repeat the primary analysis using the FAS, except all subjects who prematurely discontinue 
due to lack of efficacy, consent withdrawn, or lost to follow-up will be analyzed as treatment 
failures (ie, events at the time of discontinuation). 
 Repeat the primary analysis using the FAS, except all subjects who prematurely discontinue 
due to lack of efficacy or AEs only will be analyzed as treatment failures. 
 Repeat the primary analysis using the FAS, comparing the event rates prior to vs after each 
interim analysis to examine possible operational bias due to unblinding. 
Has been changed to:  
The following additional sensitivity analyses on the primary efficacy endpoint will be conducted in order to assess the effect of dropouts, important protocol deviations, and operational bias on the primary endpoint:   
 Repeat the primary efficacy analysis using the PPS. REDACTED COPY 166
REDACTED COPY 166-
REDACTED COPY -day
REDACTED COPY day
subgroup for the FAS. A KM plot for time to second PGTCS by all subgroups will also be 
REDACTED COPY subgroup for the FAS. A KM plot for time to second PGTCS by all subgroups will also be 
REDACTED COPY Section 8.1.4, Supportive and sensitivity analyses of the primary efficacy variable,
REDACTED COPY Section 8.1.4, Supportive and sensitivity analyses of the primary efficacy variable,
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.The stratified hazard ratio (HR) will be calculated using the placebo arm as the reference group. 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.The stratified hazard ratio (HR) will be calculated using the placebo arm as the reference group. 
ime to event as well as the KM estimate for the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.ime to event as well as the KM estimate for the 
median time to event and 95% CI will be provided. If the median time is not estimable, then the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.median time to event and 95% CI will be provided. If the median time is not estimable, then the 
percentile and 95% CI will be provided. The number of events will be reported by treatment 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.percentile and 95% CI will be provided. The number of events will be reported by treatment 
as well as the % of subjects 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.as well as the % of subjects 
Section 8.1.3, Secondary analyses of the primary efficacy variable, has been changed from:
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Section 8.1.3, Secondary analyses of the primary efficacy variable, has been changed from:
week Treatment Period will be 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.week Treatment Period will be 
presented by subgroup for the FAS.  A KM plot for time to second PGTC seizure by selected 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.presented by subgroup for the FAS.  A KM plot for time to second PGTC seizure by selected 
day
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.dayTreatment Period will be presented by all 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Treatment Period will be presented by all 
subgroup for the FAS. A KM plot for time to second PGTCS by all subgroups will also be 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.subgroup for the FAS. A KM plot for time to second PGTCS by all subgroups will also be 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Section 8.1.4, Supportive and sensitivity analyses of the primary efficacy variable,
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Section 8.1.4, Supportive and sensitivity analyses of the primary efficacy variable,
The following additional sensitivity analyses on the primary efficacy endpoint will be conducted 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.The following additional sensitivity analyses on the primary efficacy endpoint will be conducted 
in order to assess the effect of dropouts, important protocol deviations, and operational bias on 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.in order to assess the effect of dropouts, important protocol deviations, and operational bias on 
imary analysis using the PPS.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.imary analysis using the PPS.
Repeat the primary analysis using the FAS, except all subjects who prematurely discontinue 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Repeat the primary analysis using the FAS, except all subjects who prematurely discontinue 
due to lack of efficacy, consent withdrawn, or lost to follow
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.due to lack of efficacy, consent withdrawn, or lost to follow
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.failures (ie, events at the time of disc
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.failures (ie, events at the time of disc
Repeat the primary analysis using the FAS, except all subjects who prematurely discontinue 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Repeat the primary analysis using the FAS, except all subjects who prematurely discontinue 
due to lack of efficacy or AEs only will be analyzed as treatment failures.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.due to lack of efficacy or AEs only will be analyzed as treatment failures.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Repeat the primary analysis using the FAS, comparing the event rates prior 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Repeat the primary analysis using the FAS, comparing the event rates prior 
interim analysis to examine possible operational bias due to unblinding.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.interim analysis to examine possible operational bias due to unblinding.
Has been changed to:
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Has been changed to:
UCB   28 Mar 2019  
Statistical Analysis Plan  SP0982  
 Repeat the primary efficacy analysis using all PGTCS data (ie, all reported events) through 
each subject’s first 166 days of treatment, on the FAS. 
 Repeat the primary efficacy analysis using the FAS, except all subjects who prematurely discontinue due to lack of efficacy, consent withdrawn, or lost to follow-up will be analyzed as treatment failures (ie, events at the time of discontinuation). 
 Repeat the primary efficacy analysis using the FAS, except all subjects who prematurely 
discontinue due to lack of efficacy or AEs only will be analyzed as treatment failures. 
 Repeat the primary efficacy analysis using the FAS, comparing the event rates prior to vs 
after each interim analysis to examine possible operational bias due to unblinding. 
Section 8.2.1.1, Seizure freedom for PGTCS for the 166-day Treatment Period, has been 
modified from:  
A seizure-free day will be defined as a day where no PGTC seizures were reported in the seizure 
diary and seizures were assessed. Days in the seizure diary which are marked as “not done” on 
the CRF will be counted as a seizure free day. 
A subject will have seizure freedom (seizure free status=yes) for the  24-week Treatment Period 
if the subject completed the Treatment Period and reported zero seizures or “not done” for all 
days during the Treatment Period. 
Has been changed to:  
A seizure-free day from PGTCS will be defined as a day where no PGTCS were reported in the 
seizure diary and PGTCS were assessed. Days in the seizure diary which are marked as “not 
done” on the CRF will be counted as seizure-free days from PGTCS. 
A subject will have seizure freedom from PGTCS for the 166-day Treatment Period if the 
subject completed the Treatment Period and reported zero PGTCS or “not done” for all days 
during the 166-day Treatment Period. Ongoing subjects who are seizure-free from PGTCS on the date of the 125th event do not have seizure- freedom from PGTCS unless they are seizure- free 
from PGTCS for 166 days. 
Section 8.2.1.2, Time to 1
st PGTCS during the 166-day Treatment Period, has been changed 
from:  
For PGTC seizures, the number of days until the first seizure will be derived using the date of the 
first PGTC seizure – date of first dose of study medication +1. For subjects who prematurely discontinue or complete the 24-week Treatment Period prior to having a PGTC seizure, time to 
censor will be calculated as the date of censoring - date of first dose of study medication + 1. 
Only data up to Week 24 will be included. Censoring of subjects for this analysis will be as described in Section  3.2.2 . 
If a day is marked in the CRF as “not done”, it will be assumed that no seizures occurred on that seizure diary day. 
Has been changed to:  
For PGTCS, how the time to first PGTCS is calculated is described in Section 3.2.3.  Censoring 
of subjects for this analysis will be as described in Section  3.2.4 . REDACTED COPY free day from PGTCS will be defined as a day where no PGTCS were repor
REDACTED COPY free day from PGTCS will be defined as a day where no PGTCS were repor
seizure diary and PGTCS were assessed. Days in the seizure diary which are marked as “not 
REDACTED COPY seizure diary and PGTCS were assessed. Days in the seizure diary which are marked as “not 
done” on the CRF will be counted as seizure
REDACTED COPY done” on the CRF will be counted as seizure -
REDACTED COPY -free days from PGTCS.
REDACTED COPY free days from PGTCS.
A subject will have seizure freedom from PGTCS for the REDACTED COPY A subject will have seizure freedom from PGTCS for the 
subject completed the Treatment Period and reported zero PGTCS or “not done” for all days REDACTED COPY subject completed the Treatment Period and reported zero PGTCS or “not done” for all days 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.nt rates prior to vs 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.nt rates prior to vs 
Treatment Period, has been 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Treatment Period, has been 
no PGTC seizures were reported in the seizure 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.no PGTC seizures were reported in the seizure 
diary and seizures were assessed. Days in the seizure diary which are marked as “not done” on 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.diary and seizures were assessed. Days in the seizure diary which are marked as “not done” on 
A subject will have seizure freedom (seizure free status=yes) for the
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.A subject will have seizure freedom (seizure free status=yes) for the 24
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.24week Treatment Period 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.week Treatment Period 
if the subject completed the Treatment Period and reported zero seizures or “not done” for all 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.if the subject completed the Treatment Period and reported zero seizures or “not done” for all 
free day from PGTCS will be defined as a day where no PGTCS were repor
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.free day from PGTCS will be defined as a day where no PGTCS were repor
seizure diary and PGTCS were assessed. Days in the seizure diary which are marked as “not 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.seizure diary and PGTCS were assessed. Days in the seizure diary which are marked as “not 
free days from PGTCS.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.free days from PGTCS.
A subject will have seizure freedom from PGTCS for the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.A subject will have seizure freedom from PGTCS for the 
subject completed the Treatment Period and reported zero PGTCS or “not done” for all days 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.subject completed the Treatment Period and reported zero PGTCS or “not done” for all days 
Treatment Period. Ongoing subjects who are seizure
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Treatment Period. Ongoing subjects who are seizure
date of the 125th event do not have seizure
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.date of the 125th event do not have seizure
PGTCS during the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.PGTCS during the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.For PGTC seizures, the number of days until the first seizure will be derived using the date
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.For PGTC seizures, the number of days until the first seizure will be derived using the date
first PGTC seizure 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.first PGTC seizure –
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.–date of first dose of study medication +1. For subjects who prematurely 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.date of first dose of study medication +1. For subjects who prematurely 
discontinue or complete the 24
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.discontinue or complete the 24
censor will be calculated as the date of censoring 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.censor will be calculated as the date of censoring 
Only data up to Week 24 will be included. Censoring of subjects for this analysis will be as 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Only data up to Week 24 will be included. Censoring of subjects for this analysis will be as 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.described in 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.described in 
If a day is marked in the CRF as “not done”, it will be assumed that no seizures occurred on that 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.If a day is marked in the CRF as “not done”, it will be assumed that no seizures occurred on that 
seizure diary day.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.seizure diary day.
UCB   28 Mar 2019  
Statistical Analysis Plan  SP0982  
If a day is marked in the CRF as “not done”, it will be assumed that no seizures occurred on that 
seizure diary day. 
Section 8.2.2 has been updated to:  
Analyses of secondary efficacy variables will be performed for the FAS. 
Section 8.2.2.1: Seizure freedom for the 166-day Treatment Period, has been modified from:  
Analysis of the key secondary efficacy variable, seizure freedom for PGTC seizures for the 
24-week Treatment Period, will be evaluated using a Cox proportional hazards regression model 
(Cox, 1972), with an effect for treatment, stratifying for the subjects’ Baseline PGTC seizure frequency (≤2 per 28 days vs >2 per 28 days in the Combined Baseline Period) and age at informed consent (≥ 4 to <12 years of age, ≥12 to <18 years of age vs ≥18 years of age). The 
analysis will use the stratification factors from IRT. If 5 events or less (ie, less than 6 subjects 
who had a second PGTC seizure) occur in a stratum, then data will be pooled by Baseline PGTC seizure frequency for analysis as follows:  
9. If 5 events or less occur in the group of subjects who are ≥12 and <18 years of age with ≤2 
Baseline PGTC seizures per 28 days, then this group will be combined for analysis with either the group of subjects who are ≥4 to <12 years of age with ≤2 Baseline PGTC seizures 
per 28 days or the group of subjects who are ≥18 years of age with ≤2 Baseline PGTC 
seizures per 28 days, whichever has the smallest number of events. 
10. If 5 events or less occur in the group of subjects who are ≥4 to <12 years of age with ≤2 
Baseline PGTC seizures per 28 days, then this group will be combined for analysis with the 
group of subjects who are ≥12 to <18 years of age with ≤2 Baseline PGTC seizures per 28 days. 
11. If 5 events or less occur in the group of subjects who are ≥18 years of age with ≤2 Baseline PGTC seizures per 28 days, then this group will be combined for analysis with the group of subjects who are ≥12 to <18 years of age with ≤2 Baseline PGTC seizures per 28 days.  
12. Similarly, rules 1 to 3 apply to those age groups within subjects with > 2 Baseline PGTC seizures per 28 days. 
The percentage of seizure-free subjects at 24 weeks will be estimated from the KM estimates of 
time to first seizure using 2-sided 95% confidence intervals. A stratified estimate of the seizure 
freedom rate in each treatment arm will be derived using KM methods to estimate the seizure freedom rate for each stratum and then combining the rates using a Cochran-Mantel-Haenszel-
like approach. The stratified HR will be calculated using the placebo arm as the reference group. 
If the primary endpoint is statistically significant at the 5% level, then the key secondary efficacy endpoint will also be assessed at the 5% significance level. If the primary endpoint fails to reach statistical significance, then the key secondary efficacy endpoint will be exploratory only. 
Has been modified to:  
Analysis of the key secondary efficacy variable, seizure freedom for PGTCS for the 166-day 
Treatment Period, will be evaluated using an extended Mantel-Haenszel testing procedure which 
takes into account that the subjects were initially stratified for the subjects’ Baseline PGTCS frequency (≤2 per 28 days vs >2 per 28 days in the Combined Baseline Period) and age at REDACTED COPY per 28 days or the group of subjects who are ≥18 years of age with ≤2 Baseline PGTC 
REDACTED COPY per 28 days or the group of subjects who are ≥18 years of age with ≤2 Baseline PGTC 
seizures per 28 days, whichever has the smallest number of events.
REDACTED COPY seizures per 28 days, whichever has the smallest number of events.
in the group of subjects who are ≥4 to <12 years of age with ≤2 
REDACTED COPY in the group of subjects who are ≥4 to <12 years of age with ≤2 
Baseline PGTC seizures per 28 days, then this group will be combined for analysis with the 
REDACTED COPY Baseline PGTC seizures per 28 days, then this group will be combined for analysis with the 
group of subjects who are ≥12 to <18 years of age with ≤2 Baseline PGTC seizures per 28 
REDACTED COPY group of subjects who are ≥12 to <18 years of age with ≤2 Baseline PGTC seizures per 28 
ents or less occur in the group of subjects who are ≥18 years of age with ≤2 Baseline REDACTED COPY ents or less occur in the group of subjects who are ≥18 years of age with ≤2 Baseline 
PGTC seizures per 28 days, then this group will be combined for analysis with the group of REDACTED COPY PGTC seizures per 28 days, then this group will be combined for analysis with the group of 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.portional hazards regression model
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.portional hazards regression model
, with an effect for treatment, stratifying for the subjects’ Baseline PGTC seizure 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof., with an effect for treatment, stratifying for the subjects’ Baseline PGTC seizure 
frequency (≤2 per 28 days vs >2 per 28 days in the Combined Baseline Period) and age at 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.frequency (≤2 per 28 days vs >2 per 28 days in the Combined Baseline Period) and age at 
onsent (≥ 4 to <12 years of age, ≥12 to <18 years of age vs ≥18 years of age). The 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.onsent (≥ 4 to <12 years of age, ≥12 to <18 years of age vs ≥18 years of age). The 
analysis will use the stratification factors from IRT. If 5 events or less (ie, less than 6 subjects 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.analysis will use the stratification factors from IRT. If 5 events or less (ie, less than 6 subjects 
led by Baseline PGTC 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.led by Baseline PGTC 
If 5 events or less occur in the group of subjects who are ≥12 and <18 years of age with ≤2 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.If 5 events or less occur in the group of subjects who are ≥12 and <18 years of age with ≤2 
Baseline PGTC seizures per 28 days, then this group will be combined for analysis with 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Baseline PGTC seizures per 28 days, then this group will be combined for analysis with 
roup of subjects who are ≥4 to <12 years of age with ≤2 Baseline PGTC seizures 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.roup of subjects who are ≥4 to <12 years of age with ≤2 Baseline PGTC seizures 
per 28 days or the group of subjects who are ≥18 years of age with ≤2 Baseline PGTC 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.per 28 days or the group of subjects who are ≥18 years of age with ≤2 Baseline PGTC 
seizures per 28 days, whichever has the smallest number of events.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.seizures per 28 days, whichever has the smallest number of events.
in the group of subjects who are ≥4 to <12 years of age with ≤2 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.in the group of subjects who are ≥4 to <12 years of age with ≤2 
Baseline PGTC seizures per 28 days, then this group will be combined for analysis with the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Baseline PGTC seizures per 28 days, then this group will be combined for analysis with the 
group of subjects who are ≥12 to <18 years of age with ≤2 Baseline PGTC seizures per 28 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.group of subjects who are ≥12 to <18 years of age with ≤2 Baseline PGTC seizures per 28 
ents or less occur in the group of subjects who are ≥18 years of age with ≤2 Baseline 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.ents or less occur in the group of subjects who are ≥18 years of age with ≤2 Baseline 
PGTC seizures per 28 days, then this group will be combined for analysis with the group of 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.PGTC seizures per 28 days, then this group will be combined for analysis with the group of 
subjects who are ≥12 to <18 years of age with ≤2 Baseline PGTC seizures per 28 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.subjects who are ≥12 to <18 years of age with ≤2 Baseline PGTC seizures per 28 
Similarly, rules 1 to 3 apply to those age groups within subjects with > 2 Baseline PGTC 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Similarly, rules 1 to 3 apply to those age groups within subjects with > 2 Baseline PGTC 
The percentage of seizure
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.The percentage of seizure -
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.-free subjects at 24 weeks will be estimated from the KM estimates of 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.free subjects at 24 weeks will be estimated from the KM estimates of 
time to first seizure using 2
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.time to first seizure using 2
freedom rate in each treatment arm will be derived using KM methods to estimate the seizure 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.freedom rate in each treatment arm will be derived using KM methods to estimate the seizure 
freedom rate for each stratum and then combining the rates using a Cochran
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.freedom rate for each stratum and then combining the rates using a Cochran
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.like approach. Th
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.like approach. Th e stratified HR will be calculated using the placebo arm as the reference group.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.e stratified HR will be calculated using the placebo arm as the reference group.
If the primary endpoint is statistically significant at the 5% level, then the key secondary efficacy 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.If the primary endpoint is statistically significant at the 5% level, then the key secondary efficacy 
endpoint will also be assessed at the 5% significance level. If the prima
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.endpoint will also be assessed at the 5% significance level. If the prima
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.statistical significance, then the key secondary efficacy endpoint will be exploratory only.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.statistical significance, then the key secondary efficacy endpoint will be exploratory only.
Has been modified to:
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Has been modified to:
Analysis of the key secondary efficacy variable, seizure freedom for PGTCS for the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Analysis of the key secondary efficacy variable, seizure freedom for PGTCS for the 
UCB   28 Mar 2019  
Statistical Analysis Plan  SP0982  
informed consent (≥ 4 to <12 years of age, ≥12 to <18 years of age vs ≥18 years of age). The 
analysis will use the stratification factors from IRT and pooled as described in Section 4.9.  
The hypothesis for the assessment of the key secondary efficacy (PGTC seizure-freedom) is as 
follows: 
H0: S(t=166) LCM = S(t=166) PBO  
Versus 
H1: S(t=166) LCM ≠ S(t=166) PBO  
Where S(t=166) is th e cumulative rate of subjects remaining seizure-free from PGTCS for 166 
days. 
Estimation of treatment difference: 
KM methods will be used to estimate the proportion of subjects remaining seizure-free from 
PGTCS at Day 166. The estimate for the difference in Day 166 seizure-freedom from PGTCS will be adjusted for subjects’ Baseline PGTCS frequency (≤2 per 28 days vs >2 per 28 days in 
the Combined Baseline Period) and age at informed consent (≥ 4 to <12 years of age, ≥12 to <18 
years of age vs ≥18 years of age). The estimate for the stratified difference in proportion of subjects who are seizure-free from PGTCS on LCM vs PBO and a corresponding 95% two-sided 
confidence interval (CI
LCM -PBO) will be produced using mantel Haenszel methods (LaVange et al, 
2005). The statistical methodology is expressed as follows: 
 d=∑wh(Sh1-Sh2)6
h=1  
Where Shi=KM estimate of 166-day seizure freedom from PGTCS for treatment i (1=LCM and 
2=PBO) in stratum h (1= ≤2 per 28 days Baseline PGTCS frequency and ≥ 4 to <12 years of age, 
2= ≤2  per 28 days Baseline PGTCS frequency and ≥12 to <18 years of age, 3= =≤2 per 28 days 
Baseline PGTCS frequency and ≥18 years of age, 4= >2 per 28 days Baseline PGTCS frequency 
and ≥ 4 to <12 years of age, 5= >2 per 28 days Baseline PGTCS frequency and ≥12 to <18 years 
of age and 6= >2 per 28 days Baseline PGTCS frequency and ≥18 years of age and 
wh={(nh1*nh2)/(nh1+nh2)}/∑{(nh1*nh2)6
h=1 /(nh1+nh2)}} 
where n hi is the number of subjects in I treatment group and stratum h.  The variance of d is 
calculated as Var(d)=∑wh2 6
h=1{Var(S h1)+Var(S h2)} where Var(S h1) and Var(S h2) are the 
Greenwood estimates of variance for Sh1 and S h2. 
The stratified proportion of subjects remaining seizure free from PGTCS for at least 166 days in 
each treatment group and the associated variance are derived as follows using Mantel Haneszel 
methods: 
The KM estimate for the LCM 166-day seizure-freedom from PGTCS rate is calculated as 
𝑆1=∑𝑤ℎ6
ℎ=1𝑆ℎ1 
The KM estimate for the PBO 166-day seizure-freedom from PGTCS rate is calculated as 
𝑆2=∑𝑤ℎ6
ℎ=1𝑆ℎ2 
The variance is S1 is calculated as Var (𝑆1) =∑𝑤ℎ6 6
ℎ=1𝑉𝑎𝑟(𝑆ℎ1) 
The variance of S2 is calculated as Var (𝑆2) =∑𝑤ℎ6 6
ℎ=1𝑉𝑎𝑟(𝑆ℎ2) REDACTED COPY ) will be produced using mantel Haenszel methods (LaVange et al, 
REDACTED COPY ) will be produced using mantel Haenszel methods (LaVange et al, 
he statistical methodology is expressed as follows:
REDACTED COPY he statistical methodology is expressed as follows:
seizure freedom from PGTCS for treatment i (1=LCM and 
REDACTED COPY seizure freedom from PGTCS for treatment i (1=LCM and 
2=PBO) in stratum h (1= ≤2 per 28 days Baseline PGTCS frequency and ≥ 4 to <12 years of age, 
REDACTED COPY 2=PBO) in stratum h (1= ≤2 per 28 days Baseline PGTCS frequency and ≥ 4 to <12 years of age, 
per 28 days Baseline PGTCS frequency and ≥12 to <18 years of age, 3= =≤2 per 28 days REDACTED COPY per 28 days Baseline PGTCS frequency and ≥12 to <18 years of age, 3= =≤2 per 28 days 
Baseline PGTCS frequency and ≥18 years of age, 4= >2 per 28 days Baseline PGTCS frequency REDACTED COPY Baseline PGTCS frequency and ≥18 years of age, 4= >2 per 28 days Baseline PGTCS frequency 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.free from PGTCS for 166 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.free from PGTCS for 166 
KM methods will be used to estimate the proportion of subjects remaining seizure
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.KM methods will be used to estimate the proportion of subjects remaining seizure free from 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.free from 
freedom from PGTCS 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.freedom from PGTCS 
will be adjusted for subjects’ Baseline PGTCS frequency (≤2 per 28 days vs >2 per 28 days in 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.will be adjusted for subjects’ Baseline PGTCS frequency (≤2 per 28 days vs >2 per 28 days in 
the Combined Baseline Period) and age at informed consent (≥ 4 to <12 years of age, ≥12 to <18 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.the Combined Baseline Period) and age at informed consent (≥ 4 to <12 years of age, ≥12 to <18 
e). The estimate for the stratified difference in proportion of 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.e). The estimate for the stratified difference in proportion of 
free from PGTCS on LCM vs PBO and a corresponding 95% two
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.free from PGTCS on LCM vs PBO and a corresponding 95% two
) will be produced using mantel Haenszel methods (LaVange et al, 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.) will be produced using mantel Haenszel methods (LaVange et al, 
he statistical methodology is expressed as follows:
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.he statistical methodology is expressed as follows:
seizure freedom from PGTCS for treatment i (1=LCM and 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.seizure freedom from PGTCS for treatment i (1=LCM and 
2=PBO) in stratum h (1= ≤2 per 28 days Baseline PGTCS frequency and ≥ 4 to <12 years of age, 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.2=PBO) in stratum h (1= ≤2 per 28 days Baseline PGTCS frequency and ≥ 4 to <12 years of age, 
per 28 days Baseline PGTCS frequency and ≥12 to <18 years of age, 3= =≤2 per 28 days 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.per 28 days Baseline PGTCS frequency and ≥12 to <18 years of age, 3= =≤2 per 28 days 
Baseline PGTCS frequency and ≥18 years of age, 4= >2 per 28 days Baseline PGTCS frequency 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Baseline PGTCS frequency and ≥18 years of age, 4= >2 per 28 days Baseline PGTCS frequency 
and ≥ 4 to <12 years of age, 5= >2 per 28 days Baseline PGTCS frequency and ≥12 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.and ≥ 4 to <12 years of age, 5= >2 per 28 days Baseline PGTCS frequency and ≥12 
of age and 6= >2 per 28 days Baseline PGTCS frequency and ≥18 years of age and 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.of age and 6= >2 per 28 days Baseline PGTCS frequency and ≥18 years of age and 
}/
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.}/∑
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.∑{
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.{6
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.6
h=1
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.h=1
is the number of subjects in I treatment group and stratum h.  The variance of 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.is the number of subjects in I treatment group and stratum h.  The variance of 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.∑
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.∑
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.w
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.w2
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.26
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.6
h=1
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.h=1
Greenwood estimates of variance for 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Greenwood estimates of variance for 
The stratified proportion of subjects remaining seizure free from PGTCS for at least 166 days in 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.The stratified proportion of subjects remaining seizure free from PGTCS for at least 166 days in 
each treatment group and the associate
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.each treatment group and the associate
The KM estimate for the LCM 166
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.The KM estimate for the LCM 166
∑
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.∑6
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.6
ℎ
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.ℎ=
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.=
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.The KM estimate for the PBO 166
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.The KM estimate for the PBO 166
𝑆
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.𝑆
UCB   28 Mar 2019  
Statistical Analysis Plan  SP0982  
In order to assess superiority, 2- sided testing with α=0.05 will be used. The superiority test 
statistic, Q=d2/Var(d)  will be assessed by a chi-square distribution with 1 degree of freedom. 
This statistic is referred to as the “row mean score statistic” when using Proc Freq. 
The number and percentage of subjects who experience a PGTCS or censoring and the KM 
seizure-free rate from PGTCS (and 2-sided 95% CI) by Day 166 will be presented by treatment 
group for each stratum and overall. The stratified seizure-freedom rate from PGTCS (and 2-sided 
95% CI) at Day 166 for each treatment group and the difference between treatment groups will be presented. A Kaplan-Meier plot will be presented by treatment group for each stratum and 
overall. 
For the gatekeeping strategy, if the primary endpoint is statistically significant at the 5% level, 
then the key secondary efficacy endpoint will also be assessed at the 5% significance level. If the 
primary endpoint fails to reach statistical significance, then the key secondary efficacy endpoint 
will be exploratory only. 
Section 9.2.2.2, Analysis of Percent Change in PGTC seizure frequency from Combined Baseline 
has been removed from the SAP.  
The percent change in log-transformed PGTC seizure frequency during the first 6 weeks of the 
Treatment Period will be analyzed using analysis of covariance, controlling for Baseline seizure 
freque ncy.  
The percent change in log-transformed PGTC seizure frequency during the Treatment Period will be analyzed analysis of covariance, controlling for Baseline seizure frequency.  
All PGTC seizure frequency per 28 days data will be listed. 
Section 8.2.2.2, Time to first PGTCS during the 166-day Treatment Period, has been changed 
from:  
Time to the first PGTC seizure during the 24-week Treatment Period will be evaluated using a 
Cox proportional hazards regression model (Cox, 1972), with an effect for treatment, stratifying 
for the subjects’ Baseline PGTC seizure frequency (≤2 per 28 days vs >2 per 28 days in the 
Combined Baseline Period) and age at informed consent (≥ 4 to <12 years of age, ≥12 to <18 years of age vs ≥18 years of age). The analysis will use the stratification factors from IRT. If 5 
events or less (ie, less than 6 subjects who had a PGTC seizure) occur in a stratum, then data will 
be pooled by Baseline PGTC seizure frequency for analysis as follows:  
13. If 5 events or less occur in the group of subjects who are ≥12 and <18 years of age with ≤2 
Baseline PGTC seizures per 28 days, then this group will be combined for analysis with 
either the group of subjects who are ≥4 to <12 years of age with ≤2 Baseline PGTC seizures 
per 28 days or the group of subjects who are ≥18 years of age with ≤2 Baseline PGTC seizures per 28 days, whichever has the smallest number of events. 
14. If 5 events or less occur in the group of subjects who are ≥4 to <12 years of age with ≤2 Baseline PGTC seizures per 28 days, then this group will be combined for analysis with the 
group of subjects who are ≥12 to <18 years of age with ≤2 Baseline PGTC seizures per 28 
days. REDACTED COPY transformed PGTC seizure frequency during the Treatment Period 
REDACTED COPY transformed PGTC seizure frequency during the Treatment Period 
will be analyzed analysis of covariance, controlling for Baseline seizure frequency. 
REDACTED COPY will be analyzed analysis of covariance, controlling for Baseline seizure frequency. 
All PGTC seizure frequency per 28 days data will be listed.
REDACTED COPY All PGTC seizure frequency per 28 days data will be listed.
, Time to first PGTCS during the 
REDACTED COPY , Time to first PGTCS during the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Meier plot will be presented by treatment group for each stratum and 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Meier plot will be presented by treatment group for each stratum and 
For the gatekeeping strategy, if the primary endpoint is statistically significant at the 5% level, 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.For the gatekeeping strategy, if the primary endpoint is statistically significant at the 5% level, 
ndpoint will also be assessed at the 5% significance level. If the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.ndpoint will also be assessed at the 5% significance level. If the 
primary endpoint fails to reach statistical significance, then the key secondary efficacy endpoint 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.primary endpoint fails to reach statistical significance, then the key secondary efficacy endpoint 
uency from Combined Baseline 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.uency from Combined Baseline 
transformed PGTC seizure frequency during the first 6 weeks of the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.transformed PGTC seizure frequency during the first 6 weeks of the 
Treatment Period will be analyzed using analysis of covariance, controlling for Baseline seizure 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Treatment Period will be analyzed using analysis of covariance, controlling for Baseline seizure 
transformed PGTC seizure frequency during the Treatment Period 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.transformed PGTC seizure frequency during the Treatment Period 
will be analyzed analysis of covariance, controlling for Baseline seizure frequency. 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.will be analyzed analysis of covariance, controlling for Baseline seizure frequency. 
All PGTC seizure frequency per 28 days data will be listed.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.All PGTC seizure frequency per 28 days data will be listed.
, Time to first PGTCS during the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof., Time to first PGTCS during the 166
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.166
Time to the first PGTC seizure during the 24
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Time to the first PGTC seizure during the 24
Cox proportional hazards regression model
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Cox proportional hazards regression model
for the subjects’ Baseline PGTC seizure frequency (≤2 per 28 days vs >2 per 28 days in the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.for the subjects’ Baseline PGTC seizure frequency (≤2 per 28 days vs >2 per 28 days in the 
Combined Baseline Period) and age at informed consent (≥ 4 to <12 years of age, ≥12 to <18 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Combined Baseline Period) and age at informed consent (≥ 4 to <12 years of age, ≥12 to <18 
years of age vs ≥18 years of a
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.years of age vs ≥18 years of a ge). The analysis will use the stratification factors from IRT. If 5 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.ge). The analysis will use the stratification factors from IRT. If 5 
events or less (ie, less than 6 subjects who had a PGTC seizure) occur in a stratum, then data will 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.events or less (ie, less than 6 subjects who had a PGTC seizure) occur in a stratum, then data will 
be pooled by Baseline PGTC seizure frequency for analysis as follows: 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.be pooled by Baseline PGTC seizure frequency for analysis as follows: 
If 5 events or l
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.If 5 events or l ess occur in the group of subjects who are ≥12 and <18 years of age with ≤2 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.ess occur in the group of subjects who are ≥12 and <18 years of age with ≤2 
Baseline PGTC seizures per 28 days, then this group will be combined for analysis with 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Baseline PGTC seizures per 28 days, then this group will be combined for analysis with 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.either the group of subjects who are ≥4 to <12 years of age with ≤2 Baseline PGTC seizures 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.either the group of subjects who are ≥4 to <12 years of age with ≤2 Baseline PGTC seizures 
r 28 days or the group of subjects who are ≥18 years of age with ≤2 Baseline PGTC 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.r 28 days or the group of subjects who are ≥18 years of age with ≤2 Baseline PGTC 
seizures per 28 days, whichever has the smallest number of events.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.seizures per 28 days, whichever has the smallest number of events.
14.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.14.If 5 events or less occur in the group of subjects who are ≥4 to <12 years of age with ≤2 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.If 5 events or less occur in the group of subjects who are ≥4 to <12 years of age with ≤2 
UCB   28 Mar 2019  
Statistical Analysis Plan  SP0982  
15. If 5 events or less occur in the group of subjects who are ≥18 years of age with ≤2 Baseline 
PGTC seizures per 28 days, then this group will be combined for analysis with the group of 
subjects who are ≥12 to <18 years of age with ≤2 Baseline PGTC seizures per 28 days.  
16. Similarly, rules 1 to 3 apply to those age groups within subjects with > 2 Baseline PGTC seizures per 28 days. 
The stratified HR will be calculated using the placebo arm as the reference group. 
Additionally, a KM plot for time to first PGTC seizure as well as the KM estimate for the 
median time to first PGTC seizure will be provided. If the median time is not estimable, then the 
25
th percentile will be provided.  
Has been changed to:  
Time to the first PGTCS during the 24-week Treatment Period will be evaluated using a Cox proportional hazards regression model (Cox, 1972), with an effect for treatment, stratifying for the subjects’ Baseline PGTCS frequency (≤2 per 28 days vs >2 per 28 days in the Combined 
Baseline Period) and age at informed consent (≥ 4 to <12 years of age, ≥12 to <18 years of age 
vs ≥18 years of age). The analysis will use the stratification factors from IRT and pooled as described in Section 4.9.  
The hypothesis for the assessment of the time to first PGTCS is as follows: 
H
0: β=0  
Versus 
H1: β≠0 
where β is the coefficient of an independent variable representing the treatment effect in the model. The hazard function is represented by 
ℎ(𝑡,𝑋)= ℎ
0(𝑡)exp(∑𝛽 𝑗𝑋𝑗𝑝
𝑗=1 
where xj is the collection of independent variables and h0(t) is the baseline hazard at time t. For 
the null hypothesis, the testing will be 2- sided with an α=0.05. The assumptions of proportional 
hazards will also be checked.  
The stratified HR will be calculated using the placebo arm as the reference group. The SE and 
95% CI for the HR will also be reported.  
Additionally, a KM plot for time to 1st PGTCS  as well as the KM estimate for the median time 
to 1st PGTCS and 95% CI will be provided. If the median time is not estimable, then the 25th 
percentile and 95% CI will be provided. The number of 1st PGTCS  will be reported by treatment 
group for the Titration Period, first 12 Weeks, and Treatment Period as well as the % of subjects 
who were censored. 
Section 8.3, the following sentence has been added:  
All seizure data recorded during the treatment period will be summarized and listed for the 
seizure related other efficacy variables. Analyses of seizure-related other efficacy variables will 
be performed for the FAS. REDACTED COPY of the time to first PGTCS is as follows:
REDACTED COPY of the time to first PGTCS is as follows:
: β=0
REDACTED COPY : β=0
H
REDACTED COPY H1
REDACTED COPY 1: β≠0
REDACTED COPY : β≠0
where β is the coefficient of an independent variable representing the treatment effect in the 
REDACTED COPY where β is the coefficient of an independent variable representing the treatment effect in the 
model. The hazard function is represented by REDACTED COPY model. The hazard function is represented by
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.ided. If the median time is not estimable, then the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.ided. If the median time is not estimable, then the 
week Treatment Period will be evaluated using a Cox 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.week Treatment Period will be evaluated using a Cox 
, with an effect for treatment, stratifying for 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof., with an effect for treatment, stratifying for 
the subjects’ Baseline PGTCS frequency (≤2 per 28 days vs >2 per 28 days in the Combined 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.the subjects’ Baseline PGTCS frequency (≤2 per 28 days vs >2 per 28 days in the Combined 
Baseline Period) and age at informed consent (≥ 4 to <12 years of age, ≥12 to <18 years of age 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Baseline Period) and age at informed consent (≥ 4 to <12 years of age, ≥12 to <18 years of age 
8 years of age). The analysis will use the stratification factors from IRT and pooled as 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.8 years of age). The analysis will use the stratification factors from IRT and pooled as 
of the time to first PGTCS is as follows:
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.of the time to first PGTCS is as follows:
: β≠0
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.: β≠0
where β is the coefficient of an independent variable representing the treatment effect in the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.where β is the coefficient of an independent variable representing the treatment effect in the 
model. The hazard function is represented by
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.model. The hazard function is represented by
ℎ
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.ℎ(
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.(𝑡
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.𝑡,
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.,𝑋
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.𝑋)
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.)
is the collection of independent variables and 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.is the collection of independent variables and 
the null hypothesis, the testing will be 2
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.the null hypothesis, the testing will be 2
hazards will also be checked. 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.hazards will also be checked. 
The stratified HR will be calculated
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.The stratified HR will be calculated
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.95% CI for the HR will also be reported. 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.95% CI for the HR will also be reported. 
Additionally, a KM plot for time to 1st 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Additionally, a KM plot for time to 1st 
PGTCS and 95% CI will be provided. If the median time is
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.PGTCS and 95% CI will be provided. If the median time is
percentile and 95% CI will be provided. 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.percentile and 95% CI will be provided. 
group 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.group for the Titration Period
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.for the Titration Period
who were censored.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.who were censored.
Section 8.3, 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Section 8.3, 
UCB   28 Mar 2019  
Statistical Analysis Plan  SP0982  
Section 8.3.1.2 Days with seizures per 28 days, the following sentence was added to the 2nd to 
last paragraph: 
PCH will be calculated for the 6-week Titration Period, first 12 weeks of the Treatment Period 
and the 24-week Treatment Period. 
Section 8.3.1.3, Seizure-free status, was modified from:  
Refer to Section  8.2.1.1 for PGTC seizure-free status. 
A subject will have seizure freedom (seizure free s tatus=yes) for all generalized seizure types for 
the applicable Treatment Period if the subject completed the Treatment Period and reported zero 
generalized seizures for all days during the Treatment Period when the number of seizures was available, and had <10% of days during the Treatment Period with seizure data reported as “not 
done”. 
Has been changed to:  
A subject will have seizure- free status for PGTCS=yes for the Treatment Period if the subject 
completed the Treatment Period (with a minimum 166 days) and reported zero PGTCS or “not 
done” for all days during the Treatment Period. If the subject is exited from the study due to the 125
th event occurring reporting zero PGTCS or “not done” for all days and duration of the 
Treatment Period is < 166 days, then the subject has not achieved seizure-free status for PGTCS.  
A subject will have seizure free status=yes for all generalized seizure types for the applicable Treatment Period if the subject completed the Treatment Period and reported zero generalized 
seizures for all days during the Treatment Period when the number of generalized seizures was 
available, and had <10% of days during the Treatment Period with seizure data reported as “not 
done”. 
Seizure-free statuses will be calculated for 6-week Titration Period, first 12 weeks of the 
Treatment Period and the 24-week Treatment Period. 
Section 8.3.1.4, Responder status – reduction in PGTCS frequency, has been changed from:  
Response to treatment regarding PGTC seizure frequency will be based on the percent change in 
seizure frequency, calculated as described in Section 8.3.1.1. A responder is defined as a subject experiencing ≥50% reduction in PGTC seizure frequency per 28 days from the Combined 
Baseline to the period of interest (first 12 weeks of the Treatment Period or the 24-week 
Treatment Period).  
Has been changed to:  
Response to treatment will be based on the percent change in PGTCS frequency, calculated as 
described in  Section  8.3.1.1 . A 50% responder is defined as a subject experiencing ≥50% 
reduction in PGTCS frequency per 28 days from the Combined Baseline to the period of interest 
(6-week Titration Period, first 12 weeks of the Treatment Period or the 24-week Treatment 
Period). A 75% responder is defined as a subject experiencing ≥75% reduction in PGTCS 
frequency per 28 days from Combined Baseline to the period of interest (6-week Titration Period, first 12 weeks of the Treatment Period or the 24-week Treatment Period). 
Section 8.3.1.5 PGTCS worsening, is new:  REDACTED COPY en the subject has not achieved seizure
REDACTED COPY en the subject has not achieved seizure
A subject will have seizure free status=yes for all generalized seizure types for the applicable 
REDACTED COPY A subject will have seizure free status=yes for all generalized seizure types for the applicable 
Treatment Period if the subject completed the Treatment Period and reported zero generalized 
REDACTED COPY Treatment Period if the subject completed the Treatment Period and reported zero generalized 
izures for all days during the Treatment Period when the number of generalized seizures was 
REDACTED COPY izures for all days during the Treatment Period when the number of generalized seizures was 
available, and had <10% of days during the Treatment Period with seizure data reported as “not 
REDACTED COPY available, and had <10% of days during the Treatment Period with seizure data reported as “not 
free statuses will be calculated for 6 REDACTED COPY free statuses will be calculated for 6
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.tatus=yes) for all generalized seizure types for 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.tatus=yes) for all generalized seizure types for 
the applicable Treatment Period if the subject completed the Treatment Period and reported zero 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.the applicable Treatment Period if the subject completed the Treatment Period and reported zero 
generalized seizures for all days during the Treatment Period when the number of seizures was 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.generalized seizures for all days during the Treatment Period when the number of seizures was 
d <10% of days during the Treatment Period with seizure data reported as “not 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.d <10% of days during the Treatment Period with seizure data reported as “not 
free status for PGTCS=yes for the Treatment Period if the subject 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.free status for PGTCS=yes for the Treatment Period if the subject 
and reported zero PGTCS or “not 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.and reported zero PGTCS or “not 
done” for all days during the Treatment Period. If the subject is exited from the study due to the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.done” for all days during the Treatment Period. If the subject is exited from the study due to the 
event occurring reporting zero PGTCS or “not done” for all days and duration of the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.event occurring reporting zero PGTCS or “not done” for all days and duration of the 
en the subject has not achieved seizure
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.en the subject has not achieved seizure
A subject will have seizure free status=yes for all generalized seizure types for the applicable 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.A subject will have seizure free status=yes for all generalized seizure types for the applicable 
Treatment Period if the subject completed the Treatment Period and reported zero generalized 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Treatment Period if the subject completed the Treatment Period and reported zero generalized 
izures for all days during the Treatment Period when the number of generalized seizures was 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.izures for all days during the Treatment Period when the number of generalized seizures was 
available, and had <10% of days during the Treatment Period with seizure data reported as “not 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.available, and had <10% of days during the Treatment Period with seizure data reported as “not 
free statuses will be calculated for 6
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.free statuses will be calculated for 6 -
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.-week Titration 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.week Titration 
week Treatment Period.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.week Treatment Period.
–
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.–reduction in PGTCS frequency, has been changed from:
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.reduction in PGTCS frequency, has been changed from:
Response to treatment regarding PGTC seizure frequency will be based on the percent ch
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Response to treatment regarding PGTC seizure frequency will be based on the percent ch
seizure frequency, calculated as described in
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.seizure frequency, calculated as described in
experiencing ≥50% reduction in PGTC seizure frequency per 28 days from the Combined 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.experiencing ≥50% reduction in PGTC seizure frequency per 28 days from the Combined 
Baseline to the period of interest (first 12 weeks of the Treatme
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Baseline to the period of interest (first 12 weeks of the Treatme
Treatment Period). 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Treatment Period). 
Has been changed to:
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Has been changed to:
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Response to treatment will be based on the percent change in PGTCS frequency, calculated as 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Response to treatment will be based on the percent change in PGTCS frequency, calculated as 
described in
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.described in
reduction in PGTCS frequency per 28 days from the Combined Baseline to the period of interest 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.reduction in PGTCS frequency per 28 days from the Combined Baseline to the period of interest 
(6
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.(6-
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.-week Titration Period, first 12 weeks of the Treatment Period or the 24
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.week Titration Period, first 12 weeks of the Treatment Period or the 24
Period). A 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Period). A 
frequency per 28 days from Combined Baseline to the period of interest (6
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.frequency per 28 days from Combined Baseline to the period of interest (6
UCB   28 Mar 2019  
Statistical Analysis Plan  SP0982  
Seizure worsening is defined as a subject experiencing ≥50% increase in PGTCS frequency per 
28 days from Combined Baseline to the period of interest (6-week Titration Period, first 12 
weeks of the Treatment Period or the 24- week Treatment Period). 
Section 8.3.1.6 Responder status – reduction in days with absence seizures, is new:  
Response to treatment for absence seizures per 28 days will be based on the percent change in days with absence seizures, calculated as described in  Section  8.3.1.2. A 50% responder is 
defined as a subject experiencing ≥50% reduction in days with absence seizures per 28 days 
from the Prospective Baseline to the period of interest (6-week Titration Period, first 12 weeks of 
the Treatment Period or the 24-week Treatment Period). A 75% responder is defined as a subject experiencing ≥75% reduction in days with absence seizures per 28 days from the Pros pective 
Baseline to the period of interest (6-week Titration Period, first 12 weeks of the Treatment 
Period or the 24-week Treatment Period). 
Section 8.3.1.7 Responder status – reduction in days with myoclonic seizures, is new:  
Response to treatment for myoclonic seizures per 28 days will be based on the percent change in 
days with myoclonic seizures, calculated as described in  Section  8.3.1.2. A 50% responder is 
defined as a subject experiencing ≥50% reduction in days with myoclonic seizures per 28 days 
from the Prospective Baseline to the period of interest (6-week Titration Period, first 12 weeks of 
the Treatment Period or the 24-week Treatment Period). A 75% responder is defined as a subject experiencing ≥75% reduction in days with myoclonic seizures per 28 days from the Prospective 
Baseline to the period of interest (6-week Titration Period, first 12 weeks of the Treatment 
Period or the 24-week Treatment Period). 
Section 8.3.2.1, Percent Change in PGTCS frequency per 28 days from Combined Baseline, is 
new:  
Descriptive statistics will be provided on the percent change in PGTCS frequency for the first 6 
weeks of (entire Titration Period), first 12 weeks of, and the entire Treatment Period.   
All PGTCS frequency per 28 days data will be listed. 
Section 8.3.2.2 Reduction in days with seizures per 28 days was changed from:  
The following data will be summarized with descriptive statistics only: 
 Change in days with absence seizures per 28 days during the Treatment Period relative to the 
Prospective Baseline 
 Percent change in days with absence seizures per 28 days during the first 6 weeks of the 
Treatment Period (Titration Period) relative to the Prospective Baseline 
 Percent change in days with absence seizures per 28 days during the Treatment Period 
relative to the Prospective Baseline 
 Percentage of subjects with at least a 50% reduction in absence seizure days compared to the 
Prospective Baseline 
 Change in days with myoclonic seizures per 28 days during the Treatment Period relative to the Prospective Baseline REDACTED COPY od). A 75% responder is defined as a subject 
REDACTED COPY od). A 75% responder is defined as a subject 
experiencing ≥75% reduction in days with myoclonic seizures per 28 days from the Prospective 
REDACTED COPY experiencing ≥75% reduction in days with myoclonic seizures per 28 days from the Prospective 
week Titration Period, first 12 weeks of the Treatment 
REDACTED COPY week Titration Period, first 12 weeks of the Treatment 
Section 8.3.2.1, Percent Change in PGTCS frequency per 28 days from Combined Baseline, is 
REDACTED COPY Section 8.3.2.1, Percent Change in PGTCS frequency per 28 days from Combined Baseline, is 
Descriptive statistics will be provided on the percent change in PGTCS frequency for the first 6 REDACTED COPY Descriptive statistics will be provided on the percent change in PGTCS frequency for the first 6 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.week Titration Period, first 12 weeks of 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.week Titration Period, first 12 weeks of 
week Treatment Period). A 75% responder is defined as a subject 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.week Treatment Period). A 75% responder is defined as a subject 
experiencing ≥75% reduction in days with absence seizures per 28 days from the Pros
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.experiencing ≥75% reduction in days with absence seizures per 28 days from the Pros pective 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.pective 
week Titration Period, first 12 weeks of the Treatment 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.week Titration Period, first 12 weeks of the Treatment 
reduction in days with myoclonic seizures, is new:
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.reduction in days with myoclonic seizures, is new:
oclonic seizures per 28 days will be based on the percent change in 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.oclonic seizures per 28 days will be based on the percent change in 
8.3.1.2
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.8.3.1.2 . A 50% 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.. A 50% 
defined as a subject experiencing ≥50% reduction in days with myoclonic seizures per 28 days 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.defined as a subject experiencing ≥50% reduction in days with myoclonic seizures per 28 days 
week Titration Period, first 12 weeks of 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.week Titration Period, first 12 weeks of 
od). A 75% responder is defined as a subject 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.od). A 75% responder is defined as a subject 
experiencing ≥75% reduction in days with myoclonic seizures per 28 days from the Prospective 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.experiencing ≥75% reduction in days with myoclonic seizures per 28 days from the Prospective 
week Titration Period, first 12 weeks of the Treatment 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.week Titration Period, first 12 weeks of the Treatment 
Section 8.3.2.1, Percent Change in PGTCS frequency per 28 days from Combined Baseline, is 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Section 8.3.2.1, Percent Change in PGTCS frequency per 28 days from Combined Baseline, is 
Descriptive statistics will be provided on the percent change in PGTCS frequency for the first 6 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Descriptive statistics will be provided on the percent change in PGTCS frequency for the first 6 
weeks of (entire Titration Period), first 12 weeks of, and the entire Treatment Period.  
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.weeks of (entire Titration Period), first 12 weeks of, and the entire Treatment Period.  
All PGTCS frequency per 28 days data will be listed.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.All PGTCS frequency per 28 days data will be listed.
Reduction in days with seizures per 28 days was changed from:
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Reduction in days with seizures per 28 days was changed from:
The following data will be summarized with descriptive statistics only:
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.The following data will be summarized with descriptive statistics only:
Change in days with absence seizures per 28 days during the Treatment Period relative to the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Change in days with absence seizures per 28 days during the Treatment Period relative to the 
Prospective Baseline
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Prospective Baseline
change in days with absence seizures per 28 days during the first 6 weeks of the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.change in days with absence seizures per 28 days during the first 6 weeks of the 
Treatment Period (Titration Period) relative to the Prospective Baseline
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Treatment Period (Titration Period) relative to the Prospective Baseline
Percent change in days with absence seizures per 28 days during the Treatment Period 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Percent change in days with absence seizures per 28 days during the Treatment Period 
relative to the P
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.relative to the P

This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Percentage of subjects with at least a 50% reduction in absence seizure days compared to the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Percentage of subjects with at least a 50% reduction in absence seizure days compared to the 
UCB   28 Mar 2019  
Statistical Analysis Plan  SP0982  
 Percen t change in days with myoclonic seizures per 28 days during the first 6 weeks of the 
Treatment Period (Titration Period) relative to the Prospective Baseline 
 Percent change in days with myoclonic seizures per 28 days during the Treatment Period 
relative to the Prospective Baseline 
 Percentage of subjects with at least a 50% reduction in myoclonic seizure days compared to the Prospective Baseline 
All seizure days data for absence and myoclonic seizures will be listed. 
Has been changed to:  
The following data will be summarized with descriptive statistics only: 
 Change in days with absence seizures per 28 days during the Treatment Period relative to the 
Prospective Baseline 
 Percent change in days with absence seizures per 28 days during the first 6 weeks of the 
Treatment Period (Titration Period) relative to the Prospective Baseline 
 Percent change in days with absence seizures per 28 days during the first 12 weeks of the 
Treatment Period relative to the Prospective Baseline 
 Percent change in days with absence seizures per 28 days during the Treatment Period relative to the Prospective Baseline 
 Change in days with myoclonic seizures per 28 days during the Treatment Period relative to the Prospective Baseline 
 Percent change in days with myoclonic seizures per 28 days during the first 6 weeks of the Treatment Period (Titration Period) relative to the Prospective Baseline 
 Percent change in days with myoclonic seizures per 28 days during the first 12 weeks of the Treatment Period relative to the Prospective Baseline 
 Percent change in days with myoclonic seizures per 28 days during the Treatment Period 
relative to the Prospective Baseline 
All seizure days data for absence and myoclonic seizures will be listed. 
Section 8.3.2.3, Seizure-free status, was modified from:  
The following seizure-free status (yes/no) summaries will be provided: 
 Seizure-free status (yes, no) for PGTC seizures for the first 12 weeks of the Treatment Period  
 Seizure-free status (yes, no) for PGTC seizures for the 24-week Treatment Period  
 Seizure- free status (yes, no) for all generalized seizure types for the first 12 weeks of the 
Treatment Period  
 Seizure-free status (yes, no) for all generalized seizure types for the 24-week Treatment 
Period  
Has been changed to:  
The following seizure-free status (yes/no) summaries will be provided: REDACTED COPY ures per 28 days during the Treatment Period 
REDACTED COPY ures per 28 days during the Treatment Period 
Change in days with myoclonic seizures per 28 days during the Treatment Period relative to 
REDACTED COPY Change in days with myoclonic seizures per 28 days during the Treatment Period relative to 
Percent change in days with myoclonic seizures per 28 days
REDACTED COPY Percent change in days with myoclonic seizures per 28 days
Treatment Period (Titration Period) relative to the Prospective BaselineREDACTED COPY Treatment Period (Titration Period) relative to the Prospective Baseline
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Change in days with absence seizures per 28 days during the Treatment Period relative to the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Change in days with absence seizures per 28 days during the Treatment Period relative to the 
Percent change in days with absence seizures per 28 days during the first 6 weeks of the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Percent change in days with absence seizures per 28 days during the first 6 weeks of the 
reatment Period (Titration Period) relative to the Prospective Baseline
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.reatment Period (Titration Period) relative to the Prospective Baseline
Percent change in days with absence seizures per 28 days during the first 12 weeks of the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Percent change in days with absence seizures per 28 days during the first 12 weeks of the 
ures per 28 days during the Treatment Period 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.ures per 28 days during the Treatment Period 
Change in days with myoclonic seizures per 28 days during the Treatment Period relative to 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Change in days with myoclonic seizures per 28 days during the Treatment Period relative to 
Percent change in days with myoclonic seizures per 28 days
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Percent change in days with myoclonic seizures per 28 days
Treatment Period (Titration Period) relative to the Prospective Baseline
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Treatment Period (Titration Period) relative to the Prospective Baseline
Percent change in days with myoclonic seizures per 28 days during the first 12 weeks of the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Percent change in days with myoclonic seizures per 28 days during the first 12 weeks of the 
Treatment Period relative to the Prospective Baseline
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Treatment Period relative to the Prospective Baseline
ent change in days with myoclonic seizures per 28 days during the Treatment Period 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.ent change in days with myoclonic seizures per 28 days during the Treatment Period 
relative to the Prospective Baseline
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.relative to the Prospective Baseline
All seizure days data for absence and myoclonic seizures will be listed.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.All seizure days data for absence and myoclonic seizures will be listed.
Section 8.3.2.3, Seizure
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Section 8.3.2.3, Seizure -
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.-free status, was modified from:
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.free status, was modified from:-free status, was modified from:-
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.-free status, was modified from:-
following seizure
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.following seizure
Seizure
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Seizure -
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.-free status (yes, no) for PGTC seizures for the first 12 weeks of the Treatment Period 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.free status (yes, no) for PGTC seizures for the first 12 weeks of the Treatment Period 
Seizure
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Seizure free status (yes, no) for PGTC seizures for the 24
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.free status (yes, no) for PGTC seizures for the 24
Seizure
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Seizure
Treatment Period 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Treatment Period 
UCB   28 Mar 2019  
Statistical Analysis Plan  SP0982  
 Seizure-free status (yes, no) for PGTCS for the first 6 weeks of the Treatment Period 
(Titration Period) 
 Seizure-free status (yes, no) for PGTCS for the first 12 weeks of the Treatment Period  
 Seizure-free status (yes, no) for PGTCS for the 24-week Treatment Period  
 Seizure-free status (yes, no) for all generalized seizure types for the first 6 weeks of the Treatment Period (Titration Period) 
 Seizure-free status (yes, no) for all generalized seizure types for the first 12 weeks of the 
Treatment Period  
 Seizure-free status (yes, no) for all generalized seizure types for the 24-week Treatment Period  
Section 8.3.2.4, Responder status – reduction in PGTCS frequency 
The number and percentage of responders will be summarized with descriptive statistics only for 
the following periods of interest: 
 PGTC seizures during the first 12 weeks of the Treatment Period 
 PGTC seizures during the 24-week Treatment Period 
A histogram of ≥50%, ≥75% and 100% responder status for PGTC seizure frequency during the 
first 12 weeks and the 24-week Treatment Period by treatment group will be provided. 
Has been changed to:  
The following data will be summarized with descriptive statistics only: 
 Percentage of subjects with at least a 50% reduction in PGTCS frequency during the first 
6 weeks (Titration Period) compared to the Combined Baseline 
 Percentage of subjects with at least a 50% reduction in PGTCS frequency during the first 12 weeks of the Treatment Period compared to the Combined Baseline 
 Percen tage of subjects with at least a 50% reduction in PGTCS frequency during the 
Treatment Period compared to the Combined Baseline 
 Percentage of subjects with at least a 75% reduction in PGTCS frequency during the first 6 weeks (Titration Period) compared to the Combined Baseline 
 Percentage of subjects with at least a 75% reduction in PGTCS frequency during the first 
12 weeks of the Treatment Period compared to the Combined Baseline 
 Percentage of subjects with at least a 75% reduction in PGTCS frequency during the 
Treatment Period compared to the Combined Baseline 
A histogram of ≥50%, ≥75%, and 100% (seizure freedom) responder status for PGTCS frequency during the first 6 weeks (Titration Period), first 12 weeks, and the 24-week Treatment Period by treatment group will be provided. 
Section 8.3.2.5, Responder status – reduction in days with absence seizures, is new:  
The following data will be summarized with descriptive statistics only: REDACTED COPY A histogram of ≥50%, ≥75% and 100% responder status for PGTC seizure f
REDACTED COPY A histogram of ≥50%, ≥75% and 100% responder status for PGTC seizure f
week Treatment Period by treatment group will be provided.
REDACTED COPY week Treatment Period by treatment group will be provided.
The following data will be summarized with descriptive statistics only:
REDACTED COPY The following data will be summarized with descriptive statistics only:
Percentage of subjects with at least a 50% reduction in REDACTED COPY Percentage of subjects with at least a 50% reduction in 
6 weeks (Titration Period) compared to the Combined BaselineREDACTED COPY 6 weeks (Titration Period) compared to the Combined Baseline
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.weeks of the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.weeks of the 
week Treatment 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.week Treatment 
with descriptive statistics only for 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.with descriptive statistics only for 
PGTC seizures during the first 12 weeks of the Treatment Period
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.PGTC seizures during the first 12 weeks of the Treatment Period
A histogram of ≥50%, ≥75% and 100% responder status for PGTC seizure f
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.A histogram of ≥50%, ≥75% and 100% responder status for PGTC seizure f
week Treatment Period by treatment group will be provided.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.week Treatment Period by treatment group will be provided.
The following data will be summarized with descriptive statistics only:
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.The following data will be summarized with descriptive statistics only:
Percentage of subjects with at least a 50% reduction in 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Percentage of subjects with at least a 50% reduction in 
6 weeks (Titration Period) compared to the Combined Baseline
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.6 weeks (Titration Period) compared to the Combined Baseline
Percentage of subjects with at least a 50% reduction in PGTCS frequency during the first 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Percentage of subjects with at least a 50% reduction in PGTCS frequency during the first 
12 weeks of the Treatment Period compared to the Combined Baseline
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.12 weeks of the Treatment Period compared to the Combined Baseline
tage of subjects with at least a 50% reduction in PGTCS frequency during the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.tage of subjects with at least a 50% reduction in PGTCS frequency during the 
Treatment Period compared to the Combined Baseline
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Treatment Period compared to the Combined Baseline
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Percentage of subjects with at least a 75% reduction in PGTCS frequency during the first 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Percentage of subjects with at least a 75% reduction in PGTCS frequency during the first 
6 weeks (Titration Period) compared to 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.6 weeks (Titration Period) compared to 
Percentage of subjects with at least a 75% reduction in PGTCS frequency during the first 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Percentage of subjects with at least a 75% reduction in PGTCS frequency during the first 
12 weeks of the Treatment Period compared to the Combined Baseline
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.12 weeks of the Treatment Period compared to the Combined Baseline
Percentage of subjects with at least a 75% reduction in PGTCS frequency during
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Percentage of subjects with at least a 75% reduction in PGTCS frequency during
Treatment Period compared to the Combined Baseline
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Treatment Period compared to the Combined Baseline
A histogram of ≥50%, ≥75%, and 100% (seizure freedom) responder status for PGTCS 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.A histogram of ≥50%, ≥75%, and 100% (seizure freedom) responder status for PGTCS 
frequency during the first 6 weeks (Titration Period), first 12 weeks, and the 24
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.frequency during the first 6 weeks (Titration Period), first 12 weeks, and the 24
UCB   28 Mar 2019  
Statistical Analysis Plan  SP0982  
 Percentage of subjects with at least a 50% reduction in absence seizure days during the first 6 
weeks of the Treatment Period (Titration Period) compared to the Prospective Baseline 
 Percentage of subjects with at least a 50% reduction in absence seizure days during the first 12 weeks of the Treatment Period compared to the Prospective Baseline 
 Percentage of subjects with at least a 50% reduction in absence seizure days during the Treatment Period compared to the Prospective Baseline 
 Percentage of subjects with at least a 75% reduction in absence seizure days during the first 6 weeks of the Treatment Period (Titration Period) compared to the Prospective Baseline 
 Percentage of subjects with at least a 75% reduction in absence seizure days during the first 
12 weeks of the Treatment Period compared to the Prospective Baseline 
 Percentage of subjects with at least a 75% reduction in absence seizure days during the 
Treatment Period compared to the Prospective Baseline 
 A histogram of ≥50%, ≥75%, and 100% (seizure freedom) responder status for reduction in days with absence seizures during the first 6 weeks (Titration Period), first 12 weeks, and the 24-week Treatment Period by treatment group will be provided. 
Section 8.3.2.6, Responder status – reduction in days with myoclonic seizures 
The following data will be summarized with descriptive statistics only: 
 Percentage of subjects with at least a 50% reduction in myoclonic seizure days during the 
first 6 weeks of the Treatment Period (Titration Period) compared to the Prospective Baseline  
 Percentage of subjects with at least a 50% reduction in myoclonic seizure days during the first 12 weeks of the Treatment Period compared to the Prospective Baseline  
 Percentage of subjects with at least a 50% reduction in myoclonic seizure days during the Treatment Period compared to the Prospective Baseline  
 Percentage of subjects with at least a 75% reduction in myoclonic seizure days during the 
first 6 weeks of the Treatment Period (Titration Period) compared to the Prospective Baseline 
 Percentage of subjects with at least a 75% reduction in myoclonic seizure days during the 
first 12 weeks of the Treatment Period compared to the Prospective Baseline 
 Percentage of subjects with at least a 75% reduction in myoclonic seizure days during the Treatment Period compared to the Prospective Baseline 
Section 8.4.2.1, QOLIE- 31-P variables, the following paragraph was added:  
QOLIE-31-P data, for a specific visit may have a status of Abandoned if the subject doesn’t complete the questionnaire. If the subject has duplicate QOLIE-31-P data for the same visit, where one record is deemed as Abandoned and one record is deemed as Completed, the 
Completed data will be used in the analysis and not the Abandoned record. All recorded QOLIE-
31-P data will be listed. 
Section 8.4.2.1, QOLIE- 31-P variables, the following sentence was add ed to the 2
nd paragraph:  REDACTED COPY reduction in days with myoclonic seizures
REDACTED COPY reduction in days with myoclonic seizures
The following data will be summarized with descriptive st
REDACTED COPY The following data will be summarized with descriptive st
Percentage of subjects with at least a 50% reduction in myoclonic seizure days during the 
REDACTED COPY Percentage of subjects with at least a 50% reduction in myoclonic seizure days during the 
first 6 weeks of the Treatment Period (Titration Period) compared to the Prospective Baseline 
REDACTED COPY first 6 weeks of the Treatment Period (Titration Period) compared to the Prospective Baseline 
Percentage of subjects with at least a 50% reduction in 
REDACTED COPY Percentage of subjects with at least a 50% reduction in 
first 12 weeks of the Treatment Period compared to the Prospective Baseline REDACTED COPY first 12 weeks of the Treatment Period compared to the Prospective Baseline 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Percentage of subjects with at least a 75% reduction in absence seizure days during the first 6 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Percentage of subjects with at least a 75% reduction in absence seizure days during the first 6 
of the Treatment Period (Titration Period) compared to the Prospective Baseline
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.of the Treatment Period (Titration Period) compared to the Prospective Baseline
Percentage of subjects with at least a 75% reduction in absence seizure days during the first 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Percentage of subjects with at least a 75% reduction in absence seizure days during the first 
of subjects with at least a 75% reduction in absence seizure days during the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.of subjects with at least a 75% reduction in absence seizure days during the 
A histogram of ≥50%, ≥75%, and 100% (seizure freedom) responder status for reduction in 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.A histogram of ≥50%, ≥75%, and 100% (seizure freedom) responder status for reduction in 
first 6 weeks (Titration Period), first 12 weeks, and the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.first 6 weeks (Titration Period), first 12 weeks, and the 
week Treatment Period by treatment group will be provided.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.week Treatment Period by treatment group will be provided.
reduction in days with myoclonic seizures
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.reduction in days with myoclonic seizures
The following data will be summarized with descriptive st
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.The following data will be summarized with descriptive st atistics only:
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.atistics only:
Percentage of subjects with at least a 50% reduction in myoclonic seizure days during the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Percentage of subjects with at least a 50% reduction in myoclonic seizure days during the 
first 6 weeks of the Treatment Period (Titration Period) compared to the Prospective Baseline 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.first 6 weeks of the Treatment Period (Titration Period) compared to the Prospective Baseline 
Percentage of subjects with at least a 50% reduction in 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Percentage of subjects with at least a 50% reduction in 
first 12 weeks of the Treatment Period compared to the Prospective Baseline 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.first 12 weeks of the Treatment Period compared to the Prospective Baseline 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Percentage of subjects with at least a 50% reduction in myoclonic seizure days during the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Percentage of subjects with at least a 50% reduction in myoclonic seizure days during the 
Treatment Period compared to the Prospective Baseline 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Treatment Period compared to the Prospective Baseline 
Percentage of subjects with at least a 75% reduction in myoclonic seizure days during the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Percentage of subjects with at least a 75% reduction in myoclonic seizure days during the 
first 6 weeks of the Treatment Period (Titration Period) compared to the Prospective Baseline
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.first 6 weeks of the Treatment Period (Titration Period) compared to the Prospective Baseline
Percentage of subjects with at least a 75% reduction in myoclonic seizur
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Percentage of subjects with at least a 75% reduction in myoclonic seizur
first 12 weeks of the Treatment Period compared to the Prospective Baseline
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.first 12 weeks of the Treatment Period compared to the Prospective Baseline
Percentage of subjects with at least a 75% reduction in myoclonic seizure days during the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Percentage of subjects with at least a 75% reduction in myoclonic seizure days during the 
Treatment Period compared to the Prospective Baseline
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Treatment Period compared to the Prospective Baseline
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Section 8.4.2.1, Q
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Section 8.4.2.1, Q
QOLIE
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.QOLIE -
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.-31
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.31
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.P data, for a specific visit may have a status of Abandoned if the subject doesn’t 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.P data, for a specific visit may have a status of Abandoned if the subject doesn’t 
complete the questionnaire. If the subject has duplicate QOLIE
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.complete the questionnaire. If the subject has duplicate QOLIE
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.where one recor
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.where one recor
Completed data will be used in the analysis and not the Abandoned record. All recorded QOLIE
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Completed data will be used in the analysis and not the Abandoned record. All recorded QOLIE
UCB   28 Mar 2019  
Statistical Analysis Plan  SP0982  
The means of the QOLIE-31-P total score, subscale scores and health status item score will be 
plotted by visit. 
Section 8.4.2.2, PedsQL variables, the following sentence was added:  
The means of the PedsQL subscale scores and total score will be plotted by visit. 
Section 8.4.2.3, EQ-5D-3L quality of life variables, the following sentence was added:  
The mean of the EQ-5D-3L VAS will be plotted by visit.  For the EQ-5D-3L, the percentage of 
subjects reporting a level within each dimension will be plotted in a histogram. 
Section 10.1.2, Analysis of exposure variables, the 2nd paragraph was changed from:  
Treatment duration will be summarized with the number and percentage of subjects with 
treatment duration by 3 Week categories: 1-21 days, 22–42 days, 43–63 days, 64–84 days, 
85-105 days, 106–126 days, 127-147 days, 148-168 days, and > 168 days. Furthermore, the 
subject years exposed will be presented for the entire Treatment Period. 
 Has been changed to:  
Treatment duration will be summarized with the number and percentage of subjects with 
treatment duration by 3 Week categories: 1 to 21 days, 22 to 42 days, 43 to 63 days, 64 to 84 
days, 85 to 105 days, 106 to 126 days, 127 to 147 days, 148 to 168 days, and > 168 days. 
Furthermore, the subject years exposed will be presented for the entire Treatment Period. 
If actual dosing information is presented, the LCM dose categories for oral solution are as 
follows: 0mg/kg/day/Unknown, >0 to <4mg/kg/day, ≥4mg/kg/day to <8mg/kg/day, and ≥8mg/kg 
day.  The LCM dose categories for tablets are as follows: 0mg/day/Unknown, >0 to 
<200mg/day, ≥200 to <400mg/day, ≥400 to <600mg/day, ≥600 to 800mg/day, and ≥800mg/day. 
Section 10.2, Adverse events, the following paragraphs were modified from:  
 Incidence of other significant TEAEs (See Section 12.2 for details). 
The following summary will be presented by actual dose at onset (Placebo oral solution, 
0mg/kg/day, >0 to <4mg/kg/day, ≥4 to <8mg/kg/day, ≥8 to <12mg/kg/day, >12mg/kg/day, Placebo tablets, 0mg/day, >0 to <200mg/day, ≥200 to <300mg/day, ≥300 to <400mg/day and 
≥400mg/day). AEs of pediatric subjects weighing <50kg randomized to LCM but where no LCM 
was taken will be summarized in the 0mg/kg/day column; AEs of adult subjects and pediatric subjects weighing ≥50kg randomized to LCM but where no LCM was taken will be summarized 
in the 0mg/day column. AEs of unknown dosing are not summarized but those taken where LCM 
dose is 0mg/kg/day or 0mg/day are in the applicable column.  AEs of unknown dosing are those with UNK as the dose or known dosing and partial AE start or stop dates. 
 Incidence of TEAEs by actual dose at onset  
Subject data listings will be presented for the following: 
 Subjects experiencing TEAEs 
 Subjects experiencing Serious TEAEs 
 Subjects experiencing TEAEs leading to discontinuation REDACTED COPY treatment duration by 3 Week categories: 1 to 21 days, 22 to 42 days, 43 to 63 days, 64 to 84 
REDACTED COPY treatment duration by 3 Week categories: 1 to 21 days, 22 to 42 days, 43 to 63 days, 64 to 84 
days, 85 to 105 days, 106 to 126 days, 127 to 147 days, 148 to 168 days, and > 168 days. 
REDACTED COPY days, 85 to 105 days, 106 to 126 days, 127 to 147 days, 148 to 168 days, and > 168 days. 
he subject years exposed will be presented for the entire Treatment Period.
REDACTED COPY he subject years exposed will be presented for the entire Treatment Period.
If actual dosing information is presented, the LCM dose categories for oral solution are as 
REDACTED COPY If actual dosing information is presented, the LCM dose categories for oral solution are as 
follows: 0mg/kg/day/Unknown, >0 to <4mg/kg/day, ≥4mg/kg/day to <8mg/kg/day, and ≥8mg/kg 
REDACTED COPY follows: 0mg/kg/day/Unknown, >0 to <4mg/kg/day, ≥4mg/kg/day to <8mg/kg/day, and ≥8mg/kg 
day.  The LCM dose categories for tablets are as follows: 0mg/day/Unknown, >0 to 
REDACTED COPY day.  The LCM dose categories for tablets are as follows: 0mg/day/Unknown, >0 to 
<200mg/day, ≥200 to <400mg/day, ≥400 to <600mg/day, ≥600 to 800mg/day, and ≥800mg/day. REDACTED COPY <200mg/day, ≥200 to <400mg/day, ≥400 to <600mg/day, ≥600 to 800mg/day, and ≥800mg/day.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.3L, the percentage of 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.3L, the percentage of 
Treatment duration will be summarized with the number and percentage of subjects with 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Treatment duration will be summarized with the number and percentage of subjects with 
–
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.–84 days, 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.84 days, 
168 days, and > 168 days. Furthermore, the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.168 days, and > 168 days. Furthermore, the 
summarized with the number and percentage of subjects with 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.summarized with the number and percentage of subjects with 
treatment duration by 3 Week categories: 1 to 21 days, 22 to 42 days, 43 to 63 days, 64 to 84 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.treatment duration by 3 Week categories: 1 to 21 days, 22 to 42 days, 43 to 63 days, 64 to 84 
days, 85 to 105 days, 106 to 126 days, 127 to 147 days, 148 to 168 days, and > 168 days. 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.days, 85 to 105 days, 106 to 126 days, 127 to 147 days, 148 to 168 days, and > 168 days. 
he subject years exposed will be presented for the entire Treatment Period.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.he subject years exposed will be presented for the entire Treatment Period.
If actual dosing information is presented, the LCM dose categories for oral solution are as 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.If actual dosing information is presented, the LCM dose categories for oral solution are as 
follows: 0mg/kg/day/Unknown, >0 to <4mg/kg/day, ≥4mg/kg/day to <8mg/kg/day, and ≥8mg/kg 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.follows: 0mg/kg/day/Unknown, >0 to <4mg/kg/day, ≥4mg/kg/day to <8mg/kg/day, and ≥8mg/kg 
day.  The LCM dose categories for tablets are as follows: 0mg/day/Unknown, >0 to 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.day.  The LCM dose categories for tablets are as follows: 0mg/day/Unknown, >0 to 
<200mg/day, ≥200 to <400mg/day, ≥400 to <600mg/day, ≥600 to 800mg/day, and ≥800mg/day.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.<200mg/day, ≥200 to <400mg/day, ≥400 to <600mg/day, ≥600 to 800mg/day, and ≥800mg/day.
Section 10.2, Adverse events, the following paragraphs were modified from:
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Section 10.2, Adverse events, the following paragraphs were modified from:
other significant TEAEs (See Section 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.other significant TEAEs (See Section 
The following summary will be presented by actual dose at onset (Placebo oral solution, 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.The following summary will be presented by actual dose at onset (Placebo oral solution, 
<4mg/kg/day, ≥4 to <8mg/kg/day, ≥8 to <12mg/kg/day, >12mg/kg/day, 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.<4mg/kg/day, ≥4 to <8mg/kg/day, ≥8 to <12mg/kg/day, >12mg/kg/day, 
Placebo tablets, 0mg/day, >0 to
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Placebo tablets, 0mg/day, >0 to
≥400mg/day). AEs of pediatric subjects weighing <50kg randomized to LCM but where no LCM 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.≥400mg/day). AEs of pediatric subjects weighing <50kg randomized to LCM but where no LCM 
as taken will be summarized in the 0mg/kg/day column; AEs of adult subjects and pediatric 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.as taken will be summarized in the 0mg/kg/day column; AEs of adult subjects and pediatric 
subjects weighing ≥50kg randomized to LCM but where no LCM was taken will be summarized 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.subjects weighing ≥50kg randomized to LCM but where no LCM was taken will be summarized 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.in the 0mg/day column. AEs of unknown dosing are not summarized but those take
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.in the 0mg/day column. AEs of unknown dosing are not summarized but those take
dose is 0mg/kg/day or 0mg/day are in the applicable column.  AEs of unknown dosing are those 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.dose is 0mg/kg/day or 0mg/day are in the applicable column.  AEs of unknown dosing are those 
with UNK as the dose or known dosing and partial AE start or stop dates.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.with UNK as the dose or known dosing and partial AE start or stop dates.
Incidence of TEAEs by actual dose at onset 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Incidence of TEAEs by actual dose at onset 
Subject data listings will be pres
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Subject data listings will be pres
UCB   28 Mar 2019  
Statistical Analysis Plan  SP0982  
A glossary of AEs will be presented showing the mapping of investigator terms to coded SOC 
and PTs. 
A list of further AE tables required for EudraCT and clinicaltrials.gov is provided in 
Section  12.5. 
Has been changed to:  
 Incidence of other significant TEAEs (See Section 12.2.1  for details) 
 Incidence of TEAEs for potential drug-induced liver injury (PDILI) (See Section 12.2.2 for details) 
To assess TEAEs related to epilepsy, PTs will be identified by ongoing manual medical review.  The following PTs (including those identified from continuing medical review) will be 
summarized: petit mal epilepsy, myoclonus, and myoclonic epilepsy. 
 Incidence of TEAEs of interest related to epilepsy by 3-month exposure period of TEAE 
onset 
The dose at onset TEAE summaries will be presented by the LCM dosing categories presented in 
Section  10.1.2. AEs of unknown dosing are those with no known dose or known dosing and 
partial AE start or stop dates. 
 Incidence of TEAEs by actual dose at onset  
Subject data listings will be presented for the following: 
 Subjects experiencing adverse events on the ES 
 Subjects experiencing Serious TEAEs on the SS 
 Subjects experiencing TEAEs leading to discontinuation on the SS 
A glossary of AEs will be presented showing the mapping of investigator terms to coded SOC 
and PTs. 
A list of further AE tables required for EudraCT and clinicaltrials.gov is provided in 
Section  12.5. 
Section 10.3, clinical laboratory evaluations, the following paragraphs were modified from:  
Markedly abnormal (MA) values indicate significant deviations from the expected range of 
age-appropriate values. Marked laboratory abnormalities observed post-Baseline during the 
Treatment Period but not present at Baseline are considered treatment emergent. MA values for 
serum chemistry and hematology laboratory parameters are provided in UCB conventional 
(traditional) and standard units. The definition of MA values for hematology and chemistry 
values can be found in Section 12.3. 
The number and percentage of subjects with at least 1 treatment-emergent markedly abnormal 
(TEMA) value will be summarized by visit for each laboratory parameter (hematology and 
clinical chemistry) with markedly abnormal criteria specified. TEMA values are those that are 
observed during the defined treatment period at scheduled or unscheduled visits and were not 
observed at any visit during the Baseline period. A table summarizing the number of subjects 
meeting the potential drug induced liver injury criteria will also be presented. REDACTED COPY Subject data listings will be presented for the following:
REDACTED COPY Subject data listings will be presented for the following:
Subjects experiencing adverse events on the ES
REDACTED COPY Subjects experiencing adverse events on the ES
Subjects experiencing Serious TEAEs on the SS
REDACTED COPY Subjects experiencing Serious TEAEs on the SS
Subjects experiencing TEAEs leading to discontinuation on the SS REDACTED COPY Subjects experiencing TEAEs leading to discontinuation on the SS
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.for 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.for 
To assess TEAEs related to epilepsy, PTs will be identified by ongoing manual medical review.  
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.To assess TEAEs related to epilepsy, PTs will be identified by ongoing manual medical review.  
ng medical review) will be 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.ng medical review) will be 
month exposure period of TEAE 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.month exposure period of TEAE 
The dose at onset TEAE summaries will be presented by the LCM dosing c
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.The dose at onset TEAE summaries will be presented by the LCM dosing c
. AEs of unknown dosing are those with no known dose or known dosing and 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.. AEs of unknown dosing are those with no known dose or known dosing and 
Subject data listings will be presented for the following:
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Subject data listings will be presented for the following:
Subjects experiencing adverse events on the ES
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Subjects experiencing adverse events on the ES
Subjects experiencing Serious TEAEs on the SS
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Subjects experiencing Serious TEAEs on the SS
Subjects experiencing TEAEs leading to discontinuation on the SS
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Subjects experiencing TEAEs leading to discontinuation on the SS
glossary of AEs will be presented showing the mapping of investigator terms to coded SOC 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.glossary of AEs will be presented showing the mapping of investigator terms to coded SOC 
A list of further AE tables required for EudraCT and clinicaltrials.gov is provided in 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.A list of further AE tables required for EudraCT and clinicaltrials.gov is provided in 
Section 10.3, clinical laboratory evaluations, the following paragraphs were modified from:
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Section 10.3, clinical laboratory evaluations, the following paragraphs were modified from:
Markedly abnormal (MA) values indicate significant deviations from the expected range of 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Markedly abnormal (MA) values indicate significant deviations from the expected range of 
appropriate values. M
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.appropriate values. M
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Treatment Period but not present at Baseline are considered treatment emergent. MA values for 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Treatment Period but not present at Baseline are considered treatment emergent. MA values for 
serum chemistry and hematology laboratory parameters are provided in UCB conventional 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.serum chemistry and hematology laboratory parameters are provided in UCB conventional 
(traditiona
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.(traditiona l) and standard units. The definition of MA values for hematology and chemistry 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.l) and standard units. The definition of MA values for hematology and chemistry 
values can be found in Section 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.values can be found in Section 
The 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.The number and percentage of subjects with at least 1 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.number and percentage of subjects with at least 1 
(TEMA) value
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.(TEMA) value
UCB   28 Mar 2019  
Statistical Analysis Plan  SP0982  
The NCI CTC criteria can be found in Section  12.4 .  The number and percentage of subjects 
with treatment emergent laboratory abnormalities of NCI CTC grade 2 or higher (hematology 
and clinical chemistry) will be summarized by treatment group, laboratory parameter, and visit for the Treatment Period. Treatment emergent abnormalities of grade 2 or higher are those that 
were observed during the Treatment Period at scheduled visits and not reporting a grade 2 or 
higher abnormality during the Baseline Period.  
Has been changed to:  
Treatment -emergent markedly abnormal (TEMA) values indicate significant deviations from the 
expected range of age-appropriate values. TEMA laboratory abnormalities results are those that 
are observed post-Baseline during the Treatment Period but are not present at Baseline. TEMA 
values for serum chemistry and hematology laboratory parameters are provided in UCB 
conventional (traditional) and standard units. The definition of MA values for hematology and 
chemistry values can be found in Section 12.3. The number and percentage of subjects with at 
least 1 TEMA value will be summarized by scheduled visit, Last Visit, minimum and maximum post-Baseline values obtained during the Treatment Period for each laboratory parameter (hematology and clinical chemistry) with markedly abnormal criteria specified. TEMA values 
are those that are observed during the defined treatment period at scheduled or unscheduled visits 
and were not observed at any visit during the Baseline period.  
A table summarizing the number of subjects meeting the potential drug induced liver injury 
criteria will also be presented. 
The National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTC) 
can be found in Section 12.4 . The number and percentage of subjects with treatment emergent 
laboratory abnormalities of NCI CTC grade 2 or higher (hematology and clinical chemistry) will 
be summarized by treatment group, laboratory parameter, and visit for the Treatment Period. 
Treatment emergent abnormalities of grade 2 or higher are those that were observed during the 
Treatment Period at scheduled visits and not reporting a grade 2 or higher abnormality during the Basel ine Period. All treatment emergent laboratory abnormalities of NCI CTC grade 2 or higher 
will be presented in a subject number listing. 
Section 10.4.1, Vital Signs, the following sentence was inserted:  
All TEMA results summarized will be presented in a subject number listing. 
Section 10.4.2.2, Analysis of ECG parameters, was modified from:  
Absolute values and change from Baseline of ECG parameters will be summarized using 
descriptive statistics for the scheduled visits, overall, Last Visit, minimum and maximum post-
Baseline values obtained during the Treatment Period, and in each of the age groups. 
Unscheduled ECG assessments during the study will not be presented in by-visit summaries, but will be considered when determining the last visit, minimum, and maximum post-Baseline 
values during the Treatment Period. If repeat measurements are taken at a particular visit, then 
the average value is used in summaries and the original values are listed. 
The number and percentage of subjects who met each of the treatment-emergent abnormality 
criteria specified in Section  12.3.4 will be presented within the specified age groups. For each 
parameter, the number and percentage of subjects with an abnormality (ie subjects who met any 
of the criteria specific to their age) will be summarized for heart rate, PR interval and QRS REDACTED COPY ects meeting the potential drug induced liver injury 
REDACTED COPY ects meeting the potential drug induced liver injury 
The National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTC) 
REDACTED COPY The National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTC) 
. The number and percentage of subjects with treatment emergent 
REDACTED COPY . The number and percentage of subjects with treatment emergent 
laboratory abnormalities of NCI CTC grade 2 or higher (hematology and clinical chemistry) will 
REDACTED COPY laboratory abnormalities of NCI CTC grade 2 or higher (hematology and clinical chemistry) will 
laboratory parameter, and visit for the Treatment Period. REDACTED COPY laboratory parameter, and visit for the Treatment Period. 
Treatment emergent abnormalities of grade 2 or higher are those that were observed during the REDACTED COPY Treatment emergent abnormalities of grade 2 or higher are those that were observed during the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.emergent markedly abnormal (TEMA) values indicate significant deviations from the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.emergent markedly abnormal (TEMA) values indicate significant deviations from the 
appropriate values. TEMA laboratory abnormalities results are those that 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.appropriate values. TEMA laboratory abnormalities results are those that 
Baseline during the Treatment Period but are not present at Baseline. TEMA 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Baseline during the Treatment Period but are not present at Baseline. TEMA 
UCB 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.UCB 
conventional (traditional) and standard units. The definition of MA values for hematology and 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.conventional (traditional) and standard units. The definition of MA values for hematology and 
number and percentage of subjects with at 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.number and percentage of subjects with at 
will be summarized by scheduled visit, Last Visit, minimum and maximum 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.will be summarized by scheduled visit, Last Visit, minimum and maximum 
Baseline values obtained during the Treatment Period for each laboratory parameter 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Baseline values obtained during the Treatment Period for each laboratory parameter 
criteria specified. TEMA values 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.criteria specified. TEMA values 
are those that are observed during the defined treatment period at scheduled or unscheduled visits 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.are those that are observed during the defined treatment period at scheduled or unscheduled visits 
ects meeting the potential drug induced liver injury 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.ects meeting the potential drug induced liver injury 
The National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTC) 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.The National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTC) 
. The number and percentage of subjects with treatment emergent 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.. The number and percentage of subjects with treatment emergent 
laboratory abnormalities of NCI CTC grade 2 or higher (hematology and clinical chemistry) will 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.laboratory abnormalities of NCI CTC grade 2 or higher (hematology and clinical chemistry) will 
laboratory parameter, and visit for the Treatment Period. 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.laboratory parameter, and visit for the Treatment Period. 
Treatment emergent abnormalities of grade 2 or higher are those that were observed during the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Treatment emergent abnormalities of grade 2 or higher are those that were observed during the 
Treatment Period at scheduled visits and not reporting a grade 2 or higher abnormality during the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Treatment Period at scheduled visits and not reporting a grade 2 or higher abnormality during the 
ine Period. All treatment emergent laboratory abnormalities of NCI CTC grade 2 or higher 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.ine Period. All treatment emergent laboratory abnormalities of NCI CTC grade 2 or higher 
will be presented in a subject number listing.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.will be presented in a subject number listing.
Section 10.4.1, Vital Signs, the following sentence was inserted:
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Section 10.4.1, Vital Signs, the following sentence was inserted:
All TEMA results summarized will be presented in a 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.All TEMA results summarized will be presented in a 
Section 10.4.2.2, Analysis of ECG parameters, was modified from:
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Section 10.4.2.2, Analysis of ECG parameters, was modified from:
Absolute values and change from Baseline of ECG parameters will be summarized using 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Absolute values and change from Baseline of ECG parameters will be summarized using 
descriptive statistics for the scheduled visits, overall, Last Visit, minimum and m
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.descriptive statistics for the scheduled visits, overall, Last Visit, minimum and m
Baseline values obtained during the Treatment Period, and in each of the age groups. 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Baseline values obtained during the Treatment Period, and in each of the age groups. 
Unscheduled ECG assessments during the study will not be presented in by
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Unscheduled ECG assessments during the study will not be presented in by
will be considered when determining the last visit, minimum, and 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.will be considered when determining the last visit, minimum, and 
values during the Treatment Period. If repeat measurements are taken at a particular visit, then 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.values during the Treatment Period. If repeat measurements are taken at a particular visit, then 
the average value is used in summaries and the original values are listed.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.the average value is used in summaries and the original values are listed.
UCB   28 Mar 2019  
Statistical Analysis Plan  SP0982  
interval. Subject numbers for those with treatment-emergent abnormal ECG values will be listed 
by abnormality criteria. Treatment -emergent abnormal results for a subject are those that are 
observed during the defined treatment period at scheduled or unscheduled visits and were not 
observed at any visit during the Baseline period. 
Detailed information on the quantitative and qualitative ECG findings will be presented in 
subject data listings. 
Has been changed to 
For quantitative ECG measurements (heart rate, PR interval, QRS interval, QT interval, RR 
Interval and corrected QT intervals using Bazett and Fridiricia correction methods), summary statistics of the actual values and change from Baseline will be summarized using descriptive 
statistics for the scheduled visits, overall, Last Visit, minimum and maximum post-Baseline 
values obtained during the Treatment Period, and in each of the TEMA ECG criteria age 
categories. Last visit is the value from the last post baseline visit during the Treatment Period. 
Repeated or unscheduled ECG assessments during the study will not be presented in by-visit 
summaries, but will be considered when determining the last visit, minimum, and maximum post-Baseline values during the Treatment Period. If repeat measurements are taken at a particular visit, then the average value is used in summaries and the original values are listed. 
The number and percentage of subjects who met each of the TEMA criteria specified in 
Section  12.3.4 will be presented within the specified age groups. For each parameter, the number 
and percentage of subjects with an abnormality (ie subjects who met any of the criteria specific to their age) will be summarized for heart rate, PR interval, QRS interval, QT interval and corrected QT intervals by scheduled visit and Last Visit during the Treatment Period. Repeated 
or unscheduled ECG assessments during the study will not be presented in by-visit summaries, 
but will be considered when determining the last visit values during the Treatment Period. Subject numbers for those with TEMA ECG values will be listed by abnormality criteria. TEMA 
results for a subject are those that are observed during the defined treatment period at scheduled 
or unscheduled visits and were not observed at any visit during the Baseline period. 
Detailed information on the quantitative and qualitative ECG findings will be presented in 
subject data listings. 
Section 10.4.4.1, New Seizure Type, was modified from:  
The incidence of new seizure types i.e. those not experienced in the Prospective Baseline but 
experienced during the Treatment Period as recorded in the diary will be summarized. 
Has been changed to:  
The number and percentage of subjects with seizure types present or absent in the Treatment 
Period vs whether the seizure type was present or absent in Combined Baseline will be tabulated. 
The number and percentage of subjects with seizure types present or absent in the Treatment Period vs whether the seizure type was present or absent in Seizure History (including Combined Baseline) will be tabulated. 
The number and percentage of subjects with new absence or myoclonic seizure types 
experienced in the Treatment Period with absence or myoclonic seizure type, respectively, 
indicated by the Seizure History Classification but not experienced in the Combined Baseline as 
recorded in the diary will be summarized.  REDACTED COPY The number and percentage of subjects who met each of the TEMA criteria specified in 
REDACTED COPY The number and percentage of subjects who met each of the TEMA criteria specified in 
d age groups. For each parameter, the number 
REDACTED COPY d age groups. For each parameter, the number 
and percentage of subjects with an abnormality (ie subjects who met any of the criteria specific 
REDACTED COPY and percentage of subjects with an abnormality (ie subjects who met any of the criteria specific 
to their age) will be summarized for heart rate, PR interval, QRS interval, QT interval and 
REDACTED COPY to their age) will be summarized for heart rate, PR interval, QRS interval, QT interval and 
by scheduled visit and Last Visit during the Treatment Period. Repeated 
REDACTED COPY by scheduled visit and Last Visit during the Treatment Period. Repeated 
or unscheduled ECG assessments during the study will not be presented in by
REDACTED COPY or unscheduled ECG assessments during the study will not be presented in by
but will be considered when determining the last visit values during the Treatment Period.REDACTED COPY but will be considered when determining the last visit values during the Treatment Period.
TEMA REDACTED COPY TEMA ECG values will be listed by abnormality criteria.REDACTED COPY ECG values will be listed by abnormality criteria.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.For quantitative ECG measurements (heart rate, PR interval, QRS interval, QT interval, RR 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.For quantitative ECG measurements (heart rate, PR interval, QRS interval, QT interval, RR 
and Fridiricia correction methods), summary 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.and Fridiricia correction methods), summary 
statistics of the actual values and change from Baseline will be summarized using descriptive 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.statistics of the actual values and change from Baseline will be summarized using descriptive 
statistics for the scheduled visits, overall, Last Visit, minimum and maximum post
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.statistics for the scheduled visits, overall, Last Visit, minimum and maximum post -
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.-Baseline 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Baseline 
Treatment Period, and in each of the TEMA ECG criteria age 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Treatment Period, and in each of the TEMA ECG criteria age 
categories. Last visit is the value from the last post baseline visit during the Treatment Period. 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.categories. Last visit is the value from the last post baseline visit during the Treatment Period. 
Repeated or unscheduled ECG assessments during the study will not be presented in by
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Repeated or unscheduled ECG assessments during the study will not be presented in by
ies, but will be considered when determining the last visit, minimum, and maximum 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.ies, but will be considered when determining the last visit, minimum, and maximum 
Baseline values during the Treatment Period. If repeat measurements are taken at a 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Baseline values during the Treatment Period. If repeat measurements are taken at a 
particular visit, then the average value is used in summaries and the original values 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.particular visit, then the average value is used in summaries and the original values 
The number and percentage of subjects who met each of the TEMA criteria specified in 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.The number and percentage of subjects who met each of the TEMA criteria specified in 
d age groups. For each parameter, the number 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.d age groups. For each parameter, the number 
and percentage of subjects with an abnormality (ie subjects who met any of the criteria specific 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.and percentage of subjects with an abnormality (ie subjects who met any of the criteria specific 
to their age) will be summarized for heart rate, PR interval, QRS interval, QT interval and 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.to their age) will be summarized for heart rate, PR interval, QRS interval, QT interval and 
by scheduled visit and Last Visit during the Treatment Period. Repeated 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.by scheduled visit and Last Visit during the Treatment Period. Repeated 
or unscheduled ECG assessments during the study will not be presented in by
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.or unscheduled ECG assessments during the study will not be presented in by
but will be considered when determining the last visit values during the Treatment Period.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.but will be considered when determining the last visit values during the Treatment Period.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.ECG values will be listed by abnormality criteria.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.ECG values will be listed by abnormality criteria.
results for a subject are those that are observed during the defined treatment period at scheduled 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.results for a subject are those that are observed during the defined treatment period at scheduled 
or unscheduled visits and were not observed at any visit during 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.or unscheduled visits and were not observed at any visit during 
Detailed information on the quantitative and qualitative ECG findings will be presented in 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Detailed information on the quantitative and qualitative ECG findings will be presented in 
Section 10.4.4.1, New Seizure Type, was modified from:
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Section 10.4.4.1, New Seizure Type, was modified from:
The incidence of new seizure types i.e. those not experienced in t
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.The incidence of new seizure types i.e. those not experienced in t
experienced during the Treatment Period as recorded in the diary will be summarized.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.experienced during the Treatment Period as recorded in the diary will be summarized.
Has been changed to:
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Has been changed to:
The number and percentage of subjects with seizure types present or absent in the Treatment 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.The number and percentage of subjects with seizure types present or absent in the Treatment 
Period vs whether the seizure 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Period vs whether the seizure 
The number and percentage of subjects with seizure types present or absent in the Treatment 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.The number and percentage of subjects with seizure types present or absent in the Treatment 
Period vs whether the seizure type was present or absent in Seizure History (including Combined 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Period vs whether the seizure type was present or absent in Seizure History (including Combined 
B
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Baseline) will be tabulated.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.aseline) will be tabulated.
UCB   28 Mar 2019  
Statistical Analysis Plan  SP0982  
The number and percentage of subjects with new absence or myoclonic seizure types 
experienced in the Treatment Period but not experienced in the Combined Baseline or indicated 
in Seizure History Classification will also be summarized. 
The number and percentage of subjects with new absence or myoclonic seizure types in the 
Treatment Period, with absence or myoclonic, respectively, indicated by the Seizure History 
Classification but not experienced in the Combined Baseline Period or subjects with ≥50% worsening in days with absence or myoclonic seizures, respectively, will be summarized.  
Section 10.4.8.2, Analysis of Achenbach variables, the following sentence was added:  
The means of the calculated T-score will be plotted by visit. Section 10.4.9.1, BRIEF-P scores, the following sentence was added:  
The means of the BRIEF-P assessment data will be plotted by visit. 
Section 10.4.9.2, BRIEF scores, the following sentence was added:  
The means of the BRIEF assessment data will be plotted by visit. Section 12.2.1, Other Significant AEs, the table has been update with the latest criteria. Liver 
injury related criteria has been moved to the table in Section 12.2.2. 
Section 12.2.2, AEs for Potentially Drug Induced Liver Injury, this table is newly added. 
Section 12.3.4, Table 11, ECGs – Abnormality Criteria, categories for QT, QTc(F), and QTc(B) 
have been updated. 
Section 12.5, Registry Required Tables, the list of tables required has been updated. 
Section 12.6, Additional Subgroups to be programmed in ADSL, is newly added.  
13.4 Amendment 4 
13.4.1 Rationale for the amendment 
A Type C Meeting request was submitted to FDA on Dec 12, 2018 to IND 057939 Sequence No. 
1268 cross-reference IND 068407 and IND 073809.  Included in the package was the SP0982 
SAP Amendment 3.  A Type C Written Response dated 4Mar2019 was received which prompted 
this amendment.  Other items were clarified or added. 
13.4.2 Modification and changes 
At the request of FDA, the following items were added or clarified: 
 New sensitivity analysis of the primary endpoint was added involving dropouts after 1st 
PGTCS  
 Clarification regarding the checking of the proportional hazards assumption was added 
 Variables and analyses involving reduction and increase in seizure frequency , responder 
status and worsening for absence and myoclonic seizures were added 
 Analyses involving post-treatment vital sign and QTc measurements were added 
The following items were clarified: 
 Stratum pooling algorithm REDACTED COPY iver Injury, this table is newly added.
REDACTED COPY iver Injury, this table is newly added.
Abnormality Criteria, categories for QT, QTc(F), and QTc(B) 
REDACTED COPY Abnormality Criteria, categories for QT, QTc(F), and QTc(B) 
Section 12.5, Registry Required Tables, the list of tables required has been updated.
REDACTED COPY Section 12.5, Registry Required Tables, the list of tables required has been updated.
Additional Subgroups to be programmed in ADSL, is newly added.
REDACTED COPY Additional Subgroups to be programmed in ADSL, is newly added.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.AEs, the table has been update with the latest criteria
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.AEs, the table has been update with the latest criteria
injury related criteria has been moved to the table in Section 12.2.2.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.injury related criteria has been moved to the table in Section 12.2.2.
iver Injury, this table is newly added.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.iver Injury, this table is newly added.
Abnormality Criteria, categories for QT, QTc(F), and QTc(B) 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Abnormality Criteria, categories for QT, QTc(F), and QTc(B) 
Section 12.5, Registry Required Tables, the list of tables required has been updated.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Section 12.5, Registry Required Tables, the list of tables required has been updated.
Additional Subgroups to be programmed in ADSL, is newly added.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Additional Subgroups to be programmed in ADSL, is newly added.
Rationale for the amendment
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Rationale for the amendment
A Type C Meeting request was submitted to FDA on Dec 12, 2018 to IND 057939 Sequence No. 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.A Type C Meeting request was submitted to FDA on Dec 12, 2018 to IND 057939 Sequence No. 
reference IND 068407 and IND 073809.  Included in th
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.reference IND 068407 and IND 073809.  Included in th
SAP Amendment 3.  A Type 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.SAP Amendment 3.  A Type C 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.C Written Response dated 4Mar2
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Written Response dated 4Mar2
this amendment.  Other items were clarified
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.this amendment.  Other items were clarified
Modification and changes
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Modification and changes
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.At the request of FDA, the following items were added or clarifie
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.At the request of FDA, the following items were added or clarifie
New sensitivity analysis of the primary endpoint was added involving dropouts after 1
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.New sensitivity analysis of the primary endpoint was added involving dropouts after 1
PGTCS
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.PGTCS

This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Clarification regarding the checking of the proportional hazards assumption was added
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Clarification regarding the checking of the proportional hazards assumption was added

This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
UCB   28 Mar 2019  
Statistical Analysis Plan  SP0982  
 Algorithm for identifying rescue medications 
The following items were added: 
 A new listing of rescue medications 
 References specific to the Cox proportional hazards analysis 
 Additional analyses using the Development subgroup 
 New variable identifying Asian sites 
13.4.2.1 Specific changes 
The information below was revised from:  
SAP/Amendment Number  Date  
Final SAP  09 Aug 2016  
Amendment #1  24 Feb 2017  
Amendment #2  14 Mar 2017  
Amendment #3  4 Jan 2019 
Has been revised to:  
SAP/Amendment Number  Date  
Final SAP  09 Aug 2016  
Amendment #1  24 Feb 2017  
Amendment #2  14 Mar 2017  
Amendment #3  4 Jan 2019 
Amendment #4  26 Mar 2019  
Section 3.2.5, the 3rd paragraph was changed from:  
Benzodiazepines taken for rescue will be flagged with “RESCUE” in the indication field on the 
CRF, although rescue benzodiazepines will also be identified programmatically as any 
benzodiazepines taken intermittently for 1 day at any frequency. Rescue medication is defined as 
the intermittent use of benzodiazepines (limited to 2 doses per 28 days) for epilepsy indications if established at least 28 days prior to Visit 1.  Lifetime benzodiazepines are defined as benzodiazepines taken in the subject’s history and stopped at least 28 days prior to Visit 1. 
Has been revised to:  
Benzodiazepines taken for rescue will be flagged with “RESCUE” in the indication field on the 
CRF, although rescue AEDs will also be identified programmatically as any AED taken 
intermittently for 1 or 2 days, at any frequency, with an epilepsy or seizure related indication. 
Rescue medication is defined as the intermittent use of benzodiazepines (limited to 2 doses per 
28 days) for epilepsy indications if established at least 28 days prior to Visit 1.  Lifetime 
benzodiazepines are defined as benzodiazepines taken in the subject’s history and stopped at least 28 days prior to Visit 1. 
Section 3.9, the changes to protocol-defined analyses has been changed from:  
For the key secondary efficacy variable, the Protocol Section 4.1.2 says that seizure freedom for 
PGTCS during the 24-week Treatment Period, will be estimated using Kaplan-Meier analysis. REDACTED COPY 26 Mar 2019
REDACTED COPY 26 Mar 2019
paragraph was changed from: REDACTED COPY paragraph was changed from:
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.paragraph was changed from:
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.paragraph was changed from:
Benzodiazepines taken for rescue will be flagged with “RESCUE” in the indication field on the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Benzodiazepines taken for rescue will be flagged with “RESCUE” in the indication field on the 
CRF, although rescue benzodiazepin
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.CRF, although rescue benzodiazepin es will also be identified programmatically as any 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.es will also be identified programmatically as any 
benzodiazepines taken intermittently for 1 day at any frequency. Rescue medication is defined as 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.benzodiazepines taken intermittently for 1 day at any frequency. Rescue medication is defined as 
the intermittent use of benzodiazepines (limited to 2 doses per 28 days) for epilepsy indications 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.the intermittent use of benzodiazepines (limited to 2 doses per 28 days) for epilepsy indications 
shed at least 28 days prior to Visit 1.  Lifetime benzodiazepines are defined as 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.shed at least 28 days prior to Visit 1.  Lifetime benzodiazepines are defined as 
benzodiazepines taken in the subject’s history and stopped at least 28 days prior to Visit 1.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.benzodiazepines taken in the subject’s history and stopped at least 28 days prior to Visit 1.
Has been revised to:
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Has been revised to:
Benzodiazepines taken for rescue will be flagged with “RESCU
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Benzodiazepines taken for rescue will be flagged with “RESCU
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.CRF, although rescue AEDs will also be identified programmatically as any AED taken 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.CRF, although rescue AEDs will also be identified programmatically as any AED taken 
intermittently for 1 or 2 days, at any frequency, with an epilepsy or seizure related indication. 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.intermittently for 1 or 2 days, at any frequency, with an epilepsy or seizure related indication. 
Rescue medication is defined as the inte
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Rescue medication is defined as the inte
28 days) for epilepsy indications if established at least 28 days prior to Visit 1.  Lifetime 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.28 days) for epilepsy indications if established at least 28 days prior to Visit 1.  Lifetime 
benzodiazepines are defined as benzodiazepines taken in the subject’s history and stopped at 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.benzodiazepines are defined as benzodiazepines taken in the subject’s history and stopped at 
least 28 days
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.least 28 days
UCB   28 Mar 2019  
Statistical Analysis Plan  SP0982  
The analysis of the key secondary endpoint has been clarified to assess the seizure-free rate using 
an extended Mantel-Haenszel technique which combines Kaplan-Meier estimates within each 
stratum. The extended Mantel-Haenszel technique is a randomization-based nonparametric method that provides a more robust method to assess seizure freedom. 
Has been revised to:  
For the key secondary efficacy variable, the Protocol Section 4.1.2 says that seizure freedom for 
PGTCS during the 24-week Treatment Period, will be estimated using Kaplan-Meier analysis. 
Also, Protocol Section 13.3.2.1 states that the key secondary efficacy variable will be analyzed in the same manner as the primary endpoint using the FAS and that the percentage of seizure- free 
subjects at 24 weeks will be estimated from the KM estimates of time to first seizure. The 
analysis of the key secondary endpoint has been clarified to assess the seizure-free rate at 24 
weeks using an extended Mantel-Haenszel technique which combines Kaplan-Meier estimates 
within each stratum. The extended Mantel-Haenszel technique is a randomization-based 
nonparametric method that provides a more robust method to assess seizure freedom. Thus, the 
key secondary efficacy variable will not be analyzed in the same manner as the primary efficacy endpoint; the other secondary efficacy variable, time to first PGTCS, will be analyzed in the same manner as the primary efficacy endpoint. 
Section 4.9, the stratum pooling algorithm has been updated from:  
For the subjects with Baseline PGTCS frequency ≤2 per 28 days, the events for each of the 3 age 
at informed consent categories will be summed.   
 If 2 of the age at informed consent categories combined have < 3 total events, then all age 
categories are combined for the analysis.  
 If ≥4 to <12 years of age is the category with the smallest number of events that are 2 events 
or less, it should be combined with the ≥12 and <18 years of age category. 
 If ≥18 years of age is the category with the smallest number of events that are 2 events or less, it should be combined with the ≥12 and <18 years of age category. 
 If ≥12 and <18 years of age is the category with the smallest number of events that are 2 events or less, it should be combined with the strata with the 2
nd smallest number of events. 
For the subjects with Baseline PGTCS frequency >2 per 28 days, repeat the same exercise to determine stratum pooling. 
Has been revised to:  
For the subjects with Baseline PGTCS frequency ≤2 per 28 days, the events for each of the 3 age 
at informed consent categories will be summed.  For categories with < 3 total events, the combining should occur as follows: 
 If 2 of the age at informed consent categories combined have < 3 total events, then all age 
categories are combined for the analysis.  
 If ≥4 to <12 years of age is the category with the smallest number of events that are 2 events or less, it should be combined with the ≥12 and <18 years of age category. REDACTED COPY Section 4.9, the stratum pooling algorithm has been updated from:
REDACTED COPY Section 4.9, the stratum pooling algorithm has been updated from:
For the subjects with Baseline PGTCS frequency ≤2 per 28 days, the events for each of the 3 age 
REDACTED COPY For the subjects with Baseline PGTCS frequency ≤2 per 28 days, the events for each of the 3 age 
If 2 of the age at informed consent categories combined have < 3 total events, then all age 
REDACTED COPY If 2 of the age at informed consent categories combined have < 3 total events, then all age 
ined for the analysis. 
REDACTED COPY ined for the analysis. 
If ≥4 to <12 years of age is the category with the smallest number of events that are 2 events REDACTED COPY If ≥4 to <12 years of age is the category with the smallest number of events that are 2 events 
or less, it should be combined with the ≥12 and <18 years of age category. REDACTED COPY or less, it should be combined with the ≥12 and <18 years of age category.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.that the key secondary efficacy variable will be analyzed in 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.that the key secondary efficacy variable will be analyzed in 
the same manner as the primary endpoint using the FAS and that the percentage of seizur
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.the same manner as the primary endpoint using the FAS and that the percentage of seizur e
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.e-
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.-free 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.free 
om the KM estimates of time to first seizure. The 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.om the KM estimates of time to first seizure. The 
free rate at 24 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.free rate at 24 
Meier estimates 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Meier estimates 
Haenszel technique is a randomization
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Haenszel technique is a randomization -
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.-based 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.based 
nonparametric method that provides a more robust method to assess seizure freedom. Thus, the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.nonparametric method that provides a more robust method to assess seizure freedom. Thus, the 
in the same manner as the primary efficacy 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.in the same manner as the primary efficacy 
endpoint; the other secondary efficacy variable, time to first PGTCS, will be analyzed in the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.endpoint; the other secondary efficacy variable, time to first PGTCS, will be analyzed in the 
Section 4.9, the stratum pooling algorithm has been updated from:
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Section 4.9, the stratum pooling algorithm has been updated from:
For the subjects with Baseline PGTCS frequency ≤2 per 28 days, the events for each of the 3 age 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.For the subjects with Baseline PGTCS frequency ≤2 per 28 days, the events for each of the 3 age 
If 2 of the age at informed consent categories combined have < 3 total events, then all age 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.If 2 of the age at informed consent categories combined have < 3 total events, then all age 
If ≥4 to <12 years of age is the category with the smallest number of events that are 2 events 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.If ≥4 to <12 years of age is the category with the smallest number of events that are 2 events 
or less, it should be combined with the ≥12 and <18 years of age category.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.or less, it should be combined with the ≥12 and <18 years of age category.
If ≥18 years of age is the category with the smallest number o
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.If ≥18 years of age is the category with the smallest number o
less, it should be combined with the ≥12 and <18 years of age category.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.less, it should be combined with the ≥12 and <18 years of age category.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.If ≥12 and <18 years of age is the category with the smallest number of events that are 2 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.If ≥12 and <18 years of age is the category with the smallest number of events that are 2 
events or less, it should be combined with the strata with the 2
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.events or less, it should be combined with the strata with the 2
For the subjects with Baseline PGTCS frequency >2 per 28 days, repeat the same exercise to 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.For the subjects with Baseline PGTCS frequency >2 per 28 days, repeat the same exercise to 
determine stratum pooling.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.determine stratum pooling.
Has been revised to:
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Has been revised to:
For the subjects with Baseline PGTCS frequency ≤2 per 28 days, the events for each of t
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.For the subjects with Baseline PGTCS frequency ≤2 per 28 days, the events for each of t
at informed consent categories will be summed.  For categories with < 3 total events, the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.at informed consent categories will be summed.  For categories with < 3 total events, the 
combining should occur as follows:
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.combining should occur as follows:

This document cannot be used to support any marketing authorization application and any extensions or variations thereof.If 2 of the age at informed consent categories combined have < 3 total events, then all age 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.If 2 of the age at informed consent categories combined have < 3 total events, then all age 
UCB   28 Mar 2019  
Statistical Analysis Plan  SP0982  
 If ≥18 years of age is the category with the smallest number of events that are 2 events or 
less, it should be combined with the ≥12 and <18 years of age category. 
 If ≥12 and <18 years of age is the category with the smallest number of events that are 2 events or less, it should be combined with the strata with the 2
nd smallest number of events. 
Repeat the algorithm for combining strata for the subjects who did not have events if there are categories with < 3 total non-events. 
For the subjects with Baseline PGTCS frequency >2 per 28 days, repeat the same exercise to 
determine stratum pooling for both events and non-events. 
For each primary efficacy endpoint sensitivity analysis which uses stratum pooling, the pooling of the strata should be reassessed since the event distribution for the specific sensitivity may be 
different than the distribution in the primary efficacy endpoint analysis.  
Section 6.6, the following sentence was added at the end of this section:  
AEDs flagged as rescue medications will also be list ed in subject data listings. 
Section 8.1.2, the 2
nd paragraph was revised from:  
The hypothesis for the assessment of primary efficacy variable (time to event) is as follows: 
H0: β=0  
Versus 
H1: β≠0 
where β is the coefficient of an independent variable representing the treatment effect in the 
model. The hazard function is represented by 
ℎ(𝑡,𝑋)= ℎ0(𝑡)exp(∑𝛽 𝑗𝑋𝑗𝑝
𝑗=1) 
where xj is the collection of independent variables and h0(t) is the baseline hazard at time t. For 
the null hypothesis, the testing will be 2-sided with an α=0.05; the p -value will be presented. The 
assumptions of proportional hazards will also be checked. 
The stratified hazard ratio (HR) will be calculated using the placebo arm as the reference group. 
The SE and 95% CI for the HR will also be reported. 
Has been revised to:  
The hypothesis for the assessment of primary efficacy variable (time to event) is as follows: 
H0: β=0  
Versus 
H1: β≠0 
where β is the coefficient of an independent variable representing the treatment effect in the 
model. The hazard function is represented by REDACTED COPY H
REDACTED COPY H1
REDACTED COPY 1: β≠0
REDACTED COPY : β≠0
where β is the coefficient of an independent variable representing the treatment effect in the 
REDACTED COPY where β is the coefficient of an independent variable representing the treatment effect in the 
represented by
REDACTED COPY represented by
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.For each primary efficacy endpoint sensitivity analysis which uses stratum pooling, the pooling 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.For each primary efficacy endpoint sensitivity analysis which uses stratum pooling, the pooling 
of the strata should be reassessed since the event distribution for the specific sensitivity may be 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.of the strata should be reassessed since the event distribution for the specific sensitivity may be 
in subject data listings.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.in subject data listings.
The hypothesis for the assessment of primary efficacy variable (time to event) is as follows:
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.The hypothesis for the assessment of primary efficacy variable (time to event) is as follows:
: β≠0
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.: β≠0
where β is the coefficient of an independent variable representing the treatment effect in the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.where β is the coefficient of an independent variable representing the treatment effect in the 
represented by
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.represented by
𝑋
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.𝑋)
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.)
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.=
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.=ℎ
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.ℎ
is the collection of independent variables and 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.is the collection of independent variables and 
the null hypothesis, the testing will be 2
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.the null hypothesis, the testing will be 2
ns of proportional hazards will also be checked.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.ns of proportional hazards will also be checked.
The stratified hazard ratio (HR) will be calculated using the placebo arm as the reference group. 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.The stratified hazard ratio (HR) will be calculated using the placebo arm as the reference group. 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.The SE and 95% CI for the HR will also be reported.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.The SE and 95% CI for the HR will also be reported.
Has been revised to:
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Has been revised to:
The hypothesis for the assessment of
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.The hypothesis for the assessment of
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Versus
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Versus
UCB   28 Mar 2019  
Statistical Analysis Plan  SP0982  
ℎ(𝑡,𝑋)= ℎ0(𝑡)exp(∑𝛽 𝑗𝑋𝑗𝑝
𝑗=1) 
where xj is the collection of independent variables and h0(t) is the baseline hazard at time t. For 
the null hypothesis, the testing will be 2-sided with an α=0.05; the p -value will be presented. The 
assumptions of proportional hazards will also be assessed graphically (e.g. log (log S) plot vs 
time, empirical score process ) for any departure; non-proportionality is not expected when using 
a stratified Cox model. Depending on the departure from proportional hazards, a sensitivity analysis (e.g. piecewise proportional hazards, time-varying coefficient, restricted mean survival) may be performed. 
The stratified hazard ratio (HR) will be calculated using the placebo arm as the reference group. 
The 95% CI for the HR will also be reported. 
Section 8.1.4, the following sensitivity analysis was clarified from:  
 Repeat the primary efficacy analysis using all PGTCS data (ie, all reported events) through 
each subject’s first 166 days of treatment, on the FAS. 
Was revised to: 
 Repeat the primary efficacy analysis using all PGTCS data (ie, all reported events after the 
date of the 125
th event) through each subject’s first 166 days of treatment, on the FAS. 
Section 8.1.4, the following sensitivity analysis was added:  
 Repeat the primary efficacy analysis using the FAS, except all subjects who prematurely 
discontinue after their 1st PGTCS will be analyzed as treatment failures. 
Section 8.2.2.2, the following sentence was clarified from:  
The assumptions of proportional hazards will also be checked.  
Was revised to:  
The assumptions of proportional hazards will also be checked using the same approach as for the 
primary efficacy endpoint. 
Section 8.3, was revised from:  
All seizure data recorded during the treatment period will be summarized and listed for the 
seizure related other efficacy variables. Analyses of seizure-related other efficacy variables will be performed for the FAS. 
Was revised to:  
All seizure data recorded during the treatment period will be summarized and listed for the 
seizure related other efficacy variables. Analyses of seizure-related other efficacy variables will 
be performed for the FAS. For absence seizure analyses, this analysis population will be further 
restricted to the subset of subjects who reported a history of absence seizures or reported abs ence 
seizures during baseline or the 24-week treatment period.  For myoclonic seizure analyses, this 
analysis population will be further restricted to the subset of subjects who reported a history of 
myoclonic seizures or reported myoclonic seizures during baseline or the 24-week treatment period. REDACTED COPY l PGTCS data (ie, all reported events after the 
REDACTED COPY l PGTCS data (ie, all reported events after the 
event) through each subject’s first 166 days of treatment, on the FAS.
REDACTED COPY event) through each subject’s first 166 days of treatment, on the FAS.
Section 8.1.4, the following sensitivity analysis was added:
REDACTED COPY Section 8.1.4, the following sensitivity analysis was added:
Repeat the primary efficacy analysis using the FAS, except
REDACTED COPY Repeat the primary efficacy analysis using the FAS, except
PGTCS will be analyzed as treatment failures.
REDACTED COPY PGTCS will be analyzed as treatment failures.
e following sentence was clarified fromREDACTED COPY e following sentence was clarified from
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.proportionality is not expected when using 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.proportionality is not expected when using 
varying coefficient, restricted mean survival) 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.varying coefficient, restricted mean survival) 
The stratified hazard ratio (HR) will be calculated using the placebo arm as the reference group. 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.The stratified hazard ratio (HR) will be calculated using the placebo arm as the reference group. 
Repeat the primary efficacy analysis using all PGTCS data (ie, all reported events) through 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Repeat the primary efficacy analysis using all PGTCS data (ie, all reported events) through 
l PGTCS data (ie, all reported events after the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.l PGTCS data (ie, all reported events after the 
event) through each subject’s first 166 days of treatment, on the FAS.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.event) through each subject’s first 166 days of treatment, on the FAS.
Section 8.1.4, the following sensitivity analysis was added:
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Section 8.1.4, the following sensitivity analysis was added:
Repeat the primary efficacy analysis using the FAS, except
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Repeat the primary efficacy analysis using the FAS, except
PGTCS will be analyzed as treatment failures.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.PGTCS will be analyzed as treatment failures.
e following sentence was clarified from
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.e following sentence was clarified from
The assumptions of proportional hazards will also be checked. 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.The assumptions of proportional hazards will also be checked. 
assumptions of proportional hazards will also be checked using the same approach as for the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.assumptions of proportional hazards will also be checked using the same approach as for the 
primary efficacy endpoint.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.primary efficacy endpoint.
Section 8.3, was revised from:
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Section 8.3, was revised from:
All seizure data recorded during the treatment period will be summarized and listed for the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.All seizure data recorded during the treatment period will be summarized and listed for the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.d other efficacy variables. Analyses of seizure
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.d other efficacy variables. Analyses of seizure
be performed for the FAS.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.be performed for the FAS.
Was revised to:
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Was revised to:
All seizure data recorded during the treatment period will be summarized and listed for the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.All seizure data recorded during the treatment period will be summarized and listed for the 
seizure related other efficacy varia
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.seizure related other efficacy varia
be performed for the FAS. For absence seizure analyses, this analysis population will be further 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.be performed for the FAS. For absence seizure analyses, this analysis population will be further 
restricted to the subset of subjects who reported a history of absence seizures or reported abs
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.restricted to the subset of subjects who reported a history of absence seizures or reported abs
UCB   28 Mar 2019  
Statistical Analysis Plan  SP0982  
Section 8.3.1.1, the following text was removed:  
The percent change in log-transformed (PCHL) PGTCS frequency per 28 days from the 
Combined Baseline (CB) to the appropriate analysis period (T) is defined as: 
PCHL = [(ln(SFT) – ln(SFCB)) / ln(SFCB)] x 100 
where SFT corresponds to the 28-day PGTCS frequency during the relative period and SFCB 
corresponds to the 28-day Combined Baseline PGTCS frequency. 
Section 8.3.1.2, paragraphs 3, 4, and 5 were revised from:  
The percent change (PCH) in days with absence seizures per 28 days from the appropriate 
Baseline (B) to the appropriate analysis period (T) is defined as: 
PCH = [(DT – DB) / DB] x 100 
where DT corresponds to the number of days with absence seizures per 28 days during the 
relative period and DB corresponds to the number of days with absence seizures per 28 days during the Baseline Period. If DB is zero, then PCH will be missing and any such subjects will 
be excluded from the percent change summary. PCH will be calculated for the 6-week Titration 
Period, first 12 weeks of the Treatment Period and the 24-week Treatment Period. 
Similarly, the percent change in the number of days with myoclonic seizures per 28 days from the appropriate Baseline Period will be calculated. 
Were revised to:  
The percent change (PCH) in days with absence seizures per 28 days from the Prospective 
Baseline (B) to the appropriate analysis period (T) is defined as: 
PCH = [(DT – DB) / DB] x 100 
where DT corresponds to the number of days with absence seizures per 28 days during the 
relative period and DB corresponds to the number of days with absence seizures per 28 days 
during the Prospective Baseline Period. If DB is zero, then PCH will be missing and any such subjects will be excluded from the percent change summary. PCH will be calculated for the 6-week Titration Period, first 12 weeks of the Treatment Period and the 24-week Treatment Period. 
Similarly, the percent change in the number of days with myoclonic seizures per 28 days from the Prospective Baseline Period will be calculated. 
Section 8.3.1.8, Variable: Days with absence and myoclonic seizures – worsening is new:  
Safety of the LCM treatment will be based on the percent change in days with absence seizure 
per 28 days and days with myoclonic seizure per 28 days. The increase in days with absence 
seizures per 28 days from Prospective Baseline will be categorized as >0 to 25%, >25 to 50%, 
>50 to 75%, and >75% for the Treatment Period. The increase in days with myoclonic seizures per 28 days from Prospective Baseline will be categorized as >0 to 25%, >25 to 50%, >50 to 75%, and >75% for the Treatment Period. 
Section 8.3.1.9, Variable: Absence and myoclonic seizure frequencies per 28 days is new: 
In order to account for potential differences in the durations of the study periods for individuals, 
absence and myoclonic seizure data will be normalized to 28 days.  REDACTED COPY Similarly, the percent change in the number of days with myoclonic seizures per 28 days from 
REDACTED COPY Similarly, the percent change in the number of days with myoclonic seizures per 28 days from 
The percent change (PCH) in days with absence seizures per 28 days from the Prospective 
REDACTED COPY The percent change (PCH) in days with absence seizures per 28 days from the Prospective 
Baseline (B) to the appropriate analysis period (T) is defined as:
REDACTED COPY Baseline (B) to the appropriate analysis period (T) is defined as:
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.rcent change (PCH) in days with absence seizures per 28 days from the appropriate 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.rcent change (PCH) in days with absence seizures per 28 days from the appropriate 
where DT corresponds to the number of days with absence seizures per 28 days d
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.where DT corresponds to the number of days with absence seizures per 28 days d uring the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.uring the 
relative period and DB corresponds to the number of days with absence seizures per 28 days 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.relative period and DB corresponds to the number of days with absence seizures per 28 days 
during the Baseline Period. If DB is zero, then PCH will be missing and any such subjects will 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.during the Baseline Period. If DB is zero, then PCH will be missing and any such subjects will 
culated for the 6
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.culated for the 6
week Treatment Period.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.week Treatment Period.
Similarly, the percent change in the number of days with myoclonic seizures per 28 days from 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Similarly, the percent change in the number of days with myoclonic seizures per 28 days from 
The percent change (PCH) in days with absence seizures per 28 days from the Prospective 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.The percent change (PCH) in days with absence seizures per 28 days from the Prospective 
Baseline (B) to the appropriate analysis period (T) is defined as:
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Baseline (B) to the appropriate analysis period (T) is defined as:
where DT corresponds to the number of days with abse
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.where DT corresponds to the number of days with abse
relative period and DB corresponds to the number of days with absence seizures per 28 days 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.relative period and DB corresponds to the number of days with absence seizures per 28 days 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.during the Prospective Baseline Period. If DB is zero, then PCH will be missing and any such 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.during the Prospective Baseline Period. If DB is zero, then PCH will be missing and any such 
subjects will be excluded from the p
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.subjects will be excluded from the p
week Titration Period, first 12 weeks of the Treatment Period and the 24
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.week Titration Period, first 12 weeks of the Treatment Period and the 24
Similarly, the percent change in the number of days with myoclonic seizures per 28 days from 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Similarly, the percent change in the number of days with myoclonic seizures per 28 days from 
tive Baseline Period will be calculated.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.tive Baseline Period will be calculated.
Section 8.3.1.8, Variable: Days with absence and myoclonic seizures 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Section 8.3.1.8, Variable: Days with absence and myoclonic seizures 
Safety of the LCM treatment will be based on the percent change in days with absence seizure 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Safety of the LCM treatment will be based on the percent change in days with absence seizure 
per 28 days and days with myocloni
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.per 28 days and days with myocloni
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.seizures per 28 days from Prospective Baseline will be categorized as >0 to 25%, >25 to 50%, 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.seizures per 28 days from Prospective Baseline will be categorized as >0 to 25%, >25 to 50%, 
>50 to 75%, and >75% for the Treatment Period. The increase in days with myoclonic seizures 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.>50 to 75%, and >75% for the Treatment Period. The increase in days with myoclonic seizures 
per 28 days fr
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.per 28 days fr
75%, and >75% for the Treatment Period.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.75%, and >75% for the Treatment Period.
UCB   28 Mar 2019  
Statistical Analysis Plan  SP0982  
The 28-day absence SF will be calculated for the Prospective Baseline and Treatment Periods as: 
SF =  
(# absence seizures in the relative period/# days in relative period with evaluable absence seizure 
data)*28 
The PCH in Absence seizure frequency per 28 days from the Prospective Baseline (PB) to the 
appropriate analysis period (T) is defined as: 
PCH = [(SFT – SFPB) / SFPB] x 100 
where SFT corresponds to the 28-day absence seizure frequency during the relative period and 
SFPB corresponds to the 28-day Prospective Baseline absence frequency; if subjects had no absence seizures in Prospective Baseline, then PCH cannot be calculated. PCH is calculated for 
6-week Titration Period, first 12 weeks of the Treatment Period and the 24-week Treatment 
Period. 
SF and PCH are calculated for subjects with myoclonic seizures using the same algorithm 
described above. 
Section 8.3.1.10, Variable: Responder statu s – reduction in absence and myoclonic seizure 
frequencies is new:  
Response to treatment will be based on the percent change in absence and myoclonic seizure 
frequencies, calculated as described in  Section  8.3.1.9 . A 50% responder is defined as a subject 
experiencing ≥50% reduction in absence (or myoclonic) seizure frequency per 28 days from the 
Prospective Baseline to the period of interest (6-week Titration Period, first 12 weeks of the 
Treatment Period or the 24-week Treatment Period). A 75% responder is defined as a subject 
experiencing ≥75% reduction in absence (or myoclonic) seizure frequency per 28 days from 
Prospective Baseline to the period of interest (6-week Titration Period, first 12 weeks of the 
Treatment Period or the 24-week Treatment Period). 
Section 8.3.1.11, Variable: Absence and myoclonic seizure frequency - worsening is new: 
Safety of the LCM treatment will be based on the percent change in absence seizure frequency 
per 28 days and myoclonic seizure frequency per 28 days. The increase in absence seizure frequency per 28 days from Prospective Baseline will be categorized as >0 to 25%, >25 to 50%, 
>50 to 75%, and >75% for the Treatment Period. The increase in myoclonic seizure frequency 
per 28 days from Prospective Baseline will be categorized as >0 to 25%, >25 to 50%, >50 to 75%, and >75% for the Treatment Period. 
Section 8.3.2.5, the following last bullet was changed from:  
A histogram of ≥50%, ≥75%, and 100% (seizure freedom) responder status for reduction in days 
with absence seizures during the first 6 weeks (Titration Period), first 12 weeks, and the 24-week Treatment Period by treatment group will be provided. 
Was revised to:  
A histogram of ≥50% and ≥75% responder status for reduction in days with absence seizures 
during the first 6 weeks (Titration Period), first 12 weeks, and the 24-week Treatment Period by 
treatment group will be provided. REDACTED COPY Response to treatment will be based on the percent change in absence and myoclonic seizure 
REDACTED COPY Response to treatment will be based on the percent change in absence and myoclonic seizure 
8.3.1.9
REDACTED COPY 8.3.1.9 . A 50% responder is defined as a subject 
REDACTED COPY . A 50% responder is defined as a subject 
experiencing ≥50% reduction in absence (or myoclonic) seizure frequency per 28 days from the 
REDACTED COPY experiencing ≥50% reduction in absence (or myoclonic) seizure frequency per 28 days from the 
Prospective Baseline to the period of interest (6
REDACTED COPY Prospective Baseline to the period of interest (6 -
REDACTED COPY -week Titr
REDACTED COPY week Titr
week Treatment Period). A 75% responder is defined as a subject 
REDACTED COPY week Treatment Period). A 75% responder is defined as a subject 
experiencing ≥75% reduction in absence (or myoclonic) seizure frequency per 28 days from 
REDACTED COPY experiencing ≥75% reduction in absence (or myoclonic) seizure frequency per 28 days from 
Prospective Baseline to the period of in REDACTED COPY Prospective Baseline to the period of in terest (6REDACTED COPY terest (6
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.day absence seizure frequency during the relative period and 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.day absence seizure frequency during the relative period and 
day Prospective Baseline absence frequency; if subjects had no 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.day Prospective Baseline absence frequency; if subjects had no 
absence seizures in Prospective Baseline, then PCH cannot be calculated. PCH is calcu
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.absence seizures in Prospective Baseline, then PCH cannot be calculated. PCH is calcu lated for 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.lated for 
week Treatment 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.week Treatment 
SF and PCH are calculated for subjects with myoclonic seizures using the same algorithm 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.SF and PCH are calculated for subjects with myoclonic seizures using the same algorithm 
reduction in absence and myoclonic seizure 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.reduction in absence and myoclonic seizure 
Response to treatment will be based on the percent change in absence and myoclonic seizure 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Response to treatment will be based on the percent change in absence and myoclonic seizure 
. A 50% responder is defined as a subject 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.. A 50% responder is defined as a subject 
experiencing ≥50% reduction in absence (or myoclonic) seizure frequency per 28 days from the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.experiencing ≥50% reduction in absence (or myoclonic) seizure frequency per 28 days from the 
week Titr
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.week Titr
week Treatment Period). A 75% responder is defined as a subject 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.week Treatment Period). A 75% responder is defined as a subject 
experiencing ≥75% reduction in absence (or myoclonic) seizure frequency per 28 days from 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.experiencing ≥75% reduction in absence (or myoclonic) seizure frequency per 28 days from 
terest (6
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.terest (6
week Treatment Period).
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.week Treatment Period).
, Variable: Absence and myoclonic seizure
This document cannot be used to support any marketing authorization application and any extensions or variations thereof., Variable: Absence and myoclonic seizure
Safety of the LCM treatment will be based on the percent chang
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Safety of the LCM treatment will be based on the percent chang
per 28 days and myoclonic seizure frequency per 28 days. The increase in absence seizure 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.per 28 days and myoclonic seizure frequency per 28 days. The increase in absence seizure 
frequency per 28 days from Prospective Baseline will be categorized as >0 to 25%, >25 to 50%, 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.frequency per 28 days from Prospective Baseline will be categorized as >0 to 25%, >25 to 50%, 
>50 to 75%, and >75% for the Treatment Per
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.>50 to 75%, and >75% for the Treatment Per
per 28 days from Prospective Baseline will be categorized as >0 to 25%, >25 to 50%, >50 to 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.per 28 days from Prospective Baseline will be categorized as >0 to 25%, >25 to 50%, >50 to 
75%, and >75% for the Treatment Period.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.75%, and >75% for the Treatment Period.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Section 8.3.2.5, the following last bullet was changed from:
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Section 8.3.2.5, the following last bullet was changed from:
A histogram of 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.A histogram of 
with absence seizures during the first 6 weeks (Titration Period), first 12 weeks, and the 24
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.with absence seizures during the first 6 weeks (Titration Period), first 12 weeks, and the 24
Treatment Period by treatment group will be provided.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Treatment Period by treatment group will be provided.
Was revised to:
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Was revised to:
UCB   28 Mar 2019  
Statistical Analysis Plan  SP0982  
Section 8.3.2.6, the following bullet was inserted:  
A histogram of ≥50% and ≥75% responder status for reduction in days with myoclonic seizures 
during the first 6 weeks (Titration Period), first 12 weeks, and the 24-week Treatment Period by treatment group will be provided. 
Section 8.3.2.7, Analysis: Percent change in absence and myoclonic seizure frequency per 28 
days from Prospective Baseline is new: 
Descriptive statistics will be provided on the percent change in absence and myoclonic seizure 
frequencies for the first 6 weeks of (entire Titration Period), first 12 weeks of, and the entire 
Treatment Period.   
All absence and myoclonic seizure frequency per 28 days data will be listed. 
Section 8.3.2.8, Analysis: Responder status – reduction in absence and myoclonic seizure 
frequency is new: 
The following data will be summarized with descriptive statistics only: 
 Percentage of subjects with at least a 50% reduction in absence seizure frequency during 
the first 6 weeks (Titration Period) compared to the Prospective Baseline 
 Percentage of subjects with at least a 50% reduction in myoclonic seizure frequency during the first 6 weeks (Titration Period) compared to the Prospective Baseline 
 Percentage of subjects with at least a 50% reduction in absence seizure frequency during 
the first 12 weeks of the Treatment Period compared to the Prospective Baseline 
 Percentage of subjects with at least a 50% reduction in myoclonic seizure frequency 
during the first 12 weeks of the Treatment Period compared to the Prospective Baseline 
 Percentage of subjects with at least a 50% reduction in absence seizure frequency during 
the Treatment Period compared to the Prospective Baseline 
 Percentage of subjects with at least a 50% reduction in myoclonic seizure frequency during the Treatment Period compared to the Prospective Baseline 
 Percentage of subjects with at least a 75% reduction in absence seizure frequency during the first 6 weeks (Titration Period) compared to the Prospective Baseline 
 Percentage of subjects with at least a 75% reduction in myoclonic seizure frequency during the first 6 weeks (Titration Period) compared to the Prospective Baseline 
 Percentage of subjects with at least a 75% reduction in absence seizure frequency during 
the first 12 weeks of the Treatment Period compared to the Prospective Baseline 
 Percentage of subjects with at least a 75% reduction in myoclonic seizure frequency 
during the first 12 weeks of the Treatment Period compared to the Prospective Baseline 
 Percentage of subjects with at least a 75% reduction in absence seizure frequency during the Treatment Period compared to the Prospective Baseline 
Percentage of subjects with at least a 75% reduction in myoclonic seizure frequency during the Treatment Period compared to the Prospective Baseline REDACTED COPY least a 50% reduction in myoclonic seizure frequency 
REDACTED COPY least a 50% reduction in myoclonic seizure frequency 
during the first 6 weeks (Titration Period) compared to the Prospective Baseline
REDACTED COPY during the first 6 weeks (Titration Period) compared to the Prospective Baseline
Percentage of subjects with at least a 50% reduction in absence seizure frequency during 
REDACTED COPY Percentage of subjects with at least a 50% reduction in absence seizure frequency during 
ent Period compared to the Prospective Baseline
REDACTED COPY ent Period compared to the Prospective Baseline
Percentage of subjects with at least a 50% reduction in myoclonic seizure frequency 
REDACTED COPY Percentage of subjects with at least a 50% reduction in myoclonic seizure frequency 
during the first 12 weeks of the Treatment Period compared to the Prospective Baseline
REDACTED COPY during the first 12 weeks of the Treatment Period compared to the Prospective Baseline
Percentage of subjects with at least REDACTED COPY Percentage of subjects with at least 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Descriptive statistics will be provided on the percent change in absence and myoclonic seizure 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Descriptive statistics will be provided on the percent change in absence and myoclonic seizure 
Period), first 12 weeks of, and the entire 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Period), first 12 weeks of, and the entire 
reduction in absence and myoclonic seizure 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.reduction in absence and myoclonic seizure 
Percentage of subjects with at least a 50% reduction in absence seizure frequency during 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Percentage of subjects with at least a 50% reduction in absence seizure frequency during 
the first 6 weeks (Titration Period) compared to the Prospective Baseline
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.the first 6 weeks (Titration Period) compared to the Prospective Baseline
least a 50% reduction in myoclonic seizure frequency 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.least a 50% reduction in myoclonic seizure frequency 
during the first 6 weeks (Titration Period) compared to the Prospective Baseline
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.during the first 6 weeks (Titration Period) compared to the Prospective Baseline
Percentage of subjects with at least a 50% reduction in absence seizure frequency during 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Percentage of subjects with at least a 50% reduction in absence seizure frequency during 
ent Period compared to the Prospective Baseline
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.ent Period compared to the Prospective Baseline
Percentage of subjects with at least a 50% reduction in myoclonic seizure frequency 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Percentage of subjects with at least a 50% reduction in myoclonic seizure frequency 
during the first 12 weeks of the Treatment Period compared to the Prospective Baseline
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.during the first 12 weeks of the Treatment Period compared to the Prospective Baseline
Percentage of subjects with at least 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Percentage of subjects with at least a 50% reduction in absence seizure frequency during 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.a 50% reduction in absence seizure frequency during 
the Treatment Period compared to the Prospective Baseline
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.the Treatment Period compared to the Prospective Baseline
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Percentage of subjects with at least a 50% reduction in myoclonic seizure frequency 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Percentage of subjects with at least a 50% reduction in myoclonic seizure frequency 
during the Treatment Period compared to the Prospective Baseli
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.during the Treatment Period compared to the Prospective Baseli
Percentage of subjects with at least a 75% reduction in absence seizure frequency during 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Percentage of subjects with at least a 75% reduction in absence seizure frequency during 
the first 6 weeks (Titration Period) compared to the Prospective Baseline
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.the first 6 weeks (Titration Period) compared to the Prospective Baseline
Percentage of subjects with at least a 75% reduction in myoclonic seizure frequency 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Percentage of subjects with at least a 75% reduction in myoclonic seizure frequency 
the first 6 weeks (Titration Period) compared to the Prospective Baseline
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.the first 6 weeks (Titration Period) compared to the Prospective Baseline
Percentage of subjects with at least a 75% reduction in absence seizure frequency during 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Percentage of subjects with at least a 75% reduction in absence seizure frequency during 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.the first 12 weeks of the Treatment Period compared to the Prospective Baseline
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.the first 12 weeks of the Treatment Period compared to the Prospective Baseline

This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Percentage o
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Percentage o
UCB   28 Mar 2019  
Statistical Analysis Plan  SP0982  
Section 10.2, the following TEAE summary was added:  
 Incidence of common TEAEs for EU labeling (above or equal to reporting threshold of 1% 
(prior to rounding) of subjects in the total LCM group) and occurring >1% than in the placebo group 
Section 10.4.4.4, Increase in absence seizure frequency is new: 
Response to treatment regarding absence seizures will also be based on the percent change in the 
absence seizure frequency per 28 days, calculated as described in Section 8.3.1.9  . The number 
and percentage of subjects experiencing an increase of up to 25%, >25% to 50%, >50% to 75%, 
and >75% in absence seizure frequency per 28 days during the Treatment Period compared to the Prospective Baseline Period will be presented.  
Section 10.4.4.5, Increase in myoclonic seizure frequency is new: 
Response to treatment regarding myoclonic seizures will also be based on the percent change in 
the myoclonic seizure frequency per 28 days, calculated as described in Secti on 8.3.1.9. The 
number and percentage of subjects experiencing an increase of up to 25%, >25% to 50%, >50% 
to 75%, and >75% in myoclonic seizure frequency per 28 days during the Treatment Period compared to the Prospective Baseline Period will be presented.  
References were revised from:  
Cox DR. Regression models and life-tables. J R Stat Soc Series B Methodol. 
1972;34(2):187-220.  
French JA, Temkin NR, Hammer AE, VanLandingham KE. Time to nth seizure analysis of 
lamotrigine as adjunctive therapy in subjects with primary generalized tonic-clonic seizures. 
Epilepsia. 2007;48(S6):77-78.  
LaVange LM, Durham TA, Koch GG. Randomization-based nonparametric methods for the 
analysis of multicentre trials. Stat Methods Med Res. 2005;14:281-301. Marcus R, Peritz E, Gabriel KR. On closed testing procedure with special reference to ordered 
analysis of variance. Biometrika. 1976;63:655-60. 
Biton V, Di Memmo J, Shukla R, Lee YY, Poverennova I, Demchenko V, et al. Adjunctive 
lamotrigine XR for primary generalized tonic-clonic seizures in a randomized, placebo-
controlled study. Epilepsy & Behavior. 2010; 19: 352-8. 
Was revised to the following:  
Allison, PD. Survival Analysis Using SAS
®: A Practical Guide. 2nd ed. Cary: SAS Institute; 
2010 Biton V, Di Memmo J, Shukla R, Lee YY, Poverennova I, Demchenko V, et al. Adjunctive 
lamotrigine XR for primary generalized tonic-clonic seizures in a randomized, placebo-
controlled study. Epilepsy & Behavior. 2010; 19: 352-8. 
Collett D. Modelling survival data in medical research. 3
rd ed. London: CRC Press; 2015 
Cox DR. Regression models and life-tables. J R Stat Soc Series B Methodol. 
1972;34(2):187-220.  REDACTED COPY tables. J R Stat Soc Series B Methodol. 
REDACTED COPY tables. J R Stat Soc Series B Methodol. 
ammer AE, VanLandingham KE. Time to nth seizure analysis of 
REDACTED COPY ammer AE, VanLandingham KE. Time to nth seizure analysis of 
lamotrigine as adjunctive therapy in subjects with primary generalized tonic
REDACTED COPY lamotrigine as adjunctive therapy in subjects with primary generalized tonic
LaVange LM, Durham TA, Koch GG. RandomizationREDACTED COPY LaVange LM, Durham TA, Koch GG. Randomization
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Response to treatment regarding absence seizures will also be based on the percent change in the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Response to treatment regarding absence seizures will also be based on the percent change in the 
. The number 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.. The number 
and percentage of subjects experiencing an increase of up to 25%, >25% to 50%, >50% to 75%, 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.and percentage of subjects experiencing an increase of up to 25%, >25% to 50%, >50% to 75%, 
and >75% in absence seizure frequency per 28 days during the Treatment Period compared to the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.and >75% in absence seizure frequency per 28 days during the Treatment Period compared to the 
Response to treatment regarding myoclonic seizures will also be based on the percent change in 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Response to treatment regarding myoclonic seizures will also be based on the percent change in 
Secti
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Secti on
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.on
number and percentage of subjects experiencing an increase of up to 25%, >25% to 50%, >50% 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.number and percentage of subjects experiencing an increase of up to 25%, >25% to 50%, >50% 
cy per 28 days during the Treatment Period 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.cy per 28 days during the Treatment Period 
tables. J R Stat Soc Series B Methodol. 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.tables. J R Stat Soc Series B Methodol. 
ammer AE, VanLandingham KE. Time to nth seizure analysis of 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.ammer AE, VanLandingham KE. Time to nth seizure analysis of 
lamotrigine as adjunctive therapy in subjects with primary generalized tonic
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.lamotrigine as adjunctive therapy in subjects with primary generalized tonic
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.LaVange LM, Durham TA, Koch GG. Randomization
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.LaVange LM, Durham TA, Koch GG. Randomization
analysis of multicentre trials. Stat Methods Med Res. 2005;14:281
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.analysis of multicentre trials. Stat Methods Med Res. 2005;14:281
Marcus R, Peritz E, Gabriel KR. On closed testing procedure with special reference to ordered 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Marcus R, Peritz E, Gabriel KR. On closed testing procedure with special reference to ordered 
analysis of variance. Biometrika. 1976;63:655
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.analysis of variance. Biometrika. 1976;63:655
Biton V, Di Memmo J, Shukla R,
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Biton V, Di Memmo J, Shukla R,
lamotrigine XR for primary generalized tonic
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.lamotrigine XR for primary generalized tonic
controlled study. Epilepsy & Behavior. 2010; 19: 352
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.controlled study. Epilepsy & Behavior. 2010; 19: 352
Was revised to the following:
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Was revised to the following:
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Allison, PD. Survival Analysi
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Allison, PD. Survival Analysi
Biton V, Di Memmo J, Shukla R, Lee YY, Poverennova I, Demchenko V, et al. Adjunctive 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Biton V, Di Memmo J, Shukla R, Lee YY, Poverennova I, Demchenko V, et al. Adjunctive 
lamotrigine XR for primary generalized tonic
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.lamotrigine XR for primary generalized tonic
controlled study. 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.controlled study. 
Collett D. Modelling survival data in medical research. 3
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Collett D. Modelling survival data in medical research. 3
UCB   28 Mar 2019  
Statistical Analysis Plan  SP0982  
French JA, Temkin NR, Hammer AE, VanLandingham KE. Time to nth seizure analysis of 
lamotrigine as adjunctive therapy in subjects with primary generalized tonic-clonic seizures. 
Epilepsia. 2007;48(S6):77-78.  
LaVange LM, Durham TA, Koch GG. Randomization-based nonparametric methods for the 
analysis of multicentre trials. Stat Methods Med Res. 2005;14:281-301. 
Marcus R, Peritz E, Gabriel KR. On closed testing procedure with special reference to ordered 
analysis of variance. Biometrika. 1976;63:655-60. 
SAS®/Stat 9.4: User’s Guide. Cary: SAS Institute Inc; 2015 
Section 12.3.3, Table 10 was updated with the post-treatment vital sign abnormalities requested 
in the Type C Written Response. 
Section 12.3.4, Table 11 was updated with the post-treatment QTc abnormalities requested in the 
Type C Written Response. 
Appendix 5: Registry Required Tables was revised from:  
The following is the list of tables required for Article 41 (EudraCT), clinicaltrials.gov and/or Article 46 (European Pediatric Regulation). These tables will be produced at the same time as the CSR required Tables. 
Disposition and Discontinuation Reasons by Development 
Discontinuation due to AEs 
Demographics by Development 
Baseline Characteristics by Development 
LCM Overall Exposure by Development 
Study Medication Duration by Development Incidence of TEAEs by Development – Overview 
Incidence of TEAEs by Development 
Incidence of Serious TEAEs by Development Incidence of Non-serious TEAEs  
Incidence of TEAEs by Relationship and Development Incidence of TEAEs Leading to Discontinuation by Development 
Incidence of Serious TEAEs by Relationship  
Incidence of Non-serious TEAEs by Relationship  
Incidence of Fatal TEAEs by Relationship  Incidence of Non-serious TEAEs Above Reporting Threshold of 5% of Subjects 
Incidence of Non-serious TEAEs Above Reporting Threshold of 5% of Subjects by Relationship 
Was revised to: REDACTED COPY Disposition and Discontinuation Reasons by Development
REDACTED COPY Disposition and Discontinuation Reasons by Development
Baseline Characteristics by Development
REDACTED COPY Baseline Characteristics by Development
LCM Overall Exposure by DevelopmentREDACTED COPY LCM Overall Exposure by Development
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.treatment vital sign abnormalities requested 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.treatment vital sign abnormalities requested 
treatment QTc abnormalities requested in the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.treatment QTc abnormalities requested in the 
The following is the list of tables required for Article 41 (EudraCT), clinicaltrials.gov and/or 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.The following is the list of tables required for Article 41 (EudraCT), clinicaltrials.gov and/or 
Article 46 (European Pediatric Regulation). These tables will be produced at the same time as
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Article 46 (European Pediatric Regulation). These tables will be produced at the same time as
Disposition and Discontinuation Reasons by Development
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Disposition and Discontinuation Reasons by Development
Study Medication Duration by Development
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Study Medication Duration by Development
Incidence of TEAEs by Development 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Incidence of TEAEs by Development –
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.–
Incidence of TEAEs by Development
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Incidence of TEAEs by Development
Incidence of Serious TEAEs by Development
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Incidence of Serious TEAEs by Development
serious TEAEs 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.serious TEAEs 
Incidence of TEAEs by Relationship and Development
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Incidence of TEAEs by Relationship and Development
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Incidence of TEAEs Leading to Discontinuation by Dev
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Incidence of TEAEs Leading to Discontinuation by Dev
Incidence of Serious TEAEs by Relationship 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Incidence of Serious TEAEs by Relationship 
Incidence of Non
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Incidence of Non
Incidence of Fatal TEAEs by Relationship 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Incidence of Fatal TEAEs by Relationship 
Incidence of Non
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Incidence of Non
UCB   28 Mar 2019  
Statistical Analysis Plan  SP0982  
The following is the list of tables required for Article 41 (EudraCT), clinicaltrials.gov and/or 
Article 46 (European Pediatric Regulation). These tables will be produced at the same time as the 
CSR required Tables. 
Disposition and Discontinuation Reasons by Development Discontinuation due to AEs 
Demographics by Development 
Baseline Characteristics by Development ILAE Seizure Classification History by Development 
Classification of Epileptic Syndrome by Development 
AEDs and Benzodiazepines at Study Entry by Development 
Summary of Time to Second PGTCS by Development 
Proportion of Subjects with Seizure Freedom at Day 166 by Development 
PGTCS Frequency Observed Results and Percent Changes from Combined Baseline by 
Development 
Absence Seizure Frequency Observed Results and Percent Changes from Prospective Baseline 
by Development 
Myoclonic Seizure Frequency Observed Results and Percent Changes from Prospective Baseline 
by Development 
Responder Status for PGCTS by Development 
Responder Status for Absence Seizure Frequency by Development 
Responder Status for Myoclonic Seizure Frequency by Development 
Seizure-free Status for PGTCS by Development 
Days with Absence Seizures Observed Results and Percent Changes from Prospective Baseline 
by Development 
Increase in Days with Absence Seizures During the Treatment Period Compared to Prospective 
Baseline by Development 
Increase in Absence Seizure Frequency During the Treatment Period Compared to Prospe ctive 
Baseline by Development 
Responder Status and Seizure Worsening for Days with Absence Seizures by Development 
Days with Myoclonic Seizures Observed Results and Percent Changes from Prospective 
Baseline by Development 
Increase in Days with Myoclonic Seizures During the Treatment Period Compared to 
Prospective Baseline by Development 
Increase in Myoclonic Seizure Frequency During the Treatment Period Compared to Prospective 
Baseline by Development 
Responder Status and Seizure Worsening for Days with Myoclonic Seizures by Development REDACTED COPY Absence Seizure Frequency Observed Results and Percent Changes from Prospective Baseline 
REDACTED COPY Absence Seizure Frequency Observed Results and Percent Changes from Prospective Baseline 
Myoclonic Seizure Frequency Observed Results and Percent Changes from Prospective Baseline 
REDACTED COPY Myoclonic Seizure Frequency Observed Results and Percent Changes from Prospective Baseline 
nder Status for PGCTS by Development
REDACTED COPY nder Status for PGCTS by Development
Responder Status for Absence Seizure Frequency by DevelopmentREDACTED COPY Responder Status for Absence Seizure Frequency by Development
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Proportion of Subjects with Seizure Freedom at Day 166 by Development
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Proportion of Subjects with Seizure Freedom at Day 166 by Development
es from Combined Baseline by 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.es from Combined Baseline by 
Absence Seizure Frequency Observed Results and Percent Changes from Prospective Baseline 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Absence Seizure Frequency Observed Results and Percent Changes from Prospective Baseline 
Myoclonic Seizure Frequency Observed Results and Percent Changes from Prospective Baseline 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Myoclonic Seizure Frequency Observed Results and Percent Changes from Prospective Baseline 
nder Status for PGCTS by Development
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.nder Status for PGCTS by Development
Responder Status for Absence Seizure Frequency by Development
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Responder Status for Absence Seizure Frequency by Development
Responder Status for Myoclonic Seizure Frequency by Development
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Responder Status for Myoclonic Seizure Frequency by Development
free Status for PGTCS by Development
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.free Status for PGTCS by Development
Days with Absence Seizures Observed Results and 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Days with Absence Seizures Observed Results and 
Increase in Days with Absence Seizures During the Treatment Period Compared to Prospective 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Increase in Days with Absence Seizures During the Treatment Period Compared to Prospective 
Baseline by Development
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Baseline by Development
Increase in Absence Seizure Frequency During the Treatment Period Compared to Prospe
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Increase in Absence Seizure Frequency During the Treatment Period Compared to Prospe
Baseline by Development
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Baseline by Development
Responder Status and Seizure Worsening for Days with Absence Seizures by Development
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Responder Status and Seizure Worsening for Days with Absence Seizures by Development
Days with Myoclonic Seizures Observed Results and Percent Changes from Prospective 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Days with Myoclonic Seizures Observed Results and Percent Changes from Prospective 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Baseline by Development
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Baseline by Development
Increase in Days with Myoclonic Se
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Increase in Days with Myoclonic Se
Prospective Baseline by Development
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Prospective Baseline by Development
UCB   28 Mar 2019  
Statistical Analysis Plan  SP0982  
Incidence of Absence Seizure Emergence or Worsening by Development 
Incidence of Myoclonic Seizure Emergence or Worsening by Development 
Seizure-free Status for All Generalized Seizure Types by Development 
Study Medication Duration by Development 
Cumulative Study Medication Duration by Development 
Study Medication Daily Dosing by Development 
Incidence of TEAEs by Development – Overview Incidence of TEAEs by Development 
Incidence of Serious TEAEs by Development 
Incidence of Non-serious TEAEs  
Incidence of TEAEs by Relationship and Development 
Incidence of TEAEs Leading to Discontinuation by Development 
Incidence of Serious TEAEs by Relationship  Incidence of Non-serious TEAEs by Relationship  
Incidence of Fatal TEAEs by Relationship  
Incidence of Non-serious TEAEs Above Reporting Threshold of 5% of Subjects 
Incidence of Non-serious TEAEs Above Reporting Threshold of 5% of Subjects by Relationship 
12-Lead ECG Summary by Development 
Treatment -Emergent Abnormal 12- Lead ECG Findings for Subjects by Development 
Section 12.6 was revised from:  
The following subgroup variable will also be programmed: Subjects enrolled at Japanese study sites (Japanese, non- Japanese)  
Was revised to: 
The following subgroup variable will also be programmed: 
Subjects enrolled at Japanese study sites (Japanese, non- Japanese)  
Subjects enrolled at Asian study sites (Asian, non-Asian) – Asian sites are those in Taiwan, 
South Korea, China and Japan 
  
 
  REDACTED COPY serious TEAEs Above Reporting Threshold of 5% of Subjects
REDACTED COPY serious TEAEs Above Reporting Threshold of 5% of Subjects
serious TEAEs Above Reporting Threshold of 5% of Subjects by Relationship
REDACTED COPY serious TEAEs Above Reporting Threshold of 5% of Subjects by Relationship
Lead ECG Summary by Development
REDACTED COPY Lead ECG Summary by Development
LeREDACTED COPY Lead ECG Findings for Subjects by DevelopmentREDACTED COPY ad ECG Findings for Subjects by Development
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.serious TEAEs Above Reporting Threshold of 5% of Subjects
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.serious TEAEs Above Reporting Threshold of 5% of Subjects
serious TEAEs Above Reporting Threshold of 5% of Subjects by Relationship
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.serious TEAEs Above Reporting Threshold of 5% of Subjects by Relationship
ad ECG Findings for Subjects by Development
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.ad ECG Findings for Subjects by Development
The following subgroup variable will also be programmed:
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.The following subgroup variable will also be programmed:
Subjects enrolled at Japanese study sites (Japanese, non
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Subjects enrolled at Japanese study sites (Japanese, non
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.The following subgroup variable will also
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.The following subgroup variable will also
Subjects enrolled at Japanese study sites (Japanese, non
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Subjects enrolled at Japanese study sites (Japanese, non
Subjects enrolled at Asian study sites (Asian, non
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Subjects enrolled at Asian study sites (Asian, non
South Korea, China and Japan
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.South Korea, China and Japan
UCB   28 Mar 2019  
Statistical Analysis Plan  SP0982  
STATISTICAL ANALYSIS  PLAN SIGNATURE PAGE  
This document has been reviewed and approved per the Review and Approval of Clinical 
Documents Standard Operating Procedures. Signatures indicate that the final version of the 
Statistical Analysis Plan (SAP) or amended SAP is released for execution. 
  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
